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Since the discovery of cisplatin as an anti-cancer agent, there has been a broad and 
multidisciplinary interest over four decades in the development of metal complexes as 
metallotherapeutic drugs. The principal objective of this thesis was to develop and characterize 
a novel library of gold(III) complexes of aromatic and non-aromatic quinoline- and pyridine-
amido ligands and to test their efficacy as cytotoxic agents against multiple human cancer cell 
lines. To this end, fifteen novel (16 in total) gold(III) complexes have been prepared and studied 
by multiple methods including FTIR, NMR, MS, and UV-visible spectroscopy, and in numerous 
cases, single crystal X-ray diffraction.  
Ligands H2L1–HL14 were prepared via the reaction of the relevant pyridine or quinoline 
carboxylic acid in the presence of triphenylphosphite and either picolylamine or 8-
aminoquinoline in pyridine, in moderate to good yields. Ligands HL15 and HL16 were prepared 
via the reaction between benzoyl or 1-naphthoyl chloride and 8-aminoquinoline in good yields. 
The synthesis of complexes [Au(HL1)Cl2]–[Au(L4)Cl2] were prepared by the reaction between 
the respective ligand, K[AuCl4] and NaOAc in 1:1 MeOH:DCM. Metal complexes [Au(L5)Cl](PF6)–
[Au(L14)Cl](PF6) were synthesised by encouraging the formation of a AuCl4
- counter ion in acetic 
acid and 3-fold excess of NaHCO3. Subsequent metathesis afforded the desired PF6
- anion. 
Complexes [Au(L15)Cl] and [Au(L16)Cl] were synthesised by the reaction of H[AuCl4] and 
respective ligand in acetic acid and a 3-fold excess of NaHCO3.     
The solubility of all complexes was assessed, with complexes [Au(L8)Cl](PF6)–[Au(L14)Cl](PF6) 
proving to be the most stable in biologically relevant media (TBS 50 mM, NaCl 10mM, pH 7.34, 
37°C). Complex [Au(L12)Cl](PF6) was further evaluated for its stability in the presence of 
glutathione and imidazole and found to be sensitive to reduction by thiols, but substitution-
inert to N-donor heterocycles such as imidazole. The DNA binding constants of [Au(L8)Cl](PF6)–
[Au(L11)Cl](PF6) were subsequently evaluated by UV-vis spectroscopy and found to be in the 
range of 2.7(5) x 105 to 4.7(6) x 105 M-1. Complexes [Au(L12)Cl](PF6)–[Au(L14)Cl](PF6) were 
similarly assessed using ethidium bromide displacement fluorescence assays, however their 
ability to bind DNA could not be conclusively proven. The log Po/w values of complexes 
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[Au(L12)Cl](PF6)–[Au(L14)Cl](PF6) were measured and spanned the range -0.8 to -2.16, 
consistent with significant hydrophilic character.   
The solid state structures of all complexes, with the exception of [Au(L10)Cl](PF6), [Au(L14)Cl](PF6) 
and [Au(L16)Cl](PF6), were determined by X-ray crystallography with the gold(III) ion co-
ordinated to the ligand in a square planar geometry. The co-ordination mode in complexes 
[Au(HL1)Cl2]–[Au(HL3)Cl2] was unexpected with the metal centre only co-ordinating to half the 
tetradentate ligand with a pair of cis-dichloro ions completing the square planar geometry. The 
average Au–Npy/qu distance is 2.02(2) Å while the average Au–Namide distance is 1.97(4) Å. In all 
complexes the trans labilising effect of the anionic amide nitrogen was observed through a 
structural elongation of the respective Au–Cl bond length. Almost all complexes studied 
exhibited π-stacking interactions, with compound [Au(L12)Cl](PF6) exhibiting a mean plane 
separation between rings of 3.307 Å.  This is a result of the extended aromatic rings present in 
all compounds 
DFT geometry optimizations, frequency, NMR, and energy calculations were carried out on all 
the gold(III) complexes at the HSEH1PBE/6-311G(d,p)/LanL2DZ level of theory. The 6-311G(d,p) 
basis set was used for all atoms with the exception of the gold atom for which the LanL2DZ 
basis set was used. In general, the chosen level of theory satisfactorily correlates with the 
experimental data for all complexes and was instrumental in deconvoluting the UV-vis spectra 
of all complexes. The lowest energy transitions (300–500 nm) were assigned to a LMCT while 
the higher energy transitions were assigned to π-π* transitions.    
The cytotoxicity profiles of all compounds, with the exception of [Au(HL1)Cl2] and [Au(L16)Cl], 
were evaluated through one-dose screens against the 60 human cancer cell lines at the NCI, 
where [Au(HL3)Cl2], [Au(L6)Cl](PF6)–[Au(L8)Cl](PF6), [Au(L10)Cl](PF6)–[Au(L13)Cl](PF6) and 
[Au(L15)Cl](PF6) were deemed sufficiently cytotoxic to proceed further to five-dose screening. 
The cytotoxicity results for compound [Au(L12)Cl](PF6) were most encouraging with GI50, TGI 
and LC50 values of  0.11(0.1), 0.70(0.7) and 26.5(1.5) μM, respectively, against the breast cancer 
cell line MDA-MB-468.  
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Statistical analysis of the GI50 values for complexes [Au(HL3)Cl2] and [Au(L12)Cl](PF6) revealed 
they may exert their cytotoxicity through the inhibition/poisoning of topoisomerase II and I 
enzymes, respectively. Both compounds were assessed for this through a topoisomerase IB 
DNA unwinding assay and a topoisomerase IIα decatenation assay. [Au(HL3)Cl2] was found to 
be a dual catalytic inhibitor and poison of topoisomerase IIα between concentrations of 500 nM 
and 50 μM while [Au(L12)Cl](PF6) was found to be a dual catalytic inhibitor and poison of 
topoisomerase IB between concentrations of 1 and 100 μM.  
Electrophoretic mobility shift assays were performed on both complexes, with [Au(HL3)Cl2] 
indicating DNA binding at a concentration of 50 μM, while [Au(L12)Cl](PF6) displayed no 
evidence for DNA binding despite an unexpected increase in mobility shift of the substrate 
DNA. This is indicative of an alternative mechanism of DNA interaction such as electrostatic 
binding. 
In summary, we present in this thesis, the discovery, synthesis and application of a novel series 
of gold(III) amide-based metal complexes as anti-cancer agents with the mechanism of action 
by which the complexes exert their cytotoxic activity being elucidated. The compounds show 
immense potential in the metallo-drug discovery field of research, and with further 
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In the fight against cancer there have been many successful drugs that have made a 
substantial impact, none more than cisplatin. Since the discovery of cisplatin in the 1940’s 
there has been a steadily increasing research focus into the use of metal complexes as 
chemotherapeutics. The use of gold complexes as medicinal drugs is not a new idea as in 
1890 it was discovered that gold(I) dicyanide was able to exhibit anti-tubercular activity.1 
This complex was not pursued further due to its toxic side effects. Nevertheless this was 
encouraging and further research into gold(I) anti-tubercular complexes led to the discovery 
of gold(I) thiolate complexes.1 These complexes were used extensively in the early twentieth 
century in the treatment of tuberculosis. Following this discovery it was also found that 
another gold(I) complex, auranofin, was effective in the treatment of rheumatoid arthritis. 
Despite these encouraging finds, there are inherent problems with gold-based drugs, 
specifically, gold(III)-based drugs. The gold(III) ion is fairly redox unstable and is particularly 
susceptible to reduction.1, 2 This particular trait becomes problematic when placed in the 
reducing environment of living cells. Gold(III) complexes can undergo reduction to gold(I) 
species as well as to colloidal gold through several reducing agents present in living cells, 
e.g. glutathione.1, 2 These problems are inherent and are carried through to the laboratory 
where redox and hydrolysis reaction take place readily. Another problem encountered when 
trying to synthesise cationic gold(III) complexes is the tendency for the formation of [AuCl4]
- 
and [AuCl2]
- counterions. In some cases the formation of these counterions can be 
circumvented through specific reaction conditions but in others, like the work presented 
here, alternative methods have to be employed to arrive at the desired product. There is 
one report in literature by Yang and co-workers that presents a similar class of amide based 
gold(III) chelates.3 The work presented herein contains fifteen novel metal chelates of 
gold(III) with one previously reported. Their basic structure has shown to interact with DNA 
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1.2 Gold: The royal metal 
Pure metallic gold was probably one of the first metals known to early civilizations. The 
symbol derives from the Latin word aurum, which is related to the goddess of dawn, Aurora. 
Early civilizations equated gold with gods and power, possibly due to its alluring physical 
nature. This is evident in Egyptian culture where pharaohs were surrounded by gold. Some 
of the oldest pieces of gold jewellery were discovered in the tombs of Queen Zer of Egypt 
dating back to the third millennium BC,4 however the oldest known golden treasure was 
found in the Varna Necropolis,4 a burial site in the western industrial zone of Varna, 
Bulgaria. Archaeological findings suggest that gold was first used in the Middle East and 
Europe where the first civilizations developed.4 Pieces of natural gold have also been found 
in Spanish caves of Palaeolithic Man (40 000 BC).4 A 27% Silver: 63% Gold mixture, stamped 
out into lumps, called ‘electrum’ was first used as money by Lydian merchants (700 BC), 
hence it is one of the so called ‘coinage metals’, along with silver.4 Geographically, gold is 
found worldwide in its natural state in rivers and streams and through its discovery as such 
has led to the development of some of the largest cities in the world. The California Gold 
Rush of 1848 led to the substantial growth of San Francisco from a small settlement of 200 
residents, to 36 000 by 1852. The establishment of Johannesburg, aptly named the city of 
gold or ‘Isidingo’, was also due the discovery of gold and consequently the Witwatersrand 
Gold Rush.  
 
Figure 1.2.1: Gold nuggets.5 
Gold (Figure 1.2.1) is a shiny, malleable and ductile 5d metal with an atomic number of 79. It 
is chemically unreactive and does not tarnish, hence its use in coinage and jewellery. One of 
the only liquids able to dissolve gold is aqua regia (3 : 1 mixture of HCl and HNO3). Aqua 
regia is Latin for “king’s water” and named so for its ability to dissolve the so-called noble 
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metals, gold and platinum. It is able to dissolve gold because once the metal has been 
oxidised by the nitric acid, the chloride anions from the HCl bind to the AuIII metal centre 
forming a co-ordination complex that is stable (Equation 1.2.1).6 
 Au(s)  6H+(aq)  3NO3
-(aq)  4Cl-(aq)  AuCl4
-(aq)  3H2O  3NO2(g)               1.2.1 
Gold metal melts at a temperature of 1337.58 K and boils at a temperature of 3080 K. It has 
an electronic configuration of [Xe] 4f14 5d10 6s1 and like copper and silver (group congeners), 
has a single s electron outside of a completed d shell.7 In spite of the similar electronic 
structures there are few chemical resemblances between copper, silver and gold.7 There are 
no simple explanations for this, but gold’s uniqueness may be traced back to the relativistic 
effects of the 6s electrons. Gold metal’s density is 19.3 g/cm3 compared to the densest of all 
metals, osmium, which has a density of 22.6 g/cm3. Gold metal also has the lowest 
electrochemical potential of any metal as well as being the most electronegative metal. This 
means that in its cationic form it is able to accept electrons from almost any reducing agent 
to form metallic gold.4 
Gold is usually associated with metal sulphide ores or quartz conglomerates. These ores can 
be accompanied by other metals such as iron, copper, silver and zinc. The main global 
sources of gold are China and Australia.8 There are several industrial methods used for the 
processing mined gold ores. The Miller process involves a stream of chlorine gas that is 
blown over and through a crucible containing molten impure gold. This technique works on 
the principle that nearly all other elements will form chlorides before gold does. These 
chlorides are insoluble in molten metal and are removed leaving gold of 99.95% purity. 
Another is froth flotation followed by leaching with cyanide and consequent precipitation 
using zinc (Equation 1.2.2 and 1.2.3).7, 9 
4Au  8KCN  O2  2H2O  4KAu(CN)2  4KOH                                  1.2.2 
 4KAu(CN)2  Zn  K2Zn(CN)4  2Au                 1.2.3 
In order to obtain even higher purity gold (99.9999 %), the Wohlwill process is employed. 
This is an electrochemical process where the anode is a gold bar of 95%+ purity (any lower 
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purity will interfere with the reaction) and the cathode is a small sheet of 24 carat gold.9 The 
electrolyte in the system is chloroauric acid. When a current is applied to the system the 
impure gold is dissolved at the anode and is plated on the cathode through ion transfer of 
the chloroauric acid.9 
Table 1.2.1: Summary of the common oxidation states and stereochemistry of gold (table 
adapted from “Advanced Inorganic Chemistry”).7 





+1 d10 2 Linear 
  3 Trigonal 
  4 Tetrahedral 
+2 d9 4 Square planar 
+3 d8 4 Square planar 
  5 Trigonal bipyramidal 
   6 Octahedral 
+5 d6 6 Octahedral 
 
The chemistry of gold is extremely diverse with the metal being able to adopt several 
different oxidation states. These oxidation states vary from –1 to +5, although +1 and +3 
dominate its chemistry.4, 6, 10 The common oxidation states and co-ordination geometries 
are summarised in Table 1.2.1. Gold(-I)-containing compounds are called aurides and due to 
the high electronegativity of gold, the auride anion is relatively stable.4, 7 Examples of binary 
alkali metal aurides (RbAu and CsAu) have been known for a number of years,11, 12 but the 
ternary auride oxides M3AuO (M = K, Rb, Cs) and the auridaurates Rb5Au3O and M7Au5O (M 
= Rh or Cs) have only been more recently discovered.13-16 The first non-metal auride, 
NMe4
+Au-, was synthesised through ion exchange of CsAu.17 Intermediate charge (between 
0 and +1) gold compounds exist primarily as clusters containing other metals as well as 
phosphorus donor ligands. They are available through the reaction of gold(I) precursors such 
as [AuX(PR3)] (X = halide, SCN, NO3) with reducing agents such as NaBH4 or CO (Equation 
1.2.4).18 
 [Au(NO3)(PPh3)] + NaBH4 → [Au9(PPh3)8](NO3)3                           1.2.4 
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Gold(II) compounds are very scarce but occur formally in dithiophene compounds and in the 
dicarbollyl anion [Au(B9C2H11)2]
2-.7 Another legitimate gold(II) complex is that of 
[AuXe4][Sb2F11]2 which contains the nobel gas Xenon as a ligand (although very unstable).
19 
Crystals of this complex had to be grown at -78 °C.19 The highest verified oxidation state of 
gold is (+5), which is present in the compounds AuF5 and AuF6
-.7  
 3Au+(aq)  2Au(0)  Au(3+)                              1.2.5 
The gold(I) oxidation state is by far the most developed and therefore most prominent in 
literature. It can accommodate numerous geometries with many different types of ligands. 
Gold(I) is soft (according to hard soft acid base theory (HSAB)) and therefore has an affinity 
towards soft donor ligands (e.g. P- and S-donor ligands) and to this end the chemistry is well 
developed. It is also well known that gold(I) complexes can disproportionate to Au(0) and 
Au(III) (Equation 1.2.5).6 There is a relatively small energy difference between the filled d 
orbitals and the unfilled s valence shell orbital of gold(I).7 This permits the extensive 
hybridisation of the dz2 and s orbitals (Figure 1.2.2).7  
 
Figure 1.2.2: Hybrid orbitals formed from mixing     and an   orbital 1 and 2 and the 
hybrid orbitals formed from mixing 2 and an  z orbital.7 
The electron pair initially in the     orbital occupies  1, giving a circular region of relatively 
high electron density from which ligands are somewhat repelled, and regions above and 
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below the ring in which the electron density is relatively low.7 The ligands are attracted to 
the regions of lesser electron density. Two hybrid orbitals, suitable for the formation of 
linear covalent bonds can be formed by the further mixing of 2 with the  z orbital, hence 
the predominant linear geometry of gold(I) complexes.7 
The gold(III) ion has a [Xe] 4f14 5d8 electronic configuration and therefore adopts a square 
planar co-ordination geometry similar to other d8 metals such as Pt(II), Pd(II), Rh(I) and 
Ir(I).20 Valence Shell electron pair repulsion (VSEPR) theory tells us that the     orbital 
occupies the two axial co-ordination sites in the VSEPR view and therefore the four ligands 
accommodate the equatorial plane (Figure 1.2.3).20  Due to the removal of ligands in the z 
direction, orbitals containing a z component are lowered in energy, specifically    , while 
the energies of the        and     orbitals are raised. Almost all square planar d
8 metals 
are diamagnetic since the highest energy orbital (      ) is greatly destabilised and spin 
pairing in the     orbital is more favourable than placing an unpaired spin in the (      ) 
orbital.20 
 
Figure 1.2.3: VSEPR view of d8 square planar metal complexes showing the expected 
low spin configuration. 
The above stated low spin square planar d8 configuration is the ideal geometry when 
designing potential metallo-drugs to target DNA as the complex is flat and hence can 
intercalate DNA efficiently. There are, however some rare examples of gold(III) complexes 
that do not adhere to the predicted geometry (Figure 1.2.4).21, 22 
Introduction 
7 | P a g e  
 
 
Figure 1.2.4: Molecular structures of a five co-ordinate gold(III) complex, 
[Au{N2C10H7(CHMePh)-6}C13], (A) and a six co-ordinate gold(III) complex, 
[Au(L)Cl2]AuCl4 (where L = 1,8-bis(hydroxyethyl)-1,3,6,8,10,13-
hexaazacyclotetradecane) (B). The compounds are redrawn from the CSD co-ordinates 
RADLAJ and TEMMED respectively and rendered as sticks.21, 22 
1.3 Gold(III) complexes and their general applications 
The focus of this project is gold(III) complexes and their biological activity. That said, there 
are other applications of gold(III) chelates with two key focus areas, specifically that of 
catalysis and luminescence. The amount of literature on gold(III) and catalysis is quite sparse 
in relation to other metals and still has some wide scope in terms of its development.23, 24 It 
is not the focus of this research and therefore we will choose some selected examples to 
discuss.  
 
Figure 1.3.1: Reaction scheme and percentage yields for some Au3+-catalysed 
cyclizations. Redrawn from reference 24.25 
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The most common gold catalysts are the simple gold(III) compounds AuCl3
25-27 and 
H[AuCl4]
28, although there have been reports on some gold(III) complexes and their catalytic 
activity towards the ‘synthesis of propargylamines via a three-component coupling reaction 
of aldehydes, amines and alkynes’23 and the ‘synthesis of azepines by a gold-catalyzed 
intermolecular [4 + 3]-annulation’.28 An example of AuCl3 being used as a catalyst was 
reported by Hashmi et al. in 2000, where the use of AuCl3 as a catalyst in the synthesis of 
arenes was described (Figure 1.3.1).25 From Figure 1.3.1 it can be seen that for the 
derivatives tested, the percentage yields were very good, most in the 80-90% range. The 
only pitfall of this reaction is that the catalyst eventually suffers deactivation.25 They 
therefore suggest that modification of the catalyst from a simple gold salt to a complex may 
prevent this as well as enhance the catalytic activity.25 An example where this has been put 
to good use is in a previously mentioned paper by Lo et al. in 2009. They attempted the 
synthesis of propargylamines using four documented gold(III) complexes Au[TPP]+, 
[Au(C^N^C)Cl], [Au(sal2pn)]Cl and [Au(C^N)Cl2]  (Figure 1.3.2).
23      
 
Figure 1.3.2: Chemical structures of Au[TPP] (A), [Au(C^N^C)Cl] (B), [Au(sal2pn)]Cl (C) 
and [Au(C^N)Cl2] (D) used in the catalytic synthesis of propargylamines.23  
All four catalysts were tested for their catalytic activity according to the reaction scheme in 
Figure 1.3.3. Both [Au(sal2pn)]Cl and [Au(C^N)Cl2] showed good catalytic activity with yields 
of 94 and 82%, respectively. Compounds Au[TPP]+ and [Au(C^N^C)Cl] however did not 
prove fruitful in their catalytic activity with yields in both cases not detectable.23 The paper 
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goes on to use [Au(C^N)Cl2]  in a variety of experiments using different starting materials in 
the synthesis of propargylamines in good yields of up to 99 % by NMR.23 
 
Figure 1.3.3: Reaction scheme used in the synthesis of propargylamines. Redrawn from 
ref 22.23 
The traditional field of phosphorescence and luminescence of gold complexes is dominated 
by gold(I).29 Only recently has there been an interest gold(III) complexes and their 
phosphorescence and luminescence.30-33 In 2005, Wong et al. published a communication 
and soon after a patent regarding a series of gold(III) alkynyl-based organic light-emitting 
devices (Figure 1.3.4).32, 33 They found that their novel class of luminescent cyclometalated 
gold(III) alkynyl complexes was shown to possess electro-luminescent (EL) properties and 
was employed in the roles of electrophosphorescent emitters or dopants of organic light 
emitting diodes (OLEDs) with high brightness and efficiency. They showed that the colour of 
the EL was capable of being tuned from orange to blue by varying the DC voltage applied or 
varying the dopant concentration.32  
 
Figure 1.3.4: Chemical structures of gold(III) alkynyl-based organic light-emitting 
devices.32  
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Che and co-workers have recently reported an organogold(III) complex (Figure 1.3.5 (B))  
and its diverse use.34 In his communication it is reported that the complex exhibits a long-
lived emission lifetime of 506 μs.34 The emission was however seen to be oxygen sensitive 
and was tested as an oxygen sensor for living cells. When cell media was flushed with 
nitrogen and incubated with the organogold(III) complex, the cells became yellowish green 
upon illumination under a fluorescent microscope.34 Due to the complex’s high emission 
quantum yields and long lived excited states, the compound was deemed a good candidate 
for testing as a catalyst in photochemical reactions.34 It was tested with two oxidation type 
reactions that have important application in organic synthesis: the α-substitution of tertiary 
amines and the oxidation of secondary amines to imines (Figure 1.3.5 D and E).34 The 
complex performed extremely well in both cases with near 100% conversion rates and high 
yields.34 The complex was then finally successfully tested as a catalyst in the generation of 
hydrogen from water (Figure 1.3.5 C). This paper therefore identifies the richness and 
diversity of organogold(III) chemistry.34    
 
Figure 1.3.5: Oxygen sensitive Emission of Che’s organogold(III) complex (A). Ortep 
view of the complex in question (B). Hydrogen production properties of the complex 
under different reaction conditions (C). Reaction scheme showing the oxidative 
cyanation of tertiary amines (D). Reaction scheme showing the oxidation of secondary 
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1.4 Cancer and its treatment 
1.4.1 Background and history 
The human body contains roughly 10 million million cells (1013).35 These cells are subdivided 
into groups and classes to form the various tissues and organs that are programmed to 
perform various functions within the body.35 Some cells, such as nerve cells, are believed to 
be incapable of further division once they have been formed during the development of the 
embryo or in infancy.35 Other cells such as liver cells seldom divide during our lifetime but 
are able to do so if required.35 Furthermore, cells constituting the gut, skin or bone marrow, 
for example, are constantly dividing to replace those that are destroyed.35 Obviously, in 
tissues where cells multiply constantly, the total amount of cells must remain constant i.e. 
cell production must be equal to cell death.35, 36 Programmed cell production and cell death 
must therefore be under strict control.36 
In such a system where the throughput of cells is so large, it is expected that there may be 
Darwinian Selection and that the occasional cell may exhibit increased fitness in so far as it 
may be able to multiply faster than normal cells or can displace their neighbours whenever 
space is limited.35 This is the basis of ‘cancer’. When cells divide without the usual cellular 
restrains, but keep to their normal territory and do not invade surrounding tissues they 
form tumours that are labelled ‘benign’.35-37 If these rapidly dividing cells acquire the ability 
to spread to surrounding tissue the tumour is then labelled ‘malignant’.35, 36 Cancer can 
therefore be described as the uncontrolled division of a single group of abnormal cells which 
leads to the accumulation of a solid mass of cells, known as a tumour or neoplasm.36 
The initial tumour that develops generally only becomes life-threatening if it obstructs 
vessels or organs and impairs their function and/or irreversibly damages them.35 The 
primary cause of death in most cancer patients is due to secondary tumours.35-37 These 
secondary tumours arise from a process called metastasis.35, 36 Metastasis is the process 
whereby cancerous cells from the primary tumour spread to other parts of the body, 
namely vital organs, giving rise to secondary tumours.35, 36 The most common ways in which 
cancerous cells are able to metastasise are through the penetration of lymphatic vessel 
walls as well as through blood vessels, since capillary walls are very thin.36 Once cancerous 
cells have metastasised into the lymph and capillary networks it is very dangerous for the 
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patient as these networks are extensively distributed throughout the body and allow the 
formation of secondary tumours in areas far removed from the primary tumour.36 Once a 
primary tumour has metastasised (typically 50% of cancer patients) the use of curative 
surgery or radiotherapy is forgone and chemotherapy is usually proposed.36 
Tumorigenesis is the multistep process associated with the genetic transformation of 
healthy cells to cancerous cells. It is suggested that there are six modifications to cells which 
may lead to malignancy:36 
 Self-sufficiency in growth signals 
 Insensitivity to growth-inhibitory signals 
 Evasion of programmed cell death (apoptosis) 
 Limitless replicative potential 
 Sustained angiogenesis 
 Tissue invasion and metastasis 
It has been proposed that the need for a cell to acquire all of these traits prior to completing 
transformation is the reason why tumour cell formation is relatively rare during the average 
human lifespan.36  
It is generally accepted that cancer in general is a genetic disease resulting from changes to 
DNA sequence information in one or more genes, or from more profound structural 
changes.36, 38 These changes can arise from numerous processes, such as internal, external 
and hereditary.36 Internal factors include genetic mutations, addition or loss of genetic 
material, epigenetic changes and modified gene expression.36, 38, 39 Genetic mutations arise 
in the form of point and translocation mutations.36, 38, 39 In a point mutation, only one 
nucleotide base is altered, and the resulting new codon can lead to the insertion of an 
incorrect amino acid at the corresponding position of the protein.36, 38, 39 If this protein is a 
regulatory protein i.e. a tumour suppressor protein, then tumorigenesis may occur. In a 
translocation mutation, an entire segment of DNA is moved from one part of the gene or 
chromosome to another.36, 38, 39 In this case, loss of the protein associated with the original 
DNA sequence or the production of a new protein may lead to tumorigenesis. The original 
genes involved in this process are called pro-oncogenes, meaning genes that do not cause 
cancer themselves unless suitably activated to form what is called an oncogene.36, 38, 39 This 
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concept has been validated in certain types of cancer such as Burkitt’s lymphoma, in which 
the precise sequences involved in the translocation have been identified.36  
External factors include viruses, bacterial infections, chemicals, radioactivity and 
electromagnetic radiation.36 Certain chemicals in the environment, encountered through 
diet, lifestyle and occupation can lead to tumorigenesis.36 For example the link between 
lung cancer and cigarette smoke is well established as too is the link between alcohol and 
head and neck cancer.37 The production of polycyclic aromatic hydrocarbons, formed when 
frying or barbequing red meat, have also been associated with colon tumours.36 Potent 
carcinogens known as aflatoxins (Figure 1.4.1.1), found in low concentrations in peanut 
butter, are formed as secondary metabolites by a fungus that can infect peanuts during 
growth.36  
 
Figure 1.4.1.1 Chemical structure of Aflatoxin. 
There are numerous chemicals that workers can be exposed to through occupation that 
have been directly linked with cancer. One of the most infamous examples of such a 
chemical is asbestos. Asbestos was commonly used, post-World War 2, in the construction 
industry. The continuous inhalation of asbestos over time causes physical damage to the 
pleura in the lungs which, in turn, can cause the development of mesothelioma.36   
The third type of alteration is a hereditary one where the inheritance of certain genes can 
predispose one to certain types of cancer.36, 38 An example is the inheritance of two genes 
(BRCA1 and BRCA2), which have been identified and sequenced in being associated with 
breast cancer.36, 38 
There are several ways in which cancer can be treated, namely surgery, radiotherapy, 
photodynamic therapy, biological response modifying agents and chemotherapy. The 
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former methods can generally only be used when the tumour is small and/or reasonably 
well defined and, in the case of photodynamic therapy, close to the tissue surface. Surgery is 
also a very invasive technique that is very traumatic for the patient and in some cases can 
cause the ‘seeding’ of secondary tumours due to suppressed bodily function. In almost all 
cases chemotherapy is used as the exclusive treatment or in conjunction with the other 
mentioned treatments. 
1.4.2 Chemotherapy and its use in the treatment of cancer    
Cancer is one of the most serious health problems of the western world; however there has 
been significant progress and development of novel drugs and drug targets since the 
accidental discovery of the nitrogen mustards and cisplatin.36, 40, 41 There are certain forms 
of cancer that have a high success rate in being cured if detected early. Overall 
chemotherapy is the most diverse and widely used form of cancer treatment (Table 
1.4.2.1).36, 37 One advantage of chemotherapy is that the low molecular weight drugs are 
administered intravenously and are able to distribute throughout most tissues in the body 
and therefore are able to kill tumour cells in protected areas such as the brain.36 The 
problem however, is in the non-specificity of most chemotherapeutic agents and acquired 
resistance. Because of this, chemotherapy also targets healthy living cells that are rapidly 
dividing such as bone marrow, hair and nails, leading to the five common side effects of 
nausea, hair loss, gastric tract lesions and marrow suppression.36 These side effects are 
usually temporary and only last up to a couple of weeks after treatment has been 
discontinued. There are several different classes of chemotherapeutic agents, some of 
which are described in the table below.  
Table 1.4.2.1: Summary of some different classes of chemotherapeutic agents 
Drug Type Example Mode of action 
Anti-metabolites 5-Fluoro Uracil Inhibit pyrimidine synthesis 
DNA-Interactive Agents Topotecan Topoisomerase I inhibitor 
Anti-tubulin Agents Vinblastine Inhibits tubulin formation 
Molecularly Targeted Agents Erlotinib EGFR inhibitor 
Hormonal Therapies Tamoxifen Non-steroidal oestrogen 
antagonist  
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TOPOISOMERASE ENZYMES: THEIR FUNCTION AND INHIBITION/POISONING BY 
CHEMOTHERAPEUTICS: 
The gold(III) amide complexes in this work have been synthesised and designed to effect 
their cytotoxicity through DNA intercalation. This is because they contain planar regions of 
extended aromaticity that are able to intercalate between base pairs of double stranded 
DNA. Since the biological target of the complexes is DNA it seems logical that the complexes 
may exhibit their cytotoxicity by inhibiting enzymes that maintain the structure and function 
of DNA. One such class of enzymes are the topoisomerases which have two distinct forms. 
The first is topoisomerase I, which relaxes supercoiled DNA, and the second is 
topoisomerase II, which is a decatenase.42 
Nuclear DNA is an extremely long polymer. A single mammalian genome corresponds to 
approximately 2 metres of linearised DNA, which is squeezed into a cell nuclear volume of 
approximately 10–17 m3.43 Cellular DNA must therefore be highly compacted, which creates 
many curved DNA domains (loops) and points of contact between these DNA domains.43 
Moreover, DNA metabolism requires the two strands of the duplex to be separated for 
them to serve as templates for transcription, replication, recombination and repair.43 DNA 
tends to be overwound (positively supercoiled) upstream of replication or transcription 
forks and underwound (negatively supercoiled) downstream of these forks.43 Removing 
positive supercoils is required for replication and transcription progression. Otherwise, their 
accumulation in advance of replication and transcription complexes hinders the melting of 
the DNA duplex (by helicases) and consequently polymerase translocation along the DNA 
template.44 The function of the topoisomerase’s is therefore to maintain DNA integrity by 
relieving the strain caused by winding and unwinding during the replication process.42, 44-46 
The two main Eukaryotic topoisomerases are topoisomerase IB (topo IB) and topoisomerase 
IIα (topo IIα).42, 45  
TOPOISOMERASE I: 
topo IB performs its function by first forming a ‘clamp’ around the DNA.46 The active site 
tyrosine then performs a nucleophillic attack on a DNA phosphodiester bond.44, 46 The bond 
is cleaved and the enzyme forms a transient DNA–(3’-phosphotyrosyl)-enzyme ‘covalent 
complex’ and a free 5’-OH DNA end.43, 44, 46 It is interesting to note that only topo I enzymes 
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form a covalent cleavage complex with the 3’-end of the broken DNA.44 The remaining topo 
enzymes form a bond to the 5’-end (Figure 1.4.2.1).44 This specific characteristic classifies 
the eukaryotic topo I enzymes into the broader family of site-specific tyrosine recombinases 
of prokaryotes and yeast.44 
 
Figure 1.4.2.1:  Diagram showing the relaxation of the DNA supercoiled structure by 
topoisomerase I and the trapping of the cleavage complex by a drug. Adapted from 
reference 42.43 
Once the DNA–(3’-phosphotyrosyl)-enzyme ‘covalent complex’ is formed it allows the 
torsional energy within the DNA supercoil to be released by rotation of the free 5’-OH 
end.43, 44, 46 Following the removal of a number of random supercoils the free 5’-OH end is 
then religated to the backbone of the DNA and the enzyme is free to repeat the process.46 
This process does not require ATP or divalent metal binding (e.g. Mg2+), which is the case for 
topo II.44 The remarkable efficiency of the nicking-closing activity of Top I enables the 
enzyme to relax both negatively and positively supercoiled DNA (even at 0 °C) with similar 
efficiency.44 This is in contrast to topo IIα, which more efficiently relaxes positive 
supercoiling.44 This process can, however, be disrupted when the 5’-OH end, generated by 
the nicking reaction, becomes misaligned.44 In such a case the cleavage complex becomes 
without an effective religation partner.44 These covalent complexes are known as “suicide 
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complexes”.44 Nevertheless, topo I can relegate an illegitimate 5’-OH end, effectively acting 
as a recombinase.44  
 
Figure 1.4.2.2:  Chemical structures of quinolone alkaloid based topo I poisons. 
By inhibiting the function of this enzyme the integrity of the DNA structure and function 
may be compromised as the cell would not be able to replicate and hence cease to exist. 
topo I is therefore a validated target for chemotherapy and there is a significant amount of 
research in the discovery of topo I inhibitors and their mechanisms of action.42-50 Currently 
in clinical use there are several drugs based on the natural product camptothecin (Figure 
1.4.2.2), which is a quinolone-based alkaloid that is extracted from the bark of the Chinese 
camptotheca tree.36 The drug, topotecan, is effective against metastatic ovarian cancer36 
and effects its inhibition of topo I by intercalating into the nick generated by topo IB on the 
DNA, forming a ternary topo IB-DNA-drug complex that traps the enzyme on the DNA.50 This 
irreversible ternary complex is converted into cytotoxic DNA lesions that cause cell death.46, 
50 This binding mode has been studied by X-ray crystallography through the structure of a 
70-kDa form of topo I (topo 70) covalently bound to DNA in the presence of topotecan 
(Figure 1.4.2.3).50 The ternary structure shows the drug intercalated at the site of the DNA 
cleavage and its stabilisation via stacking interactions with base-pairs above and below 
itself.50 The planar ring system of topotecan mimics a DNA base-pair and occupies the same 
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area that the base-pair above it would without the drug bound.50 The intercalation binding 
site is created by conformational changes of the phosphodiester bond between the base 
pairs above and below the uncleaved strand, which effectively ‘‘opens’’ the DNA duplex.50 
Positioning of the phosphodiester in the ternary complex is stabilised through hydrogen 
bond contacts to the main chain nitrogens of residues Arg-362 and Gly-363.50  
 
Figure 1.4.2.3: Crystal structure of topo I-DNA-drug complex redrawn from the co-
ordinates in PDB1T8I. The topo I enzyme has been coloured in red, the DNA in blue and 
the drug, topotecan, has been rendered as pink spheres.50 Molecular graphics generated 
with the UCSF Chimera package.51  
TOPOISOMERASE II: 
The mechanism for topo II is much more complicated than for topo I (Figure 1.4.2.4). It 
requires the use of divalent metal ions as well as ATP to perform its function. The reaction 
cycle for type IIA topoisomerases is believed to use a ‘two-gate’ mechanism for strand 
passage.52-54 The enzyme introduces a double strand break in one DNA strand, termed the G 
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or gate segment, and will pass a second strand termed the T segment through the break.55 
In the presence of Mg2+, the enzyme can cleave the DNA, forming a phosphotyrosine linkage 
between each single strand and a tyrosine in each subunit.55 ATP binding causes the enzyme 
to form a closed clamp. The closed clamp may also capture another strand (the T strand) 
that will pass through the break made in the G strand.55 After passing through the break in 
the G strand, the T strand exits the enzyme through the carboxy end.55 ATP hydrolysis 
occurs at two steps in the reaction cycle. The first ATP hydrolysed may assist in strand 
passage.55  
 
Figure 1.4.2.4: Schematic diagram showing the mechanism through which topo II 
exhibits its function and the critical points in its function where inhibitors with well-
studied mechanisms of action arrest or inhibit the catalytic cycle. Etoposide is a poison; 
ICRF-187, merbarone, and aclarubicin are catalytic inhibitors that operate in 
mechanistically distinct ways. Adapted from reference’s 53 and 54.54, 55 
The second hydrolysis step (along with release of ADP and inorganic phosphate (P)) allows 
the clamp to reopen, and allows release of the G segment.55 Alternately, the enzyme may 
Introduction 
20 | P a g e  
 
initiate another catalytic cycle without dissociating from the G strand.55 Since the structure 
and the function of the enzyme is more complicated than for topo I, it is intuitive that there 
may be several points in the enzyme’s catalytic cycle that can be used to inhibit or poison 
the enzyme from performing its function, and so is the case. One simple mode of inhibition 
is to inhibit a step early in the enzyme reaction cycle.54 For example, competitive inhibitors 
of ATP binding prevent strand passage and do not generate enzyme-mediated DNA 
damage.54 Similar effects would occur with inhibitors that prevent the binding of topo II to 
DNA such as aclarubicin.54 Agents that prevent DNA cleavage by topo II such as merbarone 
would also be expected to act as simple catalytic inhibitors.54 Although merbarone clearly 
prevents DNA cleavage by topo II, merbarone affects other targets besides topo II.54 A 
second mode of inhibition is blocking the catalytic cycle after DNA is cleaved but before DNA 
re-ligation.54 This mode of inhibition occurs for most currently used topo II targeting agents, 
including anthracyclines and epipodophyllotoxins, as well as for agents that target 
prokaryotic type II topoisomerases.54 These agents prevent enzyme turnover and are 
therefore poisons of catalytic activity. The most obvious effect of topo II poisons is the 
generation of high levels of topo II–DNA covalent complexes.54 Therefore, poisons generate 
DNA damage and interfere with many DNA metabolic events such as transcription and 
replication.54 Topo II can be inhibited after strand passage is completed but before ATP 
hydrolysis and dissociation of amino-terminal dimerization.54 Bisdioxopiperazines such as 
dexrazoxane (ICRF-187) inhibit both ATP hydrolysis and maintain the topo II structure as a 
closed clamp.54 As is the case with topo II poisons, bisdioxopiperazines inhibit topo II 
catalytic activity mainly by blocking enzyme turnover.54 Although these agents are 
frequently termed catalytic inhibitors, they leave topo II trapped on DNA and might 
interfere with DNA metabolism in a manner that may be analagous to topo II poisons.54 Wu 
and co-workers have recently reported a high-resolution DNA-topo-etoposide complex that 
gives significant insight into how the drug performs its function. It is conclusive proof that 
the drug blocks the catalytic cycle after DNA is cleaved but before re-ligation. The etoposide 
molecules in the resolved structure were bound between base pairs, immediately flanking 
the two cleaved scissile phosphates, with the drug’s polycyclic aglycone core (rings A to D) 
sitting between base pairs, and the glycosidic group and the E ring protruding toward the 
DNA major and minor grooves, respectively.56  The insertion of etoposide removes the 
stacking interaction between base pairs.56 The 3′-OH of the neighbouring nucleotide is held 
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~8 Å away from the enzyme-linked scissile phosphate, which effectively blocks relegation of 
the cleaved phosphodiester bond.56 Due to structurally mitigating factors beyond the scope 
of this work, it suffices to say that two etoposide molecules are needed to stabilise a 
double-stranded DNA break (Figure 1.4.2.5).56   
 
Figure 1.4.2.5: Crystal structure of topo II-DNA-drug complex redrawn from the co-
ordinates in PDB 3QX3. The topo II enzyme has been coloured in red, the DNA in blue 
and the drug, topotecan, has been rendered as pink spheres. Reproduced from reference 
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1.5 Drug-DNA interactions 
Since the elucidation of the three dimensional structure of DNA there has been a concerted 
effort in synthesis of small molecules that recognise and interact with it. Initially the field 
was dominated by the synthesis of organic small molecules. More recently, there has been 
significant interest in and development of, the synthesis of transition metal complexes that 
can recognise/target DNA. Since DNA is the blueprint for life, it stands to reason that by 
designing small molecules that interact with it, we may be able to gain access to and control 
the way it behaves. Once a small molecule binds to DNA it invariably leads to distortion of 
the double helix structure and the inhibition of cell replication through many different 
established mechanisms. Hence, these small molecules are used in the fight against cancer, 
where they prevent cell division in tumours. The ternary structure of DNA is quite complex 
with multiple localised regions that small molecules may interact with. There are also 
several other more complex DNA structures that arise during certain cell cycles, lending 
themselves as possible targets for DNA-drug interactions. The four main DNA-drug 
interactions that will be discussed further are: 
 DNA intercalation and insertion 
 DNA groove binding 
 DNA three-way junction binders 
 DNA cross linkers  
1.5.1 DNA intercalation and insertion 
Some of the most successful chemotherapeutics on the market today effect their action 
through DNA intercalation. Some examples of such drugs are the anthracyclines and 
quinolone alkaloids.49, 57, 58 In context with the work in this thesis, the focus will be centred 
on metal complexes. The most common form of DNA is the anti-parallel, right-handed 
double helix termed B-DNA. The structure is essentially two complementary linear 
fragments of DNA that assemble via hydrogen-bonding between nucleo bases, A with T and 
C with G, to form a double helical structure. There is a 3.4 Å rise per base while there are ten 
base pairs per helical turn. The base pairs collectively form a central, hydrogen-bonded π-
stack that runs parallel to the helical axis between the two strands of the sugar-phosphate 
backbone. Within the 3D helical structure of DNA there are two distinct grooves, a wide 
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major groove and a narrow minor groove. All of these structural characteristics can and 
have been exploited for molecular recognition. The target of intercalator-based small 
molecules and metal complexes is the vacant space between base pairs of DNA where they 
partially unwind DNA in order to insert between them (Figure 1.5.1.1 left). A major 
characteristic required for a DNA binding metal complex is, with few exceptions, that they 
must be kinetically inert, a requisite trait due to the paramount importance of stability.59 
Most of the complexes are d6 octahedral or d8 square-planar. In addition, most exhibit a 
rigid or mostly rigid three-dimensional structure and most contain planar aromatic fused 
ring systems able to π-stack with the DNA base pairs.59  
Another type of metal complex-DNA interaction is insertion (Figure 1.5.1.1 right). There are 
very few examples of these types of complexes in literature. The way in which these 
complexes interact with DNA is remarkably specific. They recognise DNA mismatch pairs 
such as CC and AC that are destabilised due to imperfect hydrogen bonding and insert their  
 
Figure 1.5.1.1: Crystal structures showing a rhodium intercalator, Δ-α-[Rh{(R,R)-
Me2trien}(phi)]3+ (where (R,R)-Me2trien = 2R,9R-diamino-4,7-diazadecane and phi = 
9.10-Diaminophenanthrene), left, and a rhodium inserter Δ-[Rh(bipy2chrysi]3+ (where 
bipy = 2,2'-bipyridine and chrysi = 5,6-chrysene quinone diimine), right, bound to DNA. 
Adapted from reference 58.59   
planar ligand between two intact base-pairs, ejecting the bases of a single base-pair, with 
their planar ligand acting as a π-stacking replacement in the DNA base stack.59 This 
remarkable specificity was achieved by simply replacing the DNA-interacting ligand with 
ligand that is slightly wider and too bulky to intercalate in the traditional manner.59    
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1.5.2 DNA groove binding 
As mentioned previously, DNA contains two structural motifs called the major and minor 
grooves. These motifs are the targets of a class of compounds labelled ‘groove binders’. 
They are generally longer single-chain molecules that are flexible and contain a sickle shape.  
Groove binding can occur via either the major groove or the minor groove. Most DNA 
proteins interact via the major groove, while small molecules (<1000 Da) generally interact 
with the minor groove.60 The minor groove is therefore recognised as a vulnerable site of 
attack for drugs since it is generally unoccupied.60 The advantage of groove binders is that 
they are able to recognise and bind to sequence-specific regions of DNA depending on their 
structural characteristics.60-62 The literature on groove binders is far more prevalent with 
organic molecules compared to that of metal complexes. Two well-known organic groove 
binders, Hoechst 33258 and Netropsin, are able to recognise and bind AT-rich sequences of 
DNA and can even compete with synthetic zinc-chelating peptides for binding sites on 
DNA.60-62 An example of a metal complex groove binder is Cu(phen)2 (where phen = 
phenanthroline).59 Groove binders have been known to inhibit topo I and II as their 
mechanism of action in effecting cell death.60, 61, 63 The crystal structure of Hoechst 33342 
bound to DNA via the minor groove was elucidated by Sriram and co-workers in 1992 and 
confirms that Hoechst 33342 binds DNA at the AATT region, as expected, and covers six 
base pairs (Figure 1.5.2.1).63   
 
Figure 1.5.2.1: Crystal structure of Hoechst 33342 bound to DNA via the minor groove 
redrawn from the co-ordinates in PDB 129D. DNA is coloured blue and Hoechst 33342 
is rendered as spheres and coloured pink.63 Molecular graphics generated with the 
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1.5.3 DNA three-way junction binders 
DNA junctions are unique branched structures that consist of several double strands of DNA 
that converge at a single point. Three-way junctions occur within DNA and RNA. In DNA they 
are formed transiently during replication and in RNA they are involved in biological 
functions such as splicing and translation. Metallo-supramolecular cylinders are a class of 
compounds that have the remarkable ability to recognise these three-way junctions. They 
generally comprise a chiral assembly of three ditopic bidentate ligands around two metal 
centres.64-66 Initially these metallo-supramolecular cylinders were synthesised in order to 
mimic zinc finger proteins that recognise DNA via the major groove, and indeed they were 
able to bind non-covalently to the major groove of DNA.66 It was then discovered that these 
metallo-supramolecular cylinders were also able to bind to the three-way junctions 
associated with cell replication (replication fork).64-67 Further development has shown them 
to have cytotoxic and anti-bacterial properties.64-67  Hannon and co-workers have been most 
active in this field and have reported the synthesis of iron and ruthenium supramolecular 
complexes that are highly cytotoxic three-way-junction binders and in particular have 
reported the crystal structure of an iron metallo-supramolecular cylinder bound to DNA 
three way junctions (Figure 1.5.3.1).64 
 
Figure 1.5.3.1: Crystal structure of an iron metallo-supramolecular cylinder (pink) non-
covalently bound to a DNA three-way junction (blue), left,  redrawn from the co-
ordinates in PDB 3FX8.64 Molecular structure of the iron metallo-supramolecular 
cylinder, right.  Molecular graphics generated with the UCSF Chimera package.51  
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1.5.4 DNA cross-linkers 
The nitrogen mustards and the cisplatin group of complexes belong to this class of 
compounds, both of which were discovered serendipitously. There are numerous types of 
organic DNA cross linkers, but the focus will be on cisplatin and its analogues. Cisplatin and 
its ability to inhibit cell growth was discovered by Rosenburg and co-workers while passing 
an alternating electric current through platinum electrodes in an electric cell containing 
Escherichia coli. They observed that the cells were not multiplying but rather growing into 
long spindle-like shapes. This prompted the development of cisplatin into one of the most 
successful anti-cancer drugs still being used today. The way in which cisplatin effects its anti-
cancer ability is through the formation of inter- and intrastrand crosslinks within the DNA 
helix. The majority of adducts formed are guanine(N7)-guanine(N7) and guanine(N7)-
adenine(N7) intrastrand crosslinks. In 1996 Lippard and co-workers elucidated a high 
resolution crystal structure of cisplatin bound to DNA (Figure 1.5.4.1). These intrastrand 
crosslinks distort the three dimensional structure of the DNA and prevent replication from 
occurring. There is, however, acquired resistance to cisplatin treatment in some cases and it 
is thought that DNA repair surveillance enzymes learn to recognise the distorted DNA 
structure and are able to co-ordinate the repair by excising the platinum-DNA adduct.  
 
Figure 1.5.4.1: Crystal structure of a cisplatin (pink) intrastrand crosslink within a DNA 
helix (blue) redrawn from the co-ordinates in PDB 1AIO.68 Molecular graphics 
generated with the UCSF Chimera package.51 
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1.6 Gold complexes and their applications in medicine 
1.6.1 Gold(I) complexes in medicine 
Traditionally gold(I) has been the choice oxidation state when working with gold since it is 
the most stable oxidation state. The most common use of gold(I) compounds is for the 
treatment of rheumatoid arthritis and skin diseases that have similar autoimmune 
responses to that of rheumatoid arthritis.69 Three of these compounds are aurothiomalate, 
aurothioglucose and auranofin (Figure 1.6.1.1). 
 
Figure 1.6.1.1: Chemical structures of gold(I) compounds for treatment of rheumatoid 
arthritis. 
Gold(I) complexes show potential anti-cancer, anti-parasitic and anti-viral properties.69-72 
One of the most recent and promising finds was that of Rackham et al., who describes a 
gold(I) phosphine complex that is selective towards breast cancer cells (Figure 1.6.1.2).73 
Some of the most promising attributes of gold complexes are the ability to administer them 
orally in daily doses, compared to similar acting drugs that have to be administered 
intravenously or intramuscularly. They are also active against cisplatin resistant cell lines.1, 69, 
74 The mechanism of action for gold complexes is, however, not very well understood. It is 
thought that gold(I) complexes localise in the mitochondria and therefore their apoptotic 
pathway is associated with that.73, 75 The general problem with gold(I) phosphine complexes 
is that they can be fairly toxic. Generally these side effects occur after bioaccumulation in 
the body. Gold(I) phosphines are known to affect skin, blood, kidneys as well as other 
organs. Other major side effects include proteinurie, thrombocytopenia or nephropathy.75 
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Figure 1.6.1.2: Chemical structure of Au(d2pypp)2]Cl. 
1.6.2 Gold(III) complexes in medicine 
Gold(III) is highly reactive and generally unstable to the reductive physiological 
environment.76 It is readily reduced to gold(I) or colloidal gold; hence the 
metallotherapeutic use of gold(III) compounds was overlooked in earlier years. Recently, 
there has been renewed interest in gold(III) because new ligands have been designed that 
are able to further stabilise the gold(III) centre. These ligands can be bi-, tri- or tetradentate, 
generally containing strong sigma donors such as nitrogen, oxygen or carbon atoms.75 
Because gold(III) is isoelectronic and isosteric with platinum(II), but less toxic, by using 
gold(III) compounds instead of platinum(II) compounds it is hoped that there will be fewer 
side effects associated with gold complexes than with the platinum complexes. There are 
numerous gold(III) complexes that have been described in the literature, many with 
potentially useful anti-cancer properties.1, 69, 70, 75, 77-79 The most common gold(III) complexes 
include chelates with polyamines, cyclams, terpyridines, phenanthrolines and DAMP (N-
benzyl-N,N-dimethylamine), dithiocarbamates and porphyrins.78 
GOLD(III)-DITHIOCARBAMATE COMPLEXES: 
The first gold(III) dithiocarbamate complexes were reported in 1964 by Blaauw et al., who 
reported the synthesis and properties of some simple dialkylgold(III) N,N-
dialkyldithiocarbamates (Fig 1.6.2.1 A).80 Recently Ronconi et al. have reported some new 
gold(III)-dithiocarbamate complexes (Fig 1.6.2.1 B). 
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Figure 1.6.2.1: Chemical structures of gold(III) dithiocarbamate complexes. 
The first paper relating gold(III) dithiocarbamates to medicine was in 1982, when Calis et al. 
reported a ‘Mossbauer study of gold(I) and gold(III) dithiolate complexes related to anti-
arthritic drugs’,81 but it wasn’t until 2005 that Giovagnini et al. reported on the cytotoxic 
properties of these compounds.76  Since then, there have been several papers and two 
patents published highlighting the effectiveness of these compounds as anti-cancer 
compounds.82, 83 
The choice of the dithiocarbamate ligands was not random; they were chosen to observe 
their effectiveness, or lack thereof, to inhibit nephrotoxicity without decreasing its anti-
cancer activity.78 The complexes were tested in vivo for their cytotoxic activity towards a 
range of human cancer cell lines. It was shown that complexes A (Figure 1.6.2.1, where X = 
Me and R = Cl or Br) and complexes B (Figure 1.6.2.1, where X = Me and R = Cl or Br) were 1-
4 times more cytotoxic than cisplatin and were able to a large extent to overcome both 
intrinsic and acquired resistance to cisplatin.78 Since there are two cis-chloride atoms bound 
to the gold center that may undergo hydrolysis, it was thought that these complexes may 
act in a similar way to that of cisplatin. The tests showed, however, that the gold(III) 
dithiocarbamate complexes may have different molecular targets to that of cisplatin, but 
were not enlightening of what these targets might be. Through a series of tests and assays 
against various strains of cancerous and non-cancerous human breast cells, Milacic et al. 
showed that the most likely mode of action of these gold(III) dithiocarbamate complexes is, 
as previously suggested, different to that of cisplatin.84 They suggest, with strong evidence, 
that the molecular target of these gold(III) dithiocarbamate complexes is the proteasome.84 
They further suggest that the complexes may affect the production of reactive oxygen 
species (ROS) which, in turn, delivers oxidative damage to the proteasome.84 This work 
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further indicated that the complexes modify mitochondrial functions as well, which leads to 
both apoptotic and non-apoptotic mechanisms.85 Of relative importance in this study was 
the identification that the oxidation state of the metal center was central to the success of 
the complexes.76, 84 The analogous gold(I) complexes (which happen to be binuclear as a 
result of their co-ordination geometry) were tested and found to be ineffective when 
compared to the gold(III) complexes.76, 84 These compounds still need to undergo pre-clinical 
in vivo tests and ultimately clinical trials, but the results are encouraging.         
GOLD(III)-DMAMP COMPLEXES: 
Gold(III) dmamp-type complexes and their biological activities are well studied and are 
prominent in the literature.86-109 The first report of them was in 1984 when Vicente et al. 
described a series of these compounds in ‘2-[(Dimethylamino)methyl]phenylgold(III) 
complexes’.106 Again it wasn’t until later in the 90’s that their biological behaviour was 
investigated. Parish et al. synthesised two gold(III)-dmamp complexes (Figure 1.6.2.2) and 
tested for their anti-bacterial and anti-tumour activity as well as their reactivity towards 
some biomolecules.88 
 
Figure 1.6.2.2: Chemical structures of [AuCl(dmamp)], (A) and [Au(O2CMe)(dmamp)], 
(B).  
[AuCl(dmamp)] showed similar anti-tumor activity to that of cisplatin, but its anti-bacterial 
activity was not high.101 The lack of anti-bacterial activity was attributed to its insolubility in 
water, hence the synthesis of [Au(O2CMe)(dmamp)], which showed a marked improvement 
in solubility as well as its anti-tumour and anti-bacterial activity.101 Parish et al. reported 
that [Au(O2CMe)(dmamp)] demonstrated promising selectivity towards gram-positive 
bacteria and cancerous Chinese hamster ovary cells.101 Evidence was also found for an 
inherent binding preference of such complexes to sulfur-containing biomolecules, such as 
cysteine and glutathione.101 A similar, but more in-depth, study was published by Buckley et 
Introduction 
31 | P a g e  
 
al. also in 1996 that tested the anti-tumour activity of compounds [AuCl(dmamp)] and 
[Au(O2CMe)(dmamp)] as well as three other derivatives, where the chloride ions were 
replaced with thiocyanate [Au(SCN)(dmamp)], oxalate [Au(Ox)(dmamp)] and  malanato 
[Au(Mal)(dmamp)] ions.88 All the compounds were tested in vivo as well as in vitro against a 
number of human tumour xenograft models.88 [Au(O2CMe)(dmamp)] and 
[Au(Mal)(dmamp)] showed similar, if not better, activity than cisplatin. It was also observed 
that in some cases they were active against cisplatin resistant cell lines.88 Flow cytometry 
results indicated that, unlike cisplatin, [Au(SCN)(dmamp)] was not cell cycle specific, and 
plasmid mobility results showed that [Au(SCN)(dmamp)] and [Au(Mal)(dmamp)] interact 
with DNA (Figure 1.6.2.3), but significantly less than that of cisplatin.88 Both of these results 
indicate that the gold(III) complexes behave mechanistically different to that of cisplatin.  
 
Figure 1.6.2.3: Photographs of electrophoresis gels showing the changes in mobility of 
the RF I (upperband) and RF II (lowerband) forms of the Col E1 plasmid after treatment 
with [Au(SCN)(dmamp)] (left) and cisplatin (right). Left (from left to right): 
[Au(SCN)(dmamp)] at 75, 150, 300, 600, and 1500 μM and plasmid control. Right (from 
left to right): cisplatin at 6.25, 9.4, 18.8, 37.5, 50, 75, and 100 μM and plasmid control. 
Adapted from ref 87.88 
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Since then there have been a series of papers describing various derivatives of the gold(III) 
dmamp system and their biological activities.89, 92, 93, 96, 97, 110 Some of the most promising 
results were obtained by Dinger et al. who describes a series of thiosalicylate and salicylate 
complexes (Figure 1.6.2.4), which all exhibit IC50 values in the ng mL
-1 range. Of particular 
interest was the methoxy-derivatised thiosalicylate complex, which exhibited an IC50 value 
of 301 ng mL-1.91 
 
Figure 1.6.2.4: Chemical structures of thiosalicylate and salicylate gold(III) derivatives 
synthesised by Dinger et al.91 
The class of gold(III) dmamp compounds, in general, seems to show anti-cancer activities 
close to, if not better, than that of cisplatin as well as in some cases anti-microbial activity. 
The activity of these compounds appears to be related to their solubility with the more 
soluble complexes being more active than the less soluble ones in general.        
GOLD(III) PORPHYRIN COMPLEXES: 
Porphyrins date back to the earliest of civilizations and were generally used as a purple 
pigment in fabric dyes. They were extracted from sea molluscs and used to dye the robes of 
royalty and priests. Gold(III) porphyrins are well documented in the literature.2, 111-117 In 
1983 Kessel et. al. reported on the phenomena that porphyrins seem to localise in cancer 
cells,118 but it was not until 2003 that Che et. al. reported on the possibility that gold(III) 
porphyrins could potentially be used as anti-cancer agents.2 Che’s group has since reported 
several articles on gold porphyrins and their anti-cancer effects.119  The most common type 
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of porphyrin used to chelate the gold(III) centre is based on meso-tetraphenylporphyrin 
(Figure 1.6.2.5). The stability of gold(III) porphyrins in typical organic solvents as well as in 
the presence of some typical biological reducing agents has been well studied, particularly 
for the original gold(III) meso-tetraphenylporphyrin [Au(TPP)+] where TPP = 5,10,15,20-
tetraphenylporphyrin dianion.2, 119 
 
Figure 1.6.2.5: Chemical structures of cytotoxic gold(III) porphyrin complexes reported 
by Che et al.2 
Che et al. have shown that [Au(TPP)+] is stable in phosphate-buffered saline (PBS) and Tris-
buffered saline (TBS) containing 5% DMSO. Using UV-vis spectroscopy there was less than 
5% change in absorbance in each of the solutions over a period of 48 hrs.2 [Au(TPP)+] was 
also tested against reduction to gold(I) or colloidal gold by glutathione by NMR and UV-vis 
spectroscopy, both of which indicated no such action.2 The stability of gold(III) complexes in 
solution seems to be related to their biological activity, therefore understanding their 
solution stability, or lack thereof, will facilitate decoding their mechanism(s) of action. 
[Au(TPP)+] was tested in vitro, by means of MTT assay, against a panel of human cancer cell 
lines. The results showed that it was active against most of the cell lines it was screened 
against, with IC50 values ranging between 0.11 and 0.73 μM.
2, 120, 121 Most importantly, it was 
shown that [Au(TPP)+] was equally toxic towards cisplatin-resistant cell lines, having IC50 
values in the 0.15 μM range. This corresponds to a 200-1600 times greater efficacy than that 
of cisplatin.2, 120, 121 Che et al. also did a comparative test on the cytotoxic effects of 
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[Au(TPP)+] against healthy human cells and cancerous human cells. The tests showed that it 
was 10-fold more cytotoxic towards cancerous cells than towards healthy cells.120 
The presence of the gold(III) ion was proven to be critical to the in vitro anti-cancer activity 
of [Au(TPP)+], as the analogous zinc complex was 110 times less cytotoxic and the free gold 
salts K[AuCl4] and [nBu4N][AuCl4] were 30-90 times less cytotoxic.
120 It was therefore 
proposed that ‘[Au(TPP)+] acts as a stable lipophilic planar cation for binding to bio-
molecular target(s) through non-covalent interactions’, the exact targets are however 
unknown.79, 120 In the presence of serum proteins several studies have shown that certain 
metal-based drug’s exhibit diminished activity, including that of cisplatin.122, 123 [Au(TPP)+] 
was tested for its cytotoxicity in the presence of fetal bovine serum and was shown to be 
unaffected, whereas cisplatin’s cytotoxic activity was significantly reduced.124 The in vivo 
anti-cancer properties of [Au(TPP)+] were also established against various nasopharyngeal 
carcinoma cells.125 [Au(TPP)+] effectively suppressed tumor growth after treatment of 3 
mg/kg week.79, 120 No significant side effects or weight loss were observed in the treated 
animals (Figure 1.6.2.6).  
 
Figure 1.6.2.6: In vivo anti-cancer activity of [Au(TPP)+] toward nasopharyngeal 
carcinoma cells. Adapted from reference 78.79  
It was also proven by confocal microscopy that gold(III) porphyrin complexes induce 
apoptosis in cancerous cells and not necrosis (Figure 1.6.2.7). This is very important as 
necrosis triggers inflammatory tissue reactions, and could be detrimental to the treated 
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patient’s health. Overall Che et al. have shown the possibility that gold(III) porphyrin 
derivatives could be developed into successful anti-cancer drugs. 
 
Figure 1.6.2.7: Laser confocal micrographs of the HeLa cells treated with [Au(TPP)+] 
(0.5 μM) at time intervals of (a) 0 h and (b) 15 h. Healthy cells are marked by a yellow 
circle and apoptotic cells are marked by a red circle. Reproduced from ref 2.2  
 
GOLD(III) PHEN, BIPY, TERPY, AND VARIABLE CYCLOMETALLATED COMPLEXES: 
There have been several reports in the literature on the cytotoxicity of the above mentioned 
gold(III) complexes and their derivatives.126-129 Some selected examples of these compounds 
are shown below (Figure 1.6.2.8). The complexes [Au(bipy)Cl2]Cl and [Au(bipy
c-H(OH)](PF6) 
were tested for their cytotoxicity by Marcon et al. in 2002. Their activity towards various 
cisplatin-resistant and non-resistant, cancerous cell lines was investigated. Their results 
showed that [Au(bipyc-H(OH)](PF6) was the most cytotoxic of the two, but with both 
compounds having IC50 values in the low μM range.
128 Both compounds were more active 
than cisplatin. Their interaction with DNA was also investigated by electronic spectroscopy 
and circular dichroism (CD) spectroscopy; some evidence for the compounds interacting in 
some way with DNA was obtained.128 
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Figure 1.6.2.8: Chemical structures of various gold(III) complexes.  
The gold(III) complexes of traditional metallointercalator ligands phen and terpy were also 
assessed for their biological activity by Messori et al. in 2000.129 They were tested against 
the A2780 ovarian human cancer cell line either sensitive (A2780/S) or resistant (A2780/R) 
to cisplatin. The results showed that both [Au(phen)Cl2]Cl and [Au(terpy)Cl]Cl2 were 
cytotoxic with [Au(terpy)Cl]Cl2 being the most cytotoxic (IC50 = 0.2 μM) and both showing 
activity towards the cisplatin-resistant cell line.129 The free ligands were then also assessed 
for their cytotoxicity and, interestingly, it was found that they possessed close to, if not 
equal, cytotoxicity to that of the metal complex.129 Therefore the cytotoxicity of the 
complex cannot be solely attributed to the metal and more detailed investigations need to 
be completed in order for these systems to be completely understood. The complex 
[Au(C^N^C)]Cl, first synthesised by Che et al. in 1998, and was tested for its cytotoxic 
properties in 2006, again by Che et al.127, 130 It was tested against four cell lines, namely 
HeLa, HepG2, SUNE1 and CNE1 with IC50 values of 3.4, 17, 4.0, 3.1 μM respectively. Again 
the activity of [Au(C^N^C)]Cl was comparable to that of cisplatin.127, 130 Overall the 
compounds in Figure 1.6.2.8 are mostly cytotoxic with [Au(bipyc-H(OH)](PF6) being the most 
active.   
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GOLD(III) AMINE AND IMINE COMPLEXES: 
Gold(III) amine complexes include complexation with alkyl amines such as en and dien as 
well as some macrocyclic polyamines.131-133 There have been three biological studies that 
have involved the basic complexes [Au(cyclam)](ClO4)2Cl, [Au(en)2]Cl3, [Au(dien)Cl]Cl2, 
(Figure 1.6.2.9).126, 129, 134 
 
Figure 1.6.2.9: Chemical structures of [Au(cyclam)](ClO4)2Cl (left), [Au(en)2]Cl3 
(middle) and [Au(dien)Cl]Cl2 (right). 
All three studies tested these three compounds against the A2780 ovarian human cell line 
either sensitive (A2780/S) or resistant (A2780/R) to cisplatin. The first study completed by 
Carotti et al. in 1998 showed that [Au(en)2]Cl3 and [Au(dien)Cl]Cl2 were active against both 
A2780/S ([Au(en)2]Cl3 IC50 = 8.4 μM, [Au(dien)Cl]Cl2 IC50 = 8.2 μM) and A2780/R ([Au(en)2]Cl3 
IC50 = 17 μM, [Au(dien)Cl]Cl2 IC50 = 18.7 μM ) cell lines.
134 [Au(cyclam)](ClO4)2Cl was found to 
be essentially non-cytotoxic towards these cell lines.134 These results were confirmed in 
2000 by Messori et al. who further investigated these compounds.129 These workers tested 
the free ligands of the complexes [Au(cyclam)](ClO4)2Cl, [Au(en)2]Cl3 and [Au(dien)Cl]Cl2 
against the same cell lines. The free ligands were ineffective in their cytotoxic properties, 
hence the cytotoxic action of [Au(en)2]Cl3 and [Au(dien)Cl]Cl2 can be directly attributed to 
the presence of the gold(III) centre.129 
There have only been two gold(III) salen complexes reported in the literature by Barnholtz 




38 | P a g e  
 
 
Figure 1.6.2.10: Chemical structures of [Au(sal2en)](PF6) (left) and 
[Au(sal2pn)]Cl·2.5H2O (right). 
Only recently in a review has there been mention of these gold(III) salen complexes and 
their biological activity. Che et al. reported that these complexes, like the bis(amides), 
below, have limited stability in solution, with an approximately 10% reduction in absorbance 
over a short period of 4 hours compared to [Au(TPP)+] which showed a less than 5% 
reduction in absorbance over 48 hours.135 These complexes also showed instability towards 
the reducing agent glutathione, with almost instant changes in the electronic absorption 
spectrum upon the addition of glutathione.135 Notwithstanding this redox instability, the 
complexes still had appreciable cytotoxicities (IC50 values in the 10-30 μM range).
135 
1.7 Bis(amide) and mono(amide) ligands and metal complexes 
The goal of this work was to synthesise a range of known as well as novel N,N'-bis(amide) 
and N-mono(amide) ligands and chelate them to gold(III) (Figure 1.7.1). Ligands of this 
nature are known in the literature and have been used for a variety of diverse functions. The 
general structure of the N,N'-bis(amide) ligand comprises a set of heteroaromatic (pyridine 
or quinoline) rings which are joined through a di(amide) linkage, which too can be varied. 
The N-mono(amide) ligands consist of two heteroaromatic or non-heteroaromatic 
substituents linked via an amide bond to form bidentate or tridentate ligands.  
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Figure 1.7.1: Chemical structures and naming scheme of the ligands used in this work.  
In general, co-ordination of this class of compounds to a metal centre is accompanied by 
deprotonation of the amide N–H, so in the case of the N,N'-bis(amide) ligand, it becomes a 
tetradentate dianionic ligand, while the N-mono(amide) ligands become monoanionic 
bidentate or tridentate ligands. Since the amide is able to form a hybrid resonance structure 
(Figure 1.7.2), the deprotonation of the amide N–H is not always concomitant upon 
chelation to a metal centre and a suitable base is sometimes required during metallation. 
 
Figure 1.7.2: Resonance hybrid structure of a general amide bond.  
Metal chelates of both the N,N'-bis(amide) and N-mono(amide) ligands are present in the 
literature and have been used to investigate interesting molecular structures and their 
physical properties due to their ability to form dinuclear species136-139. They have also been 
used in the biological field as therapeutics and as imaging agents.140, 141 Specifically, gold(III) 
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amide chelates are not very prominent in the literature with only a few examples having 
been published. Yang et al. synthesised the first and only reported gold(III) mono-amide 
complex in 2003 and tested its reactivity towards 5’-GMP.142 They found by electrospray 
mass spectrometry (ESMS) that their compound was able to form bis-GMP adducts.142 Che 
et al. have synthesised a number of bis(amide) complexes.2, 79, 143 They have reported the 
synthesis of a gold(III) amide complex: [Au(HL)Cl2] (H2L = 2,2'-bis(2-pyridylcarboxyamide)-
1,1'-binaphthyl) (Figure 1.7.3). In this complex the gold centre has only chelated to the one 
half of the tetradentate ligand along with two chloride ions to complete the square planar 
geometry, thus leaving a free amide moiety that is non-bound (Figure 1.7.3).143 
 
Figure 1.7.3: Diagram of [Au(HL)Cl2] (H2L = 2,2'-bis(2-pyridylcarboxyamide)-1,1'-
binaphthyl). 
It was assumed that because of the steric hindrance between H-atoms of the binaphthyl 
bridge, the ligand was not able to support the square planar geometry required by the 
gold(III) centre, and hence the structure above is favoured. It will be shown in this work that 
this may partly be the case, in conjunction with intrinsic properties of bis(amide) ligands 
that evidently detract from co-ordination of two pyridyl-amide moieties to gold(III). A recent 
review by Che reported some tetradentate chelates of the bis(amide) ligand system, 
including a discussion of their biological activities (Figure 1.7.4). From the four compounds 
shown, only two of them have appreciable cytotoxicities (A and B). Complex B showed 
similar cytotoxicity to the following literature compounds: [Au(en)2] [IC50 (human ovarian 
carcinoma A2780, 48 h) = 8.4 μM];66 [Au(esal)]Cl2 [IC50 (human ovarian carcinoma A2780, 72 
h) = 2.1 μM;74 [AuCl2(dmamp)] [IC50 (human colon carcinoma SW620, 72 h) = 50 μM],
26 and 
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Na[AuCl4] [IC50 (human ovarian carcinoma A2780, 72 h) = 11 μM],
129 while complex A 
showed cytotoxicity towards SUNE1 cells (IC50 = 21.1 μM).
 The compounds have only been 
tested against a small range of cells and further studies are warranted.79 Complex B is again 
fairly unstable to reduction by common biological reducing agents such as glutathione; a 
10% reduction in absorbance was noted over a period of 4 hours compared to [Au(TPP)+], 
which showed a less than 5% reduction in absorbance over 48 hours.79 
 
Figure 1.7.4: Chemical structures of bis(amide) gold(III) complexes. 
In 2003 there were two reports published on the chelation of gold(III) with picolinamide to 
form the complex  [Au(pla)Cl2], where pla = picolinamide.
144, 145 The first was by Fan et al.144 
who reported “Chemical and biological studies of gold(III) complexes with uninegative 
bidentate N–N ligands”. In this study, the cytotoxic properties of the complex against MOLT-
4 (human leukemia) and C2C12 (mouse tumour) cell lines were determined as, 3.1 and 8.0 
µM, respectively.144 In a study published not more than a week later, Hill and co-workers 
reported a gold-197 Mossbauer study on the same complex. More recently Cinellu and co-
workers reported on the synthesis and reactivity of chiral pyridinyl–oxazoline ligands co-
ordinated to gold(III).146 This prompted a study by Maiore et al., published in 2012, focusing 
on the biological properties of these complexes. They investigated their solution stability, 
interaction with horse cytochrome c and their anti-proliferative profiles against human 
ovarian cancer cell lines A2780R (cisplatin resistant) and A2780S (cisplatin susceptible). They 
found that the complexes were stable at least for a few hours, were able to form adducts 
with horse cytochrome c and in general were active against the cell lines tested.147 
In 2003, Yang and co-workers published an article on three 8-aminoquinoline based gold(III) 
amide complexes (Figure 1.7.5). They reported that these compounds were highly cytotoxic 
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against the cell lines B16-BL6, P388, HL-60, A-549 and BEL-7402 and tentatively suggested 
they may be able to intercalate DNA.3 The data from this paper are, however, compromised 
by the lack of experimental DNA binding constants or IC50 values.   
 
Figure 1.7.5: Chemical structures of the complexes synthesised by Yang et al.3 
The cytotoxic gold(III) complexes in Yang et al.'s report underpin our interest in this class of 
tridentate complexes and we hypothesised that by derivitising this class of compounds 
through functional group changes, extending or removing aromaticity, and/or including 
hydrogen bonding groups we might be able to develop a wider group of cationic gold(III) 
complexes with enhanced cytotoxicity towards human cancer cell lines. A full and more 
complete investigation into this class of compounds has been undertaken in this thesis. 
In December 2011, after the synthesis and characterisation work of this project was 
complete, a patent was published by Wang et al. directly pertaining to a class of gold(III) 
compounds to be presented in this thesis (Figure 1.7.6).148 Since the intention of this thesis 
is not to seek a patent on the 8-aminoquinolylamide gold(III) chelates, for which prior art 
exists, but to investigate structure-activity relationships and the physical and biological 
properties of numerous compounds falling into this promising group of compounds, the 
patent by Wang and co-workers corroborates the general importance of the compounds 
studied in this work. Moreover, we have been able to structurally characterise the patented 
gold(III) complexes and have thereby obtained heretofore unprecedented data crucial to 
outlining any structure-based mechanism of action for these and related compounds.  
 
Figure 1.7.6: Chemical structures of the compounds relating to the recent patent.   
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1.8 Objectives 
The field of metallodrug discovery is becoming increasingly competitive and popular with 
several compounds in recent times earmarked for commercialisation as chemotherapeutic 
agents as well as diagnostics. Some examples are the ruthenium-based compounds NAMI-A 
and KP1019 (Figure 1.8.1) which are currently under investigation in clinical trials.149  
 
Figure 1.8.1: Chemical structure of the ruthenium-based anti-cancer agents NAMI-A 
and KP1019 which are currently undergoing clinical trials.  
As a consequence of the similar chemical properties between platinum(II) and gold(III), 
investigations into the use of gold(III) complexes have become more prominent in the 
literature and have resulted in some promising candidates such as the gold(III) porphyrin 
complex [Au(TPP)+]. Therefore, the holistic objective of this project is to further the 
investigation of gold(III) compounds and their potential use as anti-cancer agents. With this 
view the specific objectives of the project are:    
1) To synthesise the proposed range of N,N'-bis(amide) and N-mono(amide) ligands 
and characterise them fully via 1H and 13C NMR, infra-red and mass spectrometry.  
2) To investigate and fully understand the chelation of gold(III) to the proposed ligands. 
3) To analyse and fully characterise the metal chelates by 1H and 13C NMR, infra-red, 
mass and UV/visible spectrometry. 
4)  To analyse the metal chelates in the solid state by single crystal X-ray 
crystallography. 
5) To perform computational studies on the metal chelates using density functional 
theory to delineate their gas phase structures and properties and to compare these 
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with appropriate experimental data in order to determine the precision of the 
calculations. 
6) To determine, by spectroscopy, a series of biologically relevant parameters such as: 
octanol/water partition coefficients, DNA binding properties, stability in a 
physiologically representative medium such as a buffer as well as stability towards 
biomolecules such as glutathione and imidazole.  
7) To submit the complexes for cytotoxicity screening at the National Cancer Institute 
(NCI) in the USA and to analyse the cytotoxicity profiles of complexes proceeding to 
5-dose screens for cell-line specificity.  
8) To determine the possible mechanism of action of metal chelates proceeding to 5-
dose NCI cytotoxicity screens by statistical cluster analysis methods. To confirm the 
biological targets of lead drug candidates by standard enzyme-inhibition or other 
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2. Experimental 
2.1 General methods and instrumentation 
All reactions were carried out open to the atmosphere unless otherwise stated. All solvents 
used were either dry or of high purity. Pyridine, methanol and nitromethane were 
Chromosolve® HPLC grade solvents, used as received from Aldrich. THF and DCM were 
distilled over calcium hydride. All reagents were used as received from Aldrich unless 
otherwise stated. Gold pellets were received as a loan from Mintek as part of project AuTEK 
Biomed. 
Electronic spectra were recorded with a Schimadzu UV-1800 (fixed slit width = 1 nm) 
spectrophotometer using varying solvents in 1.0 cm pathlength quartz cuvettes.  IR spectra 
were obtained on a Bruker Alpha spectrometer (36 scans, spectral resolution = 1.0 cm-1) 
with an ATR platinum Diamond 1 reflectance accessory for analysis of microcrystalline 
samples. 1H and 13C NMR spectra were recorded using saturated solutions in DMSO-d6, 
CD3CN or CDCl3 using either a 500 MHz Bruker Avance III spectrometer equipped with a 11.7 
T magnet and 5 mm BBO probe, or a 400 MHz Bruker Avance III spectrometer equipped 
with a 9.4 T magnet and 5 mm BBOF probe. The solvent signal was used as the reference. All 
spectra were recorded at 303.15 K unless otherwise stated.  The proton and carbon NMR 
spectra were assigned using 2D COSY data, with the help of HSQC and HMBC data where 
needed. High resolution masses were recorded by direct injection into a Waters Acquity-LCT 
Premier mass spectrometer using electrospray ionisation in either positive or negative 
mode. Emission spectra were recorded on a Photon Technologies Int. (PTI) fluorescence 
spectrometer controlled by PTI‘s Felix32© Version 1.1 software. Steady state emission 
spectra were recorded using PTI‘s XenoFlash™ 300 Hz pulsed light source. Detection was by 
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2.2 Synthesis of 3-Aroyl-2-pyridinecarboxylic acid precursors, APC1, APC2, APC3. 
 
Figure 2.2.1: labelling scheme used for aroyl-2-pyridinecarboxylic acids. 
 A modified procedure of Youssef1 and co-worker’s procedure was used, whereby; 
anhydrous aluminium chloride (4.00 g, 30.0 x 10-3 mol) was added to a stirred mixture of dry 
aromatic substrate (10 mL) and quinolinic anhydride (1.00 g, 6.70 x 10-3 mol). The reaction 
mixture was then heated to 80 °C for 4-5 h after which the formed complex was 
decomposed with conc. HCl to form a clear solution. The solution was then placed on ice 
while 10 mL of ice-water was added and the mixture stirred vigorously until a cream/white 
coloured precipitate had formed. The precipitate was collected by vacuum filtration and 
allowed to air dry before characterisation. APC1: 1H NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 
8.83 (d, 1H); 7.99 (d, 1H); 7.74 (m, 3H), 7.65 (m, 3H); 7.52 (m, 2H); 4.32 (s, 1H). APC2: 1H 
NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 8.83 (d, 1H); 7.99 (d, 1H); 7.75 (m, 3H), 7.34 (m, 2H); 
4.48 (s, 1H). APC3: 1H NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 8.80 (d, 1H); 7.94 (d, 1H); 7.73 
(m, 1H), 7.63 (m, 2H); 7.04 (m, 2H); 4.77 (s, 1H); 3.83 (s, 3H). All other characterisation data 
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2.3 Synthesis of gold(III) metal precursors 
2.3.1 Synthesis of tetrabutylammonium tetrachloroaurate(III),  [Bu4N][AuCl4],  gold 
precursor 
Elemental gold (500 mg, 2.54 x 10-3 mol) was added to aqua regia (3 mL) and allowed to 
dissolve overnight. The solution was then stirred and heated to boiling while a further 2 mL 
of HCl (33%) was added. Heating was continued and the solution was allowed to evaporate 
to about 5% of the original volume before ultra-pure water (3 mL) was added. The solution 
was again allowed to boil and evaporate to about 5% of the original volume; this process 
was repeated until the vapours released were no longer acidic. The viscous aurochloric acid 
was then dissolved in ultra-pure water (100 mL), to which tertabutylammonium hydrogen 
sulphate (0.82 g, 2.54 x 10-3 mol) was added to form a yellow precipitate. The solid was 
extracted repeatedly with DCM. The DCM extract was then dried over anhydrous MgSO4 
and then evaporated to dryness to afford [Bu4N][AuCl4] as a yellow solid. 
2.3.2 Synthesis of potassium tetrachloroaurate(III), KAuCl4, gold precursor 
Hydrogen tetrachloroaurate(III) was prepared from gold pellets as described above. The 
viscous aurochloric acid was then dissolved in ultra-pure water/EtOH (2:8, 100 mL), to which 
KCl (0.189 g, 2.54 x 10-3 mol) was added. The solution was then stirred for 6 h after which 
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2.4 Synthesis of amide ligands 
2.4.1 General procedure for synthesis of bis(amide) ligands 
To a solution of  pyridine- or isoquinoline-3-carboxylic acid (1.624 x 10-2 mol) in dry pyridine 
(15 mL) was added diamine (8.122 x 10-3 mol) in pyridine (5 mL). The mixture was stirred for 
5 minutes during which a white precipitate formed. The mixture was then heated to 110 °C 
and triphenylphosphite (5.041 g, 1.624 x 10-2 mol) was added drop-wise and the mixture 
stirred at 110 °C for 4 h. 
2.4.1.1 N,N'-ethane-1,2-diyldipyridine-2-carboxamide, H2L1 
The solution was then allowed to cool and stand overnight, after which the product 
crystallised out of solution. The product was isolated by filtration and washed with 
diethylether (2 x 25 mL) and distilled water (2 x 25 mL) to obtain colourless clear crystals of 
H2L1. X-ray quality crystals were obtained by slow evaporation of a saturated solution of 
H2PyEt in DMSO. 
1H NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 8.56 (d, 2H, J = 4.41 Hz); 8.40 (s, 
2H); 8.21 (d, 2H, J = 7.76 Hz); 7.84 (t, 2H, J = 7.71 Hz); 7.43 (m, 2H); 3.77 (m, 4H). All further 
characterization data were in agreement with the relevant data in the literature.2 
2.4.1.2 N,N'-propane-1,3-diyldipyridine-2-carboxamide, H2L2 
The solution was then allowed to cool and 15 mL of chloroform added. This solution was 
then washed with distilled water (3 x 25 mL), followed by a saturated solution of sodium 
hydrogen carbonate (4 x 25 mL) and then again with distilled water (3 x 25 mL). The solution 
was then dried over anhydrous MgSO4, filtered and the solvent removed to leave a brown 
oil. The oil was taken up in a minimal amount of chloroform and added drop-wise to 
vigorously stirred ice-cold diethylether. The solution was then filtered and washed with 
diethylether (2 x 25 mL) and distilled water (2 x 25 mL) to obtain a cream solid. A solution of 
H2L2 in chloroform/diethylether (1 : 6) was allowed to slowly evaporate from a test tube to 
afford X-ray quality crystals.1H NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 8.55 (d, 2H, J = 4.80 
Hz); 8.41 (s, 2H); 8.21 (d, 2H, J = 7.79 Hz); 7.84 (t, 2H, J = 7.71 Hz); 7.41 (m, 2H); 3.60 (m, 4H); 
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2.4.1.3 N,N'-benzene-1,2-diyldiisoquinoline-3-carboxamide, H2L3 
The solution was then allowed to cool and stand overnight, after which the product 
precipitated out of solution. The product was then filtered and washed with diethylether (2 
x 25 mL) and distilled water (2 x 25 mL) to obtain a white powder. X-ray quality crystals were 
obtained by diffusion of diethyl ether into a saturated solution of H2QuPh in DCM. 
 
Figure 2.4.1.1: Numbering scheme employed for NMR characterisation of H2L3, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 65% (colourless crystals). TOF MS ES: m/z 419.1507 (calc, 419.1508), M+. IR 
(powder, cm1): 3337 (s, ν(N–H), R–NH–COR); 1689 (s, ν(CO), RNH–CO–R). 1H NMR (500 
MHz, DMSO-d6, 303.15 K) [δ, ppm]: 10.90 (s, 2H, g); 9.36 (s, 2H, a); 8.73 (s, 2H, f); 8.25 
(d, 4H, J = 9.0 Hz, e,b); 7.90 (ddd, 2H, J1 = 9.4 Hz, J2 = 4.3 Hz, J3 = 1.2 Hz, d); 7.87 (dd, 2H, 
J1 = 5.9 Hz, J2 = 3.6 Hz, h); 7.82 (ddd, 2H, J1 = 9.3 Hz, J2 = 4.3 Hz, J3 = 1.1 Hz c,); 7.33 (dd, 
2H, J1 = 6.0 Hz, J2 = 3.6 Hz, i). 
13C NMR (123 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 163.62 
(C-10); 152.13 (C-1); 143.76 (C-9); 135.91 (C-11); 132.01 (C-5); 131.67 (C-7); 129.92 (C-4); 
129.89 (C-2); 128.59 (C-3); 128.37 (C-6); 126.07 (C-12); 125.68 (C-13); 121.04 (C-8). 
 
Experimental 
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Figure 2.4.1.2: Fully labelled thermal ellipsoid view (50% probability surfaces) of the 
molecular structure of H2L3. All hydrogen atoms are shown as sticks. The four 
intramolecular hydrogen bonds present are rendered as a broken black line (N1···H100, 
2.23 Å; N1···N2, 2.681(2) Å; N1···H100–N2, 113(1)°; O2···H100, 2.14 Å; O2···N2, 
2.830(2) Å; O2···H100–N2, 137(2)°; O1···H12, 2.39 Å; O1···C12, 2.882(2) Å; O2···H100–
N2, 113(1)°; N4···H200, 2.26 Å; N4···N3, 2.684(2) Å; N4···H200–N3, 111(2)°. 
Chemical formula, C26H18N4O2; Mr, 418.44; crystal system, monoclinic; space group, P21/n 
temperature (K), 296 (2); a, b, c (Å): 5.7773 (2), 13.3867 (5), 26.7245 (9);  α, β, γ (°): 90, 
93.836 (3), 90; V (Å3), 2062.22 (13); Z, 4; radiation type, Mo Kα; μ (mm–1), 0.09; crystal size 
(mm), 0.60 × 0.20 × 0.10; Nm (number of measured refelctions), Ni (number of independent 
reflections), No (number of observed reflections with I > 2σ(I)): 21333, 4036, 3035;  Rint, 
0.038; R1, 0.049; wR(F
2), 0.138;  S, 1.06; Np (number of parameters), 297; Nres (number of 
restraints), 0; Δρmax, Δρmin (e Å
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2.4.2 General procedure for synthesis of mono(amide) N-donor ligands 
To a solution of pyridine-, isoquinoline-3- or isoquinoline-1-carboxylic acid (1.624 x 10-2 mol) 
in dry pyridine (15 mL) was added the relevant aryl or alkyl amine (1.624 x 10-2 mol) in 
pyridine (5 mL). The mixture was stirred for 5 minutes after which it was heated to 110 °C 
and triphenylphosphite (5.041 g, 1.624 x 10-2 mol) was added drop-wise and the mixture 
stirred at 110 °C for 4 h. 
2.4.2.1 N-(4-methoxyphenyl)pyridine-2-carboxamide, HL4 
The solution was then allowed to cool and stand overnight, after which the product 
crystallised out of solution. The product was then filtered and washed with diethylether (2 x 
5 mL) and distilled water (2 x 25 mL) to obtain colourless clear crystals of HL4. 1H NMR 
(400MHz, CDCl3, 303 K) [δ, ppm]: 9.92 (s, 1H); 8.62 (d, 1H, J = 4.79 Hz ); 8.31 (d, 1H, U, J  = 
7.80 Hz); 7.91 (t, 1H, J = 7.76 Hz); 7.71 (d, 2H, J = 9.02 Hz); 7.48 (m, 1H); 6.94 (d, 2H, J = 9.04 
Hz) 3.84 (s, 3H). All further characterisation data were in agreement with the relevant data 
in the literature.3 
2.4.2.2 N-(pyridin-2-ylmethyl)pyridine-2-carboxamide, HL5  
The solution was then allowed to cool and 15 mL of chloroform added. This solution was 
then washed with distilled water (3 x 25 mL), then with a saturated solution of sodium 
hydrogen carbonate (4 x 25 mL) and then again with distilled water (3 x 25 mL). The solution 
was then dried over anhydrous MgSO4, filtered and the solvent removed to leave a brown 
oil. 1H NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 8.94 (s, 1H); 8.58 (m, 2H); 8.21 (d, 1H, J = 7.83 
Hz); 7.83 (t, 1H, J = 7.73 Hz); 7.66 (t, 1H, J = 7.74 Hz); 7.42 (m, 1H); ); 7.35 (d, 1H, J = 7.83 Hz); 
7.20 (t, 1H, J = 5.01 Hz). All further characterisation data were in agreement with the 






58 | P a g e  
 
2.4.2.3 N-(pyridin-2-ylmethyl)isoquinoline-1-carboxamide, HL6 
To the solution was added 20 mL of EtOH and 10 mL of H2O and the flask stoppered and 
placed in the freezer overnight, after-which a microcrystalline product was isolated via 
vacuum filtration. 
 
Figure 2.4.2.1: Numbering scheme employed for NMR characterisation of HL6, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 62% (colourless crystals). TOF MS ES: m/z 286.0959 (calc, 286.0956), M+. IR 
(powder, cm1): 3298 (s, ν(N–H), R–NH–COR); 1646 (s, ν(CO), RNH–CO–R). 1H NMR (400 
MHz, CDCl3, 303.15 K) [δ, ppm]: 9.58 (d, 1H, J = 8.30 Hz, f); 9.06 (s, 1H, g); 8.60 (d, 1H, J = 
4.24 Hz, l); 8.50 (d, 1H, J = 5.52 Hz, a); 7.84 (m, 1H, c); 7.79 (d, 1H, J = 5.48 Hz, b); 7.71 
(m, 1H, e); 7.69 (m, 2H, d, k); 7.41 (d, 1H, J = 7.80 Hz, i); 7.21 (m, 1H, j); 4.87 (d, 2H, J = 
5.7 Hz, h). 13C NMR (100 MHz, CDCl3, 303.15 K) [δ, ppm]: 166.26 (C-10); 157.15 (C-12); 
149.21 (C-16); 148.27 (C-9); 140.41 (C-1); 137.39 (C-8); 136.90 (C-15); 130.43 (C-6); 
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2.4.2.4 N-(pyridin-2-ylmethyl)quinoline-3-carboxamide, HL7 
To the solution was added 20 mL of EtOH and 10 mL of H2O and the flask stoppered and 
placed in the freezer overnight, after-which, a microcrystalline product was isolated via 
vacuum filtration. 
 
Figure 2.4.2.2: Numbering scheme employed for NMR characterisation of HL7, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 58% (colourless crystals). TOF MS ES: m/z 286.0960 (calc, 286.0956), M+. IR 
(powder, cm1): 3349 (s, ν(N–H), R–NH–COR); 1652 (s, ν(CO), RNH–CO–R). 1H NMR (400 
MHz, CDCl3, 303.15 K) [δ, ppm]: 9.19 (s, 1H, a); 9.11 (s, 1H, g); 8.63 (s, 1H, f); 8.60 (d, 1H, 
J = 4.28 Hz, l); 8.02 (d, 1H, J = 7.72 Hz, e); 8.98 (d, 1H, J = 8.12 Hz, b); 7.75 (m, 1H, c); 7.68 
(m, 2H, d, j); 7.38 (d, 1H, J = 7.80 Hz, i); 7.20 (m, 1H, k); 4.86 (d, 2H, J = 5.72 Hz, h); 13C 
NMR (100 MHz, CDCl3, 303.15 K) [δ, ppm]: 165.07 (C-10); 157.13 (C-12); 151.2 (C-1); 
149.23 (C-16); 143.58 (C-9); 136.85 (C-14); 135.97 (C-7); 130.98 (C-4); 129.73 (C-2); 
128.81 (C-5); 128.11 (C-3); 127.63 (C-6); 122.32 (C-15); 122.01 (C-13); 120.42 (C-8); 44.83 
(C-11). 
2.4.2.5 N-(quinolin-8-yl)pyridine-2-carboxamide, HL8 
To the solution was added 20 mL of H2O which afforded a light brown/cream coloured 
precipitate which was isolated by vacuum filtration and recrystallized from EtOH to afford 
pure HL8. 1H NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 10.65 (s, 1H); 9.00 (m, 1H); 8.67 (m, 
1H); 8.52 (m, 1H); 7.79 (m, 1H); 7.70 (m, 2H); ); 7.61 (m, 1H); 7.54 (m, 2H); 7.24 (m, 1H). All 
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2.4.2.6 5-butyl-N-(quinolin-8-yl)pyridine-2-carboxamide, HL9 
To the solution was added 20 mL of H2O which afforded a light brown/cream coloured 
precipitate which was isolated by vacuum filtration and recrystallised from EtOH to afford 
pure HL9.  
 
 
Figure 2.4.2.3: Numbering scheme employed for NMR characterisation of HL9, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 73% (colourless crystals). TOF MS ES: m/z 328.1427 (calc, 328.1426), M+. IR 
(powder, cm1): 3303 (s, ν(N–H), R–NH–COR); 2958, 2926, 2857 (s, ν(C–H), butyl chain); 
1676 (s, ν(CO), RNH–CO–R). 1H NMR (400 MHz, CDCl3, 303.15 K) [δ, ppm]: 12.22 (s, 1H, 
h); 9.00 (d, 1H, J = 8.32 Hz, n); 8.96 (m, 1H, i); 8.61 (s, 1H, a); 8.26 (d, 1H, J = 7.96 Hz, g); 
8.18 (d, 1H, J = 8.24 Hz, k); 7.71 (m, 1H, f); 7.58 (m, 2H, l, m); 7.47 (m, 1H, j); 2.73 (t, 2H, J 
= 8.24 Hz, b); 1.67 (m, 2H, c); 1.39 (m, 2H, d); 0.96 (t, 3H, J = 7.32 Hz, e). 13C NMR (100 
MHz, CDCl3, 303.15 K) [δ, ppm]: 162.98 (C-10); 148.75 (C-1); 148.62 (C-18); 148.31 (C-
11); 141.31 (C-9); 139.31 (C-19); 137.14 (C-7); 136.32 (C-14); 134.58 (C-15); 128.19 (C-2); 
127.37 (C-17); 122.18 (C-8); 121.87 (C-16); 121.55 (C-13); 116.93 (C-12); 33.02 (C-6); 
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2.4.2.7 N-(quinolin-8-yl)isoquinoline-1-carboxamide, HL10 
To the solution was added 20 mL of H2O which afforded a light brown/cream coloured 
precipitate which was isolated by vacuum filtration and recrystallised from EtOH to afford 
pure HL10.  
 
Figure 2.4.2.4: Numbering scheme employed for NMR characterisation of HL10, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 80% (colourless crystals). TOF MS ES: m/z 322.0955 (calc, 322.0956), M+. IR (powder, 
cm1): 3272 (s, ν(N–H), R–NH–COR); 1671 (s, ν(CO), RNH–CO–R). 1H NMR (500 MHz, CDCl3, 
303.15 K) [δ, ppm]: 12.42 (s, 1H, g); 9.69 (m, 1H, f); 9.07 (dd, 1H, J1 = 7.57 Hz, J2 = 1.32 Hz, 
h); 8.97 (dd, 1H, J1 = 4.22 Hz, J2 = 1.67 Hz, m); 8.71 (d, 1H, J = 5.50 Hz, a); 8.23 (dd, 1H, J1 = 
8.22 Hz, J2 = 1.52 Hz, j); 7.91 (m, 1H, c); 7.89 (m, 1H, b); 7.75 (m, 2H, d, e); 7.65 (m, 1H, l); 
7.59 (m, 1H, k); 7.51 (m, 1H, i). 13C NMR (123 MHz, CDCl3, 303.15 K) [δ, ppm]: 164.32 (C-10); 
148.53 (C-11); 148.40 (C-18); 140.42 (C-1); 139.08 (C-19); 137.66 (C-9); 136.79 (C-14);  
134.58 (C-15); 130.64 (C-5 or 6); 128.82 (C-5 or 6); 128.30 (C-8); 127.77 (C-7); 127.52 (C-17); 
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2.4.2.8 N-(quinolin-8-yl)isoquinoline-3-carboxamide, HL11 
To the solution was added 20 mL of H2O which afforded a light brown/cream coloured 
precipitate which was isolated by vacuum filtration and recrystallised from EtOH to afford 
pure HL11.  
 
Figure 2.4.2.5: Numbering scheme employed for NMR characterisation of HL11, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 85% (colourless crystals). TOF MS ES: m/z 322.0958 (calc, 322.0956), M+. IR (powder, 
cm1): 3301 (s, ν(N–H), R–NH–COR); 1677 (s, ν(CO), RNH–CO–R). 1H NMR (400 MHz, CDCl3, 
303.15 K) [δ, ppm]: 12.46 (s, 1H, g); 9.39 (s, 1H, a); 9.09 (d, 1H, J1 = 8.14 Hz, h); 9.01 (d, 1H, J1 
= 4.20 Hz, m); 8.78 (s, 1H, f); 8.20 (d, 1H, J1 = 8.26 Hz, j); 8.09 (d, 1H, J = 7.84 Hz, e); 8.04 (d, 
1H, J = 8.08 Hz, b);  7.78 (m, 1H, c); 7.73 (m, 1H, d); 7.64 (m, 1H, l); 7.57 (m, 1H, k); 7.50 (dd, 
1H, J1 = 8.24 Hz, J2 = 4.20 Hz, i). 
13C NMR (100 MHz, CDCl3, 303.15 K) [δ, ppm]: 163.28 (C-10); 
151.58 (C-1); 148.73 (C-18); 144.36 (C-9); 139.42 (C-19); 136.25 (C-14); 136.11 (C-7); 134.71 
(C-15); 131.07 (C-4); 129.82 (C-2); 128.96 (C-5); 128.20 (C-3); 127.79 (C-6); 127.37 (C-17); 
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2.4.2.9 3-benzoyl-N-(quinolin-8-yl)pyridine-2-carboxamide, HL12 
To the solution was added 20 mL of H2O which afforded a light brown/cream coloured 
precipitate which was isolated by vacuum filtration and recrystallised from EtOH to afford 
pure HL12.  
 
 
Figure 2.4.2.6: Numbering scheme employed for NMR characterisation of HL12, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 69% (colourless crystals). TOF MS ES: m/z 376.1054 (calc, 376.1062), M+. IR (powder, 
cm1): 3289 (s, ν(N–H), R–NH–COR); 1664 (s, ν(CO), R–CO–R), 1579 (s, ν(CO), RNH–CO–R). 1H 
NMR (400 MHz, CDCl3, 303.15 K) [δ, ppm]: 12.17 (s, 1H, g); 8.97 (d, 1H, J = 4.24 Hz, m); 8.93 
(d, 1H, J = 4.72 Hz, a); 8.76 (d, 1H, J = 7.52 Hz, h); 8.18 (d, 1H, J = 8.26 Hz, k); 7.84 (m, 2H, d); 
7.80 (d, 1H, J = 7.70 Hz, c); 7.63 (dd, 1H, J1 = 7.66 Hz J2 = 4.74 Hz, b); 7.43-7.58 (m, 6H, e, f, i, 
j, l). 13C NMR (100 MHz, CDCl3, 303.15 K) [δ, ppm]: 195.16 (C-5); 161.50 (C-11); 149.09 (C-1); 
148.66 (C-19); 147.93 (C-10); 139.14 (C-20); 137.09 (C-4); 136.39 (C-17); 136.29 (C-3); 133.84 
(C-6); 133.15 (C-8, 9, 14, 15 or 18); 129.33 (C-7); 128.58 (C-8, 9, 14, 15 or 18); 128.09 (C-16); 
127.23 (C-8, 9, 14, 15 or 18); 125.88 (C-2); 122.29 (C-8, 9, 14, 15 or 18); 121.61 (C-8, 9, 14, 15 
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2.4.2.10 3-(4-fluorobenzoyl)-N-(quinolin-8-yl)pyridine-2-carboxamide, HL13 
To the solution was added 20 mL of H2O which afforded a light brown/cream coloured 
precipitate which was isolated by vacuum filtration and recrystallised from EtOH to afford 
pure HL9.  
 
Figure 2.4.2.7: Numbering scheme employed for NMR characterisation of HL13, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 60% (colourless crystals). TOF MS ES: m/z 394.0969 (calc, 394.0968), [(M+Na)+]. IR 
(powder, cm1): 3290 (s, ν(N–H), R–NH–COR); 1672 (s, ν(CO), R–CO–R), 1597 (s, ν(CO), RNH–
CO–R). 1H NMR (400 MHz, CDCl3, 303.15 K) [δ, ppm]: 12.19 (s, 1H, f); 8.97 (d, 1H, J = 4.18 Hz, 
l); 8.93 (d, 1H, J = 4.68 Hz, a); 8.74 (d, 1H, J = 7.52 Hz, g); 8.18 (d, 1H, J = 8.24 Hz, j); 7.86 (m, 
2H, d); 7.80 (d, 1H, c); 7.64 (m, 1H, b); 7.46-7.55 (m, 3H, h, i or k); 7.12 (m, 2H, e). 13C NMR 
(100 MHz, CDCl3, 303.15 K) [δ, ppm]: 193.64 (C-5); 165.73 (C-9, J = 254.71 Hz); 161.42 (C-11); 
149.22 (C-1); 148.75 (C-19); 147.88 (C-10); 139.25 (C-20); 136.77 (C-12); 136.27 (C-17); 
136.23 (C-3); 133.85 (C-4); 133.66 (C-5, J = 3.09 Hz); 131.85 (C-7, J = 9.50 Hz); 128.09 (C-16); 
127.19 (C-14, 15 or 18); 125.93 (C-2); 122.34 (C-14, 15 or 18); 121.64 (C-14, 15 or 18); 
117.28 (C-13); 115.77 (C-8, J = 22.01 Hz). 19F NMR (376 MHz, CDCl3, 303.15 K) [δ, ppm]: -
105.07 (m, 1F). 
Experimental 
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Figure 2.4.2.8: Fully labelled thermal ellipsoid view (50% probability surfaces) of the 
molecular structure of HL13. All hydrogen atoms are shown as sticks. The three 
intramolecular hydrogen bonds present are rendered as broken black lines (N1···H100, 
2.26 Å; N1···N2, 2.655(1) Å; N1···H100–N2, 109(1)°; N3···H100, 2.48 Å; N3···N2, 
2.640(1) Å; N3···H100–N2, 114(1)°; O1···H7, 2.32 Å; O1···C7, 2.918(1) Å; O1···H7–C7, 
121(1)°. 
Chemical formula, C22H14N3O2F; Mr, 371.36; crystal system, monoclinic; space group, P21/c 
temperature (K), 298 (2); a, b, c (Å): 11.4112 (6), 7.6790 (5), 20.2481 (12);  α, β, γ (°): 90, 
91.217 (5), 90; V (Å3), 1773.87 (18); Z, 4; radiation type, Mo Kα; μ (mm–1), 0.09; crystal size 
(mm), 0.40 × 0.20 × 0.40; Abs. correction, Multi-scan; Tmin, Tmax: 0.962, 0.981; Nm (number of 
measured refelctions), Ni (number of independent reflections), No (number of observed 
reflections with I > 2σ(I)): 18426, 5690, 1968;  Rint, 0.052; R1, 0.044; wR(F
2), 0.109;  S, 0.723; 
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2.4.2.9 3-(4-methoxybenzoyl)-N-(quinolin-8-yl)pyridine-2-carboxamide, HL14 
To the solution was added 20 mL of H2O which afforded a light brown/cream coloured 
precipitate which was isolated by vacuum filtration and recrystallised from EtOH to afford 
pure HPy8AmQ.  
 
Figure 2.4.2.9: Numbering scheme employed for NMR characterisation of HL14, black 
letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR signals. 
Yield, 71% (colourless crystals). TOF MS ES: m/z 406.1164 (calc, 406.1168), [(M+Na)+]. IR 
(powder, cm1): 3289 (s, ν(N–H), R–NH–COR); 1664 (s, ν(CO), R–CO–R), 1579 (s, ν(CO), RNH–
CO–R). 1H NMR (400 MHz, CDCl3, 303.15 K) [δ, ppm]: 12.09 (s, 1H, g); 9.02 (d, 1H, J = 4.24 
Hz, m); 8.99 (d, 1H, J = 4.72 Hz, a); 8.59 (d, 1H, J = 7.70 Hz, h); 8.43 (d, 1H, J = 8.30 Hz, k); 
8.01 (d, 1H, J = 7.70 Hz, c); 7.86 (d, 2H, J = 7.74 Hz, b); 7.66-7.71 (m, 4H, d, j, l); 7.54 (m, 2H, 
e); 3.81 (s, 3H, f). 13C NMR (100 MHz, CDCl3, 303.15 K) [δ, ppm]: 193.36 (C-5); 163.67 (C-9); 
161.56 (C-12); 149.87 (C-1); 149.82 (C-19); 146.65 (C-11); 138.62 (C-13); 137.37 (C-4); 137.34 
(C-3); 137.20 (C-18); 133.76 (C-21); 131.70 (C-7, 15 or 18); 130.32 (C-6); 128.34 (C-17); 
127.57 (C-2); 127.45 (C-14); 123.11 (C-7, 15 or 18); 122.89 (C-7, 15 or 18); 116.46 (C-13); 
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2.4.3 General procedure for synthesis of mono(amide) C, N-donor ligands 
To a solution of acid chloride dissolved in dry THF was added a solution of 8-aminoquinoline 
in dry THF via cannula transfer under nitrogen atmosphere. The solution turned orange 
immediately and a precipitate started to form. The solution was stirred at room 
temperature overnight, after which it was washed with a saturated aqueous bicarbonate 
solution and extracted with 3 x 100 mL of chloroform. The organic phase was then isolated, 
dried over anhydrous magnesium sulphate, and its volume reduced to dryness in vacuo to 
afford the respective amide as a white solid. N-(quinolin-8-yl)benzamide, H2L15: 
1H NMR 
(400 MHz, CDCl3, 303 K) [δ, ppm]: 10.76 (s, 1H); 8.96 (d, 1H); 8.87 (d, 1H), 8.20 (d, 1H); 8.11 
(d, 2H); 7.55-7.62 (m, 5H); 7.49 (dd, 1H). All other characterisation were in agreement with 
literature.6  N-(quinolin-8-yl)napthamide, H2L16: 
1H NMR (400 MHz, CDCl3, 303 K) [δ, ppm]: 
10.45 (s, 1H); 9.09 (d, 1H); 8.76 (d, 1H), 8.57 (m, 1H); 8.20 (d, 1H); 8.02 (d, 1H); 7.94 (m, 2H); 
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2.5 Synthesis of gold(III) metal complexes 
2.5.1 General synthesis of cis-dichloro gold(III) chelates 
A solution of the relevant ligand (5.29 x 10-4 mol) in DCM (15 mL) was added to a solution of 
K[AuCl4] (5.29 x 10
-4 mol) in methanol (10 mL). This solution was then stirred while sodium 
acetate (6.00 x 10-4 mol) in methanol (10 mL) was added drop-wise, after which the reaction 
mixture was brought to reflux for 2 hours. The reaction mixture was then cooled to room 
temperature and allowed to stir overnight to afford an orange/red precipitate that was 
filtered off and washed with methanol (2 x 10 mL). 
2.5.1.1 ((Pyridine-2-ylcarbonyl){2-[(pyridine-2-ylcarbonyl)amino]ethyl}azanido) 
dichlorogold(III), [Au(HL1)Cl2]  
 
Figure 2.5.1.1: Numbering scheme employed for NMR characterisation of [Au(HL1)Cl2], 
black letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR 
signals. 
Yield, 72% (orange powder). TOF MS (ES): m/z 558.9976 (calc, 558.9979), [(M+Na) +]. UV-
vis (CH2Cl2) [λmax, nm (ε, M
-1 cm-1)]: 312 (5.1 x 103), 453 (1.6 x 102). IR (powder, cm-1): 
3360 (s, ν(N-H), R-NH-COR); 1645 (s, ν(CO), RNH-CO-R); 1602 (s, ν(CO), RN-CO-R).  1H 
NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.32 (d, 1H, J = 3.04 Hz, a); 8.88 (t, 1H, J = 
5.93 Hz, g); 8.56 (d, 1H, J = 2.04 Hz, k); 8.48 (t, 1H, J = 7.64 Hz, c); 8.03 (t, 1H, J = 6.82 Hz, 
b); 7.92 (m, 3H, d,h,i); 7.54 (m, 1H, j); 3.72 (t, 2H, J = 5.42 Hz, e); 3.57 (m, 2H, f).  13C NMR 
(100 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 171.66 (C-6); 164.73 (C-9); 150.60 (C-11); 
149.40 (C-10); 148.70 (C-5); 145.51 (C-1); 145.31 (C-3); 138.06 (C-2); 130.33 (C-4); 128.65 
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2.5.1.2 ((pyridine-2-ylcarbonyl){3-[pyridine-2-ylcarbonyl)amino]propyl}azanido) 
dichlorogold(III), [Au(HL2)Cl2]  
 
Figure 2.5.1.2: Numbering scheme employed for NMR characterisation of [Au(HL2) 
Cl2], black letters correspond to 1H NMR signals and blue numbers correspond to 13C 
NMR signals. 
Yield, 78% (orange powder). TOF MS (ES): m/z 573.0134 (calc, 573.0135), [(M+Na) +]. UV-
vis (CH2Cl2) [λmax, nm (ε, M
-1 cm-1)]: 310 (3.9 x 103), 449 (1.2 x 102). IR (powder, cm-1): 
3392 (s, ν(N-H), R-NH-COR); 1666 (s, ν(CO), RNHCO- R); 1643 (s, ν(CO), RN-CO-R). 1H 
NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.29 (d, 1H, J = 2.85 Hz, a); 8.81 (t, 1H, J = 
6.13 Hz, h); 8.61 (m, 1H, i); 8.50 (t, 1H, J = 7.72 Hz, b); 8.00 (m, 4H, c, d, k, l); 7.58 (m, 1H, 
j); 3.56 (m, 2H, e); 3.36 (m, 2H, g); 1.86 (m, 2H, f). 13C NMR (100 MHz, DMSO-d6, 303.15 
K) [δ, ppm]: 170.96 (C-6); 163.55 (C-10); 149.95 (C-15); 148.82 (C-11); 148.28 (C-5); 
145.03 (C-1); 144.91 (C-3); 137.77 (C-13); 129.82 (C-2); 128.18 (C-4); 126.34 (C-14); 















The same procedure as the rest of the complexes was adopted except instead of the 
product being isolated by filtration, the solution was allowed to evaporate to dryness from a 
beaker to afford AuL3 as well as by product. The mixture was then dissolved in DCM and the 
byproduct filtered off. The solution was layered in test tubes with diethylether to afford 
clean AuL3 as a dark red powder. X-ray quality crystals were obtained by slow diffusion of 
diethylether into a saturated solution of AuL3 in nitromethane.  
 
Figure 2.5.1.3: Numbering scheme employed for NMR characterisation of [Au(HL3) 
Cl2], black letters correspond to 1H NMR signals and blue numbers correspond to 13C 
NMR signals. 
Yield, 30% (dark red powder). TOF MS (ES): m/z 685.0463 (calc, 685.0472), M+. IR (powder, 
cm-1): 3324 (s, ν(N-H), R-NH-COR); 1697 (s, ν(CO), RNH-CO-R); 1622 (s, ν(CO), RN-CO-R). UV-
vis (CH2Cl2) [λmax, nm (ε, M
-1 cm-1)]: 240 (1.2 x 105), 247 (1.0 x 105), 297 (3.0 x 104), 326 (2.2 x 
104), 468 (2.9 x 103). 1H NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 10.85 (s, 1H, k); 10.33 
(s, 1H, a); 9.10 (s, 1H, q); 8.84 (m, 2H, e, f); 8.69 (s, 1H, l); 8.53 (d, 1H, J = 8.14 Hz, b); 8.48 (d, 
1H, J = 8.14 Hz, j); 8.29 (t, 1H, J = 7.75 Hz, c); 8.22 (s, 1H, J = 4.00 Hz, p); 8.13 (m, 2H, m, d); 
7.88 (t, 1H, J = 7.51 Hz, o); 7.78 (t, 1H, J = 7.63 Hz, n); 7.47 (m, 2H, h, g); 7.22 (t, 1H, J = 7.54 
Hz, i). 13C NMR (100 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 169.95 (C-10); 161.62 (C-17); 151.76 
(C-26); 150.37 (C- 1); 142.89 (C-18); 138.93 (C-5); 136.90 (C-9); 136.25 (C-16); 135.40 (C-11); 
134.90 (C-4); 133.80 (C-14); 131.98 (C-3); 131.65 (C-22); 131.27 (C-7); 129.93 (C-12); 129.59 
Experimental 
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(C-8); 129.51 (C-20); 129.27 (C-23); 128.64 (C-6); 128.60 (C-24), 128.11 (C-21); 127.88 (C-2); 
127.86 (C-25); 123.64 (C-13); 120.25 (C-19); 119.30 (C-15). 
2.5.1.4 {(4-Methoxyphenyl)(pyridine-2-ylcarbonyl)azanido}dichlorogold(III), [Au(L4)Cl2] 
 
Figure 2.5.1.4: Numbering scheme employed for NMR characterisation of [Au(L4)Cl2], 
black letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR 
signals. 
Yield, 69% (dark red powder). TOF MS (ES): m/z 494.9947 (calc, 494.9941), M+. IR (powder, 
cm-1): 2947, 3063, 3105 (s, ν(CH); OCH3) 1593 (s, ν(CO), RN-CO-R). UV-vis (CH2Cl2) [λmax, nm 
(ε, M-1 cm-1)]: 269 (1.8 x 104), 377 (9.7 x 103), 404 (6.5 x 103), 477 (6.3 x 103). 1H NMR (400 
MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.36 (d, 1H, J = 2.86 Hz, a); 8.55 (t, 1H, J = 7.73 Hz, c); 
8.09 (t, 1H, b); 8.08 (d, 1H, d); 7.20 (m, 2H, e); 6.91 (m, 2H, f); 3.78 (s, 3H, g). 13C NMR (100 
MHz, DMSO-d6, 303.15 K) [δ, ppm]: 169.83 (C-6); 158.26 (C-10); 148.26 (C-5); 144.98 (C-1); 
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2.5.2 General synthesis of N-donor aminomethyl-based tridentate gold(III) chelates 
K[AuCl4] (2.943 x 10
-4 mol) and the relevant ligand (2.943 x 10-4 mol) were dissolved in 25 mL 
ethanol and placed in a 50 mL round bottom flask and stirred. To this was added sodium 
acetate (2.943 x 10-4 mol) in 5 mL methanol and the solution brought to reflux for 4 h, after 
which a yellow precipitate was isolated by centrifugation and washed with 2 x 5 mL aliquots 
of methanol. The yellow precipitate was then added to a round bottom flask containing 
tetrabutylammonium chloride (3.100 x 10-4 mol) dissolved in DCM and the resulting 
suspension stirred for 3 h. The yellow precipitate was again collected by centrifugation and 
washed with 2 x 5 mL aliquots of DCM. The solid was then added to a test tube containing 
potassium hexafluorophosphate (3.100 x 10-4 mol) dissolved in acetonitrile and the solution 
heated until clear and then placed in a freezer at -20 °C for 15 minutes. The solution was 
then filtered to remove potassium chloride and precipitation was induced by addition of 
diethylether. The product was then isolated by centrifugation and washed with 2 x 5 mL 
portions of diethylether to afford the respective hexafluorophosphate salt of each complex. 
X-ray quality crystals were grown by vapour diffusion of diethylether into a saturated 
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2.5.2.1 (Pyridin-2-ylcarbonyl)(pyridin-2-ylmethyl)azanidogold(III) hexafluorophosphate(V), 
[Au(L5)Cl](PF6) 
 
Figure 2.5.2.1: Numbering scheme employed for NMR characterisation of 
[Au(L5)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 60% (yellow powder, based on gold). TOF MS (ES): m/z 444.0182 (calc, 444.0178), 
M+. IR (powder, cm-1): 1676 (s, ν(CO), RN-CO-R). UV-vis (MeCN) [λmax, nm (ε, M
-1 cm-1)]: 
224 (3.2 x 104), 256 (5.5 x 103), 317 (4.0 x 103). 1H NMR (400 MHz, CD3CN, 303.15 K) [δ, 
ppm]: 9.12 (d, 1H, J = 5.36 Hz, a); 9.08 (d, 1H, J = 5.72 Hz, i); 8.54 (m, 1H, c); 8.38 (m, 1H, 
g); 8.03 (d, 1H, J = 8.11 Hz, d); 8.00 (m, 1H, b); 7.89 (d, 1H, J = 8.00 Hz, f); 7.78 (m, 1H, h); 
5.36 (s, 2H, e). 13C NMR (100 MHz, CD3CN, 303.15 K) [δ, ppm]: 170.69 (C-8); 166.15 (C-6); 
152.53 (C-5); 148.91 (C-1); 148.58 (C-12); 146.21 (C-3); 144.47 (C-10); 131.03 (C-2); 
129.35 (C-4); 126.39 (C-11); 125.06 (C-9); 56.52 (C-7). 19F NMR (376 MHz, CD3CN, 303.15 


















Figure 2.5.2.2: Numbering scheme employed for NMR characterisation of 
[Au(L6)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 58% (yellow powder, based on gold). TOF MS (ES): m/z 494.0337 (calc, 494.0334), 
M+. IR (powder, cm-1): 1672 (s, ν(CO), RN-CO-R). UV-vis (MeCN) [λmax, nm (ε, M
-1 cm-1)]: 
226 (4.5 x 104), 247 (5.1 x 104), 301 (8.2 x 103). 1H NMR (500 MHz, CD3CN, 303.15 K) [δ, 
ppm]: 9.85 (d, 1H, J = 8.90 Hz, f); 9.13 (t, 1H, J = 5.53 Hz, k); 9.07 (t, 1H, J = 6.55 Hz, a); 
8.42 (d, 1H, J = 6.55 Hz, b); 8.40 (m, 1H, i); 8.29 (d, 1H, J = 6.55 Hz, c); 8.19 (m, 1H, d); 
8.11 (m, 1H, e); 7.93 (d, 1H, J = 8.15 Hz,  h); 7.80 (m, 1H, j); 5.42 (s, 2H, g). 13C NMR (123 
MHz, CD3CN, 303.15 K) [δ, ppm]: 170.15 (C-12); 168.00 (C-10); 148.63 (C-16); 144.48 (C-
14); 140.17 (C-9); 138.99 (C-1);  137.64 (C-8); 135.99 (C-5); 131.96 (C-6); 128.83 (C-3); 
128.59 (C-2); 127.87 (C-4); 126.38 (C-15); 125.03 (C-13); 124.87 (C-7);  56.69 (C-11). 19F 
NMR (376 MHz, CD3CN, 303.15 K) [δ, ppm]: -70.18 (d, 6F). 
31P NMR (162 MHz, CD3CN, 
















Figure 2.5.2.3: Numbering scheme employed for NMR characterisation of 
[Au(L7)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 47% (yellow powder). TOF MS (ES): m/z 494.0341 (calc, 494.0334), M+. IR (powder, 
cm-1): 1664 (s, ν(CO), RN-CO-R). UV-vis (CH2Cl2) [λmax, nm (ε, M
-1 cm-1)]: 244 (8.3 x 104), 
271 (1.7 x 104), 330 (5.6 x 103), 342 (2.4 x 103). 1H NMR (500 MHz, CD3CN, 303.15 K) [δ, 
ppm]: 9.88 (s, 1H, a); 9.14 (d, 1H, J = 6.34 Hz, k); 8.55 (d, 1H, J = 7.90 Hz, e); 8.50 (s, 1H, 
f); 8.39 (m, 1H, i); 8.37 (m, 1H, b); 8.26 (m, 1H, c); 8.12 (m, 1H, d); 7.92 (d, 1H, J = 7.90 
Hz, h); 7.80 (m, 1H, j); 5.42 (s, 1H, g). 13C NMR (123 MHz, CD3CN, 303.15 K) [δ, ppm]: 
170.56 (C-12); 166.42 (C-10); 154.15 (C-1); 148.54 (C-16); 144.34 (C-14); 143.64 (C-9); 
137.26 (C-7); 137.07 (C-4); 132.37 (C-5); 131.06 (C-6); 129.98 (C-2); 128.75 (C-3); 128.38 
(C-8); 126.34 (C-15); 125.00 (C-13); 56.75 (C-11). 19F NMR (376 MHz, CD3CN, 303.15 K) 
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2.5.3 General synthesis of N-donor 8-aminoquinoline-based tridentate gold(III) 
chelates. 
Initial method:  
To a stirred solution of K[AuCl4] (2.943 x 10
-4 mol) in 15 mL MeOH was added the 
relevant ligand (2.943 x 10-4 mol) dissolved in 15 mL DCM and heated. To the heated 
solution was added solid sodium acetate (2.943 x 10-4 mol) and the solution brought to 
reflux for 12 h, after which a brown precipitate was isolated by centrifugation and 
washed with 2 x 5 mL aliquots of water and dried in the oven.  
Corrected method: 
Chloride salt. K[AuCl4] (5.885 x 10
-4 mol) and relevant ligand (2.943 x 10-4 mol) were 
dissolved in 25 mL acetic acid and placed in a 50 mL round bottom flask, stirred and 
heated. To the heated solution was added solid sodium bicarbonate (8.829 x 10-4 mol) 
and the solution brought to reflux for 12 h, after which a brown precipitate was isolated 
by centrifugation and washed with 2 x 5 mL aliquots of water. The brown precipitate was 
then added to a round bottom flask containing tetrabutylammonium chloride (3.100 x 
10-4 mol) dissolved in DCM and the resulting suspension stirred for 12 h. The resulting 
orange/brown precipitate was again collected by centrifugation and washed with 2 x 5 
mL aliquots of DCM.  
Hexafluorophosphate salt. The chloride salt above was dissolved in boiling water prior 
to adding a saturated aqueous solution of potassium hexafluorophosphate. The resulting 
brown precipitate was then isolated by centrifugation and washed several times with 
water before drying in an oven at 100 °C. X-ray quality crystals were grown by slow 
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2.5.3.1 (Pyridin-2-ylcarbonyl)(quinolin-8-yl)azanidogold(III) hexafluorophosphate(V), 
[Au(L8)Cl](PF6) 
 
Figure 2.5.3.1: Numbering scheme employed for NMR characterisation of 
[Au(L8)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 86% (brown powder, based on gold). TOF MS (ES): m/z 480.0181 (calc, 480.0178), 
M+. IR (powder, cm-1): 1655 (s, ν(CO), RN-CO-R). UV-vis (MeCN) [λmax, nm (ε, M
-1 cm-1)]: 
256 (4.4 x 104), 364 (1.2 x 104). 1H NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.36 (d, 
1H, J = 5.56 Hz, j); 9.21 (d, 1H, J = 5.74 Hz, a); 9.13 (d, 1H, J = 8.40 Hz, j); 8.69 (m, 1H, c); 
8.65 (d, 1H, J = 8.40 Hz, e); 8.23 (d, 1H, J = 7.78 Hz, d); 8.16 (m, 1H, b); 8.08 (dd, 1H, J1 = 
8.36 Hz, J2 = 5.56 Hz, i); 8.01 (d, 1H, J = 8.25 Hz, g); 7.91 (m, 1H, f). 
13C NMR (100 MHz, 
DMSO-d6, 303.15 K) [δ, ppm]: 164.68 (C-6); 153.73 (C-5); 151.44 (C-14); 149.25 (C-1); 
146.87 (C-3); 146.20 (C-7); 145.50 (C-12); 141.73 (C-15); 132.26 (C-11); 132.07 (C-2); 
131.58 (C-9); 130.42 (C-4); 125.70 (C-10); 124.92 (C-13); 122.21 (C-8). 19F NMR (376 MHz, 
DMSO-d6, 303.15 K) [δ, ppm]: -70.18 (d, 6F). 
31P NMR (162 MHz, DMSO-d6, 303.15 K) [δ, 
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2.5.3.2 [(5-Butylpyridin-2-yl)carbonyl](quinolin-8-yl)azanidogold(III) dichloroaurate, 
[Au(L9)Cl](AuCl2
-) using initial method. 
Yield, 46% (brown powder, based on gold). TOF MS (ES): m/z 536.0808 (calc, 536.0804), 
M+. 1H NMR shifts were found to be the same as the hexafluorophosphate salt. No 




Figure 2.5.3.2: Numbering scheme employed for NMR characterisation of 
[Au(L9)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 64% (brown powder, based on gold). TOF MS (ES): m/z 536.0806 (calc, 536.0804), 
M+. IR (powder, cm-1): 1663 (s, ν(CO), RN-CO-R). UV-vis (MeCN) [λmax, nm (ε, M
-1 cm-1)]: 
257 (6.4 x 103), 362 (2.4 x 104). 1H NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.36 (d, 
1H, J = 5.54 Hz, m); 9.12 (d, 1H, J = 8.40 Hz, k); 8.99 (s, 1H, a); 8.64 (d, 1H, J = 7.74 Hz, h); 
8.56 (d, 1H, J = 8.02 Hz, f); 8.15 (d, 1H, J = 8.00 Hz, g); 8.07 (dd, 1H, J1 = 7.74 Hz, J2 = 7.74 
Hz, l); 8.00 (d, 2H, J = 8.31 Hz, j); 7.90 (m, 1H, i); 2.95 (t, 2H, J = 7.75 Hz, b); 1.65 (m, 2H, 
c); 1.37 (m, 2H, d); 0.94 (t, 3H, J = 7.34 Hz, e). 13C NMR (100 MHz, DMSO-d6, 303.15 K) [δ, 
ppm]: 164.67 (C-10); 151.54 (C-9); 151.40 (C-18); 148.08 (C-1); 147.67 (C-2); 146.16 (C-
7); 146.13 (C-11); 145.45 (C-16); 141.82 (C-19); 132.25 (C-15); 131.56 (C-13); 130.00 (C-
8); 125.58 (C-14); 124.87 (C-17); 122.10 (C-12); 32.70 (C-4); 32.41 (C-3); 21.99 (C-5); 
14.08 (C-6). 19F NMR (376 MHz, DMSO-d6, 303.15 K) [δ, ppm]: -70.20 (d, 6F). 
31P NMR 
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2.5.3.3 (Isoqionolin-1-ylcarbonyl)(quinolin-8-yl)azanidogold(III) hexafluorophosphate(V), 
[Au(L10)Cl](PF6) 
 
Figure 2.5.3.3: Numbering scheme employed for NMR characterisation of 
[Au(L10)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 89% (orange powder, based on gold). TOF MS (ES): m/z 530.0328 (calc, 530.0334), 
M+. IR (powder, cm-1): 1662 (s, ν(CO), RN-CO-R). UV-vis (CH2Cl2) [λmax, nm (ε, M
-1 cm-1)]: 
248 (6.7 x 104), 304 (7.0 x 103), 374 (9.0 x 103). 1H NMR (500 MHz, DMSO-d6, 303.15 K) 
[δ, ppm]: 9.86 (d, 1H, J = 8.57 Hz, f); 9.41 (d, 1H, J = 5.55 Hz, l); 9.16 (d, 1H, J = 6.45 Hz, 
a); 9.14 (d, 1H, J = 5.55 Hz, j); 8.78 (d, 1H, J = 7.80 Hz, g); 8.68 (d, 1H, J = 6.50 Hz, b); 8.45 
(d, 1H, J = 8.30 Hz, c); 8.27 (m, 1H, d); 8.21 (m, 1H, e); 8.10 (dd, 1H, J1 = 8.37, J2 = 5.52 
Hz, k); 8.05 (d, 1H, J = 8.20 Hz, i); 7.94 (m, 1H, h). 13C NMR (123 MHz, DMSO-d6, 303.15 K) 
[δ, ppm]: 166.31 (C-10); 151.38 (C-18); 151.05 (C-9); 146.31 (C-11); 145.44 (C-16); 141.88 
(C-19); 140.02 (C-8); 139.54 (C-1); 136.25 (C-5); 132.75 (C-6); 132.26 (C-15); 131.58 (C-
13); 129.61 (C-2); 128.99 (C-3); 128.82 (C-4); 125.96 (C-14); 124.92 (C-17); 124.84 (C-7); 
122.73 (C-12). 19F NMR (376 MHz, DMSO-d6, 303.15 K) [δ, ppm]: -70.10 (d, 6F). 
31P NMR 
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2.5.3.4 (Isoqionolin -3-ylcarbonyl)(quinolin-8-yl)azanidogold(III) hexafluorophosphate(V), 
[Au(L11)Cl](PF6) 
 
Figure 2.5.3.4: Numbering scheme employed for NMR characterisation of 
[Au(L11)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 87% (brown powder, based on gold). TOF MS (ES): m/z 530.0339 (calc, 530.0334), 
M+. IR (powder, cm-1): 1666 (s, ν(CO), RN-CO-R). UV-vis (MeCN) [λmax, nm (ε, M
-1 cm-1)]: 
248 (9.3 x 104), 304 (1.5 x 104), 349 (1.2 x 104). 1H NMR (500 MHz, DMSO-d6, 303.15 K) 
[δ, ppm]: 10.09 (s, 1H, a); 9.43 (d, 1H, J = 6.05 Hz, l); 9.14 (d, 1H, J = 6.05 Hz, j); 8.85 (s, 
1H, f); 8.83 (d, 1H, J = 8.20 Hz, e); 8.74 (d, 1H, J = 7.86 Hz, g); 8.55 (d, 1H, J = 8.25 Hz, b); 
8.31 (m, 1H, c); 8.17 (m, 1H, d); 8.10 (dd, 1H, J1 = 8.20 Hz, J2 = 8.20 Hz, k); 8.01 (m, 1H, J = 
7.91 Hz, i); 7.92 (m, 1H, h). 13C NMR (123 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 164.49 (C-
10); 153.89 (C-1); 150.90 (C-18); 145.44 (C-11); 144.93 (C-16); 144.66 (C-9); 141.62 (C-
19); 136.90 (C-4); 136.62 (C-7); 132.50 (C-5); 131.68 (C-15); 131.37 (C-6); 131.05 (C-13); 
129.60 (C-2); 129.23 (C-8) 128.87 (C-3); 124.93 (C-14); 124.30 (C-17); 121.74 (C-12). 19F 
NMR (376 MHz, DMSO-d6, 303.15 K) [δ, ppm]: -70.21 (d, 6F). 
31P NMR (162 MHz, DMSO-















Figure 2.5.3.5: Numbering scheme employed for NMR characterisation of 
[Au(L12)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 82% (brown powder, based on gold). TOF MS (ES): m/z 584.0439 (calc, 584.0440), 
M+. IR (powder, cm-1): 1658 (s, ν(CO), RN-CO-R), 1593 (s, ν(CO), R-CO-R). UV-vis (MeCN) 
[λmax, nm (ε, M
-1 cm-1)]: 253 (3.8 x 104), 369 (7.7 x 103). 1H NMR (400 MHz, CDCl3, 303.15 
K) [δ, ppm]: 9.37 (m, 2H, a, l); 9.12 (d, 1H, J = 7.84 Hz, j); 8.77 (d, 1H, J = 7.90 Hz, c); 8.40 
(d, 1H, J = 7.68 Hz, h); 8.28 (dd, 1H, J1 = 7.88 Hz, J2 = 5.76 Hz, b); 8.08 (dd, 1H, J1 = 8.32 
Hz, J2 = 5.64 Hz, k); 7.98 (d, 1H, i); 7.86 (d, 2H, J = 8.45 Hz, d); 7.77 (m, 1H, g); 7.73 (m, 
1H, f); 7.58 (m, 2H, e). 13C NMR (100 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 190.75 (C-5); 
164.17 (C-11); 151.67 (C-19); 150.73 (C-10); 150.12 (C-1); 146.05 (C-12); 145.59 (C-17); 
144.69 (C-3); 142.48 (C-4); 141.27 (C-20); 136.51 (C-6); 134.96 (C-9), 132.23 (C-16); 
131.82 (C-2); 131.48 (C-14); 129.78 (C-7); 129.46 (C-8); 125.89 (C-15); 124.97 (C-18); 
122.35 (C-13). 19F NMR (376 MHz, DMSO-d6, 303.15 K) [δ, ppm]: -70.18 (d, 6F). 
31P NMR 
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2.5.3.6 {[3-(4-Fluorobenzoyl)pyridin-2-yl]carbonyl}(quinolin-8-yl)azanidogold(III) 
hexafluorophosphate(V), [Au(L13)Cl](PF6)  
 
Figure 2.5.3.6: Numbering scheme employed for NMR characterisation of 
[Au(L13)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 75% (brown powder, based on gold). TOF MS (ES): m/z 602.0341 (calc, 602.0346), 
M+. IR (powder, cm-1): 1672 (s, ν(CO), RN-CO-R), 1591 (s, ν(CO), R-CO-R). UV-vis (MeCN) 
[λmax, nm (ε, M
-1 cm-1)]: 255 (3.4 x 104), 369 (7.3 x 103). 1H NMR (500 MHz, DMSO-d6, 
303.15 K) [δ, ppm]: 9.38 (m, 2H, a, k); 9.12 (d, 1H, J = 8.37 Hz, i); 8.77 (d, 1H, J = 7.90 Hz, 
c); 8.41 (d, 1H, J = 7.82 Hz, f); 8.29 (dd, 1H, J1 = 7.90 Hz, J2 = 5.75 Hz, b); 8.09 (dd, 1H, J1 = 
8.37 Hz, J2 = 5.62 Hz, j); 7.97 (m, 3H, h, d); 7.79 (m, 1H, g); 7.43 (m, 2H, e). 
13C NMR (123 
MHz, DMSO-d6, 303.15 K) [δ, ppm]: 188.86 (C-5); 166.68 (C-6); 164.66 (C-4); 163.67 (C-
11); 151.18 (C-1); 149.68 (C-19); 145.55 (C-12); 145.10 (C-17); 144.21 (C-3); 141.66 (C-
10); 140.73 (C-20); 132.94 (d, J = 2.55 Hz, C-9), 132.36 (d, J = 9.85 Hz, C-7); 131.73 (C-16); 
131.36 (C-2); 130.98 (C-14); 125.41 (C-15); 124.46 (C-18); 121.86 (C-13); 116.65 (d, J = 
22,31 Hz, C-8). 19F NMR (376 MHz, DMSO-d6, 303.15 K) [δ, ppm]: -70.14 (d, 6F); -103.53 












Figure 2.5.3.7: Numbering scheme employed for NMR characterisation of 
[Au(L14)Cl](PF6), black letters correspond to 1H NMR signals and blue numbers 
correspond to 13C NMR signals. 
Yield, 86% (brown powder, based on gold). TOF MS (ES): m/z 614.0538 (calc, 614.0546), 
M+. IR (powder, cm-1): 3070, 3084, 3109 (s, ν(CH); OCH3) 1659 (s, ν(CO), RN-CO-R), 1594 
(s, ν(CO), R-CO-R). UV-vis (MeCN) [λmax, nm (ε, M
-1 cm-1)]: 256 (3.2 x 104), 286 (2.6 x 104), 
362 (9.0 x 103). 1H NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.36 (m, 2H, a, l); 9.11 
(d, 1H, J = 7.68 Hz, j); 8.70 (d, 1H, J = 7.86 Hz, c); 8.41 (d, 1H, J = 7.84 Hz, g); 8.26 (dd, 1H, 
J1 = 7.90 Hz, J2 = 5.74 Hz, b); 8.08 (dd, 1H, J1 = 8.30 Hz, J2 = 5.66 Hz, k); 7.98 (d, 1H, J = 
8.00 Hz,  i); 7.81 (m, 3H, d, h); 7.09 (m, 2H, e); 3.86 (s, 3H, f).  13C NMR (100 MHz, DMSO-
d6, 303.15 K) [δ, ppm]: 188.98 (C-5); 164.67 (C-9); 164.07 (C-12); 151.64 (C-1); 150.39 (C-
11); 150.00 (C-20); 146.04 (C-13); 145.59 (C-18); 144.70 (C-3); 142.88 (C-4); 141.35 (C-
21); 132.32 (C-8 or 15), 132.23 (C-16); 131.74 (C-2); 131.49 (C-8 or 15); 129.65 (C-6); 
125.85 (C-16); 124.95 (C-19); 122.33 (C-14); 114.79 (C-7); 56.28 (C-10). 19F NMR (376 
MHz, DMSO-d6, 303.15 K) [δ, ppm]: -70.19 (d, 6F). 
31P NMR (162 MHz, DMSO-d6, 303.15 
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2.5.4 General synthesis of C, N-donor 8-aminoquinoline-based tridentate gold(III) 
chelates. 
KAuCl4 (5.885 x 10
-4 mol) and respective ligand (2.943 x 10-4 mol) were dissolved in 25 
mL acetic acid and placed in a 50 mL round bottom flask, stirred and heated. To the  
heated solution was added solid bicarbonate (8.829 x 10-4 mol) and the solution brought 
to reflux for 12 h, after which a brown precipitate was isolated by centrifugation and 
washed with 2 x 5 mL aliquots of water. The solid was then dissolved in a minimum 
amount of boiling dimethylformamide and any insoluble impurities filtered off. The 
dimethylformamide solution was then placed in the fridge for 6 hours after which the 
resulting golden yellow microcrystalline solid was isolated by centrifugation and washed 
with 2 x 10 mL portions of diethylether. 
2.5.4.1 Benzoyl(quinolin-8-yl) azanidogold(III), [Au(L15)Cl] 
 
Figure 2.5.4.1: Numbering scheme employed for NMR characterisation of [Au(L15)Cl], 
black letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR 
signals. 
Yield, 85% (yellow crystals). TOF MS (ES): m/z 479.0241 (calc, 479.0226), M+. IR (powder, 
cm-1): 1647 (s, ν(CO), RN-CO-R). UV-vis (DMSO) [λmax, nm (ε, M
-1 cm-1)]: 330 (5.4 x 103), 376 
(6.3 x 103). 1H NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.08 (d, 1H, J = 4.95 Hz); 8.85 
(m, 2H); 7.97 (dd, 1H, J1 = 8.37 Hz, J2 = 4.97 Hz); 7.75 (m, 2H); 7.70 (m, 1H); 7.39 (m, 3H). 
13C 
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2.5.4.2 (Naphthalen-1-ylcarbonyl)(quinolin-8-yl)azanidogold(III), [Au(L16)Cl] 
 
Figure 2.5.4.2: Numbering scheme employed for NMR characterisation of [Au(L16)Cl], 
black letters correspond to 1H NMR signals and blue numbers correspond to 13C NMR 
signals. 
Yield, 78% (yellow powder). TOF MS (ES): m/z 528.0298 (calc, 528.0304), M+. IR (powder, 
cm-1): 1644 (s, ν(CO), RN-CO-R). UV-vis (DMSO) [λmax, nm (ε, M
-1 cm-1)]: 333 (1.0 x 104), 379 
(7.7 x 103). 1H NMR (400 MHz, DMSO-d6, 303.15 K) [δ, ppm]: 9.53 (d, 1H, J = 8.60 Hz); 9.10 
(m, 1H); 8.94 (m, 1H); 8.85 (m, 1H); 7.97 (m, 4H); 7.75 (m, 2H); 7.69 (m, 1H); 7.58 (m, 1H). 
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3. Synthesis 
3.1 Synthesis of aroyl pyridine carboxylic acids  
The synthesis of aroyl pyridine carboxylic acids from quinolic anhydride is well documented 
in literature.1-3 The aroyl pyridine carboxylic acid is generated as a key intermediate en route 
to the synthesis of anthracenediones as well as anthrapyrazoles.1-3 These molecules are 
used as DNA intercalators in the fight against cancer.1-3 The procedure is relatively straight 
forward, employing a Friedal crafts acylation reaction between the anhydride and an 
aromatic substrate. 
 
Scheme 3.1.1: Mechanistic scheme depicting the formation of a 3-substituted pyridine 
carboxylic acid via a Friedel-Crafts acylation reaction. 
The lone pair from one of the carbonyl oxygen’s of the anhydride attacks the aluminium 
trichloride and forms a co-ordination complex with it. This creates an electron deficient co-
ordinated oxygen that facilitates the ring opening of the anhydride and the formation of an 
acylium ion. The acylium ion is susceptible to nucleophillic attack from the aromatic 
substrate to form the ketone which is aromatised through hydrogen elimination. Acid work 
up cleaves the complex and allows for the formation of the aroyl pyridine carboxylic acid. 
The reaction is clean and high yielding, requiring no chromatography.      
Synthesis 
 
88 | P a g e  
 
3.2 Synthesis of ligands 
The bis(amide) and amide ligand system was chosen because of its facile synthesis, solubility 
and ability to chelate metal ions.4-9 There are a number of synthetic methods that can be 
employed when considering the synthesis of bis(amide) and amide ligands. The most well-
documented method for the synthesis of bis(amide) and amide ligands was reported by 
Vagg et al. in 1978 and involves the reaction between an amine and a triphenylphosphite-
activated carboxylic acid in the presence of pyridine (acting as a base). Pyridine 
deprotonates the carboxylic acid and the lone pair from the phosphorus atom of the 
triphenylphosphite attacks the deprotonated carboxylic acid forming activated ester with 
the phosphorus atom being electron poor. The lone pair from the amine then attacks the 
carbonyl group and the triphenylphosphite leaves as triphenylphosphite oxide to afford the 
amide bond. The driving force of this reaction is the formation of the phosphorus-oxygen 
double bond. An example of the mechanistic scheme is shown below (Scheme 3.2.1). This 
method is the most common method employed in literature in the synthesis of both bis as 
well as mono(amide) ligands. The positives regarding this method are that the reaction is a 
one-pot synthetic route that is high yielding of a clean product, i.e. does not require column 
chromatography for work-up. The reaction can be performed open to the atmosphere 
without any special precautions to exclude oxygen or water. The negatives are the use of 
pyridine in the reaction, which, is harmful to males, and the work up can be lengthy, 
comprising multiple washings and extractions, if the product is aliphatic in nature.       
 
Scheme 3.2.1: Mechanistic scheme depicting the formation of an amide bond through a 
triphenylphosphite mediated pathway. 
There have been other methods reported for the synthesis of amide ligands. One of these 
methods involves the conversion of a carboxylic acid to an acid chloride via the use of an 
acylating agent such as thionyl chloride, oxalyl chloride or phosphoryl chloride.10, 11 The 
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chloride of an acyl chloride functional group acts as a good leaving group facilitating attack 
by the amine to form the required amide bond.  
 
Scheme 3.2.2: Mechanistic scheme depicting the formation of an amide bond through 
an acyl chloride mediated pathway. 
The electrons from the carbonyl double bond of the acid attack the sulfonyl group of thionyl 
chloride, causing a chloride ion to leave, and in the process forming a ester. The chloride 
anion then attacks the electron poor carbonyl of the ester, releasing HCl and SO2, on the 
way to forming the acyl chloride. The acyl chloride is then attacked by the amine, forming 
the amide and releasing HCl in the process. An example of the synthetic scheme is shown 
above (Scheme 3.2.2). This method is also quite popular in literature. The problems with this 
method are that when forming the acid chloride from a heteroaromatic carboxylic acid 
there is a tendency to form the hydrochloride salt of the acid chloride as well as polymeric 
species.10 This is particularly evident in the preparation of the acid chloride of picolinic acid 
using thionyl chloride.10 Therefore the reactions are generally performed under an inert 
atmosphere using a mild acylating reagent such as oxalyl chloride to afford the correct 
product in good yield.10 The reaction is normally a two-step reaction where the acid chloride 
is generated and isolated first, followed by the amide bond formation. Acylating reagents 
are normally very corrosive and harmful towards humans and the environment. The 
positives are that the reaction can be very high yielding of a clean product.  
The third method that can be employed is generally used in the biological synthesis of 
peptide bonds.12 It involves the reaction of the carboxylic acid with a carbodiimide coupling 
agent, such as dicyclohexylcarbodiimide (DCCI), to form an activated ester which facilitates 
nucleophllic attack by an amine to form the intended amide bond. The reaction is driven by 
the expulsion of a very stable substituted urea molecule that is generally insoluble. The 
problem with this reaction is that the activated ester is susceptible to attack from numerous 
nucleophiles present in the reaction and hence the possibility of producing by-products. The 
first of these pathways is attack by the amine to form the intended amide (pathway 1), the 
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second is attack via another activated ester molecule (since it contains an amine functional 
group) to form a diamide species (pathway 2) and the third is attack from the original acid to 
form an intermediate ether species which, after coupling with the amine, results in the 
intended amide and an equivalent amount of acid (pathway 3). The presence of these side 
reactions led to the development of a strategy to avoid this which involves the addition of a 
coupling agent such as N-hydroxysuccinamide or 1-hydroxybenzotriazole (HOBt). The 
function of these coupling agents is to intercept the activated ester and speed up the 
reaction so that the event of side reactions is significantly reduced (pathway 4). The reaction 
can be conducted as a one- or two-step process depending on the cleanliness and efficiency 
of the reaction. The final product usually requires clean-up via column chromatography. 
 
Scheme 3.2.3: Mechanistic scheme depicting the formation of an amide bond through a 
carbodiimide mediated pathway. 
The method represented in scheme 3.2.1 was employed in the synthesis for all of the 
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3.3 Synthesis of metal complexes 
3.3.1 Synthesis of cis-dichloro gold(III) complexes 
The objective of our work was to synthesise structurally unique, predominantly planar 
cationic tetradentate bis(amido) Au(III) complexes that could potentially act as DNA 
intercalators and thus anti-cancer agents by virtue of their anticipated cytotoxicity—a goal 
based on similar traits exhibited by Au(III) porphyrins.13  Well-documented ligands H2L1 and 
H2L2 were considered first in order to optimise reaction conditions for the chelation of 
Au(III).  Refluxing 1 eq. of H2L2 with 1 eq. [Bu4N][AuCl4] in dichloromethane for 24 h was 
accompanied by no colour change and both starting materials were recovered. Clearly, a 
suitable base was needed to deprotonate the amide N–H group under thermodynamically 
driving conditions (higher boiling solvent) to facilitate chelation of an apparently 
substitution-inert Au(III) species, [AuCl4]
.  We therefore attempted the reaction under 
reflux in 1:1 MeOH:DCM using [Bu4N][AuCl4] and two equivalents of sodium acetate as the 
base for 2 h (as recommended in a recent review), followed by stirring at ambient 
temperature overnight.  An orange powder precipitated from the solution that, when 
recrystallised and analysed by single crystal X-ray diffraction, was the monochelate.  The 
reaction was attempted again under the same conditions with 2 eq. of ethoxide ions 
(generated in situ) under the premise that a stronger base might yield the desired 
trischelate (Scheme 3.3.1.1). However, monochelate [Au(HL2)Cl2] was isolated a second 
time, despite the use of the stronger base under the same reaction conditions. The use of 
K[AuCl4] with either acetate or ethoxide as the base also led to the isolation of [Au(HL2)Cl2] 
after work-up. It is noteworthy that the use of more than two equivalents of either base 
resulted in the formation of a black precipitate after a few minutes of reflux, which is typical 
of the reduction of Au(III) to colloidal gold. The behaviour of Au(III) with H2L2 contrasts 
starkly with that of Pd(II) since the isoelectronic (but neutral) square-planar Pd(II) analogue 
of the trischelate (Scheme 3.1.1.1) has been synthesised and structurally characterised. 
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Scheme 3.3.1.1: Reaction scheme depicting the favored route to neutral monochelates 
of Au(III) as opposed to cationic trischelates of the metal. 
Based on these observations, we conclude that the rather covalent and substitution-inert 
Au–Cl bonds in this system (especially the bond trans to the pyridine nitrogen) militate 
against formation of the desired mononuclear trischelates. It is also possible that steric 
repulsion between the α-C–H groups of the two closely positioned cis-pyridyl rings in the 
trischelate introduces significant steric strain in the product complex—enough to limit the 
prevalence of this species in solution under the given reaction conditions.  Interestingly, if 
we reacted ligand H2L2 and either [Bu4N][AuCl4] or K[AuCl4] in metal to ligand ratio of 1:1 or 
1:2, the same mononuclear dichloro species [Au(HL2)Cl2] was always obtained, despite the 
former reaction stoichiometry potentially favouring the formation of a coordination 
polymer. Due to the interesting bidentate chelating modes of the ligands in complexes 
[Au(HL1)Cl2], [Au(HL2)Cl2], and [Au(L4)Cl2], which unintentionally provide an additional 
substituent with H-bond donor and acceptor sites and π-stacking bases in each case, no 
further attempts were made to generate tetradentate AuN2N′2 trischelates in favour of 
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3.3.2 Synthesis of tridentate gold(III) complexes 
After synthesis of the cis-dichloro monochelates mentioned above we focussed our 
attention on the synthesis of a series of tridentate gold(III) chelates. A series of three 
aminomethyl-based ligands (ligands HL5-HL7, Figure 1.7.1) were synthesised. Knowing the 
shortcomings encountered during the synthetic trials mentioned above, the initial 
metallation of the tridentate ligands involved the reaction of gold(III), K[AuCl4] or H[AuCl4], 
in the presence of equimolar amounts of ligand, NaOAc and potassium 
hexafluorophosphate in ethanol to afford a yellow solid. The reaction proceeded smoothly 
with 31P and 19F NMR indicating the correct counterion being present. This was later 
confirmed via single crystal X-ray crystallographic analysis. After discovery of the synthetic 
difficulties associated with the 8-aminoquinoline-based complexes (discussed below) a 
metathesis step was performed as a precaution to ensure the isolation of the desired 
hexafluorophosphate salt. The aminomethyl-based gold(III) chelates were abandoned upon 
realisation that they are particularly unstable. This was discovered when submitting samples 
for 1H and 13C NMR. The samples were dissolved in DMSO-d6 and a spectrum recorded. After 
satisfactory assignment of the proton signals the samples were submitted for 13C and 2-D 
NMR experiments. Due to the low concentration of the samples the spectra had to be run 
overnight with multiple scans. On returning the next morning, data analysis revealed 
multiple ‘new’ peaks. Since these complexes are being synthesised with their intended 
application as chemotherapeutics, it is imperative they display solution stability, at least, in 
traditional NMR solvents. The spectroscopic experiments used to determine the stability of 
these chelates are discussed thoroughly in Chapter 4.  
It was thought that substituting the aminomethyl group with 8-aminoquinoline we could 
render the ligand fully aromatic via the delocalisation of electrons through the amide bond 
and hence increase the σ-donor ability of the ligands and effect a more stable gold(III) 
chelate. A literature method for the synthesis of such chelates exists and was reported by 
Yang et al.14 The exact ligand ‘Quinpy’ was synthesised and the metallation method 
followed in which we refluxed equimolar amounts of ligand and H[AuCl4] in MeOH. This 
resulted in a dark brown precipitate which was filtered and analysed by TOF MS as well as 
1H NMR. Initial investigations showed the correct complex, [Au(Quinpy)Cl]Cl or 
[Au(L8)Cl2]PF6, had been synthesised. The ‘correct’ NMR shifts and solubility were observed. 
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The complex was soluble in DMSO, nitromethane and sparingly soluble in acetonitrile. 
Through 1H NMR spectroscopy the complex was deemed stable in DMSO and so a series of 
associated but structurally different ligands were synthesised.  Attempts to grow single 
crystals of [Au(L8)Cl2]x were futile due to the lack of solubility of the complex. A further 
three chelates were synthesised ([Au(L9)Cl2]x, [Au(L10)Cl2]x and [Au(L11)Cl2]x using a slightly 
modified procedure. The solvent system was modified to contain 50% DCM to facilitate the 
dissolution of ligands HL9, HL10 and HL11 due to their lack of solubility in pure MeOH as 
well as the presence of NH4PF6 to encourage formation of the PF6
- salt of the complexes. 
Evidence for the formation of the PF6
- salt of the complexes was displayed via 19F and 31P 
NMR, however, both complexes, [Au(L10)Cl2]x and [Au(L11)Cl2]x, displayed limited solubility 
akin to [Au(L8)Cl2]x while [Au(L9)Cl2]x exhibited improved solubility, presumably, due to the 
presence of the aliphatic butyl chain. Single crystals of [Au(L9)Cl2]AuCl2
- were grown by 
addition of a small amount of H2O to a saturated solution of [Au(L9)Cl2]AuCl2
- in THF. Upon 
standing overnight pale orange crystals had grown and single crystal X-ray analysis revealed 
the correct chelate cation with the incorrect linear [AuCl2]
- anion. This was quite surprising 
as 19F and 31P NMR had suggested the correct, PF6
-, ion pair was present. This was probably 
due to the presence of NH4PF6 impurities in the isolated product. This is possible as, both 
19F 
and 31P NMR, are highly sensitive and the presence of even a small amount is capable of 
registering strong signals for both nuclei. In retrospect this result was understandable and 
explained the lack of solubility the complexes exhibited. The metallation reactions for 
[Au(L8)Cl2]x, [Au(L9)Cl2]x, [Au(L10)Cl2]x and [Au(L11)Cl2]x were then repeated using the 
literature as well as the modified technique and the products analysed by negative 
ionisation TOF MS. This was done to ascertain whether the presence of DCM in the reaction 
mixture facilitated the formation of the [AuCl2]
- anion. The mass spectral data revealed the 
presence of both [AuCl2]
- and [AuCl4]
- anions irrespective of the metallation method (Figure 
3.3.2.1). The presence of gold counterions in the synthesis of cationic gold(III) chelates in 
literature is not uncommon. This is due to the aforementioned (Chapter 1) redox instability 
of gold in its +3 oxidation state as well as the tendency for the gold salts to be highly 
insoluble, driving their formation. Numerous strategies are employed in the synthesis of 
gold(III) chelates to avoid the formation of gold counterions, namely the inclusion of a PF6
- 
salt and the ligand in excess to encourage chelation to occur rapidly. Metallation reactions 
were conducted under a significant variety of conditions through varying the solvent (EtOH 
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and mixtures with DCM, MeOH and mixtures with DCM) or base (EtO-, MeO-, NaOAc and 
NaHCO3) as well as the source of gold(III) ions (H[AuCl4], K[AuCl4] and[Bu4N][AuCl4]). The 
reaction times were varied from 2 hrs to 48 hrs both under reflux and at ambient 
temperature. 
 
Figure 3.3.2.1: Negative ionisation mass spectral data of [Au(L10)Cl2]AuCl2- showing 
the presence of both [AuCl2]- and [AuCl4]- as counterions.   
No matter the conditions, base, or source of gold(III) ions, the same mixed-couterion, 
product was always obtained. Eventually a strategy was discovered that focussed on the 
formation of the [AuCl4]
- counterion by virtue of performing the metallation reaction with 
two equivalents of gold(III) salt (H[AuCl4], K[AuCl4] or [Bu4N][AuCl4]).
15 The reaction was 
performed in acetic acid with 3 equivalents of NaHCO3 affording a dark brown precipitate 
that when analysed by TOF MS revealed the intended complex as its tetrachloroaurate salt. 
This salt was then suspended in DCM in a round bottomed flask and stirred after the 
addition of excess [Bu4N][Cl]. After stirring overnight, the precipitate was isolated and 
characterised as the chloride salt of the respective complex. The metathesis is successful 
since the formation of [Bu4N][AuCl4] is driven forward by its solubility in DCM while the 
charged chloride salt of the complex is particularly insoluble in DCM. The chloride salts of all 
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the complexes were soluble in H2O and therefore metathesis with KPF6 afforded the 
hexafluorophosphate salt of each complex with ease. The solubility of the 
hexafluorophosphate salts of the complexes was markedly different to that of the gold-
based counterion salts. The PF6
- salts of all complexes were readily soluble in MeCN, MeNO2, 
MeOH and EtOH, whereas the gold-based counterion salts of the complexes were sparingly 
soluble in MeCN and not at all soluble in the alcohols. 
 
Figure 3.3.2.2: Schematic diagram depicting the different methods of synthesis used to 
generate the gold(III) chelates represented in this work. The green arrow shows the 
synthetic route employed for the synthesis of gold(III) chelates with mixed gold(I) and 
gold(III) counterions while the blue arrows show the synthetic scheme used in the 
successful synthesis of the PF6- salt of the gold(III) complexes. Ligand HL10 is used as an 
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4. Spectroscopy 
4.1 Infrared spectroscopy 
Infrared spectroscopy is based on the principle that almost all molecules that contain 
covalent bonds are able to absorb electromagnetic radiation in the IR region, with the 
exception of a few homonuclear molecules such as O2, N2 and Cl2.
1 For chemical purposes 
and general application the characteristic window is normally observed between the 
wavenumber range of 400 and 4000 cm-1.1-4 The absorption of infrared radiation is a 
quantized process with specific functional groups within a molecule absorbing certain IR 
frequencies.4 The internal molecular energy of a molecule can be separated into three 
different components: (1) the vibration of each atom in the molecule, (2) the rotation of the 
molecule, and (3) movement of electrons in the molecule.4  
 Etotal  Evib  Erot  Eel                                                                                                         4.1.1 
Only vibrational transitions occur within the IR spectral range and so it is only these 
transitions that are observed in the IR spectrum.3, 4 IR spectra are the result of photons 
being absorbed by transitions between two vibrational energy levels of the molecule in the 
ground state. The vibrations of a molecule when induced by the absorption of IR energy are 
generally of two forms: (1) stretching and (2) bending. A stretch is a vibration occurring 
along the line of the bond that changes the bond length and a bend is a vibration that does 
not occur along the line of the bond but changes the bond angle. In molecules containing 
three or more atoms these vibrations can become even more complicated. One can have 
asymmetric as well as symmetric stretches and bends. Since every type of bond has a 
different natural frequency of vibration and two of the same types of bond in different 
molecules are in different environments, all molecules exhibit a unique IR absorption 
pattern.1-4 In general IR spectroscopy is less accurate as a qualitative tool compared to other 
spectroscopic techniques such as UV-visible spectroscopy.2 This is because of its lower 
sensitivity and frequent deviation from Beer’s law.2 IR measurements are also considerably 
less precise than other spectroscopic methods.2 IR spectroscopy is, therefore, primarily used 
as a fingerprinting tool in qualitative analysis. All functional groups have a characteristic, 
narrow region in the IR spectrum that they absorb.1, 2 These individual absorption bands add 
up to collectively create a fingerprint spectrum for individual molecules. Figure 4.4.1 
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summarises the characteristic absorption bands for some common functional groups 
present in organic molecules.  
 
Figure 4.1.1: Approximate absorption regions of some common functional groups. 
Diagram adapted and modified from ‘Introduction to Spectroscopy’ 4th Edition.4  
The ligands presented in this work contain functional groups that exhibit characteristic 
absorption bands. The most prevalent and characteristic is the amide functional group. It 
contains both ν(C=O) and ν(N–H) bands, of which, the ν(N–H) disappears upon chelation to 
the gold(III) ion. The ν(C=O) band remains present, but, shifts to lower wavenumbers. The 
characteristic wavenumber for the ν(C=O) stretch is approximately 1650 cm-1, while for the 
ν(N–H) stretch it is approximately 3200-3500 cm-1.  The methyl groups associated with the 
butyl chain of ligand HL9 and methoxy group of ligands HL4 and HL14 also show 
characteristic CH3 stretches in the 2700-3300 cm
-1 region. Ligands HL12-HL14 also contain a 
ketone functional group, this displays a characteristic stretch also in the 1650 cm-1 region.  
There are relatively very few examples of gold(III) amide compounds in the literature. Of the 
few reports present the characterisation data on them is sparse at best, with only CHN data 
available for the compound, [Au(HL)Cl2] (H2L = 2,2'-bis(2-pyridylcarboxyamide)-1,1'-
binaphthyl), reported by Che and co-workers in 1994. Yang et. al reported three gold(III) 
amide compounds in 2003, namely [Au(Quinpy)Cl]Cl, [Au(Quingly)Cl]Cl and 
[Au(Quinala)Cl]Cl, with all three compounds exhibiting characteristic ν(C=O) stretches at 
1679, 1658 and 1664 cm-1 respectively.5 The metal compound stretches could not be 
compared to their respective free ligand ν(C=O) stretches as this data is not reported in the 
literature, however, the boc-protected ν(C=O) stretches are available for the ligands 
QuinglyBoc and QuinalaBoc (1713 and 1700 cm-1 respectively).6, 7 Chelation of the ligand to 
gold(III) is seen to therefore induce a shift in ν(C=O) stretch to lower frequencies. In 2009 
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Cinellu and co-workers reported the formation of two chiral tridentate gold(III) amide 
compounds, S-5 and R-6 of the deprotonated ligands N-(1-hydroxy-3-R-2-yl)pyridine-2-
carboxamide (R=iPr, Ph), which were acquired via the ring opening of a chiral piridinyl-
oxazoline ligand.8 The ν(C=O) stretches for these compounds were both reported to be 1649 
cm-1.8         
4.1.2 Objectives 
The main objective of infrared spectroscopy is a secondary analytical tool. It is used to 
determine the presence of certain functional groups (vide supra) and to compare their 
absorption bands in the free ligand to the metal complex. The characteristic absorption 
bands will also be compared to the calculated values from the DFT simulations and used to 
determine the accuracy of the computational method used. 
4.1.3 Results and discussion 
The two most prominent absorption bands present in the IR spectrum of all ligands 
presented are the ν(C=O) and ν(N–H) stretching bands. The ν(C=O) stretching bands range 
between 1579-1689 cm-1 while the ν(N–H) stretching bands range between 3272-3349 cm-1 
(Table 4.1.3.1). The ν(C=O) stretching frequency for the metal compound is shifted to a 
lower frequency relative to that of the free ligand for all complexes except [Au(L5)Cl](PF6)–
[Au(L7)Cl](PF6) (Table 4.1.3.1).  
 
Scheme 4.1.3.1: Illustration of bond resonance involving the metal-bound amide group 
of [Au(HL3)Cl2]. Lone pairs of electrons are shown for the amide group to aid 
visualisation of the two resonance forms. 
This characteristic is expected and well documented in literature.5, 9, 10 The simplest 
explanation for the shift to lower wavenumber for the metal-bound amide band, ν(C=O), 
relative to the free amide band is that the resonance hybrid structure for the compound lies 
somewhere between the two resonance forms A (–N–C=O) and B (N=C–O–) illustrated in 
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Scheme 4.1.3.1. Because a decrease in the C–O bond order is expected to reduce the 
frequency of the normal mode of vibration for the carbonyl group, the experimental data 
suggest that the resonance hybrid structures of the metal compounds lie slightly closer to 
resonance form B than form A, consistent with the behaviour previously deduced by 
Rosenberg for several peptide compounds of Cu(II).10 Compounds [Au(L5)Cl](PF6)–
[Au(L7)Cl](PF6) however display the opposite trend, suggesting their resonance hybrid 
structures of the metal compounds lie closer to resonance form A than form B compared to 
that of the free ligand.   
Table 4.1.3.1: Experimental IR data for all free ligands and metal compounds studied.a 




[Au(HL1)Cl2] 3326 1654 1647 +7 
[Au(HL2)Cl2] 3299 1650 1645 +5 
[Au(HL3)Cl2] 3335 and 3300 1685 1652 +33 
[Au(L4)Cl2] 3337 1689 1643 +46 
[Au(L5)Cl](PF6) 3359 1664 1676 -12 
[Au(L6)Cl](PF6) 3298 1646 1672 -24 
[Au(L7)Cl](PF6) 3349 1652 1664 -12 
[Au(L8)Cl](PF6) 3287 1684 1655 +29 
[Au(L9)Cl](PF6) 3303 1676 1663 +13 
[Au(L10)Cl](PF6) 3272 1671 1662 +9 
[Au(L11)Cl](PF6) 3301 1677 1666 +10 
[Au(L12)Cl](PF6) 3289 1664 1658 +6 
[Au(L13)Cl](PF6) 3290 1672 1672 0 
[Au(L14)Cl](PF6) 3289 1664 1659 +5 
[Au(L15)Cl](PF6) 3349 1669 1647 +22 
[Au(L16)Cl](PF6) 3353 1667 1644 +23 
[Au(Quinpy)Cl]Cl5 N/A 1687 1679 +8 
[Au(Quingly)Cl]Cl5  N/A 1713b,6, 7 1658 +55 
[Au(Quinala)Cl]Cl5 N/A 1700b,6, 7 1664 +36 
S-58 N/A N/A 1649 N/A 
R-68 N/A N/A 1649 N/A 
a
Abbreviations: ν1(C=O) and ν2(C=O) are the stretching frequencies for the free ligand and metal compounds 
respectively; νΔ1,2(C=O) is the difference between ν1 and ν2.
b
Tabulated stretches are for boc protected 
analogues used. 
c
 v(N-H) refers to the stretching frequency of the respective free ligand.   
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For complexes [Au(HL1)Cl2]–[Au(HL3)Cl2] it is interesting to note that the gold(III) ion only 
binds to half the donor atoms present in the ligand. One would therefore expect these 
metal compounds to have several distinct stretching modes present in their spectra and 
indeed there are. There are separate stretching modes for the metal bound amide ν(C=O) 
and the free amide ν(C=O) (vide supra) as can be expected. There is also the presence of a 
ν(N–H) stretch due to the unbound amide group. In the overlay (Figure 4.1.3.1) below the 
black trace depicts the IR spectrum of the free ligand while the green trace portrays the IR 
spectrum of the metal compound. Interestingly the black arrow in the ν(N–H) region 
indicates the presence of two sharp peaks at 3300 and 3335 cm-1, indicating the presence of 
two individual or chemically distinct ν(N–H) stretches. This is unexpected considering ligand 
H2L3 contains C2 symmetry, at least in solution, evident by NMR (see Chapter 4.2) and 
therefore the individual ν(N–H) stretches should be chemically equivalent and display one 
unique signal. The case in the solid state, however, is markedly different (see Chapter 2). 
One of the amide ν(N–H) groups is intramolecularly hydrogen bonded to the neighbouring 
amide carbonyl oxygen as well as the pyridine nitrogen. These hydrogen bonds elongate the 
ν(N–H) bond slightly so that less energy is required to induce a stretch compared to the 
other ν(N–H) bond in the same molecule. The black arrow in the ν(C=O) region indicates the 
ligand H2L3 amide carbonyl stretch at 1685 cm
-1. Hydrogen bonding does not affect the 
individual ν(C=O) moieties and one stretch is observed. The green arrow in the ν(N–H) 
region at 3322 cm-1 corresponds to the single amide ν(N–H) stretch present in the metal 
complex while the two green arrows in the ν(C=O) region at 1649 and 1622 cm-1, 
respectively, correspond to the free and bound amide ν(C=O) stretches. The rest of the 
ligands and their complexes displayed a characteristic and expected disappearance of the 
N–H stretch upon chelation of the gold(III) ion to the ligand. Ligands HL12-HL14 and their 
metal compounds contain a ketone carbonyl group in addition to their amide carbonyl 
group. These two carbonyl groups would be expected to display distinct ν(C=O) stretching 
modes in both the free ligand and metal compound IR spectrums. This is because the ketone 
has a higher bond order since it is a traditional C=O double bond, while the amide carbonyl 
C=O has a lower bond order due to the delocalisation of electrons through the N-C-O amide 
functionality (vide supra). This means that more energy is required to induce the ketone 
stretch than the amide carbonyl stretch. In reality the individual stretching modes are close 
in energy and practically indistinguishable.         
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Figure 4.1.3.1: IR spectra overlay of H2L3 (black) and [Au(HL3)Cl2] (green). 
For ligand HL12 and its respective complex there is no evidence for individual stretches, 
while for ligands HL13-HL14 and their complexes there is slight evidence as the second band 
is part of the other as a shoulder. Ligands HL4, HL9 and HL14 and their respective metal 
compounds also display sharp stretches in the 3000-3300 cm-1 range which are attributed to 
the CH3 stretches of the methoxy groups of HL4, HL14, [Au(L4)Cl2] and [Au(L14)Cl](PF6), 
while the butyl chain for HL9 and [Au(L9)Cl](PF6) contribute the same distinct stretches. 
Overall the ν(C=O) stretches for the compounds in this work follow the trend in the 
literature, shifting to a lower wavenumber when chelated to a gold(III) ion. The ν(C=O) 
stretch for the previously reported free ligand and compound, Quinpy (1687 cm-1) and 
[Au(Quinpy)Cl]Cl (1679 cm-1) compare well with the values obtained for the analogous 
compounds synthesised in this work, HL8 (1684 cm-1) and [Au(L8)Cl](PF6) (1655 cm
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4.2 NMR spectroscopy 
NMR spectroscopy was developed in the 1940s to study the properties of atomic nuclei but 
in 1951, chemists realised that NMR could also be used to determine the structures of 




  or - 
 
 
. Certain nuclei also have allowed spins states of + 
 
 
  or - 
 
 
 and this is the 
property that allows them to be studied by NMR.2, 11 Examples of such nuclei are 1H, 13C, 
15N, 19F and 31P. Spinning charged nuclei generate a magnetic field, similar to that of a bar 
magnet. In the absence of an applied magnetic field the nuclei are randomly orientated 
according to their spin; however, when a magnetic field is applied the nuclei orientate 
themselves with or against the field (Figure 4.2.1).2, 11 More energy is required to align them 
against the magnetic field than with it, hence there are more nuclei aligned with the 
magnetic field than against it.2  In the case of 1H NMR, protons that are aligned with the 
magnetic field are in the lower spin-energy α-spin state and the protons that are aligned 
against the applied magnetic field are in the higher spin-energy β-spin state.2 The difference 
in populations of the two spin states is small, but enough to form the basis of NMR.2  
 
Figure 4.2.1: The spins of nuclei in the absence (left) and in the presence (right) of a 
magnetic field. Diagram adapted and modified from ‘Organic Chemistry’ 4th Edition.2 
The energy difference (ΔE) between the α- and β-spin states depends on the strength of the 
applied magnetic field (B0).
2 The bigger the applied magnetic field, the bigger the energy 
difference between the two states. When a sample is subjected to a pulse of energy that 
corresponds with the energy difference between the α- and β-spin states, the nuclei in the 
α-spin state are promoted to the β-spin state.2 This transition is called spin ‘flipping’.2 The 
radiation required to induce spin ‘flipping’ is generally in the radiofrequency (rf) region of 
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the electromagnetic spectrum.2 When the nuclei undergo relaxation from the β-spin state 
back to the α-spin state, they emit electromagnetic signals, which are detected and 
displayed as an NMR spectrum. Planck’s constant, h, is the proportionality constant relating 
to the energy difference (ΔE) to the frequency (ν).2 The equation below shows that the 
energy difference between spin states (ΔE) depends on the operating frequency of the 
spectrometer, which in turn depends on the strength of the magnetic field (B0), and the 
gyromagnetic ratio (γ).2 The gyromagnetic ratio (γ) is a constant that depends on the 
magnetic moment of the particular nucleus.  
        
 
  
                                                                                                               4.2.1 




                                                                                                                                4.2.2 
This equation can be used to show the magnetic field (B0) is proportional to the operating 
frequency (MHz), so a spectrometer with a more powerful magnet must have a higher 
operating frequency. In general, the stronger the magnet, the higher the resolution of the 
acquired spectrum.  




 ) with a large quadrupolar moment and gyromagnetic ratio. The resonance frequency 
is therefore out of the range of most NMR spectrometers. Only the most symmetrical 
gold(III) complexes would display a 197Au signal sharp enough to observe, but even then the 
sample would have to be highly concentrated and the experiment conducted on a 
specialised spectrometer.  
Upon chelation of a gold(III) ion to the ligands presented in this work, we expect to observe 
a general downfield shift in proton signals of the respective compounds compared to those 
of the respective ligands. This is due to the deshielding environment introduced by the 
gold(III) ion. In general this shift is most prominent with the α-protons since they are the 
closest in proximity to the metal ion. This effect is observed for the previously mentioned 
literature gold(III) amide compounds, [Au(Quinpy)Cl]Cl , [Au(Quinpy)Cl]Cl, [Au(Quinpy)Cl]Cl, 
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S-5 and S-6, which all contain metal compound α-protons with a chemical shift > 8.95 ppm.5, 
8   
4.2.1 Objectives      
The main objective of NMR is a primary identification tool. Once a new ligand or complex is 
synthesised, NMR is the initial technique used to determine if the reaction was a success. It 
can also be used to determine the stability of compounds and the experimental shifts can be 
compared to calculated shifts in order to determine the accuracy of the computational 
method used.  
4.2.2 Results and discussion   
The 1H and 13C NMR spectra for all ligands and complexes are fully assigned in the 
experimental section. Ligands H2L1–H2L3 all contain C2 symmetry and therefore protons and 
carbons on both sides of the ligands are in equivalent chemical environments. The 
consequence of this is that only one signal in present for both atoms on each side of the 
molecule. This symmetry is however removed upon chelation to the gold(III) ion due to the 
unusual co-ordination of the ligand to the metal ion. The result is that each individual 
proton and carbon atom in the 1H and 13C NMR spectra of the respective complexes displays 
a unique signal. This is similarly observed for a cis-dichloro amide gold(III) complex 
synthesised by Che and co-workers.9 Effectively there is a double up in signals from the 
ligand to the metal complex with the only exception being the signal from one, as opposed 
to two, amide NH protons (deprotonation of the metal-bound amide group accounting for 
loss of the second amide proton). The rest of the ligands and complexes are asymmetrical in 
nature and therefore display individual signals for each proton and carbon atom. A more 
detailed discussion on the 1H spectra of ligands H2L3, HL12 and their respective complexes is 
presented below. The reason for this is that both complexes [Au(HL3)Cl2] and 
[Au(L12)Cl](PF6) form the focus of this research and consequently have been studied in 
detail with regards to their biological and structural aspects. The 13C spectra for all ligands 
and complexes display similar trends to that of the proton spectra and hence will not be 
discussed in detail in the view of keeping the discussion concise. Only specific details of 
interesting trends or properties in 13C pertaining to certain ligands and/or complexes will be 
discussed.  
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The 1H NMR spectrum for the free ligand H2L3 exhibits an “all-aromatic” proton spectrum 
with signals spanning the 7–11 ppm range (Figure 4.2.2.1). The chemically and magnetically 
equivalent amide NH protons of the free ligand resonate farthest downfield (10.90 ppm). 
The relatively narrow line width (2.33 Hz) of the amide N–H signal indicates negligible 
dynamic proton exchange in solution at ambient temperature. Analysis of the 
intramolecular hydrogen bonds of H2L3 (see Chapter 2) shows that the amide N–H atom 
H100 is involved in a 3-center (bifurcated) hydrogen bond in which the adjacent isoquinoline 
nitrogen (N1) and carbonyl oxygen (O1) atoms act as H-bond acceptors for the N–H donor. 
The amide N–H atom H200 is hydrogen-bonded to the adjacent isoquinoline nitrogen atom 
N4. Even if some rotational exchange of the two isoquinoline-amide moieties occurs in 
solution, the NH protons of H2L3 are expected to be rigorously H-bonded throughout such a 
process, consistent with an intrinsically narrow line width. From Figure 4.2.2.1 it is evident 
that the amide proton (k) in the gold(III) complex exhibits a minor (0.07 ppm) upfield shift 
relative to the free ligand. More marked, however, is the splitting and dramatic shifts of the 
isoquinoline α-CH proton resonances (i.e. those adjacent to the isoquinoline N atom, a and 
q) upon chelation of the metal ion. From the X-ray structure of [Au(HL3)Cl2], CH proton a 
forms an intramolecular hydrogen bond to the closest chloride ligand (Cl1). The effect of this 
particular interaction is marked deshielding of the proton (labelled a in both spectral 
traces), which culminates in a 0.97-ppm downfield shift in the signal for [Au(HL3)Cl2] relative 
to the chemical shift of the proton in the free ligand. The analogous proton on the metal-
free isoquinoline group of [Au(HL3)Cl2], proton q, is chemically and magnetically distinct 
from proton a. Because of the spatial location of proton q directly over the metal-bound 
isoquinoline ring containing N1 (at a fairly loose ring centroid-to-proton distance of 4.33 Å), 
proton q is shielded by the ring current of the ring system. The magnitude of the upfield 
shift is 0.26 ppm. Equivalent protons f in the free ligand split into two single-integral signals 
(f and l) in complex [Au(HL3)Cl2]. These protons are only marginally affected by metallation 
of the ligand, consistent with an essentially unchanged environment relative to the free 
ligand. The remaining isoquinoline ring protons of [Au(HL3)Cl2] split into independent signals 
consistent with the fact that only one isoquinoline ring serves as a ligand to Au(III) and all 
symmetry is lost in the metal complex. 
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Figure 4.2.2.1: 1H NMR spectra (500.01 MHz) of symmetric H2L3 (blue) and its 
asymmetric mono(amido) gold(III) complex (black), [Au(L3)Cl](PF6) (inset structure) 
recorded in DMSO-d6. Signal integrals and peak assignments are based on the schemes 
for H2L3 and [Au(HL3)Cl2] given in the Experimental Section. Arrows track the 
splittings and shifts for protons a and f that accompany chelation of gold(III) and the 
loss of symmetry in [Au(HL3)Cl2] relative to the free ligand. Intramolecular hydrogen 
bonds and a mid-range C–H···π interaction are shown with dashed lines and interaction 
distances (structure inset).  
For example, metallation splits the 4-fold degenerate doublet at 8.25 ppm of the free ligand 
(protons b and e) into four independent doublets (b, e, m, and p); protons b and e belonging 
to the metal-bound isoquinoline ring exhibit a ≥ 0.27 ppm downfield shift relative to the free 
ligand and reflect, in broad terms, the effect that polarization of the ring by the metal ion 
has on 1H nuclear shielding in the present system. The 1H NMR spectrum for the free ligand 
HL12 also exhibits an “all-aromatic” proton spectrum with signals spanning the 7–12.5 ppm 
range (Figure 4.2.2.2). Since the ligand is asymmetric in the first instance, compared to that 
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of H2L3, all protons display individual signals. The amide N–H resonates particularly far 
downfield at 12.17 ppm, 1.27 ppm further than that for H2L3. This may be because in the 
amide N–H (donor) is hydrogen bonded to both, pyridine and quinoline nitrogen atoms 
(acceptors), in a bifurcated hydrogen bonding system. This would create a greatly 
deshielded environment for the amide N–H, causing its far downfield resonance. This is 
however only speculation as a solid-state structure for this ligand has not been determined. 
The line width of the N–H signal is 5.2 Hz, which is slightly larger than that of H2L3 but still 
fairly narrow in general terms, indicating minimal proton exchange at ambient temperature.       
 
Figure 4.2.2.2: 1H NMR spectra (400 MHz) of asymmetric ligand HL12 (blue) and its 
mono(amido) gold(III) complex (black), [Au(L12)Cl](PF6) (inset structure) recorded in 
CDCl3 and DMSO-d6 repectively. Signal integrals and peak assignments are based on the 
schemes for HL12 and [Au(L12)Cl](PF6) given in the Experimental Section. 
Comparisons in shifts and line widths between ligands H2L3 and HL12 are only estimates and 
cannot be taken as accurate since their spectra have been recorded in different solvents 
(DMSO-d6 and CDCl3, respectively). The proton signals for e, f, i, j and l are contained within 
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similar chemical environments so that their signals overlap in a region spanning 7.43-7.58 
ppm. From Figure 4.2.2.2 it is evident that the spectral window is greatly decreased (7.58-
9.40 ppm) on chelation of the gold(III) ion to the ligand. This is due to the loss of the amide 
N–H signal. Complexes [Au(L5)Cl](PF6)-[Au(L16)Cl](PF6) intrinsically contain two ‘α’ protons 
since they are tridentate compounds. For simplistic reasons we have designated the proton 
on the amide side of the complex the α-proton and the proton on the opposite side of the 
complex, the α’-proton. A diagrammatic representation of the α-proton assignments is 
shown below for clarity. 
 
Figure 4.2.2.3: Diagrammatic representation of the α-proton designations for ligands 
HL5–HL16 and their gold(III) metal compounds. Metal compound [Au(L12)Cl](PF6) is 
used as an example. 
For the gold compound [Au(HL3)Cl2], and in fact all compounds presented in this work 
(Table 4.2.2.1), the α- and α'-protons all exhibit a marked downfield shift when compared to 
their respective ligands. For all complexes, bar two (discussed below), the α-proton signals 
are the furthest downfield. For complex [Au(L12)Cl](PF6) this effect is firstly due to two 
intramolecular hydrogen bonds between protons a and l and the chloride ligand Cl1. 
Secondly, the presence of the gold(III) ion bound to the neighbouring pyridine and quinoline 
nitrogen atoms creates a significantly deshielded environment for these protons. For the 
complex [Au(L12)Cl](PF6) protons a and l resonate at the same frequency and appear as a 
multiplet at 9.37 ppm. Proton a exhibits a downfield shift of 0.44 ppm compared to the 
same proton present in the ligand while proton l displays a downfield shift of 0.40 ppm 
compared to the same proton in the free ligand. Once again these measurements are only 
an estimate as the ligand and complex were recorded in different solvents (CDCl3 and 
DMSO-d6 respectively).    
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Table 4.2.2.1: Table comparing α- and α'-proton shifts between ligands and metal 
compounds.  
 Complex Ligand Difference Complex Ligand Difference 
 δ(1H) α / 
ppm 
δ(1H) α / 
ppm 
ppm δ(1H) α' / 
ppm 
δ(1H) α' / 
ppm 
ppm 
[Au(HL1)Cl2] 9.32 8.56 0.76 N/A N/A N/A 
[Au(HL2)Cl2] 9.29 8.55 0.74 N/A N/A N/A 
[Au(HL3)Cl2] 10.33 9.36 0.97 N/A N/A N/A 
[Au(L4)Cl2] 9.36 8.62 0.74 N/A N/A N/A 
[Au(L5)Cl](PF6) 9.12 8.58 0.54 9.08 8.21 0.87 
[Au(L6)Cl](PF6) 9.07 8.50 0.57 9.13 8.60 0.53 
[Au(L7)Cl](PF6) 9.88 9.19 0.69 9.14 8.60 0.54 
[Au(L8)Cl](PF6) 9.21 9.00 0.21 9.13 8.52 0.61 
[Au(L9)Cl](PF6) 8.99 8.61 0.38 9.36 9.00 0.36 
[Au(L10)Cl](PF6) 9.16 8.71 0.45 9.41 8.97 0.44 
[Au(L11)Cl](PF6) 10.09 9.39 0.70 9.43 9.01 0.42 
[Au(L12)Cl](PF6) 9.37 8.93 0.44 9.37 8.97 0.40 
[Au(L13)Cl](PF6) 9.38 8.93 0.45 9.38 8.97 0.41 
[Au(L14)Cl](PF6) 9.36 8.99 0.37 9.36 9.02 0.34 
[Au(L15)Cl](PF6) 9.08 8.87 0.21 8.85 8.20 0.65 
[Au(L16)Cl](PF6) 9.10 8.57 0.53 8.85 8.20 0.65 
[Au(Quinpy)Cl]Cl5 9.37 9.21 0.16 9.07 8.52 0.55 
[Au(Quingly)Cl]Cl5  9.19 8.88 0.31 N/A N/A N/A 
[Au(Quinala)Cl]Cl5 9.91 8.87 1.04 N/A N/A N/A 
S-58 8.95 N/A N/A N/A N/A N/A 
R-68 9.00 N/A N/A N/A N/A N/A 
The signals d and e at 7.86 and 7.58 ppm, respectively, integrate for two protons. This is 
because there is free rotation around carbon C5-C6 bond allowing for the ortho and meta 
protons (d and e) of the ring to be chemically equivalent and hence their individual signals 
are averaged out as one. One other point to note is that the introduction of the gold(III) ion 
creates a significant enough change in environment so that almost all individual proton 
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signals are discernible from each other which starkly contrasts with the free ligand proton 
signals. As mentioned above for all complexes, bar two, the α-proton signals are the furthest 
downfield. The downfield shift in α-proton signal for compounds in this work correlate well 
with some literature gold(III) amide compounds, [Au(Quinpy)Cl]Cl (9.37 ppm), 
[Au(Quinpy)Cl]Cl (9.19 ppm), [Au(Quinpy)Cl]Cl (9.91 ppm), S-5 (8.95 ppm) and S-6 (9.00 
ppm), which contain α-proton signals that are similarly downfield.5, 8 The two complexes 
that do not exhibit this trait are [Au(L6)Cl](PF6) and [Au(L10)Cl](PF6). Both these complexes 
contain a 1-isoquinoline moiety with proton f displaying the furthest downfield signal (9.85 
and 9.86 ppm, respectively) in both cases (see Chapter 2). The reason for this is again 
presumed to be due to hydrogen bonding. Since the amide carbonyl oxygen contains two 
lone pairs of electrons, it is able to hydrogen bond with both protons f and g (Figure 
4.2.2.4).  These interactions create pseudo six-membered rings which add to the stability of 
the bonds. This would therefore create a greatly deshielded environment for these protons 
allowing them to resonate far downfield. As mentioned this is particularly evident for proton 
f in complexes [Au(L6)Cl](PF6) and [Au(L10)Cl](PF6). The effect is less pronounced for proton 
g but still evident. In general all ligands and complexes containing 1-isoquinoline and/or 8-
aminoquinoline rings with protons that are equivalent to f and/or g displayed an increased 
downfield shift.  
 
Figure 4.2.2.4: Intramolecular hydrogen bonding between protons f and g with the 
carbonyl oxygen of the amide bond for compound [Au(L10)Cl](PF6). 
Ligand HL13 and its respective complex [Au(L13)Cl](PF6) contain a para substituted phenyl 
ketone ring. In the ring the hydrogen atom has been substituted with a fluorine atom. The 
presence of the fluorine atom adds an extra degree of intricacy to the 1H and 13C spectra 
that are already complex. This is because the 19F nucleus is able to couple to and split both 
1H and 13C resonances. For both HL13 and [Au(L13)Cl](PF6) this results in the splitting of 
what would normally be singlet carbon signals C7-C9 (see Chapter 2) into doublets while the 
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proton signals e and d (see Chapter 2) are split into triplets instead of doublets. This was 
unequivocally confirmed for the proton splitting pattern using acquisition parameters 
allowing for a 19F decoupled proton spectrum where the coupling effect of the 19F nucleus is 
removed (Figure 4.2.2.5). The black line represents the standard proton spectrum acquired 
for [Au(L13)Cl](PF6) with the peaks at approximately 7.45 and 7.95 ppm displaying the 
characteristic triplet due to the protons coupling with each other as well as the fluorine 
nucleus. The peak at 7.95 ppm is less clear due to overlap with another proton signal. The 
blue line represents the 19F decoupled proton spectrum. One can see the same proton peaks 
at 7.45 and 7.95 ppm are now represented as doublets instead of triplets. 
 
Figure 4.2.2.5: Diagram showing the 19F coupled 1H spectrum of AuL13 (black trace) 
and the 19F decoupled proton spectrum (blue trace). The figure inset graphically shows 
the proton (blue) and carbon (red) atoms of the phenyl ketone ring that the fluorine 
atom couples with. 
The series of three complexes, [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6), containing the aminomethyl 
substituent were synthesised in the hope that they showed enhanced stability over the cis-
dichloro compounds with the vision of being DNA intercalators. After their initial synthesis, 
the compounds were characterised by NMR spectroscopy. The compounds were dissolved 
in DMSO-d6 and their proton spectra were recorded immediately. The spectra displayed 
clean proton signals correlating to the correct number of protons and hence the samples 
were queued overnight to record all required spectra (1H, COSY, 13C, DEPT135, HSQC and 
HMBC). Analysis of these spectra the next day revealed multiple ‘new’ peaks which is 
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indicative of some form of chemical transformation. It was immediately assumed to be 
some sort of decomposition process as gold(III) complexes are notorious for this.12-14 This 
was investigated by setting up an array experiment where individual spectra were recorded 
every thirteen minutes for 48 h. When analysing the data for [Au(L6)Cl](PF6) (used as an 
example) (Figure 4.2.2.6) several characteristic features were observed which indeed 
confirmed that the complex was undergoing decomposition-specifically demetallation. The 
final spectra are complicated due to the presence of two species in solution; consequently 
multiple overlapping peaks are evident. Two particular regions have been excised from the 
full spectral window (9-9.75 ppm and 4.7-5.5 ppm) in order to clearly display the 
demetallation of complex [Au(L6)Cl](PF6). In Figure 4.2.2.6, the region between 9-9.75 ppm 
shows the emergence of a triplet and the disappearance of two doublets. The emergence of 
the triplet corresponds to the amide N–H proton of the free ligand while the disappearance 
of the doublet signals correspond to protons a and k (see Chapter 2) of complex [Au(HL)Cl2]. 
It is interesting that the amide signal displays a 1:2:1 splitting pattern indicative of coupling 
to a neighbouring proton. This clearly is the case when observing the 4.7-5.5 ppm region of 
the spectrum. The methylene singlet from the aminomethyl moiety associated with 
[Au(L6)Cl](PF6) slowly disappears while a doublet signal, slightly upfield, arises related to the 
free ligand. The singlet associated with the complex is characteristically further downfield 
than the signal related to the free ligand due to the deshielded environment accompanying 
the gold(III) ion. The emerging signal is split into a doublet, due to coupling with another 
proton. In this case it is due to coupling with the free ligand amide N–H proton mentioned 
above. The coupling of the amide N–H proton to the methylene protons is confirmed by a 
strong COSY correlation between the two signals. From this evidence and comparison of the 
spectral arrays to that of the free ligand in DMSO-d6 it was concluded that the complexes 
were unstable, undergoing demetallation. It is assumed that the demetallation process is 
reductive as the solution becomes colourless with the concomitant formation of a dark 
brown/black precipitate, indicative of gold(III) reduction to colloidal gold.      
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Figure 4.2.2.6: Selected regions of the spectral window showing the decomposition of 
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4.3 UV-visible spectroscopy 
UV-vis spectroscopy provides information about compounds containing conjugated double 
bonds and/or metal ions.2, 4, 15 Ultraviolet and visible light have just the right energy to cause 
an electronic transition, which is the excitation of the system from the ground electronic 
state to another of higher energy. Depending on the energy required for the transition, the 
molecule will either absorb ultraviolet or visible light. Ultraviolet light is electromagnetic 
radiation with wavelengths ranging from 180-400 nm. Visible light has wavelengths from 
400-780 nm. The normal electronic configuration of a molecule is known as its ground state 
and all the electrons are contained within the lowest energy molecular orbitals. When a 
molecule absorbs light of an appropriate wavelength and an electron is promoted to a 
higher energy orbital, the molecule is said to be in an excited state. The relative energies of 
the bonding, nonbonding and anti-bonding molecular orbitals are shown below (Figure 
4.3.1).2, 4 
 
Figure 4.3.1: Electronic energy levels and the two of the possible transitions in organic 
molecules. Diagram adapted from ‘Organic Chemistry, Fourth Edition’.2 
Ultraviolet and visible light have sufficient energy to cause only the two electronic 
transitions in Figure 4.3.1. The electronic transition with the highest energy is the promotion 
of a non-bonding electron into a π* anti-bonding molecular orbital.2, 4 This is called an n–π* 
transition. The lower energy transition is the promotion of an electron from a π bonding 
molecular orbital to a π* anti-bonding molecular orbital.2, 4 This transition is labelled a π–π* 
transition. In the case of most aromatic molecules the LUMO orbitals are generally the π*-
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orbitals while the HOMO orbitals usually contain full π-symmetry.2, 4 These transitions 
normally occur in the 200-320 nm region.2, 4  
Wilhelm Beer and John Lambert independently proposed that at a given wavelength, the 
absorbance of a sample depends on the amount of sample the light encounters as it passes 
through a solution of said sample.2, 4 This implied that absorbance depends on the 
concentration of sample as well as the length of the light path through the sample. This is 
known as the Beer-Lambert law, is given below: 
                                                                                                                                       4.3.1 




    Intensity of radiation entering sample 
    Intensity of radiation emerging from sample 
   concentration of sample (mol dm-3) 
   length of the light path through sample (cm) 
   molar absorptivity (litre mol-1 cm-1) 
The introduction of a metal ion to the system introduces the possibility of additional 
absorption bands in the 350-500 nm region.15 These absorption bands correspond to the d-d 
metal transitions and/or metal ligand charge transfer bands (ligand-to-metal-charge-
transfer, LMCT, and metal-to-ligand-charge-transfer, MLCT). These transitions are usually 
visible for square planar metal complexes.15  
For the complexes synthesised in this work the π-π* transitions associated with the ligand 
are expected to dominate the absorption spectrum in the 200-320 nm region. The low 
symmetry of the complexes allows the presence of d-d bands which may become more 
intense due to the mixing of metal d and ligand orbitals. The tridentate gold(III) amide 
compounds [Au(Quinpy)Cl]Cl , [Au(Quinpy)Cl]Cl, [Au(Quinpy)Cl]Cl and S-5, reported in the 
literature, all contain absorption bands between 300 and 400 nm. For the compounds 
[Au(Quinpy)Cl]Cl , [Au(Quinpy)Cl]Cl and [Au(Quinpy)Cl]Cl these bands are assigned to LMCT-
based transitions.5 The exact nature and wavelength maximum of the band for compound S-
5 it not disclosed in the literature, however due to the similarity of the ligands, one might 
postulate that the ≈310 nm absorption band is LMCT-based.      
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4.3.1 Objectives  
The primary objective was to use the electronic spectra of the compounds to investigate 
their biological properties. These properties include; the stability of the compounds in 
biologically relevant media, log Po/w values, calf thymus DNA binding constants and the 
interaction between the compounds and relevant biomolecules such as glutathione and 
imidazole. The experimental electronic spectra were also compared to the DFT simulated 
spectra in order to determine the accuracy of the computational method.  
4.3.2 Results and discussion 
The electronic spectra for all the complexes investigated in this study were similar in that 
there was an intense π–π* band around 240 nm and a weaker n–π* band around 290 nm. 
There is also the presence of a relatively weaker LMCT band around 450 nm.  
 
Figure 4.3.2.1: Overlaid electronic spectra of H2L3 (green line) and [Au(HL3)Cl2] (blue 
line) showing the π–π* region (A and B) for both molecules and the LMCT band (inset C) 
for [Au(HL3)Cl2]. 
The electronic spectra of the ligand, H2L3 (green line) and its metal complex, [Au(HL3)Cl2] 
(blue line), are shown as an example below in Figure 4.3.2.1. The peaks labelled A and B for 
both spectra, are assigned to the π–π* band and the n–π* band respectively, consistent with 
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the delocalised structure of the predominantly aromatic ligand. As can be seen (Figure 
4.3.2.1) upon chelation of the ligand with a gold(III) ion, the π–π* peaks red-shift slightly and 
a new peak arises (labelled C). This comparatively less intense peak is assigned to the LMCT 
band associated with the metal complex. These assignments are backed up by the 
computational work discussed in Chapter 5.  
Table 4.3.2.1: Summary of the two major λmax values in the π-π* and LMCT regions of 
the metal complexes reported in this work.   
Compound λmax/nm (ε/x 10
3 M-1cm-1) λmax/nm (ε/x 10
3 M-1cm-1) 
[Au(HL1)Cl2] 312 (5.1) 453 (0.16) 
[Au(HL2)Cl2] 310 (3.9) 449 (0.12) 
[Au(HL3)Cl2] 297 (30) 468 (2.9) 
[Au(L4)Cl2] 269 (18) 477 (6.3) 
[Au(L5)Cl](PF6) 224 (32) 317 (40) 
[Au(L6)Cl](PF6) 226 (45) 301 (8.2) 
[Au(L7)Cl](PF6) 244 (83) 342 (2.4) 
[Au(L8)Cl](PF6) 256 (44) 364 (12) 
[Au(L9)Cl](PF6) 257 (6.4) 362 (2.4) 
[Au(L10)Cl](PF6) 248 (67) 374 (9.0) 
[Au(L11)Cl](PF6) 248 (93) 349 (12) 
[Au(L12)Cl](PF6) 253 (38) 369 (7.7) 
[Au(L13)Cl](PF6) 255 (34) 369 (7.3) 
[Au(L14)Cl](PF6) 256 (32) 362 (9) 
[Au(L15)Cl](PF6) N/A
a 376 (6.3) 
[Au(L16)Cl](PF6) N/A
a 379 (7.7) 
[Au(Quinpy)Cl]Cl5 N/A ≈365b 
[Au(Quingly)Cl]Cl5  N/A ≈360b 
[Au(Quinala)Cl]Cl5 N/A ≈370b 
S-58 N/A ≈310b 
a
The electronic spectra for complexes [Au(L15)Cl](PF6) and [Au(L16)Cl](PF6) were recorded in DMSO due to lack of solubility 
in more appropriate solvents. DMSO absorbs in the region were the π-π
*
 absorption band would normally be positioned, 
hence their non-availability.
b
 Exact absorption maxima and extinction coefficients not given in the literature and have 
therefore been estimated from figures. 
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The metal compounds were essentially synthesised as four different generations of 
compounds. Metal compounds [Au(HL1)Cl2]–[Au(L4)Cl2] were synthesised first followed by 
[Au(L5)Cl](PF6)–[Au(L7)Cl](PF6), [Au(L8)Cl](PF6)–[Au(L14)Cl](PF6) and finally [Au(L15)Cl]– 
[Au(L16)Cl]. The λmax values for these complexes are similar within a generation, and even 
between generations. For example, metal compounds [Au(HL1)Cl2]–[Au(L4)Cl2] all contain a 
weak LMCT band in the ~450 nm region whereas [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) absorb in 
the lower 300 nm range and [Au(L8)Cl](PF6)–[Au(L16)Cl] absorb in the mid-to-higher 300 nm 
range. This is because there are only slight structural changes between generations and 
even smaller structural changes within a generation. The spectra for the cis-dichloro 
compounds, [Au(HL1)Cl2]–[Au(L4)Cl2], were similar to that of an analogous gold(III) amide 
compound presented in the literature, [Au(HL)Cl2] (H2L = 2,2'-bis(2-pyridylcarboxyamide)-
1,1'-binaphthyl), with absorption maxima at 250, 350 and 470 nm.9 The tridentate 
compounds from this work were also found to follow the trend set by literature compounds, 
[Au(Quinpy)Cl]Cl , [Au(Quinpy)Cl]Cl, [Au(Quinpy)Cl]Cl and S-5, which similarly obtain 
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4.4 Stability and reactivity 
The metal complexes described in this work were synthesised with the aim of being metallo-
therapeutic drugs in the fight against cancer. One of the primary characteristics one has to 
consider and evaluate when testing such drugs is their solution stability, in traditional 
solvents such as acetonitrile, methanol and ethanol, as well as biologically relevant solvents 
such as buffered aqueous media. This is particularly pertinent in the field of gold(III)-based 
metallo-therapeutics.16-18 This is because gold in its +3 oxidation state is electron deficient 
and readily undergoes hydrolysis reactions as well as reductive demetallation reactions.16, 17 
Hydrolysis reactions generally occur when the metal complex in question contains an 
accessible co-ordination site such as in the [Au(III)(terpy)Cl]+ system, however it is also 
possible for hydrolysis reactions to occur in tetradentate systems such as the bis(pyrrole-
imine) gold(III) system.19-21 For the bis(pyrrole-imine) gold(III) system this only occurs when 
the bridging unit of the system contains a two-carbon linker imposing geometries that 
deviate significantly from the norm, creating a highly strained co-ordination environment. 
This allows for the cleavage of one Au–N bond by a water molecule followed by hydrolysis 
to form the species shown below in Figure 4.4.1. 
 
Figure 4.4.1: Chemical structure of the hydrolysis product originating from a 
bis(pyrrole-imine) gold(III) compound.19 
Reductive demetallation in gold(III)-based compound systems is very common.5, 14, 17, 22 One 
way of avoiding this problem is via the introduction of multidentate-chelating ligands which 
contain strong σ-donor ability and are hence able to stabilise the gold(III) ion in its high 
oxidation state. An example of such a ligand is tetraphenylporphyrin (TPP).12, 13 This is a 
macrocyclic tetradentate ligand containing two anionic and two neutral N-donors. This 
ligand is able to stabilise the gold(III) centre in biologically relevant media as well as towards 
cellular reducing agents such as glutathione (GSH).12, 13 Most gold(III) complexes synthesised 
with the intention of being metallotherapeutic drugs are evaluated for their stability 
towards GSH. This is because GSH is one of the most prevalent intracellular reducing agents 
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and is present in animal cells at a concentration of approximately 5 mM.23 GSH is a 
tripeptide comprising glutamate, cysteine and glycine and is used in a variety of 
detoxification, transport and metabolic processes.23 An example is in its use as a substrate 
for peroxidase reactions in helping to destroy peroxides generated by oxidases.23, 24 It is 
present in either its reduced form (GSH) or its oxidised form (GSSH). The ratio of reduced 
glutathione to oxidised glutathione is often used as a measure of cellular toxicity.24 Once 
oxidised, glutathione can be reduced back by glutathione reductase using NADPH as an 
electron donor.24  
 
Figure 4.4.2: Chemical structures of reduced glutathione (GSH) and oxidised 
glutathione (GSSH).  
4.4.1 Objectives 
The objectives of this section are to evaluate the compounds synthesised in this work for 
their solution stability in biologically relevant media, such as a buffer system, using 
UV/Visible spectroscopy. Once the compounds were proven stable in said media they were 
further evaluated for their stability in the presence of certain biomolecules such as GSH and 
imidazole. 
4.4.2 Experimental 
Ultra-pure water (resistivity 18.2 MOhm.cm) was used to prepare the tris buffers used in 
this work. The correct amount of tris and sodium chloride to formulate a 50 mM and 10 mM 
solution, respectively, were weighed out and dissolved in a small amount of ultra-pure 
water. This solution was then placed in a jacketed conical flask which was connected to a 
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thermostatically regulated water bath at 37 °C. This is to mimic physiological conditions. The 
solution was then titrated with concentrated HCl to a pH of 7.34 and decanted into a 250 mL 
volumetric flask and allowed to cool to room temperature before making up to the mark. 
For all experiments below the chloride salt of each complex was used as it is water soluble. 
4.4.3 Results and discussion    
As previously mentioned, the metal compounds in this work were synthesised in four 
different generations. Metal compounds [Au(HL1)Cl2]- [Au(HL4)Cl2] were synthesised first 
and hence their stability was assessed first. Metal complex [Au(HL3)Cl2] was the only one 
from the first generation of complexes that proceeded through to the 5-dose phase of 
testing at the National Cancer Institute (NCI), hence this complex was used as a 
representative example for analysis of its solution stability. The complex was dissolved in 
pure spectroscopic grade DMSO and an amount was added to a 1 cm UV/Vis quartz cuvette 
containing a tris buffered saline (TBS, 50 mM Tris, 10 mM NaCl, pH 7.34 at 37 °C) solution so 
that the final concentration of complex was 1.16 x 10-5 M. Spectra were then recorded at 30 
min intervals over a period of 48 h to observe any significant spectral change and hence the 
solution stability of the complex. Figure 4.4.3.1 below displays graphically successive scans 
over this period with the orange line displaying time = 0.5 h, the purple line time = 12 h and 
the red line time = 48 h. It was noticed immediately that there was a shifting baseline which 
is characteristic of precipitation, and indeed this was observed. Once the 48 h period was 
complete the sample was removed from the spectrometer and a fine white precipitate was 
present along with a clear solution. This was interesting as the complex itself in solution is a 
dark red colour. From the figure below it is clearly visible that there is a steady decrease in 
absorbance over the 48 h period, specifically in the 300-400 nm region, which is where the 
LMCT band of the complex lies. 
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Figure 4.4.3.1: Spectra of [Au(HL3)Cl2] recorded as a function of time in TBS at a 
complex concentration of 1.16 x 10-5 M, pH 7.34 and at 37 °C. All spectra were corrected 
for any background offset by setting A600 = 0.  
It is therefore clear that there is some kind of decomposition of the complex occurring in 
solution. There are two hypotheses that would account for the observed spectral changes. 
The first is reductive demetallation where no substitution of the chloride ions takes place 
and the metal centre is directly reduced ‘out’ of the ligand in one step. The second and 
more likely process is the substitution of the chloride ions with water followed by reductive 
demetallation. Substitution of the chloride ions with DMSO was ruled out by observing the 
1H NMR spectrum of the complex in pure DMSO-d6 over the same time period with no 
noticeable change. If the second proposed mechanism was to be considered one would 
assume there would be at least two steps, the first comprising simultaneous substitution of 
both chloride ions followed by a second reductive demetallation step. If each of the chloride 
ions were equivalent in terms of reactivity, this assumption would hold. In the case of 
complex [Au(HL3)Cl2] the ligand contains two dissimilar N-donor moieties, the stronger σ-
donor amide nitrogen and the weaker σ-donor heterocyclic pyridine nitrogen. This causes a 
structurally evident trans effect whereby the Au–Cl bond trans to the amide nitrogen donor 
is greatly lengthened compared to the Au–Cl bond trans to the pyridine nitrogen. This in 
effect renders the chloride ion trans to the amide nitrogen more labile and susceptible to 
nucleophillic attack. In this case there should be three steps observable, two separate 
distinguishable substitution steps for each chloride ion followed by reductive demetallation. 
The concomitant formation of a precipitate does not allow for accurate rate constants to be 
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determined. That being said, the absorption of the complex was monitored at 295 nm and 
plotted against time in order to try and discern whether the process is a two- or three-step 
progression (Figure 4.4.3.2). The data fits a double exponential decay function indicating 
that there is a two-step process with the first and second rate constants being 0.024(2) h-1 
and 0.15(3) h-1, respectively. This result is interesting considering the trans effect argument 
mentioned above. The reaction is either truly biphasic, with the substitution of the chloride 
ions occurring simultaneously, or the first step in the three step process occurs extremely 
fast and takes place in under half an hour, which is the first time point in the experiment. 
The kinetic trace, however, does confirm a multi-step process over the single-step 
demetallation process. Water suppression 1H NMR experiments were performed in order to 
deconvolute the mechanistic detail. However a high enough concentration was not 
achievable in order to observe a spectrum at a reasonable signal-to-noise ratio in relation to 
acquisition time. Complexes [Au(HL1)Cl2], [Au(HL2)Cl2] and [Au(L4)Cl2] were similarly 
monitored. A similar trend to [Au(HL3)Cl2] was observed for [Au(HL1)Cl2] and [Au(HL2)Cl2] 
while [Au(L4)Cl2] exhibited a marked increase in comparable stability.      
 
Figure 4.4.3.2: Double exponential decay curve for [Au(HL3)Cl2] at 295 nm in TBS at a 
complex concentration of 1.16 x 10-5 M, pH 7.34 and at 37 °C over a period of 48 h. Non-
linear equation used:          (     )         (     ) where t = time, A1 and A3 are 
Y spans; A2 and A4 are rate constants. R is 0.9987, A1 is 0.18(1), A2 is 0.024(2) h-1, A3 is 
0.10(1) and A4 is 0.15(3) h-1.   
Due to the lack of stability and relatively poor cytotoxicity for [Au(HL3)Cl2], the cis-dichloro 
compounds were abandoned and the aminomethyl-based tridentate compounds, 
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[Au(L5)Cl](PF6)-[Au(L7)Cl](PF6) were synthesised. All three of these compounds were 
accepted at the NCI for 1-dose testing against their panel of 60 human cancer cell lines with 
both [Au(L6)Cl](PF6) and [Au(L7)Cl](PF6) progressing further to the repeat 5-dose phase. It 
has already been shown, by NMR, that this generation of complexes are unstable in DMSO-
d6 (see chapter 4.2). It was therefore expected that they would be similarly unstable in TBS, 
and indeed they were. Complex [Au(L6)Cl](PF6) is used as an example (see Figure 4.4.3.3 
below). An appropriate amount of the complex was dissolved in 1 mL spectroscopic grade 
DMSO and 19 mL of TBS added to make a solution containing 5% DMSO. This solution was 
then monitored by UV/Vis spectroscopy over a period of 12 h. As one can see below, the 
absorption peak at 365 nm displays a 57% reduction in absorbance over the 12 h. This 
agrees with the NMR data and can be attributed to reductive demetallation of the complex.  
 
Figure 4.4.3.3: UV/Vis absorption spectrum for complex [Au(L6)Cl](PF6) at a 
concentration of 2.32 x 10-5 M, pH 7.34 and at 37 °C. The spectra were recorded over a 
period of 12 h displaying a 57% drop in absorbance at 365 nm. 
Complexes [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) were similarly abandoned due to their instability 
and the next generation of complexes, [Au(L8)Cl](PF6)–[Au(L14)Cl](PF6), were synthesised to 
circumvent solution and redox instability; these complexes all contain an 8-aminoquinoline 
group in place of the aminomethyl moiety. All the complexes bar [Au(L9)Cl](PF6) and 
[Au(L13)Cl](PF6) were accepted through to the 5-dose phase of testing at the NCI with 
[Au(L10)Cl](PF6), [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) exhibiting particularly encouraging 
results (see Chapter 7). It was therefore imperative that the stability of these complexes be 
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evaluated in TBS. The chloride salts of each of the complexes were used as they are readily 
soluble in TBS. All complexes were dissolved directly in TBS, as their chloride salts, and their 
spectra observed over a period of 24 h. Complex [Au(L12)Cl](PF6) is used as an example 
below (Figure 4.4.3.4).  As Figure 4.4.3.4 depicts, complex [Au(L12)Cl](PF6) displays a 2% 
decrease in absorbance at 362 nm over a 24 h period. This decrease is effectively negligible 
and is comparable to Au[Por]+,12, 13 indicating complexes [Au(L8)Cl](PF6)–[Au(L14)Cl](PF6) 
are stable in the tested media. All complexes displayed similar stability with complex 
[Au(L13)Cl](PF6) showing the largest percentage decrease in absorbance (2.5%) at 362 nm.    
 
Figure 4.4.3.4: UV/Vis absorption spectrum taken over a period of 24 h at 37 °C in TBS, 
pH 7.34, for complex [Au(L12)Cl](PF6) (1.52 x 10-5 M) displaying a 2% drop in 
absorbance. 
Due to the marked increase in stability of complexes [Au(L8)Cl](PF6)–[Au(L14)Cl](PF6) in TBS, 
complex [Au(L7)Cl](PF6) was used as a representative example due to its potent cytotoxicity 
and evaluated further for its stability in the presence of glutathione and imidazole. 
Glutathione, as mentioned in the introduction to this section, is a biologically relevant 
reducing agent and as such it is of vital importance to assess the stability of the complexes 
towards it. Imidazole is a heterocyclic aromatic N-donor that is intended to mimic relevant 
biomolecules such as the amino acid histidine as well as the nucleobases adenine, thymine, 
guanine and cytosine.24 This would give us an idea whether the nucleobases are able to 
substitute the chloride ion in the fourth co-ordination site and hence be able to form DNA-
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drug adducts as cisplatin does.25 Figure 4.4.3.5 A below displays the spectra of complex 
[Au(L12)Cl](PF6) collected over a 24 h period in the presence of a tenfold higher 
concentration of imidazole while Figure 4.4.3.5 B displays complex [Au(L12)Cl](PF6) in the 
presence of a tenfold higher concentration of glutathione at 10 minute intervals over a 12 h 
period. As can be seen from 4.4.3.5 A, there is a minimal 3.5% decrease in the LMCT 
absorption band positioned at 364 nm. This indicates that there is no chemical reaction 
taking place under the chosen reaction conditions and complex [Au(L12)Cl](PF6) is stable 
towards nucleophillic substitution of the chloride ion by imidazole. This further suggests 
that if the complex does interact with DNA through intercalation, as it was intended by 
design, the complex will not form DNA-complex biomolecule adducts and the DNA-complex 
interaction will be driven purely by electrostatic and van der Waals forces. Figure 4.4.3.5 B 
displays effectively a 100% reduction in the LMCT absorption band in the presence of 
glutathione. After 12 h (Figure 4.4.3.5 B, red line) the reaction is effectively complete. This is 
indicative of reductive decomposition of the complex. It is interesting to note that upon 
mixing the individual solutions a fine milky white precipitate formed immediately. This was 
confirmed by the presence of a shifting baseline seen in the representative figure below.  
 
Figure 4.4.3.5: UV/Vis spectra of [Au(L12)Cl](PF6) in the presence of a tenfold increase 
in concentration of imidazole over a period of 24 h (A) and in the presence of a tenfold 
increase in concentration of glutathione (B) over 12 h. Both sets of spectra were 
recorded at 37 °C in TBS at pH 7.34. All spectra were corrected for any background 
offset by setting A600 = 0. 
After the 12 h period was complete the contents of the cuvette were centrifuged and both 
the precipitate and supernatant liquid were analysed by mass spectrometry. The 
supernatant liquid contained both oxidized and reduced glutathione as well as [AuCl2]
- while 
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the precipitate contained free ligand and [AuCl2]
-. It is therefore clear that the complex 
undergoes reductive demetallation, presumably, through a multistep process. The proposed 
mechanism is substitution of the chloride ion by the S-H moiety of glutathione followed by 
electron transfer and reduction of the gold(III) centre to gold(I), then further substitution by 
chloride ions on the gold centre to form [AuCl2]
-. The stabilities of complexes [Au(L15)Cl] 
and [Au(L16)Cl] were unable to be evaluated due to their inherent insolubility in up to 15% 
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4.5 Octanol/Water partition coefficients 
The transport of a drug to its site of action normally involves the drug having to pass 
through several lipid membrane systems.26, 27 As a result of this, the solubility of a drug in 
aqueous media relative to lipids is of considerable significance in the transport of that drug 
to its site of action.26, 27 This is specifically important at the aqueous medium/lipid interface. 
Partition coefficients are therefore a way to measure the distribution of a compound 
between two immiscible solvents in the attempt to correlate the activities of the drugs with 
their partition coefficient.28 Such correlations have been used with some success in the 
prediction of the activities of some potential drugs; however, the results are generally only 
valid when the solubility and transport by diffusion through a membrane are the main 
factors controlling the drug action.26, 27 
It is not easy to measure partition coefficients in situ and so instead the less accurate 
organic solvent/aqueous solution model system is used.26, 27 The octanol/water partition 
coefficient is the ratio between the amount of drug present in the octanol layer and the 
amount of drug present in the aqueous layer at equilibrium. Octanol/water partition 
coefficients are shown below (Figure 4.5.1) for selected literature compounds.  
 
Figure 4.5.1: Structures and log Po/w values of an anti-biotic (amoxicillin), two anti-
cancer chemotherapeutic drugs (doxorubicin and RDC11) and an anti-psychotic drug 
(chlorprothixene).   
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The log of this value (log Po/w) is the value that is normally quoted and used in quantitative-
structural-activity relationship studies.26, 27 The ratio is essentially independent of 
concentration and is generally calculated using the shake flask method.26-28 The use of n-
octanol as the representative hydrophobic phase is due to its similar structure to 
phospholipids present in cell membranes. The eight carbon chain mimics the hydrophobic 
tail while the alcohol group mimics the hydrophilic head. The second phase is water, since 
the main constituent of blood serum is water. The more hydrophobic a drug is, the more 
likely it is to be found in lipid membranes while the more hydrophilic a drug is, the more 
likely it is to be found in blood serum. Generally a drug must contain some hydrophobic 
character since some of the most important interactions between drugs and a biological 
system depend on its hydrophobicity. Some examples of such interactions are enzyme-
ligand, drug-receptor interactions and transport through biological membranes.26, 27 The 
efficient penetration through membranes is a prerequisite for most drugs, but, particularly 
important in the case of orally ingested candidates which must move from the intestine to 
the blood and on to their intended target.29 The ability of a drug candidate to cross these 
barriers until it finds its intended target and performs its function is most often described by 
the octanol/water partition coefficient.  
4.5.1 Objectives 
The objective in determination of the octanol/water partition coefficients of the metal 
compounds presented in this work is to determine whether they are hydrophilic or 
hydrophobic in nature. This will hopefully allow us to better understand the activity profiles 
of the compounds and to correlate their relative activities with their structures.  
4.5.2 Experimental  
The method that was chosen for the determination of octanol/water partition coefficients in 
this work was the ‘shake-flask’ method. This method is the most labour intensive but also 
the most reliable and accurate method. There are other methods for determination of 
octanol/water partition coefficients, such as by means of HPLC.26, 27 This method is based on 
the retention time of the candidate on the column and comparing this value to structurally 
similar compound’s retention times.26, 27 The problem with this method is that there are not 
many, if any, gold(III) metal compounds that are structurally similar to the ones developed 
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in this work who’s octanol/water partition coefficients have been determined. The ‘shake 
flask’ method requires the use of octanol-saturated water and water-saturated octanol. This 
is to avoid artificial carry-over between phases during the experimental procedure. The 
solvents were prepared by vigorously shaking high grade octanol with ultra-pure water 
(resistivity = 18.3 MOhm.cm). The two phases were allowed to separate over a period of 24 
h and then were centrifuged and collected as the individual saturated phases. These are the 
solvents that were used in the determinations. Ideally, extinction coefficients from a Beer-
Lambert plot of the candidate in both octanol-saturated water and water-saturated octanol 
should be determined in order to determine the concentration of the candidate in each 
phase so that equation 4.5.2.1 is used to determine the octanol/water partition coefficient. 
           log(
                
              
)                                                                                   4.5.2.1 
However, this was not possible for the metal compounds studied in this work as they were 
not sufficiently soluble in octanol to determine their extinction coefficients. It was therefore 
assumed that each complex exhibits a similar extinction coefficient in both solvents and the 
respective absorbance values were used to determine the octanol/water partition 
coefficients using equation 4.5.2.2. 
           log(
        
      
)                                                                                                 4.5.2.2           
An aqueous solution of approximately 10-5 M for each complex was prepared and vigorously 
shaken with an equal volume of octanol, then allowed to stand for 2 h before the solution 
was centrifuged and the individual layers isolated. The absorbance of each of the phases 
was determined in triplicate and the average used to determine the log Po/w for each 
compound.  
4.5.3 Results and discussion  
As has been discussed previously, metal compounds [Au(HL1)Cl2]–[Au(L7)Cl](PF6) and 
[Au(L15)Cl]–[Au(L16)Cl] are all either unstable in solution and/or not soluble in the media 
required. Both these factors are critical for determining octanol/water partition coefficients. 
Due to this constraint, only the octanol/water partition coefficients for metal compounds 
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[Au(L8)Cl](PF6)–[Au(L14)Cl](PF6) were determined. The results for all the complexes studied 
are displayed in Table 4.5.3.1. 
Table 4.5.3.1: Summary of the average log Po/w values for the indicated gold(III) 
compounds synthesised in this work.  
Metal compound structure  Metal complex log Po/w 
 
 [Au(L8)Cl](PF6) -2.06 
 
 [Au(L9)Cl](PF6) -0.80 
 
 [Au(L10)Cl](PF6) -0.91 
 
 [Au(L11)Cl](PF6) -2.16 
 
 [Au(L12)Cl](PF6) -1.41 
 
 [Au(L13)Cl](PF6) -1.33 
 
 [Au(L14)Cl](PF6) -1.00 
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All the metal compounds analysed in this work display large negative log Po/w values 
indicating they are extremely hydrophilic in nature and are likely to localise in the blood 
serum in vivo. This result is an expected one as the compounds studied are charged cationic 
metal compounds and will therefore be more soluble in polar solvents rather than non-polar 
solvents. Compound [Au(L11)Cl](PF6) has the lowest log Po/w value at -2.16 while complex 
[Au(L9)Cl](PF6) has the highest log Po/w value at -0.80. This result again is an expected one as 
complex [Au(L9)Cl](PF6) contains an aliphatic butyl chain which would increase its solubility 
in non-polar solvents while [Au(L11)Cl](PF6) contains a polar fully aromatic structure that 
would tend towards dissolution in more polar solvents. Within this generation, complexes 
[Au(L8)Cl](PF6)–[Au(L11)Cl](PF6) were synthesised first with complexes [Au(L11)Cl](PF6)–
[Au(L13)Cl](PF6) being synthesised subsequently. There does not appear to be any 
correlation between cytotoxicity and log Po/w for compounds [Au(L8)Cl](PF6)–
[Au(L11)Cl](PF6). Complexes [Au(L8)Cl](PF6), [Au(L10)Cl](PF6) and [Au(L11)Cl](PF6) display 
vastly different log Po/w values of -2.06, -0.91 and -2.16 yet all made it through to the repeat 
5-dose phase of testing while complex [Au(L9)Cl](PF6) failed at the 1-dose phase even 
though it exhibited the most hydrophobic log Po/w value of -0.80. Complexes 
[Au(L12)Cl](PF6)–[Au(L14)Cl](PF6) all displayed log Po/w values between 1 and 1.41. The 
reason for the addition of the fluoro and methoxy groups in the para position of the phenyl 
ketone ring was to try to increase the lipophilicity of the compounds and hence their 
activity, as was observed for some β-tryptase inhibitors as well as µ and κ opioid 
analgesics.30, 31 This imparted the desired effect with the fluoro and methoxy substituted 
complexes [Au(L13)Cl](PF6) and [Au(L14)Cl](PF6) exhibiting higher log Po/w values. They were 
however less cytotoxic and little correlation between cytotoxicity and log Po/w values for 
these three complexes was observed since [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) both made 
it through to the repeat 5-dose phase of testing (NCI-60 cytotoxicity screen)  despite 
exhibiting the two lowest log Po/w values, while [Au(L14)Cl](PF6) exhibited the highest log 
Po/w value but failed at the 1-dose phase of the NCI cytotoxicity screen against their panel of 
60 human cancer cell lines.  
When compared to other organic drugs the hydrophilicity of the metal compounds in this 
work is considerably higher. The organic drugs, gabapentin and amoxicillin, are some of the 
more hydrophilic drugs with a log Po/w values of -1.25 and -1.71.
32 This value is similar to the 
complexes [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) with values of-1.41 and -1.33 respectively. 
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The vast majority of anti-cancer drugs that are in clinical use today are highly lipophilic, 
much more so than the metal compounds studied in this work, since they are generally 
organic in nature with log Po/w values as high as 6.03 for chlorproxithene.
28 A much more 
realistic comparison of the log Po/w values could be drawn against other metallo-drugs such 
as cisplatin or octahedral ruthenium based complexes. There are very few sources of such 
information for such complexes, however, Gaiddon and co-workers have recently reported a 
large library of second generation octahedral ruthenium complexes and their correlation 
between log Po/w values, reduction potentials and IC50 values.
33 Of the 32 metal compounds 
synthesised, most displayed positive log Po/w values despite being positively charged.
33  
Specifically, metal compounds with reduction potentials between 0.4–0.6 V (vs. SCE) and log 
Po/w above 2.0 display the lowest IC50 values.
33 When looking to correlate the log Po/w values 
for all compounds studied with cytotoxic activity (via mean growth percentage values), no 
immediate correlation was evident. Upon further investigation, a correlation within the 
phenyl ketone class of compounds was observed, albeit an unconventional one. A plot of log 
Po/w vs mean growth percent revealed that the more negative the log Po/w value, the more 
cytotoxic the compound was. This was an unusual result as, in general, it is observed that an 
increase in log Po/w value for a certain class of drugs (particularly cationic metallotherapeutic 
drugs) results in an increase in cytotoxic activity.33  
 
Figure 4.5.3.1: Plot of the mean growth percent values versus their log Po/w values 
showing the unconventional correlation. The correlation coefficient of the fit is 0.985.  
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4.6 DNA binding studies 
The gold(III) metal compounds in this work were designed to be novel and effective 
metallotherapeutic agents in the fight against cancer. The mode of action through which 
they were intended to exert their cytotoxicity was topoisomerase inhibition or poisoning. 
There are several methods and steps in the topoisomerase catalytic cycle where a drug can 
effect its action.34-36 In the case for the compounds presented in this work, they are 
anticipated to effect their action via DNA intercalation. For DNA intercalation to occur the 
drug should contain two important features. Firstly; the drug must contain an extended 
planar aromatic region in order to insert itself between base pairs of the DNA and stabilise 
itself within the DNA through van der Waals interactions such as π-stacking, and secondly, 
the drug should contain a positive charge in order to interact electrostatically with the 
negatively charged phosphate backbone of the DNA.37 If a drug is to inhibit or poison 
topoisomerase through intercalation it must also to be able to interact with the enzyme 
while intercalated into DNA. 
Since DNA is the blueprint for life it is a common target for numerous drugs and biological 
agents. Some common antibiotics and anti-cancer agents such as doxorubicin and 
actinmomycin affect their biological action through DNA intercalation.38 There are also 
numerous biological agents that are used to visualise DNA via enhanced fluorescence during 
an intercalation event when performing certain assays. These compounds include ethidium 
bromide (EB) and acridine orange. DNA intercalation can be described and quantified by the 
following parameters: 
 Kb = binding constant at equilibrium 
 rf = ratio of intercalator to total nucleotide concentration 
 r = ratio of bound intercalator to total nucleotide concentration 
Calf thymus and salmon testes DNA are widely used as analogues to human DNA for 
determining the binding affinity of drugs.39-43 In this work, calf thymus DNA was chosen and 
used for all DNA binding experiments.  There are two general methods through which a 
binding constant between DNA and drug can be determined. The first and more accurate 
method is conducted via UV/Visible spectroscopy. The drug is dissolved in a buffered 
aqueous system while increasing amounts of a DNA solution are added. A spectrum is 
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recorded after every addition of DNA and the LMCT region monitored for a red shift as well 
as hypochromism. Analysis of these spectral changes results in the determination of a 
binding constant Kb (see Experimental for details). The second method is through 
competitive binding experiments with EB.44 EB displays a marked increase in fluorescence 
while intercalated between base pairs. It has been shown that the presence of a second 
intercalator is able to quench the fluorescence of the EB by displacing it from the DNA. From 
this characteristic, a less accurate, apparent binding constant is calculated (see Experimental 
for details). 
Molecules that intercalate DNA have traditionally been organic in nature such as EB and 
acridine. In more recent years however, metallo-intercalators have become a keen area of 
interest. Three proven metallo-intercalators are shown below in Figure 4.6.1.   
 
Figure 4.6.1: Chemical structures of three proven metal-based DNA intercalators. 
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All three compounds shown in Figure 4.6.1 have been shown to have great therapeutic or 
diagnostic potential. Compounds [Au(TPP)]Cl and [Au(C^N^C)(IMe)]CF3SO3 have been 
shown to intercalate ctDNA with binding affinities of 2.8 x 106 M-1 and 5.4 x 105 M-1 
respectively, with both compounds demonstrating encouraging in vivo activity against solid 
tumours.13, 45, 46 The activity of these compounds is said to be based on their intercalative 
ability. The compound [Ru(phen)2(dppz)]2Cl is well known in the literature as the ‘light 
switch’ compound for its enhanced emission in the presence of calf thymus DNA (ctDNA).47 
It binds ctDNA with a large binding constant of 5.1 x 106 M-1 and its binding mode to DNA 
has been meticulously characterised via the publication of several X-ray structures of the 
complex intercalated into different DNA oligomers.48, 49     
4.6.1 Objectives  
The objectives of these experiments are to investigate the interaction of the metal 
compounds synthesised in this work with DNA and to try and determine the specific mode 
by which this interaction occurs. The binding constants between the complexes and DNA 
will be determined and related to their three-dimensional structure and cytotoxicity profiles 
if possible. 
4.6.2 Experimental 
Calf thymus DNA was purchased from Sigma Aldrich as the high purity, highly polymerised 
sodium salt. The ratio of absorbance in the 260 and 280 nm region of the UV spectrum was 
always calculated to be between 1.8-2:1 when performing DNA binding experiments. This 
value falls between the reported range of 1.80-2:1 which indicates the DNA is sufficiently 
free of protein so that no additional purification was required. The concentration of the 
stock solution was determined spectrophotometrically using the extinction coefficient of 
13200 M-1 cm-1 at 260 nm.  
UV/VISIBLE SPECTROPHOTOMETRIC TITRATIONS: 
Generally, a complex concentration of approximately 10-5 M (TBS, pH 7.34, 37 °C, 10 mM 
NaCl) was prepared in 1cm quartz cuvette with an initial volume of 2.2 mL. Aliquots (5-100 
uL) of a concentrated DNA stock solution were added at 10 minute intervals to the reaction 
cuvette as well as to the reference cuvette. This was to correct for the absorbance of the 
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DNA and to ensure the interaction/binding process was complete and equilibrium had been 
reached before the spectra were recorded.  The absorbance of the LMCT band at 
approximately 350 nm (compound dependent) was corrected for dilution and monitored as 
a function of ctDNA concentration. The function below was fitted to the data using non-
linear regression.42 
 (  –  )  (  –  )   (  ( 
     
          )
 
 
  )                                    4.6.2.1a 
                                                                                                       4.6.2.1b 
Where:  
[DNA] =  concentration of DNA 
   =  extinction coefficient of LMCT band at a given [DNA] 
    =  extinction coefficient of the free gold(III) compound 
   =  extinction coefficient of the fully intercalated compound 
   =  equilibrium binding constant in M
-1 
Ct = total concentration of gold(III) compound 
s =  binding site size; number of nucleotides per compound 
COMPETITIVE BINDING TITRATIONS: 
The gold(III) complexes were found to be non-emissive in the presence or absence of DNA 
and had no effect on the emission properties of EB; because of this, competitive binding 
experiments were able to be performed reliably. A 1:1 or 15:15 μM ratio between DNA and 
EB was used in the displacement titrations. Aliquots (30-200 uL) of metal complex were 
added at 10 minute intervals to the EB-DNA mixture. This was to ensure the intercalation 
process was complete and equilibrium had been reached before the spectra were recorded. 
The individual spectra were recorded from 530-800 nm as the average of 10 scans at 37 °C 
with the excitation wavelength at 500 nm. The apparent binding constant, Kapp, is then 
calculated from the equation below. 
                                                                                                    4.6.2.2 
Where:  
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     = binding constant of EB to DNA: 1 x 10
-7 M-1 44 
[EB]  = concentration of EB 
      = apparent binding constant 
[Complex] = concentration of gold(III) complex that causes 50% reduction of hh
 initial EB fluorescence intensity  
The intensity of the emission peak at 610 nm was recorded and monitored as a function of 
gold(III) complex concentration and an IC50 function with a Hill coefficient fitted to the data 
in order to determine [Complex]. 
         (
 
  
)                               4.6.2.3 
Where:  
Y   = response (Y=100% when X=0) 
X   = inhibitor concentration 
A1   = IC50 value  
A2   = hill coefficient. 
4.6.3 Results and discussion 
As mentioned above (4.4 Stability and Reactivity), only metal compounds [Au(L8)Cl](PF6)–
[Au(L14)Cl](PF6) were stable enough in solution to perform reliable spectroscopic 
experiments. The UV/Visible absorption spectra of each of the complexes were monitored 
upon the addition of DNA and a decrease in the intensity of both the π-π* and LMCT region 
were observed. The percentage hypochromism (H%) is defined as: 
         (             )                                                                        4.6.3.1 
Metal compound [Au(L10)Cl](PF6) displays hypochromism of 28.11% which is similarly 
observed for the proven DNA intercalator [Ru(Im)(dppz)]2+.42 The hypochromism values for 
the rest of the compounds are summarised in Table 4.6.3.1. Identical aliquots of DNA were 
added to the reference cell to counter absorbance of the DNA itself. The DNA additions 
were continued until there where minimal spectral changes for at least three consecutive 
additions. Dilution effects of the gold(III) compounds where corrected for using absorption 
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correction techniques. The spectral changes observed for [Au(L10)Cl](PF6) upon the addition 
of DNA are displayed below (Figure 4.6.3.1). 
Table 4.6.3.1: Summary of binding affinities, binding site size, hypochromism and 
bathochromic shift for stable gold(III) compounds from this work as well as some 
literature metallointercalators determined by UV/Visible DNA titrations.  
Metal Complex s Kb( x 10
5 M-1) H(%) Bathochromic shift (nm) 
[Au(L8)Cl](PF6) 1.9(9) 3.6(6) 27.2 6 
[Au(L9)Cl](PF6) 1.4(9) 2.8(6) 33.5 8 
[Au(L10)Cl](PF6) 1.3(5) 4.7(6) 28.1 17 
[Au(L11)Cl](PF6) 1.2(9) 2.7(5) 31.2 6 
[Au(L12)Cl](PF6) 2(5) 1(1) 23.6 8 
[Au(L13)Cl](PF6) 6(6) 3(1) 51.1 8 
[Au(L14)Cl](PF6) 2(3) 2(1) 18.3 3 
[Au(C^N^C)(IMe)]CF3SO3
45 N/A 5.4(8) N/A N/A 
[Ru(phen)2(dppz)]2Cl
47 0.6 51(4) N/A N/A 
[Au(TPP)]Cl13 N/A 28(2) 53 N/A 
Generally, the larger the binding affinity (Kb) and the binding site size (s), the stronger the 
intercalation interaction between the complex and DNA is. The percentage hypochromism 
of the LMCT bands between the different gold(III) compounds varies quite significantly. 
Metal compound [Au(L13)Cl](PF6) displays the largest hypochromism at 51.10% while 
complex [Au(L14)Cl](PF6) exhibited the smallest hypochromism at 18.28%. The rest of the 
gold(III) complexes displayed hypochromism in the 30% region which is similarly observed 
for some anti-cancer gold(III) porphyrin complexes reported by Che and co-workers.13 The 
characteristic traits observed when a drug intercalates DNA are a red shift in the charge 
transfer band as well as hypochromism. A red shift occurs because as the metal complex 
intercalates DNA, there are strong π-π stacking interactions between base pairs of the DNA 
and the aromatic structure of the complex which results in a drop in energy of the LUMO. 
The end result is a slight red shift in the charge transfer band of the metal complex. It is 
generally accepted in literature that the larger the hypochromism, the stronger the 
intercalation event.42 
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Figure 4.6.3.1: UV/Visible spectrum of [Au(L10)Cl](PF6) in pH 7.34 TBS at 37 °C 
showing the hypochromism and bathochromic shift of the LMCT band upon addition of 
consecutive aliquots of ctDNA. Inset displays a plot of (εa-εf)/(εb-εf) vs [ctDNA] and the 
non-linear fit of the data resulting in the determination of Kb and s. 
However, this was not observed for the compounds in this work with [Au(L10)Cl](PF6) 
displaying the largest binding constant of 4.7(6) x 105 M-1 while its hypochromism was mid-
range for the complexes studied (28.1%). 
It has been shown that the binding affinity of [PtX(terpy)]+ ,where x = anion, complexes 
depends heavily on several structural factors such as hydrogen-bonding capability, charge, 
structure and steric effects.38 This is highlighted in the comparison of the DNA binding 
affinities of various [PtX(terpy)]+ complexes which range from as low as 3.3 x 103 to as high 
as 1.8 x 107 M-1.38 Direct comparisons between separate studies are however difficult due to 
the fact that Kb values are sensitive towards ionic strength, pH and temperature.
38 For the 
metal compounds described in this work, compounds [Au(L8)Cl](PF6)-[Au(L11)Cl](PF6) all 
displayed the expected red-shift and hypochromism consistent with intercalation of the 
complexes between DNA base pairs. The non-linear curve fit to a plot of (εa-εf)/(εb-εf) vs 
[ctDNA] resulted in binding constants ranging from 2.7(5) x 105 M for [Au(L11)Cl](PF6), to 
4.7(6) x 105 M for [Au(L10)Cl](PF6). Metal compounds [Au(L8)Cl](PF6)-[Au(L10)Cl](PF6) follow 
a trend based on structural effects with [Au(L10)Cl](PF6) exhibiting the largest binding 
constant consistent with its extended aromatic structure compared to compounds 
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[Au(L8)Cl](PF6) and [Au(L9)Cl](PF6). Metal compound [Au(L9)Cl](PF6) exhibits the weakest 
binding constant of 2.8(6) x 105 M. This weaker binding constant is consistent with the steric 
bulk introduced by the butyl chain in the para position of the pyridine ring. Compound 
[Au(L8)Cl](PF6) exhibits a binding constant of 3.8(6) x 10
5 M, which is less than that for 
[Au(L10)Cl](PF6), consistent with its less aromatic structure. The binding constant is however 
higher than [Au(L9)Cl](PF6) due to less steric bulk on the pyridine ring of the complex. Metal 
compound [Au(L11)Cl](PF6) does not follow the trend with the weakest binding constant of 
all four at 2.7(5) x 105 M. This was not expected as it shares the extended aromatic structure 
of [Au(L10)Cl](PF6) without the streic bulk of [Au(L10)Cl](PF6). The only obvious difference 
between [Au(L10)Cl](PF6) and [Au(L11)Cl](PF6) is that they contain different isoquinoline 
isomers. Compound [Au(L10)Cl](PF6) contains the 1-isoquinoline moiety while 
[Au(L11)Cl](PF6) contains the 3-isoquinoline moiety. It is known that small structural 
difference can cause fairly large difference in binding constants.38 The difference in binding 
constants between these two complexes may be associated with the difference in 
isoquinoline motifs. It is also conceivable that [Au(L10)Cl](PF6) may have a shape that 
energetically and sterically favours the left handed DNA helical structure, more so than that 
of [Au(L11)Cl](PF6), and therefore as a result obtains a higher Kb value.  
 
Figure 4.6.3.2: UV/Visible spectrum of [Au(L12)Cl](PF6) in pH 7.34 TBS at 37 °C 
showing the hypochromism and bathochromic shift of the LMCT band upon addition of 
consecutive aliquots of ctDNA. Inset displays a plot of (εa-εf)/(εb-εf) vs [ctDNA] and the 
non-linear fit of the data resulting in the determination of Kb and s. 
Spectroscopy 
144 | P a g e  
 
Complexes [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) displayed the characteristic spectral features of 
a red shift in the LMCT band as well as hypochromism. However, the non-linear curve fit to a 
plot of (εa-εf)/(εb-εf) vs [ctDNA] resulted in binding constants with extremely poor data fits 
and large errors in Kb and s (Figure 4.6.3.2), rendering the information effectively 
quantitatively useless. This was interesting and suggestive of more than one type of drug-
DNA interaction occurring in solution. This is feasible as the structure of complexes 
[Au(L12)Cl](PF6)-[Au(L14)Cl](PF6) contain a phenyl ketone moiety which in itself would be 
able to intercalate DNA. This has recently been shown by Niyazi and co-workers for Λ-
[Ru(phen)2dppz]
+. X-ray crystallographic studies show that the complex Λ-[Ru(phen)2dppz]
+ 
is able to intercalate DNA via both the dppz and phen moieties in separate binding events.48 
Due to the poor data obtained from the UV/Visible DNA titrations, another method was 
sought to investigate the ability of the metal compounds [Au(L12)Cl](PF6)-[Au(L14)Cl](PF6) to 
intercalate DNA. Another common method is based on emission spectroscopy. Ethidium 
bromide is an organic molecule that exhibits a marked increase in emission intensity when 
intercalated between base pairs.       
Therefore by titrating a drug into a solution containing EB intercalated into DNA we are able 
to displace the EB and observe a steady reduction in emission intensity upon successive 
additions of the drug.44 All three complexes, [Au(L12)Cl](PF6)-[Au(L13)Cl](PF6) displayed the 
characteristic steady decrease in emission intensity of EB upon an increase in concentration 
of metal complex (Figure 4.6.3.3 displays this for [Au(L12)Cl](PF6). The binding constants 
determined are summarised below (Table 4.6.3.2) along with the correlation coefficients of 
the IC50 fits for emission vs [metal complex] used to determine [complex]. Complex 
[Au(L14)Cl](PF6) exhibited the highest Kapp value at 8.42 x 10
5  M-1 while [Au(L13)Cl](PF6) 
displayed the lowest Kapp value at 4.51 x 10
5 M-1. The Kapp values obtained for the emission 
displacement titrations were in the same order of magnitude as for those determined via 
UV/Visible spectroscopic titrations and therefore it is safe to assume that metal compounds 
[Au(L12)Cl](PF6)–[Au(L14)Cl](PF6) are able to interact with the DNA fairly strongly. The 
emission displacement titrations however further enforced the idea that there is more than 
one DNA-drug interaction occurring in solution.  
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Figure 4.6.3.3: Emission spectrum of EB in pH 7.34 TBS at 37 °C, showing the reduction 
in intensity upon increasing the concentration of [Au(L12)Cl](PF6). Inset displays a plot 
of emission intensity as a percentage vs [[Au(L12)Cl](PF6)] and the IC50 fit of the data.  
If one observes the first and second additions of metal compound (equal amounts of 30 μl) 
in Figure 4.6.3.3, it can be seen that the drops in emission intensity are not equivalent. 
There is a much greater drop in intensity after the second addition compared to that of the 
first. This suggests that the complex interacts with the DNA in a different manner at lower 
concentrations (approximately 1 x 10-5 M), perhaps via intercalation of the phenyl ketone 
moiety. As the concentration of the metal complex is increased, the traditional 
characteristics of an intercalative binding mode are observed. In order to unequivocally 
determine whether the metal compounds [Au(L12)Cl](PF6)-[Au(L14)Cl](PF6) in fact 
intercalate DNA, electrophoretic gel mobility shift assays (EMSA) were performed (see 
Chapter 7). The EMSA results show that there is no evidence for DNA intercalation or groove 
binding and therefore contradict the spectroscopic data obtained (vide supra). There is no 
doubt that there is an interaction between complexes [Au(L12)Cl](PF6)-[Au(L14)Cl](PF6) and 
DNA, however, from the collective data we may only hypothesise that the interaction may 
be electrostatic (see Chapter 7 for further discussion). 
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Table 4.6.3.2: Summary of ctDNA binding affinities, binding site size and 
hypochromism for the selected metal compounds, determined by ethidium bromide 
displacement titrations.  
Metal Complex Kapp /M
-1 (x 105) Correlation coefficient* 
[Au(L12)Cl](PF6) 5.3(5) 0.995 
[Au(L13)Cl](PF6) 4.5(8) 0.997 
[Au(L14)Cl](PF6) 8.4(6) 0.987 
*
Correlation coefficient of the IC50 curve fit when determining [Complex]. 
Overall metal compounds [Au(L8)Cl](PF6)–[Au(L11)Cl](PF6) have been identified to 
intercalate DNA while metal compounds [Au(L12)Cl](PF6)–[Au(L14)Cl](PF6) display a spectral 
signature consistent with DNA–complex interactions; however, the complex nature of the 
spectral changes associated with DNA binding by the latter complexes suggest that further 
investigations might be required to fully elucidate the nature of the binding process (e.g. the 
use of circular dichroism spectroscopy and/or micro viscosity measurements). The binding 
affinities of the metal compounds are all in the order of 105 M and therefore can be 
classified as relatively strong DNA intercalators and are in the same region as the gold(III) 
compound, [Au(C^N^C)(IMe)]CF3SO3, which is a topoisomerase I inhibitor that shows 
encouraging in vivo results. It is therefore inferred that the interaction of the compounds 
with DNA forms the basis via which the metal compounds affect their cytotoxic activity 
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5. X-Ray crystallography 
5.1 Introduction 
There are relatively few crystal structures of gold(III)-bis(amides) and mono(amides) in the 
CSD1 (Cambridge Structural Database, September 2011 release).2-8 Although there are many 
gold(III) structures in the literature, few involve the ligand systems investigated in this 
project. This is unusual as the ligand systems would appear to be ideally suited to the 
chelation of gold(III). Specifically, the amide N–H binding sites, when deprotonated, produce 
strong σ-donors. This coupled with the pyridine nitrogen’s σ-donor/π-acceptor qualities 
afford a powerful stabilising compound. With two negative and two neutral binding sites the 
bis(amide) compounds would be expected to acquire a net positive charge for the complex 
(ideal for electrostatically targeting the polyphosphate backbone of DNA). The mono(amide) 
ligands contain a single negative binding site for ligands [Au(L4)Cl2]–[Au(L14)Cl](PF6). This 
coupled with the co-ordination of a chloride ion similarly afford singly positively charged 
complexes. Ligands H2L15 and H2L16 contain two anionic binding sites, N
- and C-, resulting in 
the formation of neutral complexes. 
 
Figure: 5.1.1: Diagram of a single molecular unit of [Au(L-N,N')Cl2], showing the co-
ordination geometry of the gold(III) centre. Redrawn from the CSD1 co-ordinates of 
Yang et al.’s structure.6 
There are only a handful of gold(III)-mono(amide) complexes listed in the CSD,1-8 of which 
[Au(L-N,N')Cl2] (where L = N-(4-methylphenyl)pyridine-2-carboxamide, CSD ref code: 
UKETUZ) was reported by Yang et al. in 2003.6 It crystallised in the monoclinic space group 
P21/c with Z = 8. These workers reported a 1:1 gold(III):amide complex where the gold(III) 
metal centre is bound to the amide and pyridine nitrogen units of the ligand along with two 
chloride ions to complete the distorted square planar geometry (Fig. 5.1.1).6 
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The only gold(III) bis(amide) complex, [Au(XL)Cl2] (where X = 2,2’-bis(pyridylcarboxamide)-
1,1’-binaphthyl), reported in the CSD1 (CSD ref code: YEHLEC) was by Che et al. in 1994. It 
crystallised in the monoclinic space group P21/c with Z = 4. He reported that the gold(III) 
centre was only bound to half the tetradentate ligand with two chloride ions completing the 
distorted square planar geometry (Fig. 5.1.2) in a similar binding fashion to that of Yang’s 
complex. This was presumably due to the steric constraints of the ligand. The 5-carbon 
bridge would induce a 7-membered compound upon binding to gold(III). The seven 
membered compound is evidently too strained to accommodate the square planar 
geometry required by the gold(III) centre, hence the gold(III) ion only binding to half the 
ligand.  
 
Figure: 5.1.2: Diagram of a single molecular unit of [Au(XL)Cl2], showing the co-
ordination geometry of the gold(III) centre. Redrawn from the CSD1 co-ordinates of Che 
et al.’s structure.2 
The distortion from the ideal square planar geometry for compounds [Au(L-N,N')Cl2] and 
[Au(XL)Cl2] arises from the bite angle of the co-ordinating ligands, which cannot 
accommodate the gold ion in a perfect square plane. The N1–Au–N2 angle is significantly 
smaller than the ideal 90˚ and the Cl2–Au–Cl1 angle approximately equal to the expected 
90˚ in both complexes (Table 5.1.1). The trans effect arising from the stronger σ-donor 
ability of the amide nitrogen is evident in the longer Cl2–Au bond lengths of both complexes 
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Table 5.1.1: Co-ordination sphere bond lengths and bond angles for CSD-reported 
gold(III) structures. 
 CSD Ref Code: YEHLEC CSD Ref Code: UKETUZ  
Co-ordination bond lengths (Å) 
N1–Au 2.018 2.018 
N2–Au 2.033 2.047 
Cl1–Au 2.272 2.258 
Cl2–Au 2.302 2.286 
Co-ordination bond angles (˚) 
N1–Au–N2 81.47 81.66 
N2–Au–Cl2 93.70 95.49 
Cl2–Au–Cl1 90.03 88.73 
Cl1–Au–N1 94.85 94.18 
 
Yang et al. published a paper entitled ‘Novel gold(III) complexes of aminoquinoline 
derivatives: crystal structure, DNA binding and cytotoxicity against melanoma and lung 
tumour cells’ in 2008 which they report the crystal structures of two 8-aminoquinoline 
amide-based tridentate compounds of gold(III) (Figure 5.1.3): [Au(Quingly)Cl]Cl (CSD ref 
code: ILIGUF)  and [Au(Quinala)Cl]Cl (CSD ref code: ILIHAM).5 The former is chiral and thus 
crystallised in the monoclinic space group P212121 while the latter crystallised in the 
monoclinic space group P21/c.  
 
Figure: 5.1.3: Diagram of a single molecular unit of [Au(Quingly)Cl]Cl (A) and 
[Au(Quinala)Cl]Cl (B), showing the co-ordination geometry of the gold(III) centre. 
Redrawn from the CSD1 co-ordinates of Yang et al.’s structures.5 
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Table 5.1.2: Co-ordination sphere bond lengths and bond angles for CSD-reported 
gold(III) structures. 
 CSD Ref Code: ILIGUF CSD Ref Code: ILIHAM 
Co-ordination bond lengths (Å) 
N1–Au 2.020 2.021 
N2–Au 1.953 1.973 
N3–Au 2.024 1.975 
Cl1–Au 2.277 2.278 
Co-ordination bond angles (˚) 
N1–Au–N2 83.54 81.66 
N2–Au–N3 83.09 95.49 
N3–Au–Cl1 94.81 88.73 
Cl1–Au–N1 98.54 94.18 
 
Once again the distortion from the ideal square planar geometry for compounds 
[Au(Quingly)Cl]Cl and [Au(Quinala)Cl]Cl arises from the bite angle of the co-ordinating 
ligands, which cannot accommodate the gold ion in a perfect square plane. The N–Au–N 
angles are significantly smaller than the ideal 90˚ while the N–Au–Cl1 angles are fairly 
obtuse (Table 5.1.2). The trans effect arising from the stronger σ-donor ability of the amide 
nitrogen is evident in the longer Cl1–Au bond lengths of both complexes (Table 5.1.2).   
5.2 Objectives 
The first objective of the single crystal X-ray analysis was to elucidate the solid state 
structures of the metal compounds studied in this work and their molecular conformations. 
The second objective was to use the solid state structures as a starting point for the gas 
phase geometry optimisation calculations. This was performed in order to investigate the 
crystal packing effects on the solid state structure compared to that of the gas phase 
optimised structure. The geometry optimised structures were then used to delineate the 
electronic structure of the complexes along with NMR shielding tensors and IR frequencies.  
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5.3 Experimental   
X-Ray diffraction data were collected on an Oxford Diffraction Xcalibur2 CCD 4-circle 
diffractometer equipped with an Oxford Instruments Cryojet for H2L3, HL13, [Au(HL1)Cl2], 
[Au(HL2)Cl2], [Au(HL3)Cl2], [Au(L4)Cl2], [Au(L5)Cl](PF6), [Au(L6)Cl](PF6), [Au(L7)Cl](PF6), 
[Au(L12)Cl](PF6) and [Au(L13)Cl](PF6). The data were collected at room temperature unless 
otherwise stated, with Mo Kα (λ = 0.71073 Å) radiation at a crystal-to-detector distance of 
50 mm using omega scans at θ  = 29.389°, with varying exposure times taken at 2.01 kW X-
ray power with 0.75° frame widths. The data were reduced with the program CrysAlis RED9 
using outlier rejection, scan speed scaling, as well as standard Lorentz and polarisation 
correction factors. Unless otherwise stated, direct methods (SHELXS-97, WinGX32)10, 11 were 
used to solve the structures. All non-H atoms were located in the E-map and refined 
anisotropically with SHELXL-97.12 All hydrogen atoms in each of the structures resolved were 
included as idealised contributors in the least squares process with standard SHELXL-9712 
parameters, unless otherwise stated. The X-Ray diffraction data for compounds 
[Au(L8)Cl](PF6), [Au(L11)Cl](PF6) and [Au(L15)Cl] were collected on a Bruker Smart APEX II 
Duo CCD 3-circle diffractometer equipped with an Oxford Instruments Cryojet. The data 
were collected at room temperature unless otherwise stated (λ = 0.71073 A, IμS Mo 
microsource) at a crystal-to-detector distance of 50 mm using omega and  psi scans, with 
varying exposure times. The frames were integrated with the Bruker SAINT software 
package using a narrow-frame algorithm. Data were corrected for absorption effects using 
the multi-scan method (SADABS). Unless otherwise stated, direct methods (SHELXS-97, 
WinGX32)10, 12 were used to solve the structures. All non-H atoms were located in the E-map 
and refined anisotropically with SHELXL-97.12 All hydrogen atoms in each of the structures 
resolved were included as idealised contributors in the least squares process with standard 
SHELXL-97 parameters, unless otherwise stated. X-Ray diffraction data for compound 
[Au(L9)Cl]AuCl2 were collected on a X8 Prospector CCD 4-circle system equipped with an 
Oxford Instruments Cryojet, multilayer monochromator (λ = 1.54178 Å, IμS Co microsource) 
at a crystal-to-detector distance of 50 mm using omega and psi scans, with varying exposure 
times. The frames were integrated with the Bruker SAINT software package using a narrow-
frame algorithm. Data were corrected for absorption effects using the multi-scan method 
(SADABS). The structure was solved and refined using the Bruker SHELXTL Software Package.  
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5.4 Results and discussion  
MOLECULAR STRUCTURES [Au(HL1)Cl2]–[Au(L4)Cl2]: 
 
Figure: 5.4.1: Labelled views of the single crystal X-ray structures of gold(III) 
compounds [Au(HL1)Cl2], [Au(HL2)Cl2], [Au(HL3)Cl2] and [Au(L4)Cl2]. Hydrogen atoms 
are rendered as sticks and bonds are represented as cylinders. Thermal ellipsoids are 
represented as 50% probability surfaces for [Au(HL1)Cl2], [Au(HL2)Cl2], and 
[Au(HL3)Cl2]. 
The X-ray structures of [Au(HL1)Cl2]–[Au(L4)Cl2] are shown in Figure 5.4.1. The gold(III) ion is 
nominally square planar in each complex with a pair of cis-chloride ions co-ordinated trans 
to the single pyridyl-amido chelating moiety of the ligand in the case of [Au(L4)Cl2], and one 
of the pair of such chelating groups in [Au(HL1)Cl2]–[Au(HL3)Cl2]. The substituent groups 
attached to the deprotonated metal-bound amide nitrogen atom (N2) in [Au(HL1)Cl2]–
[Au(L4)Cl2] adopt structure-dependent conformations that have an essentially minimal 
impact on the co-ordination geometry of the gold(III) ion in each case (Table 5.4.1). The aryl-
substituted derivatives [Au(HL3)Cl2] and [Au(L4)Cl2] have co-ordination group parameters 
that are structurally and statistically equivalent to the alkyl-substituted analogues 
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[Au(HL1)Cl2] and [Au(HL2)Cl2], despite having a substituent that is potentially capable of 
conjugation with the amide-based compound ring. 
Table 5.4.1: Selected Crystallographic Bond Distances and Bond Angles for 
[Au(HL1)Cl2]–[Au(L4)Cl2]. 
 [Au(HL1)Cl2] [Au(HL2)Cl2] [Au(HL3)Cl2] [Au(L4)Cl2] 
Bond distances 
Au1–N1 2.036(5) 2.037(3) 2.048(3) 2.031(4) 
Au1–N2 2.019(4) 2.014(3) 2.035(3) 2.009(5) 
Au1–Cl1 2.290(2) 2.287(1) 2.303(1) 2.295(2) 
Au1–Cl2 2.285(2) 2.263(1) 2.270(1) 2.261(2) 
C=Oa 1.211(7) 1.230(5) 1.232(4) 1.21(1) 
C=Ob 1.228(7) 1.217(5) 1.240(6) – 
N–Ca 1.345(8) 1.341(5) 1.362(5) 1.343(9) 
N–Cb 1.340(7) 1.346(6) 1.391(5) – 
Bond angles 
N1–Au1–Cl1 94.0(1) 94.85(9) 95.68(8) 95.3(1) 
Cl1–Au1–Cl2 89.11(7) 89.00(4) 89.42(2) 88.87(6) 
Cl2–Au1–N2 95.8(1) 94.90(9) 93.83(9) 94.4(1) 
N2–Au1–N1 81.0(2) 81.3(1) 81.1(1) 81.5(2) 
Au1–N1–C5c 112.9(4) 112.9(3) 112.7(2) 113.2(4) 
Au1–N2–C6d 115.3(4) 115.0(3) 116.0(2) 115.2(4) 
N1–C5–C6e 115.9(5) 115.9(4) 116.7(3) 116.2(5) 
N2–C6–C5f 113.6(5) 113.7(3) 113.0(3) 113.9(6) 
a
 Metal-bound amide group. 
b
 Free amide group. 
c
 For [Au(HL3)Cl2], this angle is Au1–N1–C9.  
d 
For [Au(HL3)Cl2], 
this angle is Au1–N2–C9. 
e
 For [Au(HL3)Cl2], this angle is N1–C9–C10. 
f
 For [Au(HL3)Cl2], this angle is N2–C10–
C9. 
For compound [Au(HL3)Cl2] the dihedral angle between the aryl ring (C11–C16) attached to 
the metal-bound amido group (N2) and the 13-atom mean plane of the isoquinoline-amido 
gold(III) compound (Au1, N1, C1–C10, N2) is near-orthogonal, measuring 80.7°, while for 
compound [Au(L4)Cl2], the dihedral angle between the aryl substituent, C7–C12, and the 9-
atom mean plane of the pyridine-amido compound, defined by the atoms Au1, N1, C1–C6, 
and N2, measures 75.8°. Both angles are consistent with an unconjugated aryl group. The 
more perpendicular dihedral angle for [Au(HL3)Cl2] presumably reflects the intradimer C–
H···Cl hydrogen-bonding observed in the π-stacked inversion pair, as discussed later, while 
the aryl ring orientation in [Au(L4)Cl2] is possibly marginally influenced by an unconventional 
C–H···O hydrogen bond involving C11, H11, and the amide oxygen acceptor atom O1 of a 
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neighbouring molecule in the lattice (vide infra); as indicated above, this interaction does 
not significantly disturb the structure of the chelating group or its co-ordination of the 
gold(III) ion. The Au–Npyridine and Au–Namido distances for compounds [Au(HL1)Cl2], 
[Au(HL2)Cl2] and [Au(L4)Cl2] average 2.03(7) Å and 2.014(5) Å, respectively, while the Au–
NQu and Au–Namido distances for compound [Au(HL3)Cl2] measure 2.048(3) Å and 2.035(3) Å, 
respectively. These values indicate crystallographically and chemically distinct co-ordination 
interactions. Both N-donor atom types (pyridine and amido) are sp2-hybridised; however as 
might be anticipated for an anionic N-donor atom (and consequently a more powerful σ-
donor). The Au–Namido bond of [Au(HL3)Cl2] measures 2.035(3) Å and is more than four 
standard deviations (4σ) longer than the mean Au–Namido bond of [Au(HL1)Cl2], [Au(HL2)Cl2] 
and [Au(L4)Cl2] (2.014(5) Å); similarly, the Au–NIQ bond of [Au(HL3)Cl2] (2.048(3) Å) is more 
than 4(σ) longer than the mean Au–Npyridine bond distance for AuL1, AuL2 and AuL4 (2.035(3) 
Å). Note that this structural difference exists despite the pKa of pyridine (5.2) being roughly 
the same as that for isoquinoline (5.5). The underlying reasons for elongation of the Au–N 
bond distances in [Au(HL3)Cl2] are therefore likely to be electronic, as opposed to structural, 
in origin. Overall, the shorter Au–Namido bond and longer Au–Npyridine/Qu phenomenon in 
amide based compounds has been observed in the crystal structure of another N-alkylated 
pyridyl-amido gold(III) compound, notably AuCl2(N-NP2C), where N-NP2C = N-nonylpyridine-
2-carboxamido anion, Au–Npyridine = 2.032(2) Å, and Au–Namido = 2.011(2) Å.
4 The co-
ordination group asymmetry for amido-pyridine compounds of gold(III) is even more 
pronounced for the simplest amide derivative AuCl2(P2C), where P2C = pyridine-2-
carboxamido anion, Au–Npyridine = 2.047(5) Å, and Au–Namido = 1.969(5) Å.
7 Evidently, the 
sterically unencumbered amido nitrogen atom of the latter complex is capable of a 
particularly close approach to the gold(III) ion, a structural feat that apparently requires 
simultaneous elongation of the Au–Npyridine bond within the five-membered compound ring. 
Regarding the different Au–N bonds in these pyridyl-amido compounds, it is noteworthy 
that symmetric bipyridine (bipy) complexes of gold(III) such as [AuCl2(DMbipy)][PF6] and 
[AuCl2(DMObipy)][PF6], where DMbipy = 4,4'-dimethyl-2,2'-bipyridine and DMObipy = 4,4'-
dimethoxy-2,2'-bipyridine, exhibit equivalent Au–Npyridine distances of 2.03(1) and 2.02(2) Å, 
respectively.13 This confirms the idea that the amido and pyridine nitrogen atoms are 
chemically distinct (despite equivalent hybridisation), with the former acting as a strong σ-
donor and the latter as a more balanced σ-donor/π-acceptor,14 and that this electronic 
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distinction reinforces dissymmetric co-ordination of the gold(III) ion in the present 
compounds. 
The Au–Cl1 (trans to the amido group) and Au–Cl2 (trans to the pyridine or quinoline group) 
bond distances for [Au(HL1)Cl2]–[Au(L4)Cl2] average 2.293(6) and 2.260(13) Å, respectively. 
Closer inspection of the Au–Cl distances indicates that a significant “trans effect”15 is 
structurally manifest in these complexes, as briefly noted in an earlier paper by Fan et al. for 
AuCl2(P2C).
7 More specifically, the Au–Cl bond trans to the stronger σ-donor atom (N2, or 
Namido) is considerably longer than that trans to the pyridine nitrogen; in the case of 
[Au(L4)Cl2] this difference is as large as 0.034 Å and thus statistically significant relative to 
the standard uncertainties of the experimental Au–Cl bond distances. The difference 
between the co-ordination of chloride trans to the amido group relative to the pyridine or 
quinoline group becomes particularly apparent if we compare the mean Au–Cl1 distance 
above to the mean Au–Cl distance of 2.255(7) Å reported for the symmetric bipy derivatives 
[AuCl2(DMbipy)][PF6] and [AuCl2(DMObipy)Cl2][PF6].
13 These complexes epitomise the 
expected bond lenghts for the co-ordination of chloride trans to an Au–Npyridine bond in a 
symmetric five-membered compound ring system and highlight the marked elongation of 
the Au–Cl bonds trans to the amido nitrogen donor in the present complexes (especially 
[Au(L4)Cl2]). Interestingly, if the chelating σ-donor anion co-ordinated to gold(III) is switched 
to carbon, as in the complex AuCl2(2-phenylpyridine),
16 then a very large structural trans 
effect occurs with the Au–Cl distance trans to the Au–C bond elongating beyond that 
observed for the pyridyl-amido complexes reported here to 2.361(8) Å. As might be 
anticipated, the structural trans effect discussed above for oreganos-gold complexes is 
paralleled by a kinetic trans effect in the substitution reactions of the gold(III) ion. Anions 
such as chloride co-ordinated trans to a powerful σ-donor (e.g. C6H5
–) are kinetically more 
labile than those co-ordinated cis to the “labilising” ligand. This reactivity pattern clearly 
correlates with a longer, weaker Au–Cl bond trans to the strong σ-donor ligand in the 
structures of such compounds. One might logically expect that for [Au(HL1)Cl2], [Au(HL2)Cl2] 
and [Au(L4)Cl2], substitution of at least one of the chloride ions (the one trans to the amido 
group (presumably being the more reactive) might be possible for some nucleophiles. 
The bond angles (Table 5.4.1) subtended at the metal ion in [Au(HL1)Cl2–[Au(L4)Cl2] are 
normal for five-membered ring compounds of gold(III) with two N-donor atoms. The mean 
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cis Cl–Au–Cl bond angle, 89.1(2)°, falls within 1° of 90°, while the mean cis N–Au–N angle is 
quite acute, measuring 81.2(2)°. The latter bond angle, which deviates significantly from 90°, 
clearly reflects the geometric constraints on metal ion co-ordination imposed by the five-
membered chelate ring for the complexes. In each complex, the cis N–Au–Cl bond angles are 
crystallographically equivalent, averaging 95.0(7)° and 94.7(8)° for the angles to Cl1 and Cl2 
for [Au(HL1)Cl2–[Au(L4)Cl2], respectively. Both angles are slightly obtuse; this is expected if 
the sum of the angles at the metal center is required to equate to 360° for a square-planar 
metal center. The metrics of the co-ordination sphere bond angles for [Au(HL1)Cl2]–
[Au(L4)Cl2] compare favorably with other complexes of gold(III) comprising five-membered 
chelate rings with two N-donors. The cis N–Au–N bond angle is, in fact, a good measure of 
chelation by such ligands: values of 81.42(7)° for AuCl2(N-NP2C),
4 81.2(2)° for AuCl2(P2C),
7 
80.9(4)° for [AuCl2(DMbipy)][PF6],
13 and 80.6(2)° for [AuCl2(bipy)][NO3]
17 have been 
determined and indicate that both amido-pyridine and bipy-type ligands have similar “bite” 
angles to gold(III).  
Gold compounds [Au(HL1)Cl2–[Au(L4)Cl2] are polyfunctional in the sense that they possess 
hydrogen bond donor and acceptor groups as well as aromatic ring systems. The 
supramolecular structures of the compounds are accordingly both diverse and quite 
complex. The extended structures of [Au(HL1)Cl2]–[Au(L4)Cl2] are dominated by 
unconventional C–H···O and C–H···Cl hydrogen bonds in all cases, which culminates in the 
formation of one-dimensional (1D) hydrogen-bonded chains in the solid state. 
 
Figure 5.4.2: Key intermolecular H-bonds (labeled atoms) for [Au(HL1)Cl2]. Atoms and 
bonds are shown as sticks. Hydrogen bonds are shown as broken magenta cylinders. 
Compound [Au(HL1)Cl2], furthermore, forms inversion-related H-bonded dimers linked by 
conventional N–H···O hydrogen bonds involving the amide groups as part of interlinked 1D 
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H-bonded chains in the solid state (Figure 5.4.2). Several π-stacking interactions are also 
prevalent; these span lateral shift (LS) and mean plane separation (MPS) values of 1.37–2.42 
Å and 3.34–3.50 Å, respectively, and involve both the free- and Au-bound pyridine rings of 
[Au(HL1)Cl2], [Au(HL2)Cl2] and [Au(L4)Cl2]. In the case of [Au(L4)Cl2] (Figure 5.4.3), 
benzene···pyridine π-π stacking occurs and is structurally akin to that reported for the 4-
methylbenzene-substituted analogue of [Au(L4)Cl2].
6  
 
Figure 5.4.3: View of the hydrogen-bonding and π-π stacking interactions between 
molecules of [Au(L4)Cl2]. The distance between the two ring centers of gravity (Cg) is 
indicated. Atoms and bonds are shown as spheres and sticks, respectively. Hydrogen 
bonds are shown as broken magenta cylinders and individual molecules are colored 
according to their symmetry operators. A mean plane separation (MPS) for the stacked 
rings cannot be determined as the rings are not parallel. 
Given that there are no especially short intermolecular contacts for the π-stacked rings of 
[Au(HL1)Cl2], [Au(HL2)Cl2] and [Au(L4)Cl2], a situation that may partly reflect the 
temperature of the X-ray experiments, but that the interaction metrics fall within the range 
expected for π-stacked aromatic rings (MPS values of 3.3–3.8 Å),18-20 we conclude that 
multiple ring-stacking associations stabilised by attractive “π-π” occur for [Au(HL1)Cl2], 
[Au(HL2)Cl2] and [Au(L4)Cl2].
18 For compound [Au(HL3)]Cl2, however, a more interesting 
centrosymmetric hydrogen bond-stabilised π-stacked dimer formed (Figure 5.4.4). 
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Figure 5.4.4: Partially labeled view of the centrosymmetric π-stacked dimer formed by 
[Au(HL3)Cl2]. The isoquinoline ring planes are parallel; the distance between the 
isoquinoline ring centers of gravity (Cg1···Cg1i) is indicated. The dimer is additionally 
stabilised by C–H···Cl hydrogen bonds: H22···Cl2i, 2.960(1) A ; C22···Cl2i, 3.864(4) A ; 
C22–H22···Cl2i, 159.5(3)°. Crystallographic symmetry code: (i) –x, 1–y, 1–z. 
The metal-free isoquinoline rings of two neighbouring molecules of [Au(HL3)Cl2 stack with 
exactly parallel ring planes about a centre of inversion to form a relatively tight interaction 
with a MPS of 3.523 Å that is well within the 3.35–3.8 Å range expected for π-stacked aryl 
rings.19 If the isoquinoline nitrogen atom N4 is used as a frame of reference, then the 
geometry of the interacting isoquinoline rings is the typical offset antiparallel arrangement 
(N4 atoms pointing in opposite directions) for aromatic N-heterocycles.18 This particular 
ring···ring arrangement evidently represents energetically favourable dipole alignments in 
the two ring systems. The distance between the centres of gravity of the two isoquinoline 
rings, Cg1···Cg1i, measures 3.694 Å such that the lateral shift of the ring systems is 1.111 Å. 
As clearly presented and discussed by Janiak,18 the laterally-displaced ring systems seen in 
AuL4 would permit optimal π-π attraction between stacked isoquinoline groups in addition 
to normal van der Waals attraction and London forces of attraction.  
Collectively, the interactions appear to be structurally rather modest. A further conclusion 
based on our analysis of the extended structures of [Au(HL1)Cl2] and [Au(HL2)Cl2] is that the 
involvement of the metal-free pyridyl-amide side-chain groups in intermolecular H-bonding 
and π-stacking interactions most likely accounts for the different solid-state conformations 
of these groups evident in Figure 5.4.1 (e.g. the N–H hydrogen atom of [Au(HL2)Cl2], H3, 
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eclipses the adjacent methylene group’s C–H hydrogen atom, as opposed to adopting a 
staggered conformation as in [Au(HL1)Cl2]).  
Table 5.4.2: Hydrogen bond distances and angles for compounds [Au(HL1)Cl2]–
[Au(L4)Cl2] 
Donor–H···A D–H/Å H···A/Å D···A/Å D–H···A/° 
[Au(HL1)Cl2] 
N3–H3···O1i 0.8 2.33 2.933(7) 133 
C1–H1···O2ii 0.93 2.41 3.140(7) 136 
C8–H8B···Cl1ii 0.97 2.73 3.580(7) 147 
C12–H12···Cl1ii 0.93 2.75 3.602(8) 152 
Symmetry codes: (i) 1–x,1–y,1–z; (ii) –x,1–y,2–z. 
[Au(HL2)Cl2] 
C1–H1···O2i 0.93 2.50 3.088(6) 121 
C3–H3A···O1ii 0.93 2.47 3.187(6) 133 
C12–H12···Cl2ii 0.93 2.86 3.566(5) 133 
Symmetry codes: (i) -1/2+x,1/2-y,1/2+z; (ii) 3/2-x,-1/2+y,3/2-z. 
[Au(HL3)Cl2] 
C3–H3A···O1ii 0.95 2.37 3.269(4) 158 
C8–H8···Cl1ii 0.93 2.67 3.554(3) 156 
C1–H1···Cl1 (intramol.) 0.95 2. 71 3.303(4) 121 
C15–H15···O2 (intramol.) 0.95 2.39 2.999(5) 122 
N3-H3···N2 (intramol.) 0.88(5) 2. 42(5) 2.804(5) 107(4) 
N3-H3···N4 (intramol.) 0.88(5) 2.09(4) 2.619(5) 118(4) 
Symmetry codes: (i) x,1/2-y,-1/2+z; (ii) x,1/2-y,1/2+z. 
[Au(L4)Cl2] 
C1–H1···Cl2i 0.93 2.81 3.522(6) 134 
C11–H11···O1ii 0.93 2.26 3.19(1) 176 
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Table 5.4.3: Crystal Structure, X-ray Data, and Structure Model Refinement Parameters 
for and [Au(HL1)Cl2]–[Au(L4)Cl2].a 
 [Au(HL1)Cl] [Au(HL2)Cl] [Au(HL3)Cl2] [Au(L4)Cl2] 
Chemical formula C14H13AuCl2N4O2 C15H15AuCl2N4O2 C26H17AuCl2N4O2·C4H10O C13H11AuCl2N2O2 
Mr 537.15 551.18 759.42 495.10 
Crystal system Triclinic Monoclinic Monoclinic Monoclinic 
SG P¯1 P21/n P21/c P21/n 
Temperature (K) 296 (2) 296 (2) 100 (1) 296 (2) 
a, b, c (Å) 7.477 (5),  
10.210 (5), 
11.023 (5) 
11.188 (5),  
10.192 (5),  
15.132 (5) 
15.990 (5),  
12.445 (5),  
15.602 (5) 
12.971 (5),  
8.701 (5),  
14.068 (5) 
α, β, γ (°) 85.443 (5),  
79.313 (5),  
72.383 (5) 
90,  
93.350 (5),  
90 
90,  
104.487 (5),  
90 
90,  




) 787.9 (7) 1722.5 (13) 3006.0 (18) 1442.2 (11) 
Z 2 4 4 4 
Radiation type Mo Kα Mo Kα Mo Kα Mo Kα 
μ (mm
–1
) 9.69 8.87 5.11 10.57 
Crystal size (mm) 0.4 × 0.35 × 0.15 0.60 × 0.20 × 0.18 0.50 × 0.45 × 0.15 0.50 × 0.40 ×0.20 
Abs. correction Multi-scan Multi-scan Multi-scan Multi-scan 
Tmin, Tmax 0.507, 1.000 0.076, 0.298 0.184, 0.515 0.077, 0.226 
Nm, Ni, No 6130, 3427, 3043   26661, 6154, 4240   45814, 10638, 7698   14511,2837,2494   
Rint 0.040 0.045 0.058 0.045 
R1, wR(F
 2
), S 0.034, 0.083, 1.01 0.032, 0.080, 0.96 0.039, 0.096, 0.96 0.036, 0.10, 1.05 
Np, Nres 212, 0 217, 0 367, 4 182, 0 
Δρmax, Δρmin (e Å
–3
) 1.02, –1.91 1.47, –1.97 1.98, –4.55 1.38, –2.94 
a
Abbreviations: SG, space group; V, volume; Z; number of formula units per unit cell; μ, absorption coefficient; 
T, transmission coefficient; Nm, number of measured reflections, Ni, number of independent reflections; No, 
number of observed reflections with I > 2σ(I); I, intensity; Rint, internal R-factor for data set (based on the 






), weighted R-factor 
based on F
 2
; F, structure factor; S, goodness-of-fit of model to experimental data; Np, number of parameters, 
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MOLECULAR STRUCTURES [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6): 
The X-ray structures of [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) are shown in Figure 5.4.6. The 
gold(III) ion is again nominally square planar in each complex with the gold(III) ion co-
ordinated by the three N-donor atoms of the chelating ligand and a chloride ion co-
ordinated to the fourth co-ordination site, trans to the amido chelating moiety to complete 
the geometry. 
 
Figure: 5.4.6: Labelled views of the single crystal X-ray structures of gold(III) 
compounds [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6). Hydrogen atoms are rendered as sticks 
and bonds are represented as cylinders. Thermal ellipsoids are represented as 50% 
probability surfaces. 
All three compounds, [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6), contain a picolyl-amide chelating 
moiety along with either a pyridine or isoquinoline moiety as the structural variation within 
the series. The compounds are planar in nature with slight deviation for certain atoms from 
an all-atom mean plane. This deviation could partially be due to the flexibility introduced by 
the picolyl-amide functionality as opposed to the more rigid and aromatic 8-aminoquinoline 
moiety for compounds [Au(L8)Cl](PF6)–[Au(L16)Cl]. The largest single-atom deviation from 
the above all atom mean plane for each compound is 0.220 Å for atom C11 of compound 
[Au(L7)Cl](PF6). The structural variation between compounds seems to impart minimal 
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effect on the overall planarity as well as co-ordination geometry of the gold(III) ion in each 
compound (Table 5.4.4). 
Table 5.4.4: Selected Crystallographic Bond Distances and Bond Angles for 
[Au(L5)Cl](PF6)–[Au(L6)Cl](PF6). 
 [Au(L5)Cl](PF6) [Au(L6)Cl](PF6) [Au(L7)Cl](PF6) 
Bond distances 
Au1–N1 2.024(5) 2.013(5) 2.031(6) 
Au1–N2 1.918(5) 1.933(5) 1.888(6) 
Au1–N3 2.013(5) 2.015(6) 2.000(5) 
Au1–Cl1 2.292(1) 2.298(2) 2.286(2) 
C=O 1.206(7) 1.223(9) 1.231(8) 
N–C 1.390(7) 1.360(9) 1.360(8) 
Bond angles 
N1–Au1–N2 81.4(2) 82.8(2) 82.5(2) 
N2–Au1–N3 83.1 (2) 80.7(2) 82.5(2) 
N3–Au1–Cl1 96.8(1) 99.3(2) 96.8(1) 
Cl1–Au1–N1 98.8(1) 97.2(2) 98.4(2) 
N1–C5–C6 117.8(5) 117.4(5) 119.2(6) 
C5–C6–N2 107.4(4) 108.9(5) 106.0(6) 
N2–C7–C8 111.1(5) 111.2(6) 110.4(5) 
C7–C8–N3 116.4(5) 115.4(5) 114.3(5) 
 
This was to be expected as the structural derivatives incorporating pyridine, 1- and 3-
isoquinoline amide moieties were specifically chosen so that minimal steric effects between 
the co-ordinated chloride ion and adjacent hydrogen atoms (associated with the above 
mentioned heterocyclic N-donor chelate rings) would be encountered. This, opposed to 
what would be envisaged for a ligand incorporating a quinoline amide moiety. The pKa of 
pyridine (5.2) and isoquinoline (5.5) are similar (vide supra) and are therefore not expected 
to impart any significant difference between gold(III)–aminomethyl pyridine (Au–NAMP) and 
gold(III)–pyridine or isoquinoline (Au–NPy/IQ) bond lengths, particularly for [Au(L5)Cl](PF6) 
which contains two Npyridine donor atoms within the ligand scaffold. This statement, in part, 
holds true as the average Au–NAMP and Au–NPy/IQ bond distances are 2.022(9) Å and 2.009(8) 
Å, respectively, which are statistically and metrically similar. This is in agreement with the 
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equivalent bond distances observed for the similar copper complexes 
[Cu(pmpa)(4MImH)(H2O)](H2O)(ClO4) and [Cu(pmpa)(4MPy)(H2O)](H2O)(ClO4), where pmpa 
= N-(2-picolyl)picolinamide, 4MImH = 4-methylimidazole and 4Mpy = 4-methylpyridine.21 It 
must also be noted that the Au–NAMP bond distances compare well to the Au-N bond 
distances observed in the symmetrical gold(III) compounds, [AuCl2(DMbipy)][PF6] and 
[AuCl2(DMObipy)][PF6] (vide supra)
13, which suggests the N-donor atoms are chemically 
similar to each other in terms of σ-donor/π-acceptor ability. The average Au–Namide amide 
distance (1.91(2) Å) is, however, significantly shorter than the corresponding Au–NPy/IQ or 
Au–NAMP distances despite their similar hybridisation (sp
2). This renders the Au–Namide and 
Au–NPy/IQ co-ordination interactions chemically and crystallographically distinct from each 
other, as was the case for [Au(HL1)Cl2]–[Au(L4)Cl2]. This effect once again arises from the 
fact that the anionic amido nitrogen is a significantly stronger σ-donor than the 
corresponding heterocyclic nitrogen atoms and is observed for a similar gold(III) amide 
compound, AuCl2(N-NP2C) (vide supra).
4 This further reiterates the statements made (vide 
supra) regarding the dissimilar co-ordinating abilities and environments provided by the 
Namido and NPy/IQ atoms. The Au–Cl1 bond distance for compounds [Au(L5)Cl](PF6)–
[Au(L7)Cl](PF6) average 2.292(6) Å, closely matching the Au–Cl bond lengths observed trans 
to the Namido atom for compounds [Au(HL1)Cl2]–[Au(L4)Cl2], consistent with a significant 
“trans effect”15. This is similarly observed for the analogous Pt(II) complex PtCl(pmpa)·2H2O 
where the Au–Cl bond distance is slightly longer at 2.308(3). This may, in part, be due to the 
slightly larger atomic radius of platinum (139 pm) compared to gold (135 pm).22 The average 
C6–N2 bond length, 1.46(2) Å, is markedly longer, 9(σ), than the N2–C7 bond length at 
1.37(1) Å. This suggests that the lone pair of electrons associated with N2 is partially 
delocalised over the N2–C7 bond, increasing its bond order and subsequently allowing for 
the shorter length observed. These structural parameters are highlighted for the analogous 
Pt(II) complex, PtCl(pmpa)·2H2O, where the C6–N2 and N2–C7 bond lengths are 1.31(2) Å 
and 1.44(2) Å respectively.23       
The bond angles (Table 5.4.4) subtended at the metal ion in [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) 
are normal for five-membered ring compounds of gold(III) with three N-donor atoms. The 
mean N–Au–Cl bond angle, 97.8(9)°, is fairly obtuse, while the mean N–Au–N angle is quite 
acute, measuring 82.1(9)°. This is expected since the sum of the angles at the metal center 
are required to equate to 360° for a square-planar metal center. Both angles deviate 
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significantly from 90°, clearly reflecting the geometric constraints on metal ion co-ordination 
imposed by the two five-membered chelate rings for the three complexes. The metrics of 
the co-ordination spheres for [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) compare favorably with the 
mean N–Au–Cl and N–Au–N angles observed for other gold(III) complexes comprising five-
membered chelate rings with three N-donor atoms, such as [Au(terpy)Cl]CI2.3H2O (N–Au–Cl, 
98.6(1)°; N–Au–N, 81.4(1)°)24, 25. Since the anionic bridgehead nitrogen (Namido) in the case of 
[Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) is a more powerful σ-donor than that of the pyridine atom in 
[Au(terpy)Cl]CI2.3H2O, one might expect the bridgehead-to-gold(III) distance to be shorter 
for compounds [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6), therefore influencing their co-ordination 
geometries. This is, however, not the case as it is well known that the bridgehead atom-to-
metal (metal = gold(III) or platinum(II)) distance (in terpyridine-based metal compounds) is 
significantly shortened compared with the rest of the metal-N distances of the co-ordination 
sphere, so much so that there is essentially negligible difference between bridgehead atom-
to-metal distance whether the bridgehead atom is a neutral pyridine (1.950(3) Å),24, 25 
anionic pyridine (compounds in this work) or even an anionic carbon (1.950(5) Å).26 
The supramolecular structures of compounds [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) are modest at 
best as they do not contain the same functional variety that compounds [Au(HL1)Cl2]–
[Au(L4)Cl2] do. Their only conventional hydrogen bond donor functional group (amide N–H) 
is lost upon chelation to the gold(III) ion. They do, however, contain conventional hydrogen 
bond acceptor functionalities in the amide oxygen and gold(III)-bound chloride ion along 
with the fluoride atoms associated with the PF6
- anion. The short contact interactions within 
the crystal lattice for all three compounds are therefore dominated by unconventional C–
H···O, C–H···Cl and C–H···F hydrogen bonding.  
For all three compounds the extended solid state structures are built around 
centrosymmetric unconventional hydrogen-bonded dimers. Figure 5.4.7 illustrates such an 
interaction for compound [Au(L5)Cl](PF6). These centrosymmetric dimers are either 
independent of each other and constitute dimers linked via PF6
- anions to form 1D 
unconventionally hydrogen bonded chains as for [Au(L6)Cl](PF6) or comprise part of a more 
complex 2D network of molecules linked via unconventional hydrogen bonds as for 
[Au(L5)Cl](PF6). This 2D network is maintained by a series of C–H···Cl (Figure 5.4.7) and 
bifurcated C–H···O unconventional hydrogen bonds (Table 5.4.5) to form ‘sheets’ that are 
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interlinked in the third dimension via PF6
- anions. The solid state structure of compound 
[Au(L7)Cl](PF6) is even more complex, containing a 3D network linked via similar 
unconventional hydrogen bonds.  
 
Figure 5.4.7: Partially labeled view of the centrosymmetric unconventionally hydrogen 
bonded dimer formed by [Au(L5)Cl](PF6). The dimer is stabilized by C–H···Cl hydrogen 
bonds: H1···Cl1i, 2.746(1) A ; C1···Cl1i, 3.503(6) A ; C1–H1···Cl1i, 137.1(3)°. 
Crystallographic symmetry code: (i) –x,–y,–z. 
The π-stacking interactions for compounds [Au(L5)Cl](PF6)–[Au(L6)Cl](PF6) are similarly 
modest with no especially short intermolecular contacts for the π-stacked rings present. This 
could be expected for [Au(L5)Cl](PF6) as the molecule is relatively small and contains only 
two aromatic substituents capable of π-stacking interactions that are separated by a more 
bulky methylene group which is capable of hindering the approach of the respective 
aromatic rings, and therefore the presence of strong π-π interactions. This was, however, 
not expected for [Au(L6)Cl](PF6) as it contains an extended aromatic quinoline ring system 
that is well known for its π-stacking ability. Compound [Au(L7)Cl](PF6) was the only complex 
of the three that displayed any significant π-stacking interactions, the most notable of which 
is the centrosymmetric interaction between two, exactly parallel, neighbouring isoquinoline 
rings incorporating atoms N3 and C8-C16 (Figure 5.4.8). The MPS between the rings is 3.380 
Å which is well within the 3.35–3.8 Å range expected for π-stacked aryl rings.20 With 
isoquinoline nitrogen atom N3 used as a frame of reference, the geometry of the interacting 
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isoquinoline rings is the typical offset antiparallel arrangement (N3 atoms pointing in 
opposite directions for aromatic N-heterocycles) as was the case in the similar interaction for 
compound [Au(HL3)Cl2].
18 The distance between the centers of gravity of the two 
isoquinoline rings, Cg1···Cg1i, measures 3.702 Å such that the lateral shift of the ring systems 
is 1.510 Å. As mentioned before, Janiak18 states that the laterally-displaced ring systems 
seen in [Au(L7)Cl](PF6) would permit optimal π-π attraction between stacked isoquinoline 
groups in addition to normal van der Waals attraction and London forces of attraction.  
 
Figure 5.4.8: Partially labeled view of the centrosymmetric π-stacked dimer formed by 
[Au(L7)Cl](PF6). The isoquinoline ring planes are parallel; the distance between the 
isoquinoline ring centers of gravity (Cg1···Cg1i) is indicated. The mean plane separation 
(MPS) and lateral shift (LS) of the stacked isoquinoline rings (calculated from the co-
ordinates of Cg1 and Cg1i) are depicted graphically on the triangle to the right of the 
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Table 5.4.5: Hydrogen bond distances and angles for compounds [Au(L5)Cl](PF6)–
[Au(L7)Cl](PF6). 
Donor–H···A D–H/Å H···A/Å D···A/Å D–H···A/° 
[Au(L5)Cl](PF6) 
C1–H1···Cli 0.95 2.75 3.503(6) 137 
C2–H2···F3ii 0.95 2.52 3.293(8) 139 
C9–H9···F2iii 0.95 2.44 3.344(7) 159 
C10–H10···O1vi 0.95 2.38 2.993(8) 122 
C11–H11···O1v  0.95 2.52 3.186(8) 116 
C12–H12···F1v  0.95 2.44 3.238(8) 141 
C1–H1···Cl1 (intramol.) 0.95 2.78 3.365(7) 121 
C12–H12···Cl1 (intramol.) 0.95 2.76 3.331(7) 119 
Symmetry codes: (i) -x,-y,-z; (ii) -1+x,1/2-y,-1/2+z; (iii) 1+x,y,z; (vi) 2-x,-1/2+y,1/2-z, (v) 1-x,-1/2+y,1/2-z 
[Au(L6)Cl](PF6) 
C2–H2···F1i 0.95 2.38 3.332(9) 176 
C11–H11···O1ii 0.95 2.55 3.357(8) 143 
C12–H12···F5iii 0.95 2.49 3.428(9) 170 
C16–H16···F1vi 0.95 2.35 3.208(8) 149 
C1–H1···Cl (intramol.) 0.95 2.71 3.299(7) 121 
C2–H2···F1 (intramol.) 0.95 2.27 2.916(9) 125 
C2–H2···F1 (intramol.) 0.95 2.74 3.347(7) 122 
Symmetry codes: (i) -1+x,y,z; (ii) 2-x,1-y,1-z; (iii) 1+x,1+y,z; (vi) 1-x,1-y,-z 
[Au(L7)Cl](PF6) 
C14–H14···F2i 0.95 2.32 3.209(9) 155 
C13–H13···Cl1ii 0.95 2.83 3.595(8) 139 
C12–H12···F5iii 0.95 2.52 3.365(10) 148 
C11–H11···O1iv 0.95 2.55 3.314(9) 137 
C9–H9···O1iv  0.95 2.37 3.186(8) 143 
C4–H4···F1v  0.95 2.40 3.340(10) 169 
C1–H1···Cl1 (intramol.) 0.95 2.78 3.366(8) 121 
C16–H16···Cl1 (intramol.) 0.95 2.80 3.363(6) 119 
Symmetry codes: (i) 1+x,y,z; (ii) 5/2-x,-1/2+y,1/2-z; (iii) 3/2-x,-1/2+y,1/2-z; (iv) 1-x,-y,1-z, (v) -1/2+x,1/2-y,1/2+z 
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Table 5.4.6: Crystal Structure, X-ray Data, and Structure Model Refinement Parameters 
for and [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6).a 
 [Au(L5)Cl](PF6) [Au(L6)Cl](PF6) [Au(L7)Cl](PF6) 
Chemical formula C12H10AuClN3OPF6 C16H12AuClN3OPF6 C16H12AuClN3OPF6 
Mr 589.62 551.18 639.70 
Crystal system, SG Monoclinic, P21/c Triclinic, P-1 Monoclinic, P21/n 
Temperature (K) 120 (2) 120 (2) 120 (1) 
a, b, c (Å) 7.7103 (2),  
13.3343 (4), 
15.4971 (4) 
6.8147 (1),  
11.5824 (3),  
12.0731 (3) 
7.0730 (5),  
18.4770(5),  
14.3450 (5) 
α, β, γ (°) 90,  
100.897 (3),  
90 
67.202(2),  
78.352 (2),  
83.432(2) 
90,  




) 1564.44 (20) 859.71 (23) 1821.52(7) 
Z 4 2 4 
Radiation type Mo Kα Mo Kα Mo Kα 
μ (mm
–1
) 9.75 8.88 8.185 
Crystal size (mm) 0.2 × 0.15 × 0.10 0.40 × 0.20 × 0.10 0.20 × 0.20 × 0.20 
Abs. correction Multi-scan Multi-scan Multi-scan 
Tmin, Tmax 0.437, 1.000 0.125, 0.470 0.291, 0.291 
Nm, Ni, No 7042, 3546, 2808   8768, 5285, 4803   18077, 5787, 4425   
Rint 0.044 0.041 0.038 
R1, wR(F
 2
), S 0.031, 0.075, 0.96 0.050, 0.131, 1.008 0.047, 0.132, 1.064 
Np, Nres 226, 5 262, 2 262, 1 
Δρmax, Δρmin (e Å
–3
) 1.94, –1.72 11.67, –3.52 9.31, –2.99 
a
Abbreviations: SG, space group; V, volume; Z; number of formula units per unit cell; μ, absorption coefficient; 
T, transmission coefficient; Nm, number of measured reflections, Ni, number of independent reflections; No, 
number of observed reflections with I > 2σ(I); I, intensity; Rint, internal R-factor for data set (based on the 






), weighted R-factor 
based on F
 2
; F, structure factor; S, goodness-of-fit of model to experimental data; Np, number of parameters, 













171 | P a g e  
 
MOLECULAR STRUCTURES [Au(L8)Cl](PF6)–[Au(L15)Cl](PF6): 
 
Figure: 5.4.9: Labelled views of the single crystal X-ray structures of gold(III) 
compounds [Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and 
[Au(L15)Cl]. Hydrogen atoms are rendered as sticks and bonds are represented as 
cylinders. Thermal ellipsoids are represented as 50% probability surfaces. 
The X-ray structures of [Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2), [Au(L11)Cl]](PF6)–[Au(L13)Cl]](PF6) 
and [Au(L15)Cl] are shown in Figure 5.4.9. The gold(III) ion is again nominally square planar 
in each complex with the gold(III) ion co-ordinated by the three N-donor atoms of the 
chelating ligand for complexes [Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–
[Au(L13)Cl](PF6), while complex [Au(L15)Cl] comprises a NN'C donor series used to chelate 
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the gold(III) ion, followed by a chloride ion co-ordinated to the fourth co-ordination site, 
trans to the amido chelating moiety, to complete the geometry. All six compounds contain a 
8-aminoquinolamide chelating moiety along with either a pyridine (unsubstituted for 
[Au(L8)Cl](PF6); substituted for [Au(L9)Cl](AuCl2), [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6), 
isoquinoline ([Au(L11)Cl](PF6) or benzene ([Au(L15)Cl]) moiety as the structural variation 
within the series. Deviation for individual atoms from a mean plane incorporating chelating 
moieties and the co-ordination sphere are minimal for all six compounds. The mean 
deviation for all atoms from the respective mean planes for compounds [Au(L8)Cl]PF6, 
[Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl] is 0.03(3) Å which is less 
than that for compounds [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) (0.06(5) Å), while the largest single 
atom deviation from the respective mean planes for compounds [Au(L8)Cl](PF6), 
[Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl] is 0.161 Å for atom Cl of 
compound [Au(L13)Cl](PF6). This probably reflects the more rigid ligand system 
incorporating the 8-aminoquinoline moiety as opposed to the aminomethyl pyridine moiety 
which includes a flexible methylene structural motif. The structural variation between 
compounds seems to impart minimal effect on the overall planarity as well as co-ordination 
geometry of the gold(III) ion in each of the six compounds (Table 5.4.7), particularly 
considering the fact that [Au(L9)Cl](AuCl2), [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) contain 
bulky substituted pyridine rings and [Au(L15)Cl] contains the markedly more powerful C6H5
- 
σ-donor group. This again was to be expected as the structural derivatives incorporating 
pyridine or substituted pyridine, 3-isoquinoline or benzene amide moieties were specifically 
chosen so that minimal steric effects between the co-ordinated chloride ion and adjacent 
protons associated with said heterocyclic N-donor chelate rings would be encountered as 
would be envisaged for a ligand incorporating a quinoline amide moiety. The pKa of pyridine 
(5.2) and isoquinoline (5.5) are similar (vide supra) and are therefore not expected to impart 
any significant difference between gold(III)–8-aminoquinoline (Au–N8AMQ) and gold(III)–
pyridine or isoquinoline (Au–NPy/IQ) bond lengths, particularly for [Au(L11)Cl](PF6) which 
contains two Nquinoline donor atoms within the ligand scaffold. Compound [Au(L15)Cl] is co-
ordinated via the deprotonated ortho carbon (CBz) of the benzene ring which is a powerful 
σ-donor atom, therefore it would then be expected that co-ordination metrics for 
[Au(L15)Cl] may differ quite significantly from the balance of the mean co-ordination 
metrics for the NN'N'' donor compounds discussed herein.   
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Table 5.4.7: Selected Crystallographic Bond Distances and Bond Angles for [Au(L8)Cl](PF6), [Au(L9)Cl]AuCl2, [Au(L11)Cl](PF6)–
[Au(L13)Cl](PF6) and [Au(L15)Cl]. 
 [Au(L8)Cl](PF6) [Au(L9)Cl](AuCl2) [Au(L11)Cl](PF6) [Au(L12)Cl](PF6) [Au(L13)Cl](PF6) [Au(L15)Cl] 
Bond distances (Å)       
Au1–N1 2.001(4) 2.021(4) 2.010(2) 2.005(2) 2.005(3) 2.116(4) 
Au1–N2 1.969(4) 1.975(4) 1.969(2) 1.971(3) 1.971(3) 1.970(4) 
Au1–N3a 2.024(4) 2.021(5) 2.013(2) 2.022(2) 2.013(3) 2.017(4) 
Au1–Cl1 2.283(1) 2.272(1) 2.282(5) 2.283(1) 2.278(1) 2.290(2) 
C=O 1.220(6) 1.223(6) 1.223(3) 1.225(5) 1.224(4) 1.221(6) 
N–C 1.340(6) 1.354(7) 1.364(3) 1.352(4) 1.353(5) 1.356(5) 
Bond angles (°)       
N1–Au1–N2 83.2(2) 83.0(2) 83.0(1) 83.1(1) 83.1(4) 81.7(1) 
N2–Au1–N3a 81.9(2) 82.3(2) 83.0(1) 83.1(1) 82.1(3) 82.6(2) 
N3–Au1–Cl1a 97.6(1) 97.7(1) 96.4(1) 96.3(1) 97.6(1) 96.5(1) 
Cl1–Au1–N1 97.3(1) 96.9(1) 97.4(1) 97.4(1) 96.8(1) 99.2(1) 
N1–C9–C8 117.8(5) 117.8(5) 118.1(2) 117.9(2) 117.6(3) 117.8(3) 
C9–C8–N2 113.3(4) 114.4(5) 114.1(2) 114.1(2) 114.7(3) 115.0(3) 
N2–C10–C11 111.9(4) 112.0(4) 112.6(2) 112.2(2) 112.0(3) 110.5(4) 
C7–C8–N3a 117.0(4) 117.0(5) 116.5(2) 116.3(2) 116.3(3) 118.4(4) 
aFor [Au(L15)Cl] atom N3 is replaced by atom C16.
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The mean N8AMQ–Au and NPy/IQ–Au distances for the NN'N'' compounds are 2.008(7) Å and 
2.018(5) Å, respectively, which are statistically alike and indicative of their similar σ-
donor/π-acceptor ability despite their structural dissimilarity. The mean N8AMQ–Au distance 
for the NN'N'' compounds in this work is slightly shorter than for those reported for similar 
8-aminoquinoline based gold(III) compounds, [Au(Quingly)Cl]Cl (2.027(6) Å, where Quingly = 
2-amino-N-(quinolin-8-yl)acetamide) and [Au(Quinala)Cl]Cl (2.02(4) Å, where Quinala = 2-
amino-N-(quinolin-8-yl)propanamide) while the NPy/IQ–Au distance for the NN'N'' 
compounds compares well to the N8AMQ–Au distances for the reported compounds.
5 The 
primary amine–Au (NPA–Au) distances for reported compounds [Au(Quingly)Cl]Cl and 
[Au(Quinala)Cl]Cl (2.024(6) and 1.98(3) Å, respectively) differ from the N–Au distances 
reported for the NN'N'' compounds in this work.5 This may be expected since primary amine 
donor atoms are sp3 hybridised as opposed to sp2, and are weaker Lewis bases than the 
pyridine quinoline and amido donor groups in this work. The CBz–Au distance (2.017(4) Å) 
for compound [Au(L15)Cl] is equivalent to the mean NPy/IQ–Au distance and slightly longer 
than the mean N8AMQ–Au distance for compounds [Au(L8)Cl](PF6)–[Au(L9)Cl](AuCl2) and 
[Au(L11)Cl](PF6)–[Au(L13)Cl](PF6). This is not unexpected as the C6H5
- donor group is a strong 
σ-donor (Lewis base) and therefore the CBz–Au bond length is expected to be shorter than 
that of an N–Au bond length. However the ionic radius for carbon is larger than that for 
nitrogen. Both these facts would account for the similar CBz–Au, NPy/IQ–Au and N8AMQ–Au 
bond lengths. The powerful σ-donor ability of the C6H5
- donor group is manifest through a 
trans effect seen in the N8AMQ–Au bond length (2.116(4) Å), nearly 27 standard deviations 
longer than the average N8AMQ–Au bond length for the NN'N'' compounds. Similar C–Au and 
N–Au bond lengths have been observed for NN'C cyclometallated gold(III) complexes of 6-
benzyl- and 6-alkyl-2,2'-bipyridines involving two five membered chelate rings.26 The 
average Au–Namide amide bond distance for all six compounds measures 1.970(2) Å, which is 
significantly shorter than the corresponding Au–NPy/IQ (24(σ)) or Au–N8AMQ (19(σ)) distances 
despite their similar hybridisation (sp2). This renders the Au–Namide and Au–NPy/IQ/ Au–N8AMQ 
co-ordination interactions chemically and crystallographically distinct from each other, as 
was the case for all compounds discussed above. This effect, once again, arises from the fact 
that the anionic amido nitrogen is a significantly stronger σ-donor (Lewis base) than the 
corresponding heterocyclic nitrogen atoms. This is similarly observed for gold(III) amide 
compounds [Au(Quingly)Cl]Cl and [Au(Quinala)Cl]Cl.5 The Au–Cl1 bond distance for 
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compounds [Au(L8)Cl](PF6)–[Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and 
[Au(L15)Cl] average 2.281(5) Å, closely matching the Au–Cl bond lengths observed trans to 
the Namido atom for the rest of the compounds reported in this work, once again, indicating a 
significant “trans effect”15. This is similarly observed for the 8-aminoquinoline based gold(III) 
compounds  [Au(Quingly)Cl]Cl and [Au(Quinala)Cl]Cl where the mean Au–Cl bond distance is 
similarly 2.277(1) Å. The average C8–N2 bond length, 1.41(1) Å, is longer, 6(σ), than the N2–
C10 bond length at 1.353(7) Å. This suggests that the lone pair of electrons associated with 
N2 is partially delocalised over the N2–C7 bond, increasing its bond order and subsequently 
allowing for the shorter length observed. These structural parameters are highlighted for 
the similar gold(III) complexes, [Au(Quingly)Cl]Cl and [Au(Quinala)Cl]Cl, where the C8–N2 
and N2–C10 equivalent bond lengths are 1.339(9), 1.39(4) Å and 1.431(9), 1.40(4) Å 
respectively.5        
The bond angles (Table 5.4.7) subtended at the metal ion in [Au(L8)Cl](PF6), 
[Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) are normal for five-membered ring 
compounds of gold(III) with three N-donor atoms while the angles for [Au(L15)Cl] are 
normal for five-membered gold(III) compounds containing NNC-donor ligands. For 
compounds [Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) the mean N–
Au–Cl bond angle, 97.1(5)°, is fairly obtuse, while the mean N–Au–N angle is quite acute, 
measuring 82.7(4). Compound [Au(L15)Cl] contains the strong σ-donor, C6H5
- moiety, which 
imparts a significant trans effect and hence a lengthening of the N1–Au bond length (vide 
supra). This bond lengthening in turn forces a decrease in the N1–Au–N2 bond angle to 
81.7(1)° compared to the average 82.7(4)° and an increase in the Cl1–Au–N1 bond angle to 
99.2(1)° compared to the average 97.1(5)° the for the NN'N'' donor compounds. Both angles 
deviate significantly from 90°, clearly reflecting the geometric constraints on metal ion co-
ordination imposed by the two five-membered chelate rings for the six complexes. The 
metrics of the co-ordination geometries for [Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2), 
[Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) compare favourably with the mean N–Au–Cl and N–Au–N 
angles observed for other gold(III) complexes comprising five-membered chelate rings with 
three N-donor atoms, such as [Au(terpy)Cl]CI2.3H2O (N–Au–Cl, 98.6(1)°; N–Au–N, 81.4(1)°). 
The Namido–Au distances for compounds [Au(L8)Cl](PF6)–[Au(L15)Cl](PF6) (1.970(2) Å) are 
similar to compounds [Au(L5)Cl](PF6)–[Au(L7)Cl](PF6) (1.91(2) Å) as well as the NPy–Au 
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distances for [Au(terpy)Cl]CI2.3H2O (1.950(3) Å).
24, 25 This is despite the more powerful σ-
donor ability of a Namido moiety compared to that of an NPy moiety. The reason for this is the 
well-known fact that the bridgehead atom-to-metal (metal = gold(III) or platimun(II)) 
distance (in terpyridine-based metal compounds) is significantly shortened compared with 
the rest of the metal-N distances of the co-ordination sphere. The co-ordination geometry 
for [Au(L15)Cl] compares well with the 6-substituted bipyridine complex, 
[Au{N2C10H7(CMe2CH2)-6}-Cl][BF4]·5H20
27 (where {N2C10H7(CMe2CH2)-6} = 6-tert-butyl-2,2'-
bipyridine), a similar NN'C donor gold(III) compound comprising two five-membered chelate 
rings, with a similar decrease and increase in N1–Au–N2 and Cl1–Au–N1 bond angles 
respectively. The deviations are more pronounced for [Au{N2C10H7(CMe2CH2)-6}-
Cl][BF4]·5H20.
27 This may be due to the different C-donor moieties, [Au(L15)Cl] contains a 
C6H5
- donor while [Au{N2C10H7(CMe2CH2)-6}-Cl][BF4]·5H20 contains a CH2
- donor moiety. The 
latter is sterically unencumbered and flexible allowing a closer approach of the C-donor 
atom to the gold(III) centre and evidently a further elongation of the trans N1–Au bond. As a 
result the mentioned decrease and increase in N1–Au–N2 and Cl1–Au–N1 bond angles is 
observed.  
Only compounds [Au(L9)Cl](AuCl2), [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) contain substituent 
groups capable of conformational/rotational freedom that are not part of the mean plane 
chelating moiety capable of conformational freedom. Compound [Au(L9)Cl](AuCl2) contains 
a para butyl-substituted pyridine ring (Figure 5.4.9). The butyl chain adopts a staircase motif 
akin with that of the similar nonyl chain present in the compound AuCl2(N-NP2C) discussed 
above. Compounds [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) contain phenyl ketone moieties 
substituted in the ortho position of the chelating pyridine ring. In solution the phenyl ketone 
ring has free rotation around atom C12 while the phenyl motif has additional free rotation 
around atom C17. In the solid state the phenyl ketone moiety has to adopt a ‘ring up’ or 
‘ring down’ conformation with respect to the main body of the complex. This conformation 
evidently arises through differences in crystal packing energies as the rings in both 
complexes adopt different orientations:, complex [Au(L12)Cl](PF6) adopts the ‘ring up’ 
orientation while complex [Au(L13)Cl](PF6) adopts the ‘ring down’ orientation (this 
statement is with reference to the 8-aminoquinoline moiety being positioned on the left 
when viewing from above). The angle between the phenyl ketone moiety and the main 
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chelating body of each complex is near perpendicular at 86.9° and 85.5° for [Au(L12)Cl](PF6) 
and [Au(L13)Cl](PF6), respectively. The phenyl ring is almost co-planar with the amide group 
for [Au(L12)Cl](PF6) with the C12–C16–C17–C18 dihedral angle measuring 1.5(6)°, while for 
[Au(L13)Cl](PF6) the 4-fluorophenyl ring is slightly out of plane to the amide group with a 
C12–C16–C17–C18 dihedral angle of 19.0(6)°.  
 
Figure 5.4.10: Partially labelled view of a discrete unconventionally hydrogen-bonded 
centrosymmetric dimer of [Au(L12)Cl](PF6). Hydrogen atoms are represented as sticks; 
all other atoms are represented as thermal ellipsoids (50% probability). The dimer is 
stabilised by C–H···O hydrogen bonds: H6···O1i, 2.49 Å; C6···O1i, 3.318(5) Å; C6–
H6···O1i, 145°. Crystallographic symmetry code: (i) 1-x,1-y,-z. 
Consistent with the structural data for the compounds discussed earlier, compounds 
[Au(L8)Cl](PF6)–[Au(L15)Cl](PF6) contain no traditional hydrogen bond donors due to the N-
H donor being lost upon chelation of the ligand to the gold(III) centre. The short contact 
interactions within the crystal lattice for all compounds are therefore dominated by 
unconventional C–H···O, C–H···Cl and C–H···F hydrogen bonding as was the case for 
[Au(L5)Cl](PF6)–[Au(L7)Cl](PF6). The supramolecular structures of [Au(L8)Cl](PF6), 
[Au(L9)Cl](AuCl2) and [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) are again similarly dominated by 
centrosymmetric unconventionally hydrogen-bonded dimers. The  centrosymmetric dimers 
for compounds [Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2) and [Au(L12)Cl](PF6) are linked via 
unconventional hydrogen bonds that are restricted to single C–H···O interactions between 
individual molecules of each dimer and are not extended continuously through the lattice 
(Figure 5.4.10). For compound [Au(L8)Cl](PF6), the individual dimers are linked to each other 
in three dimensions via PF6
- anions to form the extended structure observed in the lattice. 
For compound [Au(L9)Cl](AuCl2) the individual dimers are successively linked to 
neighbouring molecules above and below in a staircase fashion via C–H···Cl unconventional 
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hydrogen bonds and C–Cl short contact interactions associated with the AuCl2 counterions. 
Individual dimers for [Au(L12)Cl](PF6) are linked to each other via PF6
- anions to form 
discrete 1D linear chains. These chains are then interconnected to similar chains above and 
below via strong N–O (2.887(5) Å) short contact interactions. The extended structures for 
compounds [Au(L11)Cl](PF6) and [Au(L13)Cl](PF6) similarly revolve around centrosymmetric 
dimers linked via unconventional hydrogen bonds, however the distinction between the C–
H···O unconventional hydrogen bonds between dimers for these compounds compared to 
[Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2) and [Au(L12)Cl](PF6) is that they are three-centred, 
bifurcated hydrogen bonds which form a 1D hydrogen-bonded polymer. For compound 
[Au(L9)Cl](AuCl2), the hydrogen bond acceptor is atom O1 while the donor atoms are H6 and 
H7, full metrics of the interactions are available in Table 5.4.8. The 3D extended structure 
consists of C–H···O, C–H···F and C–H···Cl unconventional hydrogen bonds as well as C–C and 
C–Cl short contact interactions between PF6
- anions, MeNO2 solvent molecules and cations.  
 
Figure 5.4.11: Partially labelled view of both types of unconventionally hydrogen 
bonded centrosymmetric dimers of [Au(L12)Cl](PF6). Hydrogen atoms are represented 
as sticks; all other atoms are represented as thermal ellipsoids (50% probability). The 
dimer on the left is stabilised by bifurcated C–H···O hydrogen bonds: H6···O1i, 2.50 Å; 
C6···O1i, 3.240(5) Å; C6–H6···O1i, 135°; H6···O2i, 2.60 Å; C6···O2i, 3.443(5) Å; C6–
H6···O2i, 147°. Crystallographic symmetry code: (i) -x,-y,-z. The dimer on the right is 
stabilized by C–H···Cl hydrogen bonds: H1···Clii, 2.79 Å; C1···Clii, 3.516(4) Å; C6–
H6···O1ii, 134°. Crystallographic symmetry code: (ii) 2-x,1-y,-z. 
The extended structure of compound [Au(L13)Cl](PF6) (Figure 5.4.11) comprises discrete 
infinite chains containing alternating centrosymmetric dimers linked via bifurcated C–H···O 
X-ray Crystallography 
179 | P a g e  
 
and C–H···Cl unconventional hydrogen bonds (metrics of the bonds can be found in Table 
5.4.8.) so that each individual molecule is simultaneously part of each type of cation pair 
(Figure 5.4.11). Compound [Au(L15)Cl] contains no appreciable (less than the sum of the van 
der Waals radii) short contact or hydrogen bond interactions. 
 
Figure 5.4.12: A: Spacefull (left) and stick (right) representation of the 
centrosymmetric π-stacked dimer between two quinoline rings in compound 
[Au(L12)Cl](PF6). The metrics of the interaction are as follows: Cg1···Cg2, 3.819 Å; MPS, 
3.307 Å; LS, 1.911. B: Partially labelled view of the centrosymmetric π-stacked dimer 
formed by [Au(L15)Cl]. The metrics of the interaction are depicted in the triangle inset 
on the left hand side while the inset on the right displays the interaction from a point of 
view perpendicular to a mean plane through an isoquinoline ring 
Several π-stacking interactions are also prevalent for all compounds bar [Au(L8)Cl](PF6); 
these span lateral shift (LS) and mean plane separation (MPS) values of 0.88–1.92 Å and 
3.26–3.42 Å, respectively, and involve both the free- and Au-bound pyridine rings. For 
compound [Au(L12)Cl](PF6), the most prominent π-π interaction occurs between the phenyl 
rings of neighbouring isoquinoline moieties. The interaction forms the basis of a π-stacked 
centrosymmetric dimer similar to that seen for compound [Au(HL3)Cl2]. In the case of 
[Au(L12)Cl](PF6), however, the dimer is not further stabilised by unconventional hydrogen 
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bond interactions as for [Au(HL3)Cl2]. The interaction is such that each individual L-shaped 
molecule of [Au(L12)Cl](PF6) interlocks via the π-stacking interaction with a neighbouring 
molecule to create the rectangle-shaped dimer seen in Figure 5.4.12 (Part A). Although the 
interacting rings do not contain any heteroatoms, a characteristic offset parallel geometry 
discussed by Janiak is observed.18 The interplanar spacing between rings is 3.307 Å, which  is 
smaller than the 3.35-3.8 Å separation expected for such rings and indicates the interaction 
is particularly strong.19 The only intermolecular interaction of significance within the crystal 
lattice of compound [Au(L15)Cl] is a π-π interaction. It occurs between two exactly parallel 
quinoline rings of neighbouring molecules, once again, so that a centrosymmetric π-stacked 
dimer is formed. The interplanar spacing between rings is 3.320 Å which is also less than the 
typical MPS of 3.35-3.8 Å, and indicates, the interaction is particularly strong.19 The LS and 
centriod···centriod distances are represented in Figure 5.4.12 (Part B). The heteroaromatic 
rings display the characteristic offset antiparallel geometry discussed by Janiak so that the 
respective nitrogen atoms (N1) are pointing in opposite directions with respect to each 
other.18  
The last intermolecular interaction that is noteworthy is that of an aurophillic interaction 
present for compound [Au(L9)Cl](AuCl2). Aurophillic interactions between gold(III) cations 
are very rare.28 This is evident through the absence of such interactions for all thirteen 
single crystal X-ray structures presented in this work. By far the most common Au–Au 
interactions occur between gold(I) ions, where the au–au bond distance and strength (3.0 Å 
and ca. 6-12 kcal, respectively) has been calculated and experimentally found to be similar 
to that of a common hydrogen bond.29-31 There are also reports in the literature of 
aurophillic interactions between mixed oxidation state complex salts such as 
[Au(terpy)Cl]2[AuCl2]3[AuCl4].
25
 Initial synthetic attempts for compound [Au(L9)Cl](PF6) 
resulted in the linear AuCl2 salt of the complex, [Au(L9)Cl](AuCl2). Single crystal analysis 
revealed the presence of Au(I)–Au(III) aurophillic interactions. The interatomic distance 
between the two gold atoms is 3.277(1) Å which compares closely with the similar Au(I)–
Au(III) aurophillic interaction (3.299(1) Å) present in the gold(III)terpy complex 
[Au(terpy)Cl]2[AuCl2]3[AuCl4].
25 The interaction is a centrosymmetric one with the gold(I) 
anion ‘sandwiched’ between two gold(III) cations (Figure 5.4.13 (Right)). The Au(I)–Au(III) 
interactions are discrete events restricted to individual ‘sandwiches’ and hence are not 
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extended throughout the lattice. When viewed from above, perpendicular to a plane 
comprising all atoms of the co-ordinating moiety, the Au atoms partially eclipse one another 
(Figure 5.4.13).  
 
Figure 5.4.13: Centrosymmetric ‘sandwich’ structure observed for compound 
[Au(L9)Cl](AuCl2) showing a linear gold(I) anion symmetrically sandwiched between 
two gold(III) cations (left). A top view of the ‘sandwich’ structure viewed perpendicular 
to a co-ordination motif mean plane.    
The laterally-displaced ring systems seen in most compounds discussed would permit 
optimal π-π attraction between stacked isoquinoline, quinoline or pyridine groups in 
addition to normal van der Waals attraction and London forces of attraction. Isoquinoline 
and quinoline ring systems are, of course, well-known for their π-stacking ability and are 
often key pharmacophores prevalent in many anti-cancer,32 anti-viral,33 and anti-malarial34 
compounds with a mechanism of action (MOA) involving DNA binding by intercalation.35 Of 
special relevance to the present work, we note that the clinically-deployed anti-cancer drug 
camptothecin (a quinoline alkaloid) poisons human topoisomerase I (TOP1) by DNA 
intercalation at a 5′-TA-3′ dinucleotide site targeted for covalent binding by the enzyme 
during its catalytic cycle.36 In short, the isoquinoline, quinoline or pyridine rings of the 
compounds discussed are clearly potentially useful functional groups that may engage in 
interactions with biological targets such as DNA by π-stacking as well as hydrogen-bonding.  
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Table 5.4.8: Hydrogen bond distances and angles for compounds [Au(L8)Cl](PF6), 
[Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl]. 
Donor–H···A D–H/Å H···A/Å D···A/Å D–H···A/° 
[Au(L8)Cl](PF6) 
C14–H14···F2i 0.95 2.36 3.190(8) 145 
C12–H12···F6ii 0.95 2.52 3.300(7) 138 
C7–H7···O1iii 0.95 2.55 3.186(7) 125 
C1–H1···F2iv  0.95 2.44 3.265(7) 145 
C1–H1···Cl (intramol.) 0.95 2.80 3.372(6) 119 
C8–H8···O1 (intramol.) 0.95 2.44 3.008(7) 119 
C14–H14···Cl1 (intramol.) 0.95 2.79 3.354(6) 119 
Symmetry codes: (i) -1+x,y,z; (ii) 1-x,1/2+y,1/2-z; (iii) 2-x,1-y,1-z; (iv) 1-x,-1/2+y,1/2-z 
[Au(L9)Cl](AuCl2) 
C5–H5···Cl3i 0.95 2.83 3.775(6) 175 
C12–H12···O1ii 0.95 2.36 3.216(7) 149 
C1–H1···Cl (intramol.) 0.95 2.78 3.341(7) 119 
C7–H7···O1 (intramol.) 0.95 2.43 3.002(7) 118 
C15–H15···Cl1 (intramol.) 0.95 2.79 3.371(6) 120 
Symmetry codes: (i) 1-x,1-y,-z; (ii) -1-x,-y,1-z 
[Au(L11)Cl](PF6) 
C2–H2···F3i 0.93 2.29 3.170(4) 158 
C3–H3···F5ii 0.93 2.45 2.908(5) 110 
C3–H3···F1iii 0.93 2.51 3.304(4) 143 
C6–H6···O1iv 0.93 2.49 3.122(4) 125 
C16–H16···Cl1v  0.93 2.74 3.609(4) 156 
C17–H17···F6vi 0.93 2.48 3.247(4) 140 
C1–H1···Cl1 (intramol.) 0.93 2.78 3.344(3) 120 
C16–H16···Cl1 (intramol.) 0.93 2.43 2.991(4) 119 
C19–H19···Cl1 (intramol.) 0.93 2.72 3.301(3) 122 
Symmetry codes: (i) 1/2-x,1/2-y,1-z; (ii) 1/2-x,1/2+y,1/2-z; (iii) -1/2+x,1/2-y,-1/2+z; (iv) -x,-y,-z, (v) 1/2-
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Table 5.4.8 continued: Hydrogen bond distances and angles for compounds 
[Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and 
[Au(L15)Cl]. 
Donor–H···A D–H/Å H···A/Å D···A/Å D–H···A/° 
[Au(L12)Cl](PF6) 
C1–H1···F3i 0.95 2.44 3.204(5) 137 
C1–H1···F6i 0.95 2.47 3.074(5) 121 
C2–H2···F6i 0.95 2.54 3.102(5) 118 
C6–H6···O1ii 0.95 2.49 3.318(5) 145 
C14–H14···F1iii 0.95 2.54 3.432(5) 156 
C14–H14···F3iv 0.95 2.42 3.084(5) 126 
C15–H15···F4iii 0.95 2.40 3.169(5) 138 
C19–H19···F2v 0.95 2.44 3.300(5) 151 
C1–H1···Cl (intramol.) 0.95 2.77 3.340(4) 119 
C7–H7···O1 (intramol.) 0.95 2.43 2.999(5) 119 
C15–H15···Cl (intramol.) 0.95 2.79 3.358(4) 120 
Symmetry codes: (i) -1+x,y,z; (ii) 1-x,1-y,-z; (iii) -x,1-y,1-z; (iv) 1-x,1-y,1-z, (v) 1+x,1+y,z 
[Au(L13)Cl](PF6) 
C1–H1···Cli 0.95 2.79 3.516(4) 134 
C2–H2···F5ii 0.95 2.48 3.307(5) 146 
C6–H6···O1iii 0.95 2.50 3.240(5) 135 
C15–H15···F7iv 0.95 2.50 3.182(5) 129 
C1–H1···Cl (intramol.) 0.95 2.77 3.333(5) 119 
C7–H7···O1 (intramol.) 0.95 2.43 3.004(5) 119 
C15–H15···Cl (intramol.) 0.95 2.74 3.182(5) 120 
Symmetry codes: (i) 2-x,1-y,-z; (ii) 1-x,1-y,-z; (iii) -x,-y,-z; (iv) 1+x,y,z 
[Au(L14)Cl](PF6) 
C7–H7···O1 (intramol.) 0.95 2.31 2.905(7) 120 
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Table 5.4.9: Crystal Structure, X-ray Data, and Structure Model Refinement Parameters for and [Au(L8)Cl](PF6), [Au(L9)Cl](AuCl2), 
[Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl]. 
 [Au(L8)Cl](PF6) [Au(L9)Cl](AuCl2) [Au(L11)Cl](PF6) [Au(L12)Cl](PF6) [Au(L13)Cl](PF6) [Au(L15)Cl] 
Chemical formula C15H10AuClN3OPF6 C19H18Au2Cl3N3O C38H24Au2Cl2N6O2P2F12·C3H3NO2 C16H10AuClN2O C22H14AuClN3O2PF6 C22H13AuClN3O2PF7 
Mr 625.65 804.65 1412.45 478.68 729.75 829.85 
Crystal system, SG Monoclinic, P21/c Triclinic P-1 Monoclinic C2/c Triclinic P-1 Triclinic P-1 Triclinic P-1 
Temperature (K) 298 100 100 100 120 120 






































) 1702.5(3) 1038.51(7) 4232.4(6) 675.76(7) 1235.29(5) 1387.77(5) 
Z 4 2 4 2 2 2 
Radiation type Mo Kα Cu Kα Mo Kα Mo Kα Mo Kα Mo Kα 
μ (mm
–1
) 8.967 29.862 7.232 11.081 6.198 5.537 
Crystal size (mm) 0.30, 0.10, 0.05 0.09, 0.08, 0.05 0.40, 0.20, 0.10 0.30, 0.10, 0.05 0.30, 0.20, 0.20 0.30, 0.30, 0.05 
Abs. correction SADABS SADABS SADABS SADABS Multi-Scan Multi-Scan 
Tmin, Tmax 0.174, 0.663 0.115, 0.199 0.420, 0.749 0.400, 0.751 0.258, 0.370 0.287, 0.769 
Nm, Ni, No 24990, 8115, 5597 3508, 3508, 3383 52994, 17898, 13385 30618, 16888, 9811 12640, 7581, 6793 14195, 8529, 7158 
Rint 0.053 0.025 0.0417 0.057 0.032 0.033 
R1, wR(F
 2
), S 0.052, 0.156, 1.025 0.026, 0.069, 1.128 0.040, 0.150,  0.067, 0.206, 1.011 0.033, 0.082, 0.992 0.036, 0.085, 0.963 
Np, Nres 254, 0 259, 0 309, 0 190, 0 325, 0 390, 0 
Δρmax, Δρmin (e Å
–3
) 4.55, -3.30 1.069, -1.471 6.170, -3.410 7.400, -6.830 1.950, -3.010 1.980, -2.820 
a
Abbreviations: SG, space group; V, volume; Z; number of formula units per unit cell; μ, absorption coefficient; T, transmission coefficient; Nm, number of measured 
reflections, Ni, number of independent reflections; No, number of observed reflections with I > 2σ(I); I, intensity; Rint, internal R-factor for data set (based on the intensity 






), weighted R-factor based on F
 2
; F, structure factor; S, goodness-of-fit of model to 
experimental data; Np, number of parameters, Nres, number of restraints; Δρ, electron density difference. 
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6. Computational chemistry 
6.1 Introduction 
Computational chemistry involves the use of mathematical methods, combined with the 
basic laws of physics, and is used to solve chemically related problems by calculation. It is a 
subfield of theoretical chemistry that falls under the broader field of physical chemistry.1 
In trying to understand how molecules behave, one has to understand the underlying 
contributing factors that affect how molecules behave, this being the electron. Quantum 
mechanics (QM) is the most correct mathematical description of the behaviour of electrons 
and their ability to behave in both a particle-like fashion and a wave-like fashion.2 In theory, 
QM can predict any property of an individual atom or molecule but in practice the QM 
equations have only been solved exactly for one-electron systems. There are several 
different methods that have been developed for approximating the solution for multiple-
electron systems. One of these methods was formulated by Schrӧdinger:3  
Ĥψ = Eψ                    6.1.1 
where Ĥ is the Hamiltonian operator, ψ a wave function and E the energy.3 
The wave function ψ, as the name implies, is the description of an electron as a wave and 
can describe the probability of electrons being in certain locations, but it cannot predict 
exactly where electrons are located. Once the wave function has been calculated, almost 
any property of the individual molecule can be determined with varying degrees of accuracy 
dependent upon the approximations used to simplify the calculations.3 Density functional 
theory (DFT) is an indirect method of calculating the wave function and focuses on 
optimising electron density. From the basic premises of DFT, the charge distribution 
determines the external potential, which in turn determines the Hamiltonian operator, 
which ultimately leads to the wave function.4 DFT theory is based upon a strategy of 
modelling electron correlation via general functional of the electron density. Electron 
correlation is based on the fact that electrons in a molecular system react to one another’s 
motion and attempt to avoid each other.2 DFT is frequently used as the method of choice 
when predicting properties of metal complexes. The most common type of functional used 
in modern DFT calculations of small molecules is a gradient-corrected functional (the 
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generalised gradient approximation (GGA)).3-5 This is over the older functionals such as the 
local density approximation (LDA) as well as the local spin density approximation (LSDA). 
Both these functionals are based on the assumption that at every point in the molecule the 
energy density has the value that would be given by a homogeneous electron gas which had 
the same electron density at that point.5 The LSDA functional extends this further and 
assigns a spin orientation to electrons similar to the Hartree-Fock (HF) method.1, 3-5 HF is 
another quantum mechanical method used to calculate the wave function and is the 
product of one-electron functions called spatial orbitals.1, 3-5 Further functionals, and the 
type used for the calculations performed in this thesis, are the hybrid GGA functionals. This 
is a GGA functional to which HF exchange has been added.5 In general the most frequently 
used hybrid-functionals are B3LYP6-8 (Becke 88 3-parameter exchange functional and the 
Lee, Yang, Parr correlation functional), PBE1PBE9 (the Adamo hybrid of the 1996 pure 
functional of Perdew, Burke and Ernzerhof) and HSEh1PBE10-13 (the full Heyd-Scuseria-
Ernzerhof) functional. These functionals are used in conjunction with a basis set which are 
the set of mathematical functions from which the wave function is constructed. For 
molecules that only contain light atoms (up to the first row of transition metals) the 6-
311G14-16 basis set is commonly used. For heavy elements, however, the situation is slightly 
different as they contain numerous core electrons which would require a large number of 
basis functions to describe them. In addition to this, the core electrons of such heavy 
elements approach velocities nearing the speed of light so that they may manifest 
relativistic effects. The solution to this problem is to use an effective core potential (ECP) 
which uses an analytical function to replace the core electrons. The most commonly used 
ECP basis sets for the study of heavy metal complexes are the Los Alamos17-19 (LanL2DZ), 
and the Stuttgart/Dresden20 (SDD) ECP’s. There is, however, no obvious choice of functional 
and basis set combination when examining the literature and one has to pick a combination 
which is relevant to the system being investigated. In the case of gold(III) d8 metal 
complexes there is a precedent for all functionals (vida supra). We have chosen the 
HSEh1PBE10-13 functional as it is the most modern of the three described, along with the use 
of a split basis set, 6-311G(d,p)14-16 being used for all atoms except the gold(III) ion, for 
which the LanL2DZ17-19 ECP was used.  
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Literature reports on the use of DFT calculations on gold complexes are fairly prevalent with 
the most common use being as an aid in understanding the experimental physical 
properties such as luminescence, reactivity, stability and UV-vis spectra of the respective 
complexes.21-26 DFT calculations are, however, also regularly used to try and understand the 
mechanistic detail underlying chemical reactions that involve gold complexes as a catalyst.27, 
28  
One such example on the use of DFT computations as an aid to understanding the physical 
properties of gold complexes is reported by Au and co-workers and titled ‘Luminescent 
Cyclometalated Alkynylgold(III) Complexes with 6-Phenyl-2,2′-Bipyridine Derivatives: 
Synthesis, Characterisation, Electrochemistry, Photophysics, and Computational Studies’ 
(Figure 6.1.1).21 
 
Figure 6.1.1: Chemical structures of some gold(III) alkynyl complexes studied by Yam 
and co-workers. 
The authors found that the electronic absorption spectra (acetonitrile, room temperature) 
of the complexes (Figure 6.1.1) revolved around an intense absorption at the higher energy 
region (wavelength < 320 nm) and a moderately intense broad adsorption band at 374-406 
nm, assigned to a metal-perturbed intraligand π-π* transition of the ligand.21 The transitions 
were found to be based on a charge transfer from the aryl ring to the bipy moiety.21 The 
complexes were all found to be emissive in butyronitrile glass (77K) with emission bands 
between 469-550 nm.21 These were assigned to an intraligand excited state of the ligand 
with some charge transfer character from the aryl ring to the bipy moiety.21  
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A recent example of the application of DFT computations in the elucidation of a catalytic 
mechanism, Ye and co-workers describe the generation of vinylidenes from terminal alkynes 
via a bifurcation pathway and facile C-H insertion (Figure 6.1.2).28  
 
Figure 6.1.2: Free energy diagram for the reaction in chloroform. All energy levels in 
kcal/mol. TS1 is transition state 1 and TS2 is transition state 2. Adapted from reference 
28.28  
The authors found that the cyclo-isomerisation of benzene -1,2-dialkynes occurs with the 
aid of two BrettPhosAuNTf2 molecules working synergistically with each other and a gold 
vinylidine structure (C) as the most likely intermediate (as opposed to structure D).    
6.2 Objectives 
The objectives of the computational work were: (1) to delineate the gas phase structures of 
all compounds and compare them to the solid state structures in order to determine the 
accuracy of the computational methods used as well as to determine the influence crystal 
packing effects have on the solid state structures, (2) to calculate the d-orbital electron 
distributions in order to gain insight on the electronic structure of the compounds, (3) to 
calculate IR, NMR and energy values for each complex and compare and contrast them to 
the respective experimentally obtained values in order to determine the accuracy of the 
computational methods used, (4) to use the calculated IR, NMR, time-dependent DFT (TD-
DFT) data to guide the assignment 
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6.3 Experimental  
There are different approximation methods, also known as levels of theory that can be used 
to determine the required parameters of a calculation. In our case DFT and TD-DFT29 
calculations were performed with Gaussian09 using the full Heyd-Scuseria-Ernzerhof 
functional (HSE06)10-13 and the double-ζ basis set 6-311G(d,p)14-16 for all atoms except Au, 
for which the Los Alamos ECP basis set (LanL2DZ)17-19 was implemented. An additional f-type 
polarisation function (α = 0.20)30, 31 was used for the Au atom. X-ray co-ordinates of the 
cations [Au(HL1)Cl2]–[Au(L9)Cl](PF6) , [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl] were 
used as a starting point for each respective geometry optimisation while the X-ray co-
ordinates of [Au(L11)Cl](PF6), [Au(L12)Cl](PF6) and [Au(L15)Cl] were modified accordingly 
and used as the starting point geometry for compounds [Au(L10)Cl](PF6), [Au(L14)Cl](PF6) 
and [Au(L16)Cl], respectively. The calculations excluded the counterions (anions). No 
negative eigenvalues were calculated for the stationary point structures located by 
geometry optimisation, consistent with location of minima on the potential energy surface 
for each gold(III) chelate. Solvent effects were added using the conductor-like polarisable 
continuum model (C-PCM)32 for TD-DFT energy calculations. Root-mean-square deviation 
(RMSD) fits between calculated and experimental structures for all complexes were 
calculated using Mercury 3.033. NMR chemical shifts were calculated and analysed relative 
to tetramethylsilane using the GIAO34-37 method at the same level of theory as stated above.  
All of the Gaussian job files can be found in Appendix C. 
6.4 Results and discussion 
GEOMETRY OPTIMISATIONS: 
The geometries of all compounds were optimised to energy minima on potential energy 
surface. The calculations were performed at the level of theory discussed above and the 
results compared to the experimental single crystal X-ray structures where possible. Where 
comparison was not possible (X-ray structure not available) the results were simply reported 
for the stationary point structure determined from the geometry optimisation. 
Considering the calculations were performed in vacuo, the calculated structures are not 
exposed to any intermolecular forces which are able to distort the solid state structure quite 
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significantly from the energy minimised structures. The intermolecular forces involved may 
comprise conventional and unconventional hydrogen bonding, van der Waals forces as well 
as ring-ring interactions. The preference for the co-ordination sphere of all the compounds 
to adopt a square planar geometry was confirmed through the geometry optimisation 
results. In addition, the metal ion, the conjugated aromatic system of the pyridine, quinoline 
and isoquinoline rings, as well as the amide functionality further serve to enforce a square 
planar geometry of the co-ordination sphere.  
Superposition of the co-ordination spheres between single crystal X-ray structures and DFT 
calculated structures was performed by least squares minimisation of the differences 
between non-H atoms of the amido compounds. The RMSD values obtained (0.0405-0.133) 
reflect a good agreement between the experimental solid state structures and the gas 
phase optimised structures. This reflects, in part, the minimal influence of crystal packing 
effect on the planar co-ordination sphere. The least squares fit between calculated and X-
ray structures for compounds [Au(HL1)Cl2]–[Au(L4)Cl2], [Au(L7)Cl](PF6), [Au(L9)Cl](PF6), 
[Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) are displayed in Figure 6.4.1. The compounds 
represented in Figure 6.4.1 were chosen because their auxiliary structures are susceptible to 
distortion via intermolecular forces and crystal packing effects while the balance of the 
compounds are included in Appendix C as they displayed exemplary all-atom fits. Without 
exception, all cation structures showed the co-ordination sphere of the compounds to be 
planar. As was the case for the X-ray structures, the DFT-calculated geometry of 
[Au(HL3)Cl2], displayed an obvious increase in the Au–N1 and Au–N2 bond lengths over 
those for [Au(HL1)Cl2], [Au(HL2)Cl2] and [Au(L4)Cl2] (Table 6.4.1). Both the Au–Cl1 and Au–
Cl2 bond lengths were overestimated for compounds [Au(HL1)Cl2]–[Au(L4)Cl2] on average, 
by 0.052(4) and 0.034(14) Å, respectively (Table 6.4.1). For compounds [Au(L5)Cl](PF6)–
[Au(L9)Cl](PF6) and [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) the computational method 
overestimated the Au–N1, Au–N2, Au–N3 and Au–Cl1 bond lengths on average by 0.021(7), 
0.03(2), 0.025(8) and 0.05(2) Å, respectively. A similar trend was observed for [Au(L15)Cl], 
with the exception that the Au–C1 distance was underestimated by 0.007 Å.   
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Figure 6.4.1: Least squares fit of the non-H atoms involved in the co-ordination sphere of the selected DFT (green) and X-ray (yellow) 
structures studied in this work. RMSD values (Å) are indicated in the diagram. 
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The co-ordination bond angles for all compounds were accurately calculated to within 2.5% 
of the single crystal X-ray structures for all of the compounds investigated. Although 
compounds [Au(HL1)Cl2]–[Au(L4)Cl2], [Au(L9)Cl](PF6), [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) 
displayed good co-ordination sphere fits between the calculated and X-ray structures, they 
also contain auxiliary functional groups that contain many torsional degrees of freedom and 
are hence able to adopt distorted conformations associated with crystal packing effects 
when compared to the in vacuo calculated structures. For chelate [Au(HL1)Cl2] the N1–C7–
C8–C9 torsion angle for the DFT-calculated structure is 6.1° while the equivalent torsion 
angle in the X-ray structure is 12.2°. This, along with the dissimilar N1–C7–C8 bond angles 
for the DFT calculated (111.8°) and X-ray determined (108.1°) structures, is a direct result of 
the intermolecular hydrogen bonding as well as π-π stacking interactions prevalent in the 
solid state. Compounds [Au(HL2)Cl2]–[Au(L4)Cl2] follow similar trends with intermolecular 
forces accounting for deviations of the auxiliary functional group positions between the 
calculated and observed structures. Chelate [Au(L7)Cl](PF6) contains no auxiliary functional 
group, yet has the highest RMSD value (0.119 Å). This is due to the methylene carbon and 
amide group puckering out of the co-ordination plane in opposite directions due to 
unconventional C–H···O  and C–H···Cl hydrogen bonding (Figure 6.4.2). Compound 
[Au(L9)Cl](AuCl2) contains a butyl group, which has many degrees of freedom, and therefore 
significant deviations between the calculated and observed structures is both expected and 
inevitable. Compounds [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) each contain a phenyl ketone 
"side-chain" functional group which are involved C–H···X (where X = Cl, F or O) 
unconventional hydrogen bonding interactions as well as van der Waals interactions. These 
lattice interactions are absent in the gas phase simulations and readily account for the 
deviations between the calculated and observed complex conformations. 
 
Figure 6.4.2: Unconventional hydrogen bonding interactions responsible for the large 
RMSD (0.199 Å) value between the experimental and calculated structures of 
[Au(L7)Cl](PF6).  
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Table 6.4.1: Comparisons of the mean bond lengths and angles of the calculated and experimental structures of the gold(III) 
compounds : [Au(HL1)Cl2]–[Au(L9)Cl](PF6), [Au(L11)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl]. 
Parameter [Au(HL1)Cl2] [Au(HL2)Cl2] [Au(HL3)Cl2] [Au(L4)Cl2] 
Bond Length / Å Calc. Exp. Diff. Calc. Exp. Diff. Calc. Exp. Diff. Calc. Exp. Diff. 
Au–N1 2.073 2.036(5) 0.037 2.071 2.037(3) 0.034 2.073 2.048(3) 0.025 2.075 2.031(4) 0.044 
Au–N2 2.035 2.019(4) 0.016 2.035 2.014(3) 0.021 2.069 2.035(3) 0.034 2.063 2.009(5) 0.054 
Au–Cl1 2.337 2.290(2) 0.047 2.339 2.287(1) 0.052 2.355 2.303(1) 0.052 2.352 2.295(2) 0.057 
Au–Cl2 2.299 2.285(2) 0.014 2.302 2.263(1) 0.039 2.306 2.270(1) 0.036 2.309 2.261(2) 0.048 
C=O 1.220 1.211(7) 0.009 1.220 1.230(5) -0.010 1.213 1.232(4) -0.019 1.215 1.21(1) 0.005 
C–N 1.349 1.345(8) 0.004 1.348 1.341(5) 0.007 1.365 1.362(5) 0.003 1.358 1.343(9) 0.015 
Bond Angle / °   
N1–Au–Cl1 94.5 94.0(1) 0.5 94.5 94.85(9) -0.35 94.3 95.68(8) -1.38 94.5 95.3(1) -0.8 
Cl1–Au–Cl2 89.6 89.11(7) 0.49 89.3 89.00(4) 0.3 90.2 89.42(2) 0.78 89.7 88.87(6) 0.83 
Cl2–Au–N2 95.3 95.8(1) -0.5 95.6 94.90(9) 0.7 94.8 93.83(9) 0.97 95.4 94.4(1) 1 
N2–Au–N1 80.6 81.0(2) -0.4 80.6 81.3(1) -0.7 80.7 81.1(1) -0.4 80.5 81.5(2) -1 
Parameter [Au(L5)Cl](PF6) [Au(L6)Cl](PF6) [Au(L7)Cl](PF6) [Au(L8)Cl](PF6) 
Bond Length / Å Calc. Exp. Diff. Calc. Exp. Diff. Calc. Exp. Diff. Calc. Exp. Diff. 
Au–N1 2.039 2.024(5) 0.015 2.044 2.013(5) 0.031 2.042 2.031(6) 0.011 2.022 2.001(4) 0.021 
Au–N2 1.972 1.918(5) 0.054 1.962 1.933(5) 0.029 1.970 1.888(6) 0.082 1.989 1.969(4) 0.02 
Au–N3 2.044 2.013(5) 0.031 2.042 2.015(6) 0.027 2.038 2.000(5) 0.038 2.035 2.024(4) 0.011 
Au–Cl1 2.330 2.292(1) 0.038 2.332 2.298(2) 0.034 2.334 2.286(2) 0.048 2.385 2.283(1) 0.102 
C=O 1.208 1.206(7) 0.002 1.211 1.223(9) -0.012 1.210 1.231(8) -0.021 1.246 1.220(6) 0.026 
C–N 1.354 1.390(7) -0.036 1.353 1.360(9) -0.007 1.357 1.360(8) -0.003 1.375 1.340(6) 0.035 
Bond Angle / °   
N1–Au–N2 81.7 81.4(2) 0.3 82.0 82.8(2) -0.8 81.7 82.5(2) -0.8 82.9 83.2(2) -0.3 
N2–Au–N3 81.9 83.1 (2) -1.2 81.0 80.7(2) 0.3 82.0 82.5(2) -0.5 82.2 81.9(2) 0.3 
N3–Au–Cl1 97.7 96.8(1) 0.9 99.0 99.3(2) -0.3 97.6 96.8(1) 0.8 97.5 97.6(1) -0.1 
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Table 6.4.1: Continued… 
Parameter [Au(L9)Cl](AuCl2) [Au(L11)Cl](PF6) [Au(L12)Cl](PF6) [Au(L13)Cl](PF6) 
Bond Length / Å Calc. Exp. Diff. Calc. Exp. Diff. Calc. Exp. Diff. Calc. Exp. Diff. 
Au–N1 2.033 2.021(4) 0.012 2.032 2.010(2) 0.022 2.032 2.005(2) 0.027 2.032 2.005(3) 0.027 
Au–N2 1.987 1.975(4) 0.012 1.987 1.969(2) 0.018 1.985 1.971(3) 0.014 1.985 1.971(3) 0.014 
Au–N3 2.042 2.021(5) 0.021 2.037 2.013(2) 0.024 2.044 2.022(2) 0.022 2.044 2.013(3) 0.031 
Au–Cl1 2.326 2.272(1) 0.054 2.328 2.282(5) 0.046 2.326 2.283(1) 0.043 2.325 2.278(1) 0.047 
C=O 1.208 1.223(6) -0.015 1.209 1.223(3) -0.014 1.208 1.225(5) -0.017 1.208 1.224(4) -0.016 
C–N 1.367 1.354(7) 0.013 1.370 1.364(3) 0.006 1.365 1.352(4) 0.013 1.365 1.353(5) 0.012 
Bond Angle / °   
N1–Au–N2 82.3 83.0(2) -0.7 82.3 83.0(1) -0.7 82.4 83.1(1) -0.7 82.4 83.1(4) -0.7 
N2–Au–N3 82.0 82.3(2) -0.3 82.3 83.0(1) -0.7 81.9 83.1(1) -1.2 81.9 82.1(3) -1.2 
N3–Au–Cl1 97.8 97.7(1) 0.1 97.6 96.4(1) 1.2 98.0 96.3(1) 1.7 98.0 97.6(1) 1.7 
Cl1–Au–N1 97.8 96.9(1) 0.9 97.8 97.4(1) 0.4 97.7 97.4(1) 0.3 97.7 96.8(1) 0.3 
Parameter [Au(L15)Cl]    
Bond Length / Å Calc. Exp. Diff.          
Au–N1 2.151 2.116(4) 0.035 
Au–N2 2.003 1.970(4) 0.033 
Au–C16 2.010 2.017(4) -0.007 
Au–Cl1 2.331 2.290(2) 0.041 
C=O 1.215 1.221(6) -0.006 
C–N 1.381 1.356(5) 0.025 
Bond Angle / °   
N1–Au–N2 80.2 81.7(1) -1.5          
N2–Au–C16 82.9 82.6(2) 0.3          
C16–Au–Cl1 98.6 96.5(1) 2.1          
Cl1–Au–N1 98.3 99.2(1) -0.9          
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The complexes [Au(L10)Cl](PF6), [Au(L14)Cl](PF6) and [Au(L16)Cl] could not be crystallised 
and their structures were therefore calculated (Figure 6.4.3) by modifying existing structures 
[Au(L8)Cl](PF6), [Au(L12)Cl](PF6) and [Au(L15)Cl], respectively. The small RMSD values 
obtained for the co-ordination spheres for the compounds studied by X-ray crystallography, 
indicate that the calculated structures are likely to be a fairly accurate reflection of the 
unknown experimental structures. 
 
Figure 6.4.3: Partially labelled diagram for calculated structures [Au(L10)Cl]+, 
[Au(L14)Cl]+ and [Au(L16)Cl]+. 
The bond lengths and bond angles for the compounds above are tabulated below (Table 
6.4.2). The data is in good agreement with the analogous data for the structurally related 
complexes that have been studied in this work.  
Table 6.4.2: Summary of calculated bond lengths and angles for complexes 
[Au(L10)Cl]+, [Au(L14)Cl]+ and [Au(L16)+. 
Structural Features [Au(L10)Cl]+ [Au(L14)Cl]+ [Au(L16)Cl] 
Bond Length / Å 
Au–N1 2.040 2.033 2.148 
Au–N2 1.978 1.985 1.992 
Au–N3 2.033 2.044 2.011 
Au–Cl1 2.326 2.326 2.334 
C=O 1.210 1.207 1.217 
C–N 1.366 1.367 1.382 
Bond Angle / °   
N1–Au–N2 82.7 82.4 80.6 
N2–Au–N3 81.3 81.8 82.1 
N3–Au–Cl1 98.9 98.1 99.4 
Cl1–Au–N1 97.1 97.7 97.8 
* For compound [Au(L16)Cl], atom N3 is replaced by atom C20. 
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FREQUENCY CALCULATIONS: 
The vibrational frequencies for all compounds were calculated for two purposes: (1) to 
determine if the geometry optimised structures reached a pure minimum on the potential 
energy surface and (2) to compare the calculated frequencies against the experimentally 
obtained results. The frequencies were compared by plotting the experimental values 
against the calculated ones and observing the trend. The slope obtained from the plot 
would give a scaling factor that could be used to correct for any systematic errors in the 
calculations. Figure 6.4.4 shows an overlay of the calculated and experimental frequency 
data for complex [Au(HL3)Cl2], which is used as a representative for the compounds 
discussed in this work.  
 
Figure 6.4.4: Overlay of calculated and experimental frequency data for the gold(III) 
chelate [Au(HL3)Cl2]. 
The relative intensities of the peaks show reasonable correlation between the calculated 
and experimental results. There is, however, some discrepancy between the absolute values 
of the calculated and experimental peak amplitudes. The functional group that is common 
to all compounds is the amide carbonyl C=O which exhibits a characteristic stretch in the ≈ 
1600 cm-1 region. The data for this particular stretching frequency were analysed by plotting 
the experimental versus calculated points (Figure 6.4.4). With the data for [Au(L8)Cl](PF6) 
removed as an outlier the plot suggests that the error observed in the prediction of the 
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amide carbonyl stretching frequency is systematic and a correction could be applied to the 
calculated values to afford more accurate predictions of vibrational mode energies.     
 
Figure 6.4.5: Plot of experimental versus calculated amide carbonyl stretching 
vibrations for all compounds discussed in the work except [Au(L8)Cl](PF6) (removed as 
an outlier). The correlation coefficient of the fit is 0.854. 
Equation 6.4.1 gives the mathematical relationship between the calculated and the 
experimental data of the amide C=O stretching vibration. There was no such relationship 
observed for any other vibration that was common throughout the series. The experimental 
and calculated vibrational frequencies are displayed in Table 6.4.3   
         
   
             
                                                                             6.4.1  
The data in Table 6.4.3 show that the calculated C=O stretching frequency was 
overestimated in all cases. Although the correlation between the experimental and the 
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Table 6.4.3: Summary of experimental and calculated frequencies for the amide C=O 
stretch for all gold(III) compounds studied in this work. 
 ν(C=O)/cm-1 
 Calc. Exp. Diff. 
[Au(HL1)Cl2] 1757 1647 155 
[Au(HL2)Cl2] 1757 1645 114 
[Au(HL3)Cl2] 1772 1652 150 
[Au(L4)Cl2] 1767 1643 174 
[Au(L5)Cl](PF6) 1803 1676 127 
[Au(L6)Cl](PF6) 1785 1672 113 
[Au(L7)Cl](PF6) 1796 1664 132 
[Au(L8)Cl](PF6) 1687 1655 32 
[Au(L9)Cl](PF6) 1791 1663 128 
[Au(L10)Cl](PF6) 1776 1662 114 
[Au(L11)Cl](PF6) 1787 1666 121 
[Au(L12)Cl](PF6) 1796 1658 138 
[Au(L13)Cl](PF6) 1793 1672 121 
[Au(L14)Cl](PF6) 1792 1659 133 
[Au(L15)Cl] 1769 1647 122 
[Au(L16)Cl] 1752 1644 108 
 
ENERGY CALCULATIONS: 
Excited state energy calculations were performed for the gold(III) compounds in this work at 
the HSE06/LanL2DZ (Au) and HSE06/6-311G(d,p) (all other atoms) level of theory  using the 
TD-SCF method, solving for N = 30 states. The additional f type polarisation function was 
added since it has been shown to be necessary for heavy atoms to obtain reasonable 
geometry optimisations and spectroscopic properties.38 The LanL2DZ basis set used makes 
use of effective core potentials and only takes into account the valence electrons. As core 
electrons are not involved in electronic transitions, this should not affect the accuracy of the 
calculations. The calculated results were compared to the experimental data by overlaying 
the respective spectra (Figure 6.4.6). 
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Figure 6.4.6: Overlay of experimental and calculated UV-vis spectra for compounds 
[Au(HL3)Cl2], [Au(L7)Cl](PF6), [Au(L13)Cl](PF6) and [Au(L15)Cl]. Extinction coefficient 
scaling factors of 0.2 and 0.75 were applied to the calculated data for compounds 
[Au(L13)Cl](PF6) and [Au(L15)Cl] respectively. Bandwidth of 2600 cm-1 was used to 
generate the calculated spectra.  
In general, the correlations between the experimental and calculated data were 
satisfactory. The purpose of the energy calculations was not only to compare experimental 
data against observed data, but also to provide insight into the orbital parentage of the 
transitions responsible for the observed UV-Vis spectra. Metal compounds [Au(HL3)Cl2], 
[Au(L7)Cl](PF6), [Au(L13)Cl](PF6) and [Au(L15)Cl] are used as representative complexes in the 
discussion below. The calculated spectra shown in Figure 6.4.6 are the result of several 
electronic transitions between various molecular orbitals, not only the HOMO and the 
LUMO. The energy levels for the major orbitals as well as the orbital plots for the frontier 
orbitals for compounds [Au(HL3)Cl2], [Au(L7)Cl](PF6), [Au(L13)Cl](PF6) and [Au(L15)Cl] are 
displayed in Figure 6.4.7.  
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Figure 6.4.7: Energy level diagram for complex cations (from left to right) of compounds [Au(HL3)Cl2], [Au(L7)Cl](PF6), 
[Au(L13)Cl](PF6) and [Au(L15)Cl], depicting the HOMO(H)→LUMO(L) electronic transition as well as the frontier orbital plots for each 
complex. 
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The method and basis set used in the calculations achieves a respectable level of accuracy in 
determining the major absorption bands as can be seen from the overlaid spectra in Figure 
6.4.6. In some cases, such as for [Au(L13)Cl](PF6) and [Au(L15)Cl], a scaling factor needs to 
be applied to the extinction coefficient. The band that was most accurately predicted was 
the higher energy π-π*band in the 200-300 nm range while the lower energy mixed 
transition band was less accurately predicted. A summary of the predicted and experimental 
absorption bands for compounds [Au(HL3)Cl2], [Au(L7)Cl](PF6), [Au(L13)Cl](PF6) and 
[Au(L15)Cl] is given in Table 6.4.4.  Since the remainder of the gold(III) compounds studies 
were all similar to one of the representative examples described in detail above.  
The HOMO plot for all representative compounds is dominated by a π-symmetry MO 
centred over the ligand with slight metal d orbital character. In the case of [Au(HL3)Cl2] the 
π-symmetry MO is centred over the phenylenediamine ring and the ligand-based MO is 
slightly admixed with the dxz (or dyz) orbital of the gold(III) ion. A large percentage of the 
HOMO for compounds [Au(L7)Cl](PF6), [Au(L13)Cl](PF6) and [Au(L15)Cl] relates to a π-
symmetry MO located over the quinoline ring with slight metal d character relating to a dyz 
MO. The LUMO plot for all representative compounds is dominated by d orbital metal 
character and for all cases the d orbital corresponds to the       * orbital. In all cases, the 
lowest energy transition occurs between the HOMO and the LUMO and can therefore be 
ascribed as a ligand-to-metal charge transfer (LMCT) transition. Interestingly, these 
transitions are calculated to be very weak with almost negligible oscillator strengths. The 
lower energy transitions with more appreciable oscillator strengths generally occur from 
lower lying orbitals with mixed π- and σ-character to the LUMO and LUMO+1. Since the 
calculated molecular orbitals are generally mixed with contributions from both ligand and 
metal it is impossible to assign a single transition to a corresponding experimentally 
observed peak. The experimental peaks, rather, have to be assumed to be the sum of 
several transitions between several different mixed orbitals. The predicted HOMO, LUMO 
and ligand field splitting energies (LFSE Δ₀) for compounds [Au(HL3)Cl2], [Au(L7)Cl](PF6), 
[Au(L13)Cl](PF6) and [Au(L15)Cl] are -6.179, -4.135, 2.004; -7.166, -4.027, 3.139; -6.701, -
4.258, 2.433 and -6.000, -2.710, 3.290 eV, respectively. Compound [Au(L15)Cl] has the 
largest LFSE at 3.290 eV consistent with a strong ligand field and reflective of the ligand's 
powerful C6H5
- σ-donor group.  
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Table 6.4.4: Summary of calculated and experimental transitions for the major peaks of 
the representative gold(III) compounds [Au(HL3)Cl2], [Au(L7)Cl](PF6), 





MOs* f* Transition assignment 
[Au(HL3)Cl2] 468 635 135(H)→136(L) 0.0910 π→σ* 
  520 130, 133, 
134→136(L) 
0.0216 π, π, π→σ* 
  448 132→136(L)  π→σ* 





  295 133→138 0.0966 π→π* 
[Au(L7)Cl](PF6) 342 342 81, 84→87(L) 0.0323 σ, σ→σ* 
  318 81, 84→87(L) 
85→88 
0.0243 σ, σ→σ*,π→π* 
 244 244 80, 82, 83→88 0.0493 π, π, π→π* 
  236 82,83→88; 83→89 1.0647 π, π→π*, π→π* 
  231 80→88; 83→89; 
85→91 
0.3198 π→π*, π→π*, 
π→π* 
[Au(L13)Cl](PF6) 369 388 113(H)→115,116; 
108→114(L) 
0.0744 π→π*, π* 
σ→σ* 
  376 113(H)→115,116; 
110→114(L) 
0.1403 π→π*, π* 
σ/π→σ* 











[Au(L15)Cl] 376 382 82(H)→84 0.1709 π→π* 
  322 79→83(L); 
82(H)→85 
0.0980 σ→σ*, π→π* 
*MO , molecular orbital; f , oscillator strength; H, HOMO; L, LUMO.   
 
The presence of the C6H5- σ-donor group significantly raises the energy of the LUMO (-
2.710 eV) while a similar, but less significant, effect is observed for the HOMO. Compound 
[Au(L7)Cl](PF6) has the second largest splitting energy at 3.139 eV which consistent with the 
fact that it comprises a less aromatic ligand with reduced pi-donor capacity (and thus more 
sigma-donor character) relative to [Au(HL3)Cl2] and [Au(L13)Cl](PF6). The energy of the 
HOMO is also noticeably lower in energy than the HOMOs [Au(HL3)Cl2], [Au(L13)Cl](PF6) and 
[Au(L15)Cl]. This trend is not only applicable to compound [Au(L7)Cl](PF6) but also to the 
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sister compounds [Au(L5)Cl](PF6) and [Au(L6)Cl](PF6) (available in Appendix C).  This 
indicates an intrinsic electronic difference between the non-aromatic aminomethyl-based 
ligands and the balance of the ligands discussed in this work. 
 
CALCULATED NMR DATA: 
The 1H and 13C NMR spectra were calculated using the same level of theory that was used 
for the geometry optimisation, frequency and energy calculations. Since a split basis set has 
been used with C, H, N, O, F and Cl atoms described the large 6-311G(d,p) basis set and the 
gold(III) ion by the ECP basis set LanL2DZ, we expected the results on a whole to be fairly 
accurate. This was found to be true for both calculated 1H and 13C chemical shifts. 
Interestingly, the 1H and 13C calculated shifts obtained for both compounds [Au(L5)Cl](PF6) 
and [Au(L13)Cl](PF6) were extremely poor and hence have been left out of all comparisons 
as outliers.  
 
Figure 6.4.8: Plot of experimental versus calculated α-(left) and α'-(right) 1H chemical 
shifts for compounds discussed in the work. Chemical shifts for compounds 
[Au(L5)Cl](PF6) and [Au(L13)Cl](PF6) have been removed as outliers. The correlation 
coefficients of the respective fits are 0.876 and 0.800. Compounds [Au(HL1)Cl2]–
[Au(L4)Cl2] do not contain an α'-proton and hence were not included in the respective 
plot.  
Since the compounds presented in this work are structurally quite diverse there are few 
proton and carbon signals that are common to all compounds and thus available for a 
systematic comparison. One such set of signals are the α- and α'-proton signals (see Chapter 
4). The computational method performs admirably when predicting the α- and α'-proton 
chemical shifts for all compounds. The predicted values were generally overestimated, but 
within 7% of the experimental values (Table 6.4.5). A plot of experimental versus calculated 
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chemical shifts for both α- and α'-protons reveals that the error seems to be systematic and 
therefore a correction factor could be determined in order to apply an empirical correction 
(Figure 6.4.8). 
Equations 6.4.2 and 6.4.3 below, represent the linear relationships between the 
experimental and the calculated chemical shift data for the α- and α'-protons, respectively. 
         
   
                  
                           6.4.2  
  
        
   
                  
                                                     6.4.3 
Table 6.4.5: Comparison of experimental and calculated 1H NMR data for the gold(III) 
compounds studied in this work. 
Complex Exp. Calc. Diff.* Exp. Calc. Diff.* 
 δ(1H) α / 
ppm 
δ(1H) α / 
ppm 
ppm δ(1H) α / 
ppm 
δ(1H) α' / 
ppm 
ppm 
[Au(HL1)Cl2] 9.32 9.39 -0.07 N/A N/A N/A 
[Au(HL2)Cl2] 9.29 9.33 -0.04 N/A N/A N/A 
[Au(HL3)Cl2] 10.33 10.37 -0.04 N/A N/A N/A 
[Au(L4)Cl2] 9.36 9.45 -0.09 N/A N/A N/A 
[Au(L5)Cl](PF6) 9.12 7.12 2 9.08 6.95 2.13 
[Au(L6)Cl](PF6) 9.07 9.30 -0.23 9.13 9.40 -0.27 
[Au(L7)Cl](PF6) 9.88 9.99 -0.11 9.14 9.35 -0.21 
[Au(L8)Cl](PF6) 9.21 8.97 0.24 9.13 9.00 0.13 
[Au(L9)Cl](PF6) 8.99 9.16 -0.17 9.36 9.58 -0.22 
[Au(L10)Cl](PF6) 9.16 9.37 -0.21 9.41 9.66 -0.25 
[Au(L11)Cl](PF6) 10.09 10.05 0.04 9.43 9.63 -0.20 
[Au(L12)Cl](PF6) 9.37 9.60 -0.23 9.37 9.47 -0.10 
[Au(L13)Cl](PF6) 9.38 -0.71 10.09 9.38 0.45 8.93 
[Au(L14)Cl](PF6) 9.36 9.44 -0.18 9.36 9.60 -0.24 
[Au(L15)Cl] 9.08 8.44 0.64 8.85 9.16 0.31 
[Au(L16)Cl] 8.85 9.24 0.39 8.85 9.24 0.39 
*Diff.: Exp. – Calc.  
As was mentioned in Chapter 4, proton f for compounds [Au(L6)Cl](PF6) and [Au(L10)Cl](PF6) 
was the furthest downfield resonance due to the deshielding effect of the unconventional 
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C–H···O hydrogen bond present. This assignment was confirmed by the similar prediction 
obtained from the calculated results. The accuracy of the prediction, however, was lower 
than for the other proton signals. The experimental chemical shifts were 9.85 and 9.86 ppm, 
respectively, while the calculated chemical shifts were predicted to be further downfield at 
10.62 and 10.73 ppm, respectively.     
The analogous calculated carbon chemical shifts, α and α', were similarly compared to the 
experimental data (Table 6.4.6). The results were encouraging with the majority of the 
calculated shifts falling within 5% of the experimental chemical shifts (Figure 6.4.9).  
 
Figure 6.4.9: Plot of experimental versus calculated α-(left) and α'-(right) 13C chemical 
shifts for compounds discussed in the work. Chemical shifts for compounds [Au(L15)Cl] 
and [Au(L16)Cl] have been left out as the corresponding experimental values could not 
be determined. The correlation coefficient of the respective fits are 0.868 and 0.046 
respectively. 
          
   
                  
                                                                        6.4.4 
  
         
   
                   
                                                                          6.4.5 
The plot shows that there is a linear relationship between the experimental and the 
calculated values for the α-carbon chemical shifts. The mathematical relationship is 
depicted by equation 6.4.4 above. A similar relationship was not observed for the α'-carbon 
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Table 6.4.6: Comparison of experimental and calculated 13C NMR data for the gold(III) 
compounds studied in this work. 
Complex Exp. Calc. Diff.* Exp. Calc. Diff.* 
 δ(13C) α / 
ppm 
δ(13C) α / 
ppm 
ppm δ(13C) α / 
ppm 
δ(13C) α' / 
ppm 
ppm 
[Au(HL1)Cl2] 145.51 151.94 -6.43 N/A N/A N/A 
[Au(HL2)Cl2] 145.03 151.90 -6.87 N/A N/A N/A 
[Au(HL3)Cl2] 150.37 156.88 -6.51 N/A N/A N/A 
[Au(L4)Cl2] 144.98 152.08 -7.1 N/A N/A N/A 
[Au(L5)Cl](PF6) 148.91 153.18 -4.27 148.58 151.31 -2.73 
[Au(L6)Cl](PF6) 138.99 145.94 -6.95 148.63 156.38 -7.75 
[Au(L7)Cl](PF6) 154.15 160.66 -6.51 148.54 156.30 -7.76 
[Au(L8)Cl](PF6) 149.25 148.20 1.05 151.44 149.59 1.85 
[Au(L9)Cl](PF6) 148.08 155.63 -7.55 151.41 156.58 -5.17 
[Au(L10)Cl](PF6) 139.54 145.86 -6.32 151.38 156.66 -5.28 
[Au(L11)Cl](PF6) 153.89 160.80 -6.91 150.90 156.69 -5.79 
[Au(L12)Cl](PF6) 150.12 156.88 -6.76 151.67 156.28 -4.61 
[Au(L13)Cl](PF6) 151.18 162.37 -11.19 149.68 103.29 46.39 
[Au(L14)Cl](PF6) 151.64 156.01 -4.37 150.00 156.86 -6.86 
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7. Biological studies 
7.1 Introduction 
Gold compounds have received much attention in recent years related to their potential use 
as chemotherapeutic agents.1, 2 The use of gold compounds as anti-cancer agents is varied 
with both gold(I) and gold(III) compounds being investigated as potential candidates.3, 4 
Gold(I) compounds are linear in geometry and therefore are generally unable to target DNA 
via intercalation. Gold(III) compounds, on the other hand, are generally square planar in 
nature (due to the vacant        orbital) and are therefore ideal candidates for the 
preparation of DNA-targeted intercalators.1 Since gold(III) complexes are highly electron 
deficient this enables them to form favourable axial Au–π interactions between the gold(III) 
ion and the DNA base pairs which stabilise the gold(III) centre. The fact that the gold ion is in 
the +3 oxidation state similarly allows for the generation of positively charged compounds 
that are able to interact electrostatically with the negatively charged phosphate backbone 
of DNA. All these properties allow for gold(III) compounds to be potential chemotherapeutic 
drugs.  
Currently the treatment of cancer is based on three major approaches depending on the 
type, location and health of the patient in question. The first two, surgery and radiation 
therapy, are locoregional and largely successful if the cancer is non-metastatic, accessible, 
and the patient is of good health and the cancer is caught early.5 Both are however fairly 
aggressive approaches with surgery being invasive and radiation causing burns. Both of 
these approaches are highly developed compared to chemotherapy which still has great 
potential for further development.5 Chemotherapy is a systematic treatment that is mainly 
used for the treatment of metastatic cancers. Combinatorial chemotherapy is most often 
used with multiple different drugs being administered simultaneously in order to maximise 
the efficacy of the treatment.6 The major problem associated with chemotherapy are the 
side-effects experienced by the patients; therefore there is a major drive in the 
development of new chemotherapeutics that are targeted and have far fewer and less 
severe side effects.  
The gold(III) compounds synthesised in this work have been designed to be 
chemotherapeutic agents via the intercalation of DNA. This process is anticipated to induce 
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apoptosis through the inhibition or poisoning of the topoisomerase group of enzymes. The 
cytotoxicity profiles of the gold(III) compounds have been assessed by the in vitro screening 
process administered by the National Cancer Institute (NCI)7 in association with the 
Developmental Therapeutics Program (DTP).7 These organisations are both part of the 
American National Institute of Health (NIH) and a key goal of these research-led entities is to 
screen synthetic compounds and natural products against their library of 60 common 
human cancer cell lines and to prioritise the development of successful candidates into 
commercial anti-cancer agents. The ranges of tumour cell lines include leukaemia, 
melanoma, lung, colon, central nervous system, ovary, breast, prostate and kidney. An 
application for the screening of a compound is submitted to the NCI and upon review is 
either denied or accepted into the first phase of testing. This phase consists of a single dose 
(10-5 M) screen across all 60 NCI human cancer cell lines. The results of this screening 
process then determine whether the compound proceeds to the second phase of testing. 
This takes the form of a 5-dose screen (ranging from 10-9 to 10-5 M in order of magnitude 
increments), from which three dose response parameters can be calculated: 
1) GI50, the concentration of the compound at which there is a 50% growth inhibition 
compared to the control.8 
2) TGI or IC50, the concentration of the compound at which there is total growth 
inhibition.8 
3) LC50, the concentration of the compound at which there is a 50% reduction in 
growth.8 
If the candidate compound performs well in the 5-dose phase of testing, the process is 
repeated, known as repeat 5-dose, in order to determine the reproducibility of the results. 
Once a compound has successfully passed the repeat 5-dose phase it is submitted to a 
biological evaluation committee who assess the candidate’s results and make a decision on 
whether the candidate is suitable for in vivo testing. Lead compound [Au(L12)Cl](PF6) made 
it to this stage of testing (an in vivo hollow fibre assay),9 where the candidate’s ability to 
effect the net cell growth of a respective cancerous cell line contained within a 
subcutaneously and/or intraperintoneally implanted hollow fibre. This is after dosage via 
intraperitoneal injection of the candidate drug in mice.  
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There are several advantages to having a drug candidate screened against a wide range of 
cell lines, as is the case for compounds screened at the NCI. The first advantage is that any 
specificity that a test compound may express towards a particular cell line or class of cell 
lines can be detected. This may allow for the more specific treatment of individual cancer 
cell lines. Secondly, it allows for the statistical comparison of the activity profile of the 
candidate against the activity profile of a series of well-known chemotherapeutic agents 
that have identified mechanisms of action (MOA). This analysis allows for the indication of a 
MOA for the drug candidate and therefore reduces the valuable time and money that would 
otherwise be required for such a determination. A large data set for comparison would tend 
to increase the reliability of the statistical analysis.  
7.2 Experimental 
7.2.1 In vitro cell screening8 
The in vitro cell screening was performed by the DTP within the NCI and therefore 
the screening protocol has been directly acquired from their website.  
The human tumour cell lines of the cancer screening panel are grown in Roswell 
Park Memorial Institute Media (RPMI) 1640 medium containing 5% fetal bovine 
serum and 2 mM L-glutamine. For a typical screening experiment, cells are 
inoculated into 96 well microtiter plates in 100 µL at plating densities ranging 
from 5,000 to 40,000 cells/well depending on the doubling time of individual cell 
lines. After cell inoculation, the microtiter plates are incubated at 37 °C, 5% CO2, 
95% air and 100% relative humidity for 24 h prior to addition of the experimental 
drugs. 
After 24 h, two plates of each cell line are fixed in situ with tricarboxylic acid 
(TCA), to represent a measurement of the cell population for each cell line at the 
time of drug addition (Tz). Experimental drugs are solubilised in dimethyl sulfoxide 
at 400-fold the desired final maximum test concentration and stored frozen prior 
to use. At the time of drug addition, an aliquot of frozen concentrate is thawed 
and diluted to twice the desired final maximum test concentration with complete 
medium containing 50 µg/mL gentamicin. Additional four, 10-fold or ½ log serial 
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dilutions are made to provide a total of five drug concentrations plus a control. 
Aliquots of 100 µL of these different drug dilutions are added to the appropriate 
microtiter wells already containing 100 µL of medium, resulting in the required 
final drug concentrations. 
Following drug addition, the plates are incubated for an additional 48 h at 37 °C, 
5% CO2, 95% air, and 100% relative humidity. For adherent cells, the assay is 
terminated by the addition of cold TCA. Cells are fixed in situ by the gentle 
addition of 50 µL of cold 50% (w/v) TCA (final concentration, 10% TCA) and 
incubated for 60 minutes at 4 °C. The supernatant is discarded, and the plates are 
washed five times with tap water and air dried. Sulforhodamine B (SRB) solution 
(100 µl) at 0.4% (w/v) in 1% acetic acid is added to each well, and plates are 
incubated for 10 minutes at room temperature. After staining, unbound dye is 
removed by washing five times with 1 % acetic acid and the plates are air dried. 
Bound stain is subsequently solubilised with 10 mM trizma base, and the 
absorbance is read on an automated plate reader at a wavelength of 515 nm. For 
suspension cells, the methodology is the same except that the assay is terminated 
by fixing settled cells at the bottom of the wells by gently adding 50 µL of 80% TCA 
(final concentration, 16% TCA). Using the seven absorbance measurements [time 
zero, (Tz), control growth, (C), and test growth in the presence of drug at the five 
concentration levels (Ti)], the percentage growth is calculated at each of the drug 
concentrations levels. Percentage growth inhibition is calculated as: 
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti≥Tz 
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz. 
Three dose response parameters are calculated for each experimental agent. 
Growth inhibition of 50% (GI50) is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, which 
is the drug concentration resulting in a 50% reduction in the net protein increase 
(as measured by SRB staining) in control cells during the drug incubation. The drug 
concentration resulting in total growth inhibition (TGI) is calculated from Ti = Tz. 
The LC50 (concentration of drug resulting in a 50% reduction in the measured 
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protein at the end of the drug treatment as compared to that at the beginning) 
indicating a net loss of cells following treatment is calculated from [(Ti-Tz)/Tz] x 
100 = -50. Values are calculated for each of these three parameters if the level of 
activity is reached; however, if the effect is not reached or is exceeded, the value 
for that parameter is expressed as greater or less than the maximum or minimum 
concentration tested. 
 7.2.2 In vivo testing9 
The in vivo cell screening was performed by the DTP within the NCI and therefore 
the screening protocol has been directly acquired from their website.  
MAXIMUM TOLERATED DOSE DETERMINATION: 
Generally, maximum tolerated dose MTD determinations are done in a way that conserves 
compound and limits the number of animals used to the barest minimum possible. Thus, a 
single mouse is given a single injection intraperintoneally, intravenously, subcutaneously, 
intramuscularly or orally (IP, IV, SC, IM or PO) of 400 mg/kg (or lower if the compound is 
anticipated to be extremely potent, e.g. natural products); a second mouse receives a dose 
of 200 mg/kg and a third mouse receives a single dose of 100 mg/kg. The mice are observed 
for a period of 2 weeks. They are sacrificed if they lose more than 20% of their body weight 
or if there are other signs of significant toxicity. If all 3 mice must be sacrificed, then the next 
3 dose levels (50, 25, 12.5 mg/kg) are tested in a similar way. This process is repeated until a 
tolerated dose is found. This dose is then designated the maximum tolerated dose and is 
used to calculate the amount of material given to experimental mice during anti-tumour 
testing. The mice are allowed ad libitum feed and water. Injections are most commonly 
administered IP, but SC, PO, and IV dosing may be required upon occasion. Dose volumes 
are generally 0.01 mL gm-1 body weight but may be up to 0.02 mL gm-1 body weight for the 
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HOLLOW FIBRE ASSAY: 
A standard panel of 12 tumour cell lines is used for the routine hollow fibre 
screening of the in vitro actives. These include NCI-H23, NCI-H522, MDA-MB-231, 
MDA-MB-435, SW-620, COLO 205, LOX, UACC-62, OVCAR-3, OVCAR-5, U251 and 
SF-295. In addition, alternate lines can be used for specialised testing of 
compounds on a non-routine basis. The cell lines are cultivated in RPMI-1640 
containing 10% foetal bovine serum (FBS) and 2 mM glutamine. On the day 
preceding hollow fibre preparation, the cells are given a supplementation of fresh 
medium to maintain log phase growth. For fibre preparation, the cells are 
harvested by the standard trypsinization technique and resuspended at the 
desired cell density ((2-10 x 106 cells/mL). The cell suspension is flushed into 1 mm 
(internal diameter) polyvinylidene fluoride hollow fibres with a molecular weight 
exclusion of 500,000 Da. The hollow fibres are heat-sealed at 2 cm intervals and 
the samples generated from these seals are placed into tissue culture medium 
and incubated at 37 0C in 5% CO2 for 24 to 48 hours prior to implantation. A total 
of 3 different tumour lines are prepared for each experiment so that each mouse 
receives 3 intraperitoneal implants (1 of each tumour line) and 3 subcutaneous 
implants (1 of each tumour line). On the day of implantation, samples of each 
tumour cell line preparation are quantitated for viable cell mass by a stable 
endpoint MTT assay so that the time zero cell mass is known. Mice are treated 
with experimental agents starting on day 3 or 4 following fibre implantation and 
continuing daily for 4 days. Each agent is administered via IP injection at 2 dose 
levels. The doses are based on the MTD determined during prior acute toxicity 
testing. The fibres are collected from the mice on the day following the fourth 
compound treatment and subjected to the stable endpoint MTT assay. The optical 
density of each sample is determined spectrophotometrically at 540 nm and the 
mean of each treatment group is calculated. The percent net growth for each cell 
line in each treatment group is calculated and compared to the percent net 
growth in the vehicle treated controls. A 50% or greater reduction in percent net 
growth in the treated samples compared to the vehicle control samples is 
considered a positive result. Each positive result is given a score of 2 and all of the 
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scores are totalled for a given compound. The maximum possible score for an 
agent is 96 (12 cell lines X 2 sites X 2 dose levels X 2 [score]). A compound is 
considered for xenograft testing if it has a combined IP + SC score of 20 or greater, 
a SC score of 8 or greater, or produces cell kill of any cell line at either dose level 
evaluated. This scoring system has been validated by Division of Cancer 
Treatment, Diagnosis and Centres (DCTDC) statisticians in Cancer Therapy 
Evaluation Program (CTEP) to represent a level of detection expected to score 
current "standard" agents as active. 
7.2.3 Mechanism of action elucidation 
The set of 60 GI50 values measured for [Au(HL3)Cl2], [Au(L6)Cl](PF6), [Au(L10)Cl](PF6) and 
[Au(L12)Cl](PF6) were compared (in negative log format) to the analogous publically 
available DTP data for 25 well-known anti-cancer drugs that have established MOAs. More 
specifically, the data were analysed using KyPlot 5.0 with a statistical multivariate cluster 
analysis algorithm (group average method, Minkowski distances) to calculate a dendrogram 
on which the analysed set of anti-cancer drugs cluster according to similarities in their GI50 
profiles and thus mechanisms of action. 
7.2.4 Gel electrophoresis experiments 
TOPOISOMERASE IB and IIα INHIBITION ASSAYS:10 
Human topoisomerase IIα (topo IIα) catalysed dsDNA decatentation reactions were 
performed with purified kinetoplast DNA (kDNA) and purified enzyme (TopoGen Inc., Port 
Orange, FL) essentially following the manufacturer’s published method. Experiments were 
performed by Alex Fagenson or Wanvipa Ruangpradit under the supervision of Professor 
Mark T. Muller at the School of Medicine, Biomolecular Research Annex, University of 
Central Florida. Briefly, 200 ng/μL of kDNA was prepared as a master mix in a topo IIα 
cleavage assay buffer containing 30 mM Tris-HCl (pH 7.6), 60 mM NaCl, 8 mM MgCl2, 15 mM 
dithiothreitol, 3 mM ATP, and 30 μg mL–1 BSA (TopoGen product code TG4040). Aliquots of 
the master mix solution (29 μL) were used for separate reactions in 1 mL polyethylene 
microcentrifuge tubes by additions (1.0 μL) of appropriate standard solutions of compound 
and etoposide (topo IIα interfacial poison control) dissolved in DMSO. All reaction tubes 
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contained 0.5% DMSO and DMSO was thus used as the zero-drug control in one reaction 
tube. Reactions were incubated with 2 units of topo IIα for 30 minutes at 37 °C, stopped 
with 3.0 μL of 10% sodium dodecyl sulfate (SDS) and digested with Proteinase K (0.5 mg mL–
1) for another 30 minutes at 37 °C. (One unit of topo IIα is defined as the amount of enzyme 
required to fully decatenate 0.1 μg of kDNA in 15 min at 37 °C.) The reaction solutions were 
then mixed with 6.0 μL of 6X electrophoresis loading dye (50% aqueous glycerol, 0.025% 
bromophenol blue). Aliquots from each dyed solution (5.0 μL) were loaded on a freshly-cast 
1% agarose gel containing 0.5 μg mL–1 ethidium bromide(EB, a cationic DNA intercalator 
control) and electrophoresed in 1X TBE buffer (88 mM boric acid, 88 mM Tris base, 10 mM 
EDTA, pH 7.8) containing 0.5 μg mL–1 EB at 50 V for 60 min. The gel was destained in 
deionised water for 15 min and imaged with UV transillumination (302 nm) on a Syngene 
ChemGenius system. 
Inhibition of topo IB-catalysed relaxation of negatively super-coiled pHOT1 plasmid DNA was 
studied by two methods: (1) conventional DNA unwinding assays as designed, marketed, 
and distributed by TopoGen Inc. and (2) a new assay contrived to discriminate between a 
topo IB catalytic inhibitor and a topo IB interfacial poison, where similar conditions to the 
conventional unwinding are used except for the use of a 5-10 fold increase in enzyme 
concentration as well as the absence of sodium chloride. 
DNA MOBILITY SHIFT ASSAY: 
The significant cytotoxicity profile of [Au(HL3)Cl2], [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) and 
the presence of chelated and metal-free isoquinoline moieties in their structures (i.e. known 
DNA intercalator groups) warranted an assessment of their DNA-binding affinity. Standard 
spectroscopic titrations of the metal complexes with calf thymus DNA in phosphate-
buffered 5% DMSO solutions (pH 7.0, 25 °C) gave irreproducible binding isotherms as a 
result of concomitant demetallation of the complex for [Au(HL3)Cl2] and possible diverse 
modes of interaction with DNA for [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6). Electrophoretic gel 
mobility shift assays (EMSAs) were required to reproducibly detect an interaction between 
the compounds and DNA. These experiments were performed by Prof Orde Munro or 
Wanvipa Ruangpradit in Prof Mark T. Mullers laboratory at the School of Medicine, 
Biomolecular Research Annex, University of Central Florida. The method below is given for 
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the sake of completeness. For these experiments, 6.3 ng μL–1 of negatively supercoiled 
pHOT1 plasmid DNA (TopoGen, Inc.) was used as the dsDNA substrate. Reaction solutions 
were prepared by mixing 1.0 μL of a 188 ng μL–1 pHOT1 stock solution, 3.0 μL pH 7.9 1X TGS 
buffer (100 mM Tris-HCl, 10 mM EDTA, 1.5 M NaCl, 1 mM spermidine, 1% BSA, 50% v/v 
glycerol), and 25.0 μL of deionised water in 1 mL polyethylene microcentrifuge tubes. To 
these solutions were added 1.0 μL aliquots of standard solutions of EB, or mAMSA (a neutral 
DNA intercalator control) in DMSO (molecular biology-grade, Sigma) to give final control 
compound concentrations of 500 nM, 5.0 μM, and 50 μM. For all compounds, additions of 
1.0 μL aliquots of appropriate freshly-made standard solutions of the test compound in 
DMSO were made to an analogous series of pHOT1-containing reaction solutions (29.0 μL 
total volumes) to give final compound concentrations of 5.0 nM, 50 nM, 100 nM, 500 nM, 
1.0 μM, 5 μM, 10 μM, 25 μM and 50 μM for [Au(HL3)Cl2]. Concentration ranges including 
0.5 μM, 1 μM, 5 μM, 15 μM, 50 μM, 150 μM and 500 μM were prepared and used in the 
experiment. The solutions were incubated at 37 °C for 15 min before adding 6.0 μL of 6X 
electrophoresis loading dye (50% aqueous glycerol, 0.025% bromophenol blue) and mixing 
by vortex centrifugation. Aliquots from each dyed solution (5.0 uL) were loaded on a freshly 
cast 1% agarose gel and electrophoresed in 1X TBE buffer (88 mM boric acid, 88 mM Tris 
base, 10 mM EDTA, pH 7.8) at 50 V for 60 min. The gel was rinsed in deionised water and 
stained for 10 min in an aqueous 1X TBE-buffered EB solution (0.5 μg mL–1) prior to imaging 
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7.3 Results and Discussion 
7.3.1 NCI-60 in vitro cytotoxicity screens 
In this work sixteen novel gold(III) compounds have been synthesised and applications for all 
compounds were sent to the NCI for screening against their 60 human cancer cell lines. All 
compounds with the exception of [Au(HL1)Cl2] were accepted since the latter complex was 
deemed structurally too similar to [Au(HL2)Cl2]. Compounds [Au(HL2)Cl2]–[Au(L15)Cl] all 
underwent one-dose screening at a concentration of 10-5 M. Compound [Au(L16)Cl] had 
limited solubility and was thus rejected by the NCI after multiple attempts at the one-dose 
screening process without success. In general, the results for the compounds that 
successfully underwent one-dose screening were extremely promising. The results of the 
one-dose screen for compound [Au(L12)Cl](PF6) are shown below in Figure 7.3.1.1. 
 
Figure 7.3.1.1: One-dose screening results for compound [Au(L12)Cl](PF6) over 60 
human cancer cell lines. The bars have been coloured according to the cell line panel.  
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Figure 7.3.1.1 shows the preliminary one-dose screening results obtained for compound 
[Au(L12)Cl](PF6) over the full 60 cell line panel against which the NCI screens all new 
candidate compounds. This preliminary data gives the NCI an idea of the cytotoxicity of the 
compound and whether it should be considered for further testing. It also gives an 
indication as to the relative susceptibility of the cell lines towards the compound. In the case 
for [Au(L12)Cl](PF6), the one-dose screen indicates that the compound exhibits inherent 
specificity towards certain cell lines. This indicates that the compound is not just a non-
specific poison, but rather a potential chemotherapeutic agent with a well-defined mode of 
action through which it exerts its cytotoxic activity. Similar data for the balance of the 
compounds was obtained and available in appendix D. The one-dose results for compound 
[Au(L12)Cl](PF6) indicate that the compound is most effective against leukaemia, colon and 
breast cancer cell lines. Compound [Au(L12)Cl](PF6) is also effective against a few isolated 
melanoma and ovarian cancer cell lines while it is least effective against non-small cell lung, 
central nervous system and renal cancer cell lines. A summary of the single dose screening 
data for all compounds is displayed in Figure 7.3.1.2  
 
Figure 7.3.1.2: Mean growth percent for all compounds submitted for one-dose testing 
against the NCI-60 cell lines. The blue bars represent compounds that failed the one-
dose screen, green bars represent compounds that were accepted to 5-dose screening 
and the red bar indicates the compound that was accepted through to the in vivo phase 
of testing. 
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Based on the results of the one-dose screening process for compounds [Au(HL2)Cl2]- 
[Au(L15)Cl], nine compounds were further selected for the second stage 5-dose screening 
process, from which, dose-response parameters could be determined. Of the nine 
compounds, [Au(L12)Cl](PF6), was further selected for the initial in vivo phase of testing. 
Some interesting trends were observed when analysing the mean growth percentage results 
as a function of structural parameters for the complexes. Compounds [Au(HL2)Cl2], 
[Au(L4)Cl] and [Au(L5)Cl](PF6) contain only pyridine rings within the compound structure 
compared to the nine compounds proceeding through to 5-dose which all contain at least 
one quinoline ring system indicating that the presence of a quinoline ring system is of vital 
importance to the biological activity of the compounds studied in this work. This is not 
surprising as many chemotherapeutic agents contain quinoline ring systems such as 
topotecan,11 a topoisomers I poison; amsacrine,12, 13 a topoisomerase II poison, and 
ciprofloxacin, a broad spectrum antibiotic that inhibits DNA gyrase in prokaryotes.14 
Compound [Au(L9)Cl](PF6) is identical to [Au(L8)Cl](PF6) except for the fact that it has a butyl 
substituent in the para position of the pyridine ring. This bulky para substitution evidently 
plays an important role in the ability of the compound to affect its cytotoxic behaviour as it 
was not selected to progress through to 5-dose testing, unlike the unsubstituted compound 
[Au(L8)Cl](PF6). An interesting trend in cytotoxicity was also observed between similar 
compounds [Au(L12)Cl](PF6) –[Au(L14)Cl](PF6). Compound [Au(L12)Cl](PF6) is the most active 
compound in the one-dose screen with a mean growth percent of 16.52% and contains an 
unsubstituted phenyl ketone moiety off the 3' position of the pyridine ring, whereas 
compounds [Au(L13)Cl](PF6) and [Au(L14)Cl](PF6) contain bulkier fluoro and methoxy para-
substituted phenyl ketone moieties. This increased bulk introduced by the substituent group 
evidently results in a poorer performance in their cytotoxicity profiles. So much so that the 
methoxy-substituted compound, [Au(L14)Cl](PF6), did not proceed past the one-dose phase 
of testing while compound [Au(L13)Cl](PF6) was accepted through to the 5-dose phase but 
did not perform to the level of [Au(L12)Cl](PF6). Compounds [Au(L15)Cl] and [Au(L16)Cl] 
were synthesised isostructurally to compounds [Au(L8)Cl](PF6) and [Au(L10)Cl](PF6) except 
for the change in chelating rings from N-donor pyridine and isoquinoline to C-donor phenyl 
and napthyl. The anionic carbon donor introduces the neutral compounds compared to the 
cationic complexes which are the main focus of this work. This was performed to assess the 
ability of the neutral compounds to similarly perform as possible chemotherapeutic agents 
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without the presence of a positive charge. Compound [Au(L16)Cl] was unable to be assessed 
due to poor solubility which was to be expected as similar neutral cyclometallated gold(III) 
compounds are generally only soluble in non-polar solvents such as DCM and CHCl3. 
Compound [Au(L15)Cl] was soluble enough to progress through the one-dose phase and 
into the 5-dose phase of testing. Interestingly it outperformed its analogous cationic 
compound, [Au(L8)Cl](PF6), in both single dose and 5-dose screens. This indicates that the 
cationic charge on the compounds is not necessarily required for the compound to be 
biologically active. This may be due to the ability of the electron deficient gold(III) centre 
being able to form strong Au–π interactions between the compound and the base pairs of 
DNA without an overall cationic charge. Further analogous compounds with a similar neutral 
charge need to be synthesised and screened in order to confirm this trend. 
Table 7.3.1.1: Summary of the average cytotoxicity data over the 60 human cancer cell 
lines for each of the nine compounds: [Au(HL3)Cl2], [Au(L6)Cl](PF6)-[Au(L8)Cl](PF6), 
[Au(L10)Cl](PF6)-[Au(L13)Cl](PF6) and [Au(L15)Cl] as well as some commercially 
available chemotherapeutic agents for comparison. 
Drug Log High Conc / M GI50 / μM TGI / μM LC50 / μM 
[Au(HL3)Cl2] -4 9.85 38.86 >100 
[Au(L6)Cl](PF6) -4 2.52 36.92 >100 
[Au(L7)Cl](PF6) -4 2.54 39.47 >100 
[Au(L8)Cl](PF6) -4 13.83 51.04 >100 
[Au(L10)Cl](PF6) -4 1.79 19.56 >100 
[Au(L11)Cl](PF6) -4 2.73 37.66 >100 
[Au(L12)Cl](PF6) -4 0.80 11.36 80.64 
[Au(L13)Cl](PF6) -4 2.41 33.86 >100 
[Au(L15)Cl] -4 9.85 87.02 >100 
Etoposide* -4 4.11 60 >100 
Topotecan* -4 0.62 26 79.6 
Cisplatin* -4 4.67 27 >100 
Daunorubicin* -4 0.20 1.4 18.9 
 *Data obtained from NCI DTP database.15   
Nine compounds from the fifteen selected for one-dose screening were further selected for 
5-dose screens. These compounds were [Au(HL3)Cl2], [Au(L6)Cl](PF6)–[Au(L8)Cl](PF6), 
[Au(L10)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl]. A summary of the average cell growth 
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response parameters for each of these three complexes against the full NCI 60 cell line 
panel is displayed in Table 7.3.1.1. This data has been compiled for 60 human cancer cell 
lines from the NCI database for the commercial drugs etoposide, topotecan, cisplatin and 
daunorubicin as well as the compounds presented in this work.15 The data show that, in 
general, the GI50 values for compounds derived from this work compare fairly well with the 
commercially available chemotherapeutic drugs. In particular, compound [Au(L12)Cl](PF6) 
performs extremely well with its average GI50 value being 0.80 μM compared to the GI50 
values of daunarobicin and topotecan at 0.20 and 0.62 μM, respectively. The GI50 values of 
[Au(L6)Cl](PF6), [Au(L7)Cl](PF6), [Au(L10)Cl](PF6), [Au(L11)Cl](PF6) and [Au(L13)Cl](PF6) at 
2.52, 2.54, 1.79, 2.73 and 2.41 μM, respectively, were similarly encouraging, being less 
potent than daunorubicin and topotecan but slightly more potent than cisplatin and 
etoposide. Compounds [Au(HL3)Cl2], [Au(L8)Cl](PF6) and [Au(L15)Cl] were the least active 
compounds that made it to the 5-dose phase of testing; however, their activities were still 
notable.  
 
Figure 7.3.1.3: Dose-response data for the commercial anti-cancer drugs, cisplatin and 
daunorubicin as well as the gold(III) compounds [Au(L6)Cl](PF6), [Au(L10)Cl](PF6) and 
[Au(L12)Cl](PF6) synthesised in this work. The data measures the response of the Colon 
cancer cell line HCT-116 to varying concentrations of the compounds mentioned above. 
The data for the commercial drugs, cisplatin and daunorubicin, were obtained from the 
DTP drug repository database.15 
The dose-response data exhibited in Figure 7.3.1.3, above, shows the growth response of 
the human colon cancer cell line, HCT-116, in response to varying concentrations of 
compounds [Au(L6)Cl](PF6), [Au(L10)Cl](PF6) and [Au(L12)Cl](PF6) as well as the commercial 
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anti-cancer agents cisplatin and daunorubicin. The response of the HCT-116 cell line to the 
three compounds synthesised in this work is interesting as it is fairly linear in nature and in 
fact, very similar to the comparative commercially available drugs. A consequence of this 
type of response is that one generally requires a significant increase in concentration to 
effect a 50% cell death (LC50) from 50% growth inhibition (GI50). A more traditional response 
is a sigmoidal, S-shaped response. This type of response has the characteristic that it 
requires a fairly high concentration to initiate 50% cell growth inhibition (GI50), however, a 
relatively small increase in concentration allows for the progression to effect a 50% cell 
death (LC50).  
Five representative compounds from this work were selected and a bar graph, depicting the 
–Log GI50 values for the above mentioned compounds as well as some commercially 
available drugs, generated (Figure 7.3.1.4).  
 
Figure 7.3.1.4: Comparison of the –log GI50 values for complexes [Au(HL3)Cl2], 
[Au(L6)Cl](PF6), [Au(L10)Cl](PF6), [Au(L12)Cl](PF6) and [Au(L15)Cl] against some 
commercially available anti-cancer drugs for some specific cancer cell lines. 
The comparison was performed to graphically assess and compare the cytotoxicity of the 
compounds synthesised in this work against some reference chemotherapeutic agents. 
From Figure 7.3.1.4 one can see that compound [Au(L12)Cl](PF6) (blue bar) is more cytotoxic 
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than the commercial chemotherapeitic agents cisplatin and etoposide in every cell line 
represented on the graph and, in most cases, quite significantly more active. The 
cytotoxicity profile of compound [Au(L12)Cl](PF6) can even compete with, and in some cases 
is more active than, the ultra high activity chemotherapeutic drugs topotecan and 
daunorubicin. Compounds [Au(L6)Cl](PF6) and [Au(L10)Cl](PF6) are less active than 
compound [Au(L12)Cl](PF6), however, are still more potent than cisplatin and etoposide in 
most cases and are therefore still promising candidates. [Au(HL3)Cl2] and [Au(L15)Cl] are the 
least active compounds but are still competitive against cisplatin and etoposide. Considering 
[Au(L12)Cl](PF6) is the most active compound synthesised in this work, it was further 
compared to cisplatin, which is currently the most widley used inorganic anti-cancer agent 
worldwide. A comparison of the efficacy of the two compounds against all common cell 
lines in the NCI-60 screen was conducted by plotting the –log GI50 values for [Au(L12)Cl](PF6) 
against the equivalent data for cisplatin (Figure 7.3.1.5).  
 
Figure 7.3.1.5: Plot of –log GI50 values for [Au(L12)Cl](PF6) versus the same data for 
cisplatin for all common cell lines in the NCI-60 screen. 
As can be seen in Figure 7.3.1.5, a line (black) with a slope of 1 depicts the border where the 
activity for each respective compound would be equal, hence any data point positioned on 
that line indicates that the activity of compound [Au(L12)Cl](PF6) and cisplatin for that 
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specific cell line are equal. Any data points above the line indicate that compound 
[Au(L12)Cl](PF6) is more active and any data points below the line indicate that cisplatin is 
more active, for each specific cell line in question. From the figure one can immediately see 
that compound [Au(L12)Cl](PF6) is significantly more active than cisplatin across almost all 
the cell lines tested (highlighted oval), with the majority (82%) of the data points (light blue) 
residing above the equal activity line. There are a few datapoints (7%) on the line, indicating 
equal activity, while there are only a handful of datapoints (11%) below the equal activity 
line where cisplatin is the more active drug. Interestingly there were no correlations 
observed between cytotoxicity, log Po/w and DNA binding affinity other than the 
counterintuitive correlation between log Po/w and one-dose mean growth percentage for 
the phenyl ketone based compounds (see Chapter 3). Compound [Au(L12)Cl](PF6) obtained 
the most negative log Po/w value (-1.41) but was most active while [Au(L14)Cl](PF6) exhibited 
the lowest log Po/w value (-1.00) but did not make it past the one-dose phase. This is 
interesting as a more positive log Po/w value is generally associated with higher cytotoxic 
activity due to the compound being able to traverse cellular membranes more efficiently 
than those with a more negative log Po/w value. The cytotoxicity data presented above for 
the gold(III) complexes, screened by the NCI, indicate that this class of gold(III) compounds 
has a potentially bright future in the emerging field of metallo-drug discovery.  
7.3.2 NCI in vivo testing  
The next phase of testing once a drug candidate has displayed significant potential during 
the in vitro screening process is a series of in vivo studies designed to determine the toxicity 
and efficacy of the lead compound in live animals. This involves the testing of a candidate in 
one or more animal models of neoplastic disease. The in vivo phase of testing is crucial to 
the advancement of a candidate drug that demonstrates in vitro activity through to 
preclinical development. Most above mentioned animal models require substantial 
materials in terms of laboratory animals and test compounds as well as substantial amounts 
of time and cost to determine whether a drug or series of drugs has even minimal in vivo 
activity. The hollow fibre assay conducted with mice, described in the Experimental Section 
7.2.2, has demonstrated the ability to provide a quantitative guide to drug efficacy with 
minimal expenditure of time and materials and hence is the initial in vivo experience for 
agents found to have reproducible activity during the in vitro drug screens.  
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Overall the cytotoxicity profiles of compounds [Au(L6)Cl](PF6), [Au(L10)Cl](PF6) and 
[Au(L12)Cl](PF6) were deemed to be effective enough to be considered for in vivo testing 
and were hence put forward to an evaluation committee at the NCI where they were 
assessed as to their potential as chemotherapeutics and hence further investigation through 
the initial in vivo hollow fibre assay. Compound [Au(L12)Cl](PF6) was the only compound 
selected, from of the three put forward for biological evaluation, to undergo initial in vivo 
testing.  
The first step of this process is to assess the MTD of the drug candidate in mice and the 
procedure is fully described in the Experimental Section 7.2.2. The reason for conducting 
this experiment is to conserve time and materials in the long term as one needs be certain 
that during the hollow fibre assay the mice are not killed by the drug due to a high dose, 
which would be wasteful in terms of time, money and mice.  
The results of the MTD test were reported as follows by the technician from the NCI 
performing the experiment: 
Day 0, [Au(L12)Cl](PF6): Several minutes after dosing, all mice became sedated. All 
mice had a very bright pink skin, the 400 mg/kg/injection mouse was dead, and the 200 
mg/kg /injection mouse was sedated but very cold and had laboured breathing (sacrificed). 
The 100 mg/kg/injection mouse was sedated and had a cool body temperature. The next 
morning, it was still sedated, had red urine, was very cold, and very delayed breathing 
(sacrificed). The mice that received the 12.5 mg/kg/injection dose and the 50 
mg/kg/injection dose were sedated with some movement several minutes after dosing. The 
12.5 mg/kg/injection mouse acted normally. The 50 mg/kg/ injection mouse had very pink 
skin and was still sedated several hours later while the other mice acted normally.  
Day 1, all the mice appeared normal. The maximum tolerated dose was therefore 
determined to be 50 mg/kg/injection. 
The hollow fibre assay was then performed using the 12 cell lines as indicated in the 
experimental section at a high dose concentration of 37.5 mg/kg/dose through IP injection. 
The NCI states that in order to progress from the hollow fibre assay to the next stage of in 
vivo testing, the xenograft, a drug candidate has to obtain a combined IP + SC score of 20 or 
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greater, a SC score of 8 or greater, or produces cell kill of any cell line at either dose level 
evaluated (see Experimental). Compound [Au(L12)Cl](PF6) performed poorly in this regard, 
with an IP score of 0 out of 48 and an SC score of 0 out of 48. This data indicates that 
compound [Au(L12)Cl](PF6) was ineffective against all cell lines tested. The obvious rationale 
for this result is that the compound is unable to progress from the injection site to the 
hollow fibre. The compound would therefore not be able to effect cell growth within the 
hollow fibre. There are several ways in which the compounds transport may have been 
affected. The calculated log Po/w value for the compound is -1.41. This indicates that the 
compound is highly hydrophilic. Drugs with hydrophilic log Po/w values have been shown to 
be less effective chemotherapeutic agents as they find it significantly more difficult to cross 
cellular membranes than chemotherapeutics with a more positive log Po/w.
16 Therefore since 
the drug was administered via intraperitoneal injection, it would have to traverse numerous 
cellular membranes before reaching the hollow fibre target and hence compound 
[Au(L12)Cl](PF6) may not be capable of doing so. Another suggestion as to the poor 
performance of the compound in the hollow fibre assay is that [Au(L12)Cl](PF6) has been 
shown to be susceptible to reductive demetallation through a cellular reducing agent, 
glutathione. This is a common problem with gold(III)-based drugs.3, 17 Therefore 
[Au(L12)Cl](PF6) may have a significantly short half-life in the in vivo cellular environment 
which has been shown to be reducing in nature. The last suggestion as to why compound 
[Au(L12)Cl](PF6) performed poorly is that it may irreversibly bind to serum albumin proteins 
found in the blood, such as human serum albumin (HSA). This would prevent the compound 
from progressing from the blood to the intended target. Drugs that bind to HSA irreversibly 
have also been shown to be less effective chemotherapeutic agents than those that do 
not.18 Overall the result was disappointing but not uninformative. The drug discovery 
pipeline is a long and arduous process with many setbacks expected. This gives us vital 
information which we can use to investigate further the means by which the compounds are 
inactivated. This would then allow us to design new compounds of a second generation that 
are structurally related with the view of being more potent than the first generation 
7.3.3 Mechanism of Action 
Although the in vivo testing results of compound [Au(L12)Cl](PF6) were poor, this does not 
discount this class of compounds from further development. The in vitro results of the 
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gold(III) amide compounds described in this work were nonetheless still extremely exciting 
and further development of this class of compounds may yet progress through the hollow 
fibre assay and into the xenograft assay. The next stage in development is to determine how 
the drugs effect their cytotoxic action. This is crucial as there is often little known about the 
mode of action of many chemotherapeutic drugs, in particular gold-based 
metallotherapeutic drugs. 
The major advantage of having the drug candidates screened for their cytotoxicity at the NCI 
is that they are tested against a vast range of cell lines. A substantial body of data are 
generated for a single compound in that three dose-response parameters, GI50, TGI and 
LC50, are generated for each cell line tested. This large amount of data makes it possible for 
a fairly accurate comparison between a drug candidate and several well-known 
chemotherapeutic drugs with well-known mechanisms of action. This is possible because 
the NCI have made available the cytotoxic data for numerous commercial chemotherapeutic 
agents that have been screened according to the same process as the compounds in this 
work. Due to the significant amount of data for each of the drug candidates as well as 
commercially available drugs, a fairly accurate and reliable hierarchical cluster analysis can 
be performed between the cytotoxicity profiles of the respective drugs. There are several 
established methods for affecting this type of analysis; however, irrespective of the method 
chosen a similar grouping together of compounds with similar mechanisms of action is 
obtained. Therefore if drug candidates, [Au(HL3)Cl2] and [Au(L12)Cl](PF6) in this case, with 
unknown mechanisms of action are clustered with well-known drugs that have 
experimentally determined mechanisms of action, one is able to get an idea of the 
mechanism of action of the new drug candidate by observing the grouping of the drugs 
presented as a dendogram. One such dendogram using the group average method and 
Minkowski distance is displayed in Figure 7.3.3.1. Minkowski metrics are non-Euclidean 
metrics which are frequently used in applications of multidimensional scaling in statistical 
analysis.19 Compounds [Au(HL3)Cl2] and [Au(L12)Cl](PF6) were chosen due to their structural 
dissimilarity and therefore different mechanisms of action. The dendogram displayed in 
Figure 7.3.3.1 shows the clustering of compounds [Au(HL3)Cl2] and [Au(L12)Cl](PF6) 
according to the probable mechanisms of action. As can be seen, compound [Au(HL3)Cl2] 
clearly has a direct link to the commercially available topoisomerase II poison etoposide 
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(highlighted in red typeface).20 Compound [Au(HL3)Cl2] also has a direct link, although more 
distant, to daunorubicin and zorubicin, which are similarly potent topoisomerase II 
poisons.21 There is also a distant but direct link to cisplatin. Cisplatin is a well-known DNA 
cross linker but has also shown to be an effective topoisomerase II inhibitor.22  
 
Figure 7.3.3.1: Statistical comparison between the –log GI50 values of 25 commercially 
available chemotherapeutic drugs with known mechanisms of action and the gold(III) 
amide compounds, [Au(HL3)Cl2] (light blue) and [Au(L12)Cl](PF6) (purple), synthesised 
in this work. 
The isostructural cis-chloride ligands present in compound [Au(HL3)Cl2] along with the 
possibility that they may undergo ligand substitution reactions suggests that [Au(HL3)Cl2] 
may be able to behave as a DNA cross-linker. This grouping characteristic strongly suggests 
that compound [Au(L12)Cl](PF6) is likely to perform as either a topoisomerase II poison or 
inhibitor, or DNA cross-linker, or both in effecting its cytotoxic activity. [Au(L12)Cl](PF6), on 
the other hand, clusters heavily with commercially available topoisomerase I poisons 
topotecan, camptothecin and 9-MeO-camptothecin (highlighted in red typeface). This 
clustering behaviour indicates that compound [Au(L12)Cl](PF6) may perform its cytotoxic 
activity as either a topoisomerase I poison or inhibitor. Based on this statistical analysis, gel 
electrophoresis experiments were designed to ascertain whether in fact compounds 
[Au(HL3)Cl2] and [Au(L12)Cl](PF6) target topoisomerase II and I, respectively. 
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DNA topoisomerases are abundant nuclear enzymes that control the topology of DNA and 
are essential to cell viability.23 In eukaryotes this group of enzymes is divided into two 
distinct classes based on their interaction with DNA. Type I topoisomerases are a 
monomeric unit that cleave one strand of the DNA and perform a controlled rotation, 
followed by re-ligation on the cleaved strand. There are two major topoisomerase I sub-
types, being type IA and type IB. Topoisomerase IB (topo IB), an essential enzyme that acts 
on the chromatin, making single-strand DNA breaks to relax supercoiled DNA during various 
genetic events such as transcription, recombination and replication.24 It is therefore a 
validated target in cancer therapy.25 Type II topoisomerases are homo dimeric and hence 
are capable of effecting a short-lived double stranded DNA break.26 The enzyme then re-
ligates the double-stranded break after passing a distant strand through it. There are two 
isoforms of topoisomerase type II enzymes, namely topoisomerase IIα and topoisomerase 
IIβ.27 Topoisomerase IIα (topo IIα) is similarly essential for cell propagation and essential for 
the decatenation of catenated DNA.26 It is therefore a validated target in cancer therapy.27, 
28 
There are two major mechanisms through which a small molecule drug can disrupt the 
function of both topo IB and IIα: (i) catalytic inhibition and (ii) interfacial poisoning.20, 29 
Most drugs in clinical use today act as interfacial poisons in that they allow the enzyme to 
make the single- or double- stranded break for topoisomerase I and II, respectively, but then 
form a stable enzyme-DNA-Drug ternary ‘cleavage complex’ which inhibits the enzyme from 
religating the DNA. This results in DNA damage that signals for cell death (apoptosis). 
Examples of such drugs are camptothecin and etoposide which act as interfacial poisons of 
topoisomerase I and II, respectively.20, 23 In gel electrophoresis experiments the enzyme-
catalysed reaction may be followed by the disappearance of supercoiled and catenated DNA 
and the emergence of nicked open circular and linear DNA for topoisomerase I and II, 
respectively. Catalytic inhibitors are less well-characterised in literature, but are of great 
interest in drug design since they are able to effect cell death with minimal DNA damage.30, 
31 Such catalytic inhibitors exert their catalytic activity by either interacting with the enzyme 
directly, such as bisdioxopiperazine,12, 30 or interacting with the DNA substrate in such a way 
the topoisomerase enzyme is ‘blocked’ from interacting and locking onto the DNA to 
perform its site-specific cleavage. In reaction followed by gel electrophoresis the supercoiled 
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and catenated DNA remain unchanged as the enzyme is not given a chance to interact with 
the DNA substrate. 
Compounds [Au(HL3)Cl2], [Au(L7)Cl](PF6) and [Au(L13)Cl](PF6) were assessed for their ability 
to inhibit/poison the activity of both topo IB and IIα. Topo IB activity was assessed using a 
commercially available topoisomerase relaxation assay kit available from TopoGEN.10 The 
assay makes use of purified topo IB, supercoiled DNA, a linear DNA marker, the drug in 
question and a control drug, in this case camptothecin. Camptothecin is a commercially 
available chemotherapeutic agent that is widely used in the treatment of colorectal, small 
cell lung, ovarian and cervical cancers.6 The choice of camptothecin as a control is based on 
the fact that it is a powerful poison, but a weak inhibitor of topo IB. Comparison of the 
results of camptothecin with the gold(III) drug in question will give a good indication of 
whether the gold(III) drug is a poison or a catalytic inhibitor of topo IB. The results for the 
topoisomerase relaxation assay for compound [Au(HL3)Cl2] are shown below in Figure 
7.3.3.2 
 
Figure 7.3.3.2: Non-EB gel showing the ineffective poisoning or inhibition of 
topoisomerase IB by compound [Au(HL3)Cl2] through all concentrations tested.  
Lane 1 of the gel (Figure 7.3.3.2) is the DNA control lane. It indicates the presence of both 
nicked open circular DNA (NOC-DNA) and supercoiled DNA (SC-DNA) without the topo IB 
enzyme. Lane 2 contains topo IB enzyme but no drug; therefore we see the supercoiled DNA 
being relaxed into its topoisomers. Lane 4 contains the commercially available topo IB 
poison, camptothecin, as a control. One can clearly see that the camptothecin control is 
working correctly since there is no evidence of SC-DNA and a heavy banding of NOC DNA. 
The remaining lanes as indicated in Figure 7.3.3.2 contain the gold(III) drug [Au(HL3)Cl2] 
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(concentration range 0-25 μM). Evidently the compound tested has a slight inhibitory effect 
on the functioning of the enzyme as we can see a decreasing concentration of the DNA 
topoisomers, with increasing drug concentration. The effect is most pronounced at the 
highest drug concentration of 25 μM. It may be concluded that compound [Au(HL3)Cl2] is a 
poor to moderate topo IB inhibitor or poison. This result was in agreement with the 
statistical results which suggested that compound [Au(HL3)Cl2] would be a more effective 
topo IIα inhibitor than a topo IB inhibitor.  
Compounds [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) were similarly tested for their ability to act 
as topo IB poisons or inhibitors. The results for [Au(L12)Cl](PF6) are shown below as a 
representative example (Figure 7.3.3.3).  
 
Figure 7.3.3.3: Non-EB gel showing the effective poisoning or inhibition of 
topoisomerase IB by compound [Au(L12)Cl](PF6) between metal compound 
concentrations of 1 and 10 μM.  
Lane 1 is the DNA control lane, containing bands of SC-, NOC and linear DNA. Lane 3 
contains VP-16 (etoposide which is a topoisomerase II poison and non-intercalator of DNA). 
We would therefore expect no inhibition of the enzyme, topo IB, by VP-16. We do however 
see a slight poisoning of the enzyme which may be due to contamination of the control. 
Lane 4 contains the topo IB control, camptothecin, which displays an increased banding of 
NOC DNA. This confirms the control is working as expected. Lanes 5-12 contain the gold(III) 
compound [Au(L12)Cl](PF6) from concentrations 0-100 μM. The test compound, 
[Au(L12)Cl](PF6), acts as a weak interfacial poison of the enzyme, particularly towards a 
compound concentration of 1 uM, as the DNA banding profile is similar to that seen in the 
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presence of camptothecin. There is, however, significant catalytic inhibition of the enzyme 
from a concentration 10 μM onwards, revealed by the heavy banding of SC-DNA and a 
marked decrease in the concentration of DNA topoisomers. This is because the enzyme is 
unable to relax the SC-DNA and therefore it remains unchanged and runs as such on the gel. 
From this gel one can conclude that compound [Au(L12)Cl](PF6), in all likelihood, acts as a 
dual mode interfacial poison (at low concentration) and a catalytic inhibitor (at higher 
concentration) of topo IB. This is further confirmed by a new, topo IB cleavage assay, 
developed by Professor Mark Muller at the University of Central Florida. In this assay almost 
all conditions are the same as for the commercially available topo IB relaxation assay except 
for the fact that there is a large increase in the amount of enzyme units present in the 
reaction, typically a 5-10 fold increase, and the absence of NaCl. Since there is no NaCl and a 
large amount of enzyme present in the reaction, DNA anion sites are unsaturated allowing 
for multiple enzymes to ‘lock’ onto the DNA making single-stranded breaks at numerous 
points along the DNA polymer. Supercoiled DNA is effectively linearised under such 
conditions and detected as a linear DNA band on the gel. In the presence of a 
topoisomerase poison, such as camptothecin, this results in the generation of linear DNA 
fragments that can be visualised in a gel electrophoresis experiment such as the one shown 
in Figure 7.3.3.4. Lane 3, in which camptothecin is the control, contains a broad band 
indicating the presence of linear DNA which therefore confirms that camptothecin is acting 
as a topoisomerase poison. Lane’s 4-12 contain compound [Au(L12)Cl](PF6) from 0-20 μM in 
which there is a slight increase in linear DNA observed from 0-5 μM. The presence of linear 
DNA then decreases from 5-20 μM. This is consistent with weak poisoning of the enzyme at 
lower concentrations and catalytic inhibition at higher concentrations of the compound. The 
experiment therefore confirms that the compound [Au(L12)Cl](PF6) primarily acts as a 
topoisomerase catalytic inhibitor but also a poison at low concentrations of compound. 
Once again this result is in agreement with the statistical prediction which suggested 
compound [Au(L12)Cl](PF6) would target topoisomerase I by virtue of clustering with 
camptothecin, and topotecan. 
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Figure 7.3.3.4: EB gel showing CPT acting as an interfacial poison through its 
generation of linear DNA. There is a slight increase in linear DNA in presence of 
compound [Au(L12)Cl](PF6) from 0-5 μM, after which, a decrease in linear DNA is 
observed.  
Compound [Au(L12)Cl](PF6) can act as a catalytic inhibitor by either binding to the enzyme 
or preventing the enzyme binding to the DNA by interacting with DNA in a site-specific 
manner that is common with the enzyme. The spectroscopic studies (Chapter 4) and DNA 
mobility shift assays (discussed below) indicate that the compound binds to DNA (specific 
mechanism unknown) and therefore is able to competitively prevent the enzyme from 
binding DNA and initiating strand cleavage at a concentration between 1 and 10 μM. This is 
a comparative result to the one of Che and co-workers presented in 2010 whereby they 
report the topoisomerase I inhibitory action of a cyclometallated gold(III) compound to be 
between 3.3 and 10 μM, which is within the same range of activity for [Au(L12)Cl](PF6).
32 
Further detailed mechanistic work on this complex has recently been reported by Castelli 
and co-workers.33 They describe how the gold(III) compound is able to inhibit the enzyme by 
preventing it binding to the DNA substrate. Since compound [Au(L12)Cl](PF6) and 
[Au(C^N^C)(IMe)]CF3SO3
32 are similar in structure, we surmise that [Au(L12)Cl](PF6) may 
work in a similar way. Overall this is an exciting result as the topoisomerase catalytic 
inhibition activity correlates well with the cytotoxicity data obtained from the NCI.  
All three compounds, [Au(HL3)Cl2], [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) were then tested 
for their ability to inhibit/poison topo IIα via a decatenation assay. From the statistical 
analysis it was envisaged that compound [Au(HL3)Cl2] would act as a poison or inhibitor 
while [Au(L12)Cl](PF6) would not. Etoposide or VP-16 is a well-known topo IIα poison, being 
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able to stabilise the double-stranded enzyme-DNA-cleavage complex thereby blocking DNA 
strand religation, and was therefore chosen as the control drug. Figure 7.3.3.5 below depicts 
a wide range topo IIα decatenation assay performed with compound [Au(HL3)Cl2]. From 
Figure 7.3.3.5, lane 1 contains only catenated DNA. Lane 2 contains catenated DNA and the 
enzyme, which results in the banding of NOC and closed covalent circular (CCC). Lane 3 
contains the linear DNA marker and lane 4 contains cantenated DNA with the control drug 
etoposide. This results in the formation of the linear band shown on the gel, due to 
poisoning of the enzyme. 
 
Figure 7.3.3.5: EB gel showing a wide range topoisomerase IIα kDNA decatenation 
assay for compound [Au(HL3)Cl2]. At low concentrations (50 nM) [Au(HL3)Cl2] acts as a 
poison while at higher concentrations [Au(HL3)Cl2] acts as a catalytic inhibitor. 
Lanes 6-15 contain the gold(III) drug [Au(HL3)Cl2] in the concentration range 0-50 μM. Upon 
analysis of the gel one can observe the slight presence of linear DNA in the nM 
concentration range (5-100 nM), indicating that the compound is behaving as a topo IIα 
poison. The presence of NOC and CCC DNA in this range as well as the similar control result 
affirms this notion as it indicates the enzyme is being allowed to perform the double 
stranded cleavage of the DNA. The reaction product profile is, however, markedly different 
at concentrations greater than 500 nM. One can clearly see the heavy presence of 
catenated DNA as well as a small amount of linear DNA, indicating dual catalytic inhibition 
and poisoning modes of activity. The gradual disappearance of linear DNA indicates that 
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[Au(HL3)Cl2] predominantly acts as a catalytic inhibitor over this concentration range rather 
than a poison.  
As previously mentioned, a topoisomerase II poison creates a ternary drug-DNA-enzyme 
‘cleavage complex’, effectively trapping the enzyme on the DNA once a double-stranded 
break has been formed. One is able to test whether this occurs by performing the reaction 
in duplicate as per the gel in Figure 7.3.3.6. One reaction is treated with proteinase K (PK) 
and other is not (Figure 7.3.3.6). PK is a broad spectrum serine protease discovered in 
extracts of the fungus Engyodontium album.34 It is able to digest DNA nucleases and is 
therefore used for the purification of DNA.34 It is for this reason that it was used in the 
above mentioned experiment to release the linear DNA from the drug-DNA-enzyme 
‘cleavage complex’. 
 
Figure 7.3.3.6: EB gel showing a topoisomerase IIα kDNA decatenation assay for 
[Au(HL3)Cl2] and the absence and presence of linear DNA before and after treatment 
with PK, respectively. 
As can be seen from Figure 7.3.3.6, lanes 1-3 contain the relevant DNA markers. Lanes five 
and six contain the topoisomerase poison, etoposide. One can clearly see that in lane 5 
where the reaction has not been treated with PK, there is no evidence of linear DNA and 
furthermore there is slight smearing of the NOC DNA band. This is because the enzyme is 
still attached to the DNA and therefore increases the total weight and mobility of the DNA. 
In lane six the reaction has been treated with PK and we can clearly see the presence of a 
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linear DNA band indicating the ‘cleavage complex’ has been digested (i.e. the enzyme 
removed from the DNA) and the linear DNA released. Lanes 8-11 and 13-16, similarly 
contain varying concentrations of [Au(HL3)Cl2] in the absence and presence of PK 
respectively. Since [Au(HL3)Cl2] behaves predominantly as a catalytic inhibitor, the presence 
of linear DNA after treatment with PK is greatly diminished compared to that of etoposide, 
however its presence indicates that [Au(HL3)Cl2] can act as a poison. This dual mechanism of 
action is an encouraging result as it is thought that a drug that behaves in such a way could 
be more effective than a specific poison or inhibitor.  
Compound [Au(L12)Cl](PF6) was similarly tested for its topo IIα inhibitory action (Figure 
7.3.3.7). In Figure 7.3.3.7 we have similar controls to Figure 7.3.3.6. Lanes 5-12 contain 
compound [Au(L12)Cl](PF6) in varying concentrations as indicated. 
 
Figure 7.3.3.7: EB gel showing a wide range topoisomerase IIα decatenation assay for 
compound [Au(L12)Cl](PF6). The compound shows no inhibitory/poisoning activity 
through the concentration range tested. 
As one can clearly see, there is almost no inhibition or poisoning of the enzyme at low 
concentrations while there is minimal catalytic inhibition from 25 μM up. These results 
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7.3.4 Electrophoretic gel mobility shift assays 
An electrophoretic gel mobility shift assay (EMSA) is an alternative from the traditional 
spectroscopic methods for determining an intercalating or groove binding interaction 
between a drug and a DNA substrate.32, 35 The DNA substrate can take many different forms 
such as supercoiled or relaxed. In the experiments performed in this work, the supercoiled 
and nicked open circular form was used as the DNA substrate. EMSA has been frequently 
used to ascertain the interaction between DNA and gold(III) drugs.32, 35 The premise behind 
an EMSA experiment is that once a drug has been incubated with the DNA substrate and 
had sufficient time to equilibrate, it alters the tertiary structure of the DNA by unwinding 
the helix slightly (most notably when intercalated). This causes the DNA to become more 
bulky and hence not as mobile through the agarose gel when a current is applied, resulting 
in the DNA-drug band traveling a lesser distance down the gel than the pure DNA band. This 
mobility shift is generally a concentration-dependant effect since the more drug molecules 
that are available to intercalate the DNA, the greater the effect on the tertiary structure of 
the DNA and hence a greater effect on the mobility of the DNA.  
EMSA experiments were only performed for compounds [Au(HL3)Cl2], [Au(L12)Cl](PF6) and 
[Au(L13)Cl](PF6). This was because [Au(HL3)Cl2] displayed variable solution stability and 
standard spectroscopic titrations of the metal compound with ctDNA in TBS gave 
irreproducible binding isotherms as a result of concomitant demetallation of the complex. 
Compounds [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) were selected as representative examples 
from the three phenyl ketone derivatives to perform EMSA experiments because, despite 
their stability in biological media, they similarly gave irreproducible binding isotherms (see 
Chapter 4) with traditional spectroscopic methods. The EMSA results for compound 
[Au(HL3)Cl2] are shown in Figure 7.3.4.1.  
Biological Studies 
241 | P a g e  
 
 
Figure 7.3.4.1: EMSA gel for EB (top left), [Au(HL3)Cl2] (top middle) and mAMSA (top 
right) at various indicated drug concentrations. Two dimensional peak deconvolution 
for EB (bottom left), [Au(HL3)Cl2] (bottom middle) and mAMSA (bottom right). DNA 
band identities: I, supercoiled DNA; II, nicked open-circular DNA. 
From the figure we can see that the top left hand gel contains the known intercalator EB as 
well as compound [Au(HL3)Cl2] from this work, while the top right hand gel contains the 
commercially available neutral anti-cancer drug, 4'-(acridinylamino)methanesulfon-m-
anisidide (mAMSA). The cationic intercalator, EB lanes 2-4, exhibits a large mobility shift of 
21% at 50 μM compared to compound [Au(HL3)Cl2], lanes 6-14, which displays a 
significantly lower mobility shift of 6% at 50 μM. This large observable difference in mobility 
shift is understandable as EB is cationic and therefore has an electrostatic attraction to the 
negatively charged backbone of the DNA. To obtain a more accurate comparison another 
EMSA assay was performed using mAMSA, which is a proven neutral intercalator. The 
mobility shift of mAMSA was observed at 3.9% at 50 μM complex concentration which was 
less than that of [Au(HL3)Cl2] at an equivalent concentration. This result indicates that 
compound [Au(HL3)Cl2] is able to intercalate DNA therefore inducing a mobility shift, 
however, what this assay does not tell us is the intercalation mode. There are two possible 
ways in which [Au(HL3)Cl2] is able to intercalate DNA, the first is via the unco-ordinated 
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isoquinoline ring and the second is through the gold(III) chelated isoquinoline ring. One 
would presume [Au(HL3)Cl2] would intercalate through the co-ordinated isoquinoline ring as 
the π-π interactions between the isoquinoline ring and the base pairs of the DNA, coupled 
with the Au(III)-π interactions between the electron deficient gold(III) centre and the base 
pairs of the DNA, would encourage this mode of interaction.  
EMSA experiments were similarly performed with compounds [Au(L12)Cl](PF6) and 
[Au(L13)Cl](PF6) to further try and elucidate whether they are able to bind DNA since the 
spectroscopic data was indicative of this but inconclusive. Compound [Au(L12)Cl](PF6) is 
used as a representative example. EMSA assays using both relaxed and SC-DNA were used. 
As seen above in Figure 7.3.4.1, when using SC-DNA one is able to detect a mobility shift of a 
respective band, however, when using relaxed DNA the effect is slightly different with the 
topoisomers displaying a smudging effect in the presence of an intercalator such as EB and 
total immobility in the presence of a minor groove binder such as Hoechst-33258 (Figure 
7.3.4.2).  
 
Figure 7.3.4.2: EMSA gel for EB, Hoechst-33258 and [Au(L12)Cl](PF6) using relaxed 
DNA as the substrate. The gel shows no evidence for DNA intercalation by compound 
[Au(L12)Cl](PF6).  
From the figure it is evident that [Au(L12)Cl](PF6) does not interact with DNA as an 
intercalator since the smudging of the relaxed topoisomer bands is not observed even at a 
high concentration of 500 μM. This result is interesting as it is contradictory to the 
spectroscopic data obtained in Chapter 4. Groove binding has been removed as a possible 
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mode of interaction as Hoechst-33258 was used as a control and almost completely 
immobilised the DNA at 0.5 μM, while [Au(L12)Cl](PF6) did not show any such effect.  
A similar EMSA experiment was performed, where the DNA substrate was SC- and NOC 
DNA. The results of this assay showed that there was in fact an increase in mobility shift for 
both the SC- and NOC DNA bands for compounds [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6). This 
increase in mobility shift was very small for compound [Au(L12)Cl](PF6) (1%), however, for 
compound [Au(L13)Cl](PF6) the increased mobility shift was quite prominent (25%). (Figure 
7.3.4.3) 
 
Figure 7.3.4.3: EMSA gel for [Au(L13)Cl](PF6) (top) at various indicated drug 
concentrations. The two dimensional peak deconvolution for [Au(L13)Cl](PF6) is shown 
below. DNA band identities: I, supercoiled DNA; II, nicked open-circular DNA. 
This result effectively means that the compound is ‘coiling’ the DNA further, which causes 
less drag in the EMSA experiment and therefore the DNA runs with a greater mobility than 
for standard SC-DNA. There are very few cases in the literature where a metal compound 
has this effect on DNA. One such case was reported by Hannon and co-workers in 2001, 
where an Fe(II) based supramolecular cylinder is shown to extensively coil DNA by 
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microscopy.36 These supramolecular cylinders have since been proven to be DNA 3-way 
junction binders.37, 38 Compounds [Au(L12)Cl](PF6) and [Au(L13)Cl](PF6) comprise an 
assymetric non-cylindrical shape and are therefore envisaged not to behave in a manner 
akin to that of the cylinders. One way in which we believe the compound may interact with 
DNA is through electrostatic interactions since the compounds are positively charged. It is 
well known that by removing/replacing the cationic sodium ions within the DNA structure, 
one is able to affect its tertiary structure.39 We therefore propose that the metal compound 
binds to the surface of the DNA through electrostatic interactions and displaces the sodium 
ions present (Figure 7.3.4.4). This change in cation within the DNA helix would therefore 
result in a conformational change of the DNA. In this case, enhanced supercoiling of the 
DNA, allowing for the increased mobility observed in the EMSA. This structural change could 
also negatively influence the binding of EB to DNA, forcing the equilibrium between the free 
and bound EB towards the free EB (Figure 7.3.4.4). This would account for the decrease in 
emission intensity observed in the EB displacement titrations.  
 
Figure 7.3.4.4: Schematic representation of the hypothetical electrostatic interaction 
between [Au(L12)Cl](PF6) and a DNA molecule. The diagram shows the displacement of 
EB and sodium ions from helical DNA structure by [Au(L12)Cl](PF6). 
The bathochromic shift and decrease in LMCT band intensity observed during the UV-vis 
ctDNA titrations could also be accounted for using this hypothesis. When the compound is 
free in solution it is uniformly surrounded by solvent molecules of a certain dielectric 
constant, however, when the compound electrostatically binds to DNA it is no longer 
uniformly surrounded by solvent molecules and hence the dielectric constant surrounding 
the molecule is different (Figure 7.3.4.4). This change in dielectric constant may cause the 
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spectral perturbations observed in the UV-vis spectra. In both the EB displacement titration 
and ctDNA binding experiments the spectral changes become more pronounced as the 
concentration of compound increases since the equilibrium between bound compound and 
unbound compound shifts towards the former. This would allow for a steady drop in 
emission intensity as the EB is displaced from the DNA as well as a change in the UV-vis 
spectrum as more and more compound becomes electrostatically bound to the DNA.  
7.3.5 Summary and Conclusions 
Overall, the compounds studied in this work were found to be effective chemotherapeutic 
agents in vitro but lack the same efficacy in vivo. Although beyond the scope of the work in 
this thesis, the lack of in vivo efficacy may be due to irreversible binding of the compounds 
to serum proteins such as HSA. The mechanism by which the more cytotoxic gold(III) 
complexes exert their cytotoxicity has been determined to be via the catalytic inhibition of 
the topoisomerase family of enzymes. Compounds [Au(HL3)Cl2] and [Au(L8)Cl](PF6)–
[Au(L11)Cl](PF6) were shown to intercalate DNA. Compounds [Au(L12)Cl](PF6)–
[Au(L14)Cl](PF6) display spectral properties consistent with DNA intercalation, however, 
EMSA studies suggest that the interaction between the compounds and DNA is not 
intercalation, but rather another mode of interaction (perhaps electrostatic) as evidenced 
by a gel mobility shift. 
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8. Summary, conclusions and future work 
8.1 Summary and conclusions 
Since the ability of cisplatin to arrest cell division was discovered in 1965, there has been a 
steady rise in the number of literature articles reporting the use of metal complexes as 
potential chemotherapeutic agents. One particular field which has garnered much interest is 
the investigation of gold(I/III) compounds as anti-cancer agents, particularly gold(III) 
compounds, since they possess isoelectronic and isostructural properties to platinum(II) 
compounds. However, the inherent problem with gold compounds, particularly gold(III) 
compounds, is their instability in biological media as well as towards cellular reducing agents 
such as GSH. Consequently, ligand design is crucial to stabilising the gold(III) ion and hence 
the structural integrity of gold(III) compounds in solution. Therefore the main objective of 
the research presented in this thesis was to synthesise a series of novel, potentially stable, 
gold(III) compounds and to assess their cytotoxicity profiles towards human cancer cell lines.  
In summary, this work describes the synthesis, characterisation, computational and 
biological studies of sixteen (fifteen novel) quinoline- and pyridine-amide-based gold(III) 
compounds. The preliminary stages of the project involved the synthesis of a tetradentate 
dianionic bis(amide) ligand (H2L1), via literature methods, as a scaffold for incorporating the 
gold(III) ion with a view of forming a cationic, tetradentate, metal complex analogous to that 
synthesised by Che and co-workers.1 This phase of the project was initiated principally to 
investigate the synthetic procedures surrounding the chelation of the gold(III) ion by 
bis(amide) ligands, since there are very few specific methodologies in the literature 
regarding this. Initial synthetic attempts involved the reflux of a gold(III) salt (H[AuCl4], 
K[AuCl4], Na[AuCl4], or [Bu4N][AuCl4]), with the bis(amide) ligand, H2L1, in a solvent (DCM, 
MeOH or a 1:1 binary mixture of these solvents). This resulted in the isolation of the 
respective starting materials with no metal complex formation. The synthesis was then 
performed using similar conditions with the addition of a base (NaMeO, NaEtO or NaOAc) 
which resulted in the formation of a cis-dichloro tris-chelate where the gold(III) ion was only 
bound to half the bis(amide) ligand. Irrespective of the combination between solvent and 
base (vida supra) the cis-dichloro tris-chelate ([Au(HL1)Cl2]) was invariably isolated. Due to 
the interesting co-ordination mode between the gold(III) ion and the bis(amide) ligand, the 
investigation into the formation of the tetradentate mono-chelate was abandoned and two 
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additional bis(amide) ligands (H2L2 and H2L3) were synthesised followed by their tris-
chelates ([Au(HL2)Cl2] and [Au(HL3)Cl2]). Upon review of the literature it became apparent 
that the use of bi- and tridentate amide ligands and the synthesis of their gold(III) complexes 
may, in fact, afford potentially cytotoxic compounds. To this end, ligands HL4–H2L16 were 
synthesised using literature methods. The chelation of the respective ligands to gold(III) was 
initially performed using the same methods to produce [Au(HL1)Cl2]. These methods 
afforded the correct gold(III) chelate cation for all ligands, however, the incorrect [AuCl2]
- 
and/or [AuCl4]
- anion(s) were always encountered. This problem was solved by encouraging 
the formation of the [AuCl4]
- anion while refluxing in acetic acid with a 3-fold molar excess 
of NaOAc. The [AuCl4]
- anion was subsequently metathesised to the Cl- and then to the PF6
- 
anion via literature methods.  
All metal complexes synthesised were fully characterised by standard IR, NMR, UV-vis as 
well as mass spectrometry. The IR spectrum for all ligands was characterised by an amide N-
H stretch between 3272 and 3359 cm-1 and an amide C=O stretch between 1646 and 1689 
cm-1. Upon chelation of ligands H2L1–H2L3 to a gold(III) ion, an amide N-H and C=O stretch  
remain at a similar stretching frequency to the free ligand due to the unusual co-ordination 
mode of the gold(III) ion to the ligand allowing for an unbound amide group, while the 
bound amide C=O stretches shifted to lower wavenumbers (from 1650-1685 cm-1 to 1645-
1652 cm-1). Ligands HL4– H2L16 all contain only one amide group which lost their respective 
amide N-H stretches upon chelation to gold(III), while the amide C=O stretching band 
shifted to higher wavenumbers upon chelation of gold(III) for ligands HL5–HL7 (1646-1664 
cm-1 to 1664-1676 cm-1). Ligands HL4 and HL8-H2L16 all displayed a decrease in amide C=O 
stretching frequency similar to that observed upon chelation of gold(III) to ligands H2L1–
H2L3. The 
1H and 13C spectra for all ligands synthesised displayed characteristic downfield 
shifts for the amide N-H (between 8.55 and 12.46 ppm) and C=O (between 162.98 and 
166.26 ppm) resonances respectively, while ligands HL12–HL14 all contained an extra 
ketone C=O resonance downfield (≈ 190 ppm) in the 13C spectrum. Upon chelation of the 
respective ligands to gold(III), there is a general downfield shift for both 1H and 13C chemical 
shifts due to the deshielding effect of the gold(III) ion. This effect is particularly evident for 
the α- and α' 1H signals where a maximum 0.97 ppm downfield shift is observed after 
chelation of a gold(III) ion to the free ligand. The UV-vis spectrum for all complexes was 
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characterised by a strong π-π* absorption band situated between 200 and 300 nm and a 
LMCT band situated between 300 and 500 nm.  
All compounds were evaluated for their solubility in a wide range of solvents with 
[Au(HL1)Cl2] and [Au(HL2)Cl2] being soluble only in polar solvents such as DMSO and 
MeNO2, while [Au(HL3)Cl2] and [Au(L4)Cl2] displayed additional solubility in organic solvents 
such as DCM and THF. The chloride salts of compounds [Au(L5)Cl](PF6)–[Au(L14)Cl](PF6) 
displayed good solubility in H2O while the corresponding PF6
- salts were more soluble in 
MeOH and/or MeCN. The neutral chelates [Au(L15)Cl]–[Au(L16)Cl] were soluble in DMSO 
and only sparingly soluble in DCM. Solution stability plays a vital role with gold(III) 
compounds and their potential as chemotherapeutic agents since they can be highly 
susceptible to decomposition. The compounds were therefore further evaluated for their 
solution stability in a biologically relevant media, TBS (50 mM Tris-HCl, NaCl 10 mM, pH 
7.34, 37 °C). Compound [Au(HL3)Cl2] was found to be susceptible to reductive 
demetallation, presumably through chloride substitution. Compounds [Au(L5)Cl](PF6)–
[Au(L7)Cl](PF6) were all unstable in solution with a large decrease in both π-π* and LMCT 
absorption bands observed over a period of 12 h. Compounds [Au(L8)Cl](PF6)–
[Au(L14)Cl](PF6) were similarly evaluated for their stability in TBS and found to be stable 
over 24 h with a less than 2.5% drop in absorbance for both π-π* and LMCT absorption 
bands, while complexes [Au(L15)Cl]–[Au(L16)Cl] were also found to be stable. Compound 
[Au(L12)Cl](PF6) was further tested for its reactivity towards biologically relevant 
nucleophiles (imidazole and glutathione; 10-fold higher concentration relative to the 
concentration of the complex). [Au(L12)Cl](PF6) was found to be stable in the presence of 
imidazole with a < 5% drop in absorbance of the LMCT absorption band over 24 h while in 
the presence of glutathione, the complex displayed an effective 100% reduction in LMCT 
band intensity over a 12 h period. In order to try and ascertain the ability of the stable 
complexes, [Au(L8)Cl](PF6)–[Au(L14)Cl](PF6), to cross cellular membranes, their log Po/w 
values were assessed via the ‘shake flask’ method. All complexes were found to have fairly 
large negative log Po/w values (-0.80-2.16) indicating that the compounds are hydrophilic in 
nature and may encounter difficulties traversing cellular membranes. Due to the planar 
nature and appropriate solubility and stability of the chloride salts of compounds 
[Au(L8)Cl](PF6)–[Au(L14)Cl](PF6) in TBS, their ability to interact with ctDNA was explored via 
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traditional UV-vis spectroscopic methods. Compounds [Au(L8)Cl](PF6)–[Au(L11)Cl](PF6) all 
displayed characteristic spectral changes associated with ctDNA intercalation upon 
sequential addition of ctDNA to a ≈10-5 M concentration of respective complex in TBS at 37 
°C. The resulting data from the UV-vis ctDNA binding experiments strongly indicated that all 
four compounds bound ctDNA via an intercalative method with binding affinities (Kb) 
ranging from 2.7(5) x 105 to 4.7(6) x 105 M-1. Compounds [Au(L12)Cl](PF6)–[Au(L14)Cl](PF6) 
gave irreproducible UV-vis ctDNA binding isotherms with large errors in ctDNA binding 
constants, characteristic of multiple modes of ctDNA binding. EB competitive binding assays 
using emission spectroscopy were then performed for compounds [Au(L12)Cl](PF6)–
[Au(L14)Cl](PF6) to try and further elucidate the mode of interaction between the complexes 
and ctDNA. These results indicated that the compounds were able to bind ctDNA via 
intercalation with the highest apparent binding constant (Kapp) being 8.4(6) x 10
5 M-1 for 
compound [Au(L14)Cl](PF6).      
Solid state structures for all chelates except [Au(L10)Cl](PF6), [Au(L14)Cl](PF6) and 
[Au(L16)Cl] were determined by X-ray crystallography. Analysis of the structures confirmed 
the co-ordination mode of the gold(III) ion to each respective ligand is, as expected, a 
distorted square planar geometry. For chelates [Au(HL1)Cl2]–[Au(L4)Cl2], the ligand donates 
two binding sites while a pair of cis chloride ions completes the square planar geometry. The 
Au–Cl1 and Au–Cl2 bond lengths average 2.293(6) and 2.260(13) Å, respectively, with the 
former bond length indicative of a structural trans effect manifested through the anionic 
amide nitrogen. The Cl–Au–Cl and N–Au–N co-ordination bond angles are 89.1(2)° and 
81.2(2)°, respectively, of which the latter represents the geometric constraints imposed on 
the metal ion co-ordination geometry by the five-membered chelate ring. For chelates 
[Au(L5)Cl](PF6)–[Au(L15)Cl](PF6) the ligand donates three binding sites and a single chloride 
ion in the fourth co-ordination site completes the square planar geometry. A similar trans 
effect is observed for the tridentate chelates with the longest Au–Cl bond length (2.298(2) 
Å) being recorded for [Au(L6)Cl](PF6). The bond angles for compounds [Au(L5)Cl](PF6)–
[Au(L15)Cl](PF6) similarly deviate from the ideal square planar geometric angle of 90° due to 
the geometric constraints imposed by the ligand system. The mean N–Au–Cl bond angle is 
fairly obtuse (97.8(9)°) while the mean N–Au–N angle is quite acute, measuring 82.1(9)°. The 
supramolecular interactions present for chelates [Au(HL1)Cl2]–[Au(HL3)Cl2] were fairly 
Summary, Conclusions and Future Work 
252 | P a g e  
 
significant, owing to their polyfunctional nature. The extended structures are dominated by 
C–H···O and C–H···Cl hydrogen bonding which culminates in 1D hydrogen-bonded chains in 
the solid state. The balance of the chelates only contain non-traditional hydrogen bond 
capabilities and therefore their supramolecular structures were accordingly less diverse. 
Due to the presence of extended aromatic ring systems present in most chelates, π-stacking 
was a prevalent feature, with the majority of the compounds exhibiting this effect. A 
particularly strong π-stacking effect was observed for the compound [Au(L12)Cl](PF6), where 
the MPS between quinoline rings was measured to be 3.307 Å. 
The main aim of the project was the development of novel gold(III) metallotherapeutic 
drugs. An obvious requirement is therefore the assessment of the compounds in vitro and, 
more specifically, their ability to act as cytotoxic agents towards human cancer cell lines. 
The cytotoxicity of all compounds except for [Au(HL1)Cl2] was therefore evaluated at the 
NCI in their initial (single-dose screen) against 60 human cancer cell lines. During this 
screening process the chelates were assessed at a concentration of 1 x 10-5 M across their 
60 human cancer cell lines in order to determine mean growth percentage values. 
Compound [Au(L12)Cl](PF6) exhibited the lowest mean growth percentage value (17%) while 
compound [Au(HL2)Cl2] displayed the highest (105%). From these values, compounds 
[Au(HL3)Cl2], [Au(L6)Cl]PF6–[Au(L8)Cl](PF6), [Au(L10)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl] 
were deemed sufficiently cytotoxic to progress through to the 5-dose phase of testing 
where the dose-response parameters, GI50, TGI and LC50 were determined. Chelate 
[Au(HL3)Cl2] performed fairly well with GI50, TGI and LC50 values averaging 10, 23 and 78 μM, 
respectively against the NCI’s 60 human cancer cell lines. Compounds [Au(L6)Cl](PF6)–
[Au(L8)Cl](PF6), [Au(L10)Cl](PF6)–[Au(L13)Cl](PF6) and [Au(L15)Cl] performed well with 
[Au(L12)Cl](PF6) being the outstanding performer, exhibiting GI50, TGI and LC50 values 
averaging 0.80, 11.36 and 80.64 μM, respectively against the NCI’s 60 human cancer cell 
lines. The cytotoxicity of compound [Au(L12)Cl]PF6 was deemed sufficient enough to 
progress through to the initial in vivo phase of testing, namely, the hollow fibre assay. The 
compound unfortunately performed poorly with a score of 0 out of 96. This may be 
attributed to several problems such as poor trans-membrane cellular transport, irreversible 
binding to serum proteins and/or the decomposition of the drug in vivo.  
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After the compounds were shown to have anti-cancer activity, the next step was to try and 
determine the MOA by which they effect their cytotoxic action. This was performed by 
taking the –log GI50 values for compounds [Au(HL1)Cl2] and [Au(L12)Cl](PF6) (due to their 
structural diversity) and applying a statistical cluster analysis with the –log GI50 values of 25 
commercially available chemotherapeutic agents with established MOA’s. This results in a 
dendogram with the test compound clustering with commercial compounds that display a 
similar cytotoxicity profile with the premise that the test compound may exert its cytotoxic 
ability through the same MOA. The results revealed that compound [Au(HL3)Cl2] and 
[Au(L12)Cl](PF6) probably target topoisomerase II and I, respectively. This was confirmed by 
topo IB relaxation and topo IIα decatenation assays, respectively. The experiments were 
performed in Prof Mark Muller’s laboratory at the University of Central Florida. Chelate 
[Au(HL3)Cl2] was determined to be a dual-mode poison and catalytic inhibitor of topo IIα. 
Poisoning of the topo IIα enzyme occurred between 5-100 nM and catalytic inhibition 
between 500 nM and 50 μM. Compound [Au(L12)Cl]PF6 was also determined to be a dual 
mode poison and catalytic inhibitor of topo IB with weak poisoning of the topo IB enzyme 
between a complex concentration of 0 and 1 μM and catalytic inhibition between 1-10 μM. 
Since the solution instability of compound [Au(HL3)Cl2] did not allow for its ctDNA binding 
ability to be assessed, an EMSA assay was employed to give an indication of whether 
intercalation of DNA might occur for [Au(HL3)Cl2]. The experiment concluded that 
[Au(HL3)Cl2] is able to intercalate DNA, albeit weakly, at a metal concentration of 50 μM. 
The EB displacement and UV-vis ctDNA binding assays were inconclusive for compounds 
[Au(L12)Cl](PF6)–[Au(L14)Cl](PF6), therefore a similar assay was performed for 
[Au(L12)Cl](PF6) and [Au(L13)Cl](PF6). The results showed that there was no evidence for 
intercalation, however, an increase in mobility shift for both chelates was detected which is 
suggestive of enhanced coiling of the DNA. It is thus postulated that the complexes may in 
fact bind electrostatically to the DNA helix.   
In conclusion, we have synthesised a promising novel class of gold(III) amide chelates as 
potential chemotherapeutic agents. To this end, the in vitro results were encouraging with 
chelate [Au(L12)Cl](PF6) proving to be the lead candidate in the series with low μM GI50 and 
IC50 values against several leukaemia, colon, ovarian and breast cancer cell lines. The in vivo 
results were however less encouraging. This is presumably due to the chelate being 
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reduced, as suggested by spectroscopic glutathione reduction experiments. The stability of 
the compounds in biological media subsequently needs to be enhanced through structural 
modifications of the existing group of compounds so that their in vivo activity may be 
enhanced. Further mechanistic detail needs to be elucidated on the topo I/II poising and 
catalytic inhibitory action so that the compounds presented in this work may be optimised 
in order to increase their cytotoxicity. The ability of [Au(L12)Cl](PF6) to bind DNA has not 
been conclusively proven since there is contradicting evidence between the spectroscopic 
data and EMSA data and the exact nature of the interaction between the complex and DNA 
needs to be determined in order to try and understand better the mechanism of topo IB 
inhibition. Overall, a solid platform has been laid from which numerous future experiments 
can be performed to further develop this area of research.  
8.2 Future work 
The future for this project is immense as the work presented herein covers only the initial 
discovery phase of a class of potential chemotherapeutic agents. The future work can be 
split into two major sections; the first being work that needs to be performed on the current 
class of compounds presented, and the second being the structural modification of chelates 
in this thesis (second generation chelates)  so that questions raised from the results of this 
work may be answered.  
From the current class of compounds, [Au(L6)Cl](PF6) and [Au(L10)Cl](PF6) need to be 
individually assessed for their ability to inhibit or poison topo IB or IIα via the same 
relaxation and decatenation assays performed for compounds [Au(HL3)Cl2] and 
[Au(L12)Cl](PF6). These experiments need to be performed since the complexes mentioned 
are structurally unique and therefore need to be independently confirmed as topo 
poisons/inhibitors. The major focus of the future work will obviously centre on 
[Au(L12)Cl](PF6) as it was the lead compound in this work. Firstly, the mechanism through 
which chelate [Au(L12)Cl](PF6) interacts with DNA needs to be unequivocally determined. 
The best method by which to do this is X-ray crystallography. In recent years there have 
been numerous structural reports of Ru(II) and Rh(III) octahedral chelates bound to proteins 
and synthetic DNA oligomers.2-5 The crystal growth process usually involves vapour diffusion 
from sitting drops and the data either collected via synchrotron radiation or via a 
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diffractometer with a high power source such as a rotating anode.3, 4 The results can be 
incredibly informative with up to three different binding modes present on a single DNA 
oligomer as was recently reported for Δ-[Ru(bpy)2dppz]
2+.3, 4 These types of experiments are 
becoming increasingly crucial to understanding how drugs in general interact with their 
target. 
One of the reasons suggested for the failure of [Au(L12)Cl](PF6) at the hollow fibre assay is 
that the chelate may bind irreversibly to serum proteins such as HSA. The ability for a drug 
to bind to HSA can be assessed via the use of a HSA binding kit available from the company 
SOVICELL.6 The kit takes the form of a ready-to-use 96-well microtiter plate, carrying 
TRANSIL beads with albumin immobilised in random orientations to expose all binding sites. 
The experiment is performed on a 96-well plate reader and is depicted graphically. The 
results from such an assay would be greatly informative and lead to a far greater 
understanding of the transport of the drug in vivo.  
From the topo I relaxation assays performed in this work we have deduced that 
[Au(L12)Cl](PF6) acts as an interfacial poison of the enzyme between a metal complex 
concentration of 0-1 μM and a catalytic inhibitor between 1 and 10 μM. A similar 
experiment needs to be performed with a metal chelate titration range of 1-10 μM at 1 μM 
increments in order to determine a more accurate inhibitory concentration. The specific 
mode by which [Au(L12)Cl](PF6) reduces the activity of topo IB also needs to be further 
investigated by analysing the effect the complex has on various steps in the enzyme’s 
catalytic cycle, as was completed for a similar gold(III) complex, [Au(C^N^C)(IMe)](CF3SO3), 
in 2011 by Castelli and co-workers.7  
The first property of the current generation of chelates that needs to be resolved, through 
synthetic modifications, is their stability towards glutathione. These chelates all have a 
chloride ion in the fourth co-ordination site which seems to allow for reductive 
demetallation of the gold(III) centre through its substitution by glutathione. Therefore by 
substituting the chloride ion with a substitution inert ligand, such as N,N’-
dimethylimidazolium, we may afford a much more stable chelate towards biological 
reducing agents. This is an ideal ligand as it allows for the use of neutral cyclometallated 
chelates [Au(L15)Cl] and [Au(L16)Cl], which after substitution of the chloride ion with N,N’-
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dimethylimidazolium, offer an ideal positively charged chelate which will be tested for their 
redox stability towards glutathione in a similar manner to [Au(L12)Cl](PF6). Literature 
methods for the substitution of chloride with N,N’-dimethylimidazolium in tridentate 
gold(III) chelates are available, however they have not been performed on tridentate amide 
chelates.8 Nevertheless, we would not expect to encounter any significant difficulties in 
affording the correct product.  Overall, the substitution of the chloride ion coupled with the 
highly stabilising C–Au bond should afford the desired redox stability. Scheme 8.2.1 shows a 
reaction sequence depicting a method through which the second generation chelates may 
be accessed. The Au–C bond represented in scheme 8.2.1 has been shown to impart redox 
stability in biologically relevant media for similar gold(III) complexes.9 The scheme below is a 
representative example; the method may be employed using any of the first generation 
chelates presented in this work, namely the derivitisation of compound [Au(L12)Cl](PF6). 
 
Scheme 8.2.1: Synthetic method that may be employed for the generation of second 
generation gold(III) amide-based chelates with improved redox stability. 
Lastly we propose the modification of the ligand scaffold in such a way that it enhances the 
cytotoxicity and topo I or II inhibitory action of the chelate. One way in which to do this 
would be to mimic the structure of commercially available chemotherapeutic topo I or topo 
II inhibitors. Daunorubicin and etoposide, both commercial topo II poisoning anti-cancer 
agents, contain sugar-type moieties within their scaffold which are central to their topo II 
inhibitory activity.10, 11 The proposed method for the generation of gold(III) chelates with 
similar sugar appendages is shown in scheme 8.2.2, and involves a method analogous to the 
one published by Kumar and co-workers in 2007.12 The condensation of 2-hydroxybenzoic 
acid with 8-aminoquinoline via the use of the coupling agent, carbonyldiimidizole (CDI), 
would afford ligand 1. The acetylated-sugar ester of compound 1 is then formed via the 
method published by Bao and co-workers13 in 2004 followed by chelation to gold(III) using 
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the method presented in this thesis to afford compound 3. The chloride ion of the neutral 
gold(III) chelate (3) would then be substituted via the use of a literature method published 
by To and co-workers8 this year, followed by deacetylation in the presence of NaOMe to 
afford the target chelate 4. The generated compound would be expected to have improved 
redox stability as well as enhanced enzyme inhibitory as well as cytotoxic activity.  
 
Scheme 8.2.2: Proposed synthetic route for the sugar-derivatised gold(III) amide-based 
second generation chelate.  
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